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ABSTRACT 
The atherosclerotic plaque is characterised by the presence of macrophage foam cells 
that arise from dysfunctional cholesterol metabolism and trafficking. Cytokines are 
highly expressed within the plaque and play a critical function in initiating and 
augmenting the disease state. Previous studies have shown that the novel cytokine, 
interleukin-33 (IL-33), exerts anti-atherogenic actions in animal and in vitro models of 
the disease.  
The effect of IL-33 on pro-atherosclerotic markers was assessed in human THP-1 and 
murine RAW264.7 macrophages and primary human monocyte-derived macrophages 
(HMDMs) by real time-quantitative polymerase chain reaction (RT-qPCR). The studies 
then focused on characterising the signalling pathways involved in the regulation of 
intercellular adhesion molecule-1 (ICAM-1) and monocyte chemotactic protein-1 
(MCP-1) expression by IL-33. The expression of key signalling components implicated 
in atherosclerosis were knocked down by RNA interference (RNAi). These experiments 
demonstrated that the extracellular signal-regulated kinase (ERK)-1 and -2, p38α, c-Jun 
N-terminal kinase (JNK)-1 and -2, phosphoinositide-3-kinase (PI3K)-γ, p50 and p65 
NF-κB were integral to the IL-33-mediated down-regulation of ICAM-1 and MCP-1 
gene expression in THP-1 macrophages.  
Another key aim was to analyse the effects of IL-33 stimulation on the lipid profiles of 
macrophages. A combination of thin layer chromatography (TLC) and gas 
chromatography (GC) was used to assess the fatty acid composition of THP-1 and 
RAW264.7 macrophages following IL-33 treatment. The cytokine promoted the 
redistribution of fatty acids and caused a general increase in saturated fatty acids (SFAs), 
accompanied with a reduction in monounsaturated fatty acids (MUFAs). Additionally, 
IL-33 increased the content of n-3 polyunsaturated fatty acids (PUFAs) whereas the 
impact on n-6 PUFAs was more specific to particular fatty acids and varied between the 
two species. Overall, the cytokine enhanced the levels of PUFAs involved in eicosanoid 
production. Also, IL-33 influenced the precursors and products of desaturases and 
appropriately increased the activities of Δ-5 and Δ-6 desaturases but reduced stearoyl-
CoA desaturase activity (SCD). The decrease in SCD activity was accompanied by a 
reduction in the mRNA expression of SCD-1 in RAW264.7 macrophages. 
The studies presented within this thesis provide new insights into the signalling 
pathways underlying the IL-33-mediated inhibition of gene expression in macrophages. 
Additionally, these experiments describe the novel effects of IL-33 stimulation on the 
lipid profile of macrophages. 
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CHAPTER 1.  
INTRODUCTION 
 
1.1. Coronary heart disease (CHD) and atherosclerosis 
Coronary heart disease (CHD) is responsible for one in three deaths and is the leading 
cause of mortality in westernised countries. An estimated 23.6 million people are 
expected to die globally from cardiovascular related diseases by 2030 and the disease 
and its complications, which include stroke and myocardial infarction (MI), have been 
predicted to have direct and indirect costs of approximately $315.4 billion in 2010 
(McLaren et al. 2011a; Go et al. 2014). Due to the prevalence of the disease and the 
associated financial burden, this area of research has received much attention with the 
intention of gaining a better understanding of the prevailing pathology. Atherosclerosis 
is a chronic inflammatory disorder of the large and medium-sized arteries and 
constitutes the major underlying cause of CHD (McLaren et al. 2011a).  
Advances in murine models capable of developing advanced atherosclerotic lesions 
such as apolipoprotein E (ApoE)
-/- 
and low-density lipoprotein receptor (LDLR)
-/- 
knockout mice have facilitated the investigation of genetic and physiological aspects of 
early events within the disease (Lusis 2000). The ApoE
-/-
 knockout mouse model was 
pioneered in 1992 and is the most frequently chosen model for studying atherosclerosis 
(Piedrahita et al. 1992; Plump et al. 1992; Knowles and Maeda 2000; Smith et al. 2001). 
ApoE is produced within the liver and by macrophages and is a component of 
lipoprotein particles where it functions as a ligand for lipoprotein receptors (Zadelaar et 
al. 2007). Homozygous deletion of the ApoE gene gives rise to mice with marked 
hypercholesterolaemia when fed a western-type diet (Plump et al. 1992). The mice 
display five times the amount of plasma cholesterol compared to parent mice, develop 
spontaneous lesions in the aortic, coronary and pulmonary arteries and also exhibit 
reduced levels of the atheroprotective high-density lipoprotein (HDL) (Zhang et al. 
1992).  
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The LDLR
-/- 
knockout mouse model was developed in 1993 and shares many features 
with those exhibited by familial hypercholesterolaemia sufferers; a rare condition in 
humans that arises from the absence of functional LDLRs (Ishibashi et al. 1993; Russell 
and Proctor 2006). LDLR
-/- 
mice are mildly hypercholesterolaemic due to defective 
clearance of plasma LDL (Kowala et al. 2000). Following feeding on a high-fat diet, the 
mice develop multiple atherosclerotic lesions accompanied with increased levels of 
cholesterol within the plasma and raised amounts of pro-atherogenic lipoproteins 
(Ishibashi et al. 1994). The formation of plaques occurs in a time-dependent fashion and 
closely resemble those found in ApoE
-/-
 mice in terms of morphology (Zadelaar et al. 
2007). 
The disruption of the genes for ApoE or LDLR may affect other crucial cellular 
processes. Studies have shown that ApoE also functions as an anti-oxidant and 
modulator of immune responses (Zadelaar et al. 2007). Furthermore, there are certain 
limitations associated with the use of animal models for the study of atherosclerosis that 
arise from inter-species differences. Mice have a distinct lipoprotein profile from 
humans and the majority of plasma cholesterol is carried on HDL particles whereas, in 
humans, 75% of cholesterol is carried on LDL particles (Jawien et al. 2004). 
Additionally, immunological responses differ as the immune system has partly evolved 
due to selective pressure from microbial exposure; as such mice are more resilient to 
inflammatory damage than humans (Seok et al. 2013). Many differences exist between 
the murine and human immune system. The rolling of leukocytes to target sites is 
mediated by adhesion molecules such as P-selectin which is constitutively expressed at 
the surface of endothelial cells within humans. However, in mice the expression of this 
molecule is induced by pro-inflammatory mediators such as lipopolysaccharide (LPS) 
(Pan et al. 1998). The expression and secretion of immunoregulatory molecules can also 
vary between species. Within humans, neutrophils are a major source of antimicrobial 
defensins but the peptides are not expressed by neutrophils within mice (Risso 2000). 
Despite these potential caveats, the use of these mice has greatly progressed our 
understanding of the disease and there are many advantages associated with the use of 
murine models. For example, environmental conditions and dietary intake can be 
carefully controlled and the generation time is short therefore facilitating cross-breeding 
and evaluation of disease progression (Jawien et al. 2004).  
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1.2. Risk factors associated with atherosclerosis  
Risk factors are measurable biological aspects that precede definable events within the 
disease, such as MI; they are causal in nature and can be used to predict the event. 
Kannel et al. (1961) outlined a number of interrelated characteristics that are associated 
with an increased risk of developing cardiovascular disease, these include raised 
cholesterol, hypertension, diabetes mellitus and smoking (Kannel et al. 1961). Table 1 
displays several risk factors that contribute towards the initiation and progression of 
atherosclerosis and are grouped under environmental or genetic factors. It is well 
accepted that the disease is initiated by a local immune response to lipid deposition 
within the arterial subendothelial compartment (Chinetti-Gbaguidi and Staels 2009). 
Since lipids and lipoproteins are crucial to the initiation and development of the disease, 
these subjects will be dealt in more detail. 
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Table 1. Risk factors linked to atherosclerosis 
Risk Factor Role in atherosclerosis Reference 
Genetic 
Aging Defective efferocytosis. (Tabas 2010) 
Type I Diabetes 
Influences plasma lipoproteins levels and 
blood pressure. Directly affects arterial 
wall. 
(Tabas 2010) 
Gender 
Men below the age of 60 are more prone 
(double the chance compared to women). 
(Lusis 2000) 
Systemic 
inflammation 
Raised levels of inflammatory markers such 
as C-reactive protein linked to CHD. 
(Lusis 2000) 
Environmental 
Cigarette smoking Free radical generation. (Ross 1999) 
High cholesterol 
diet 
Elevated circulating LDL levels. Causes 
focal endothelial activation. 
(Hansson et al. 2006) 
Infectious agents 
Proposed innate immune response from 
infections (e.g. Chlamydia Pneumonia) 
may contribute to atherogenesis. 
(Lusis 2000) 
Sedentary lifestyle Raised blood pressure, elevated cholesterol. 
(George and Johnson 
2010) 
 
 
1.3. Lipids  
The theory that atherosclerosis stems from dysfunctional lipid metabolism has arisen 
from several key observations: the first morphological sign of atherosclerotic 
development is the appearance of a fatty streak abundant with lipids. Also the disease is 
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characterised by raised levels of lipids within the blood and lastly, the pathological state 
can be induced by disturbing processes related to lipid metabolism within animals 
(Kellner 1952). Therefore it is important to understand the role of lipids during normal 
physiology in order to determine the disruptive processes that give rise to the disease. 
 
Lipids are a heterogeneous group of biomolecules that serve a range of functions within 
the body; as integral components of cellular membranes, a source of metabolic fuel and 
as mediators of signal transduction, amongst other roles (Kagan et al. 1974; Rustan and 
Drevon 2001; Vasudevan 2013). The most frequent form of lipids within the body are  
fatty acids produced during the metabolism of dietary lipids and typically esterified to 
other lipid derivatives such as triacylglycerols (TAGs) (Vasudevan 2013). Fatty acids 
are named after the parent hydrocarbon chain and the carbon atoms are either numbered 
from the carboxyl terminal, using the delta numbering system, or from the distal methyl 
end under the omega numbering system (Pelley 2011). A list of common fatty acids is 
given in Table 2.  
 
Saturated fatty acids (SFAs) are comprised of straight hydrocarbon chains and typically 
contain an even number of carbon atoms, between 12 to 22, in humans (Rustan and 
Drevon 2001). Unsaturated fatty acids contain one or more double bonds and are 
denoted by the suffix –enoic following the systematic name (Vasudevan 2013). 
Polyunsaturated fatty acids (PUFAs) contain two or more double bonds and are named 
based on the position of the first double bond from the methyl end of the molecule. For 
example the first double bond of n-3 PUFAs is located between carbons three and four 
(Ruxton et al. 2004). The PUFAs linoleic acid (LA) and α-linolenic acid (ALA) are 
termed essential fatty acids as the body is unable to produce them due to an absence of 
Δ12- and Δ15- desaturase enzymes and therefore must be obtained from the diet 
(Rustan and Drevon 2001; Vasudevan 2013). The free carboxylate group in fatty acids 
poses potential issues for the cell and therefore unsaturated and SFAs are readily 
esterified to alcohols, in particular glycerol. Esterification with glycerol molecules 
produces mono-, di- or TAGs (Pelley 2011).  
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Table 2. Some naturally occurring fatty acids and their nomenclature 
    Shorthand   
    notation 
Common name Abbreviation Chemical name 
14:0 Myristic acid  Tetradecanoic 
16:0 Palmitic acid  Hexadecanoic 
16:1n7 Palmitoleic acid  Cis-9-hexadecenoic  
16:1n9 Palmitoleic acid  Cis-7-hexadecenoic 
18:0 Stearic acid   Octadecanoic 
18:1n7 Cis-Vaccenic acid  Cis-11-octadecenoic 
18:1n9 Oleic acid  Cis-9-octadecenoic 
18:2n6 Linoleic acid LA Cis-9,12-octadecadienoic 
18:3n3 α-Linolenic acid ALA Cis-9,12,15-octadecatrienoic 
18:3n6 γ-Linolenic acid GLA Cis-6,9,12-octadecatrienoic 
18:4n3 Stearidonic acid STA Cis-6,9,12,15-octadecatetraenoic 
20:1n9 Eicosenoic acid   Cis-11-eicosenoic 
20:2n6 Eicosadienoic acid EDA Cis-11,14-eicosdienoic 
20:3n3 Eicosatrienoic acid ERA/ETrA Cis-11,14,17-eicosatrienoic 
20:3n6 
Dihomo-γ-linolenic 
acid 
DGLA Cis-8,11,14-eicosatrienoic 
20:4n3 Eicosatetraenoic acid ETA Cis-8,11,14,17-eicosatetraenoic 
20:4n6 Arachidonic acid AA/ARA Cis-5,8,11,14-eicosatetraenoic 
20:5n3 
Eicosapentaenoic 
acid  
EPA Cis-5,8,11,14,17-eicosapentaenoic 
22:0 Behenic acid  Docosanoic 
22:3n6   Cis-10,13,16-docosatrienoic 
22:5n3 
Docosapentaenoic 
acid 
DPA Cis-7,10,13,16,19-docosapentaenoic 
22:6n3 
Docosahexaenoic 
acid 
DHA Cis-4,7,10,13,16,19-docosahexaenoic 
24:0 Lignoceric acid  Tetracosanoic 
24:1n6 Nervonic acid  Cis-15-tetracosenoic 
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A diverse range of lipid, carbohydrate and protein moieties within the membrane 
ensures that the system can cope with changes to the cell such as variations in pH or 
osmolarity during normal physiological or pathological states (Simons and Sampaio 
2011). In many bacteria, archaea and eukaryotes, the major phospholipids are 
phosphatidylserine (PS), phosphatidylethanolamine (PE), phosphatidylglycerol (PG) 
and diphosphatidylglycerol (trivial name cardiolipin). Eukaryotes also contain 
phosphatidylcholine (PC) and phosphatidylinositol (PI) (van Meer and de Kroon 2011).  
1.3.1. Lipid metabolism in atherosclerosis 
Following consumption of a meal; dietary fats are either assimilated into other lipid 
moieties or re-esterified to TAGs and repackaged along with cholesterol esters (CEs), 
phospholipids and apoproteins into chylomicrons before entering the systemic 
circulation (Vasudevan 2013). Lipoproteins function as vehicles for the transport of 
insoluble lipids in the blood and are composed of a core region storing TAGs and CEs, 
with a surrounding polar region consisting of phospholipids and apolipoproteins. The 
structure of a lipoprotein particle is shown in Figure 1. Different forms of lipoproteins 
are involved in lipid trafficking; chylomicrons primarily facilitate the transport of 
dietary fats, whilst very low density lipoprotein (VLDL), LDL and HDL particles 
enable the movement of endogenously synthesised lipids (Glass and Witztum 2001).  
TAGs within chylomicrons are taken up by the adipose tissue or skeletal muscle 
following digestion by lipoprotein lipase (LPL). In contrast, shorter chain fatty acids 
can directly enter the blood system without the need for further modifications before 
transport to the liver. Alternatively, fatty acids are oxidised for energy, mainly through 
β-oxidation and the excess energy within the cell is stored as fatty acids or TAGs in 
liver and adipose tissue (Vasudevan 2013).  
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Figure 1. Organisation of a lipoprotein particle 
Lipoproteins are used as vehicles to facilitate transport of hydrophobic lipids. The particles consist 
of a central region containing the phospholipid tails, TAGs and CEs. The surrounding phospholipid 
monolayer contains apolipoproteins that stabilise the structure of the lipoprotein. Taken from Wasan  
et al.(2008). 
In 1856 Virchow observed that lipids were an integral component of atherosclerotic 
plaques and it was later discerned that cholesterol and CEs were in fact the major lipid 
types residing within the lesion in addition to phospholipids and neutral fats (Kellner 
1952). The majority of cholesterol is produced within the liver and a lower proportion is 
absorbed from dietary sources within the intestine. Intestinal cholesterol is transported 
to the liver by chylomicrons, which obtain ApoE during transit in the circulation from 
HDL particles. The chylomicron particles are partially delipidated through the action of 
LPL prior to uptake by liver receptors (Tomkin and Owens 2012). Cholesterol derived 
from the liver is repackaged along with TAGs, phospholipids and apolipoprotein B100 
(ApoB100) into VLDLs before secretion into the circulation. The activity of lipases 
residing in the capillary wall liberates TAGs giving rise to VLDL remnants and further 
enzymatic activity leads to the generation of LDL particles (Tomkin and Owens 2012).  
During atherosclerosis certain plaque-resident cells such as macrophages and smooth 
muscle cells (SMCs) express additional receptors. These scavenger receptors (SRs) are 
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not subjected to the normal lipid homeostatic mechanisms and therefore contribute 
towards the disease state by facilitating excessive accumulation of modified LDL 
particles in the absence of effective internalisation and degradation; leading to the 
formation of lipid-laden foam cells (Kzhyshkowska et al. 2012). The role of 
lipoproteins and SRs during the disease will be discussed in further detail in the sections 
describing the initiation of atherosclerosis. 
Excessive amounts of free cholesterol is toxic to cells so the body utilises two routes for 
the removal of cholesterol; either through enzymatic-driven conversion of cholesterol to 
a more soluble transportable form or through reverse cholesterol transport (RCT) (Glass 
and Witztum 2001; Cuchel and Rader 2006). RCT is the primary pathway and involves 
lipid transporters such as ATP-binding cassette transporter (ABC)-A and -G and 
scavenger receptor-B1 (SR-B1) that mediate the transfer of cholesterol from peripheral 
cells to selected extracellular acceptors such as HDL and the associated apolipoproteins 
A-I, A-II, E, J and A-IV (Vergeer et al. 2010; Kzhyshkowska et al. 2012). The 
cholesterol is then delivered to the liver for conversion to bile salts in preparation for 
excretion (Lusis 2000; Daniels et al. 2009). (Figure 2 gives a summary of cholesterol 
transport). 
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Figure 2. Cholesterol metabolism within macrophages  
Dietary lipids are absorbed in the intestine and transported by chylomicrons to peripheral tissues. 
Following lipolysis by lipases, chylomicron remnants deliver dietary lipids to the liver. Liver-
derived VLDLs containing ApoB and ApoE (E3) mediate the transport of endogenous lipids. 
VLDLs are then hydrolysed to intermediate LDLs and on to LDLs. ApoB facilitates LDL binding to 
LDLRs that are internalised and degraded through a LPL-dependent mechanism, releasing CEs. SRs 
e.g. SR-A and CD36 facilitate excessive uptake of modified LDL particles into macrophages during 
the disease. CPT-1 regulates cellular fatty acid levels and influences the availability of free 
cholesterol. Lipases such as NCEH hydrolyse CEs to free cholesterol that is either trafficked to 
peripheral cells by RCT through ABC transporters and SR-B1, or re-esterified to CEs for storage by 
ACAT-1 within the ER. NPC-1 and -2 mobilise cholesterol from intracellular stores in preparation 
for transport to the liver via RCT. Adapted from McLaren et al. (2011). Abbreviations: ACAT-1, 
Acyl coenzyme A: acylcholesterol transferase-1; CD36: Cluster of Differentiation 36; CPT-1, 
Carnitine palmitoyltransferase 1; ER, Endoplasmic reticulum; FFA, Free fatty acid; NCEH, Neutral 
cholesterol ester hydrolase; NPC, Niemann-Pick type C; SR-A, Scavenger receptor-A. 
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1.3.2. The integral role of lipoproteins within atherosclerosis 
The crucial involvement of lipoproteins within atherosclerosis was discovered through 
studies on subjects with familial hypercholesterolaemia. Heterozygous sufferers are 
relatively common (1 in 500) and carry mutations in the gene encoding for LDLR that 
give rise to half the number of receptors within the liver (Kovacic and Bakran 2012). In 
contrast, homozygotes are less frequent (1 in a million), exhibit six to ten times the 
levels of LDL within their plasma compared to non-sufferers and are prone to MIs at an 
early age. The disease demonstrates a genetic link between heightened LDL levels and 
atherosclerotic development, independent of other risk factors (Goldstein and Brown 
2009). In 1973, Brown and colleagues demonstrated that the activity of 3-hydroxy-3-
methyl glutaryl coenzyme A reductase (HMG-CoA reductase); the rate-limiting enzyme 
in cholesterol synthesis, was inversely related to levels of LDL and a fall in cellular 
levels of cholesterol causes an up-regulation in the expression of LDLRs (Tomkin and 
Owens 2012). However, these feedback mechanisms are dysfunctional in homozygote 
sufferers of familial hypercholesterolaemia due to the deficit in LDLRs and leads to the 
advent of MI (Kovacic and Bakran 2012). 
Several factors control levels of intracellular cholesterol. The ApoB100 component of 
LDL mediates binding to the LDLR and therefore determines the rate of uptake, 
clearance and ultimately catabolism of LDL (Tomkin and Owens 2012). Cellular levels 
of cholesterol influence the expression of LDLR through sterol feedback loops to 
control cholesterol homeostasis (Daniels et al. 2009). Furthermore, cholesterol is 
enzymatically modified through a number of processes such as hydroxylation and fatty 
acylation within the endoplasmic reticulum (ER) to produce oxysterols and sterol esters 
(SEs) respectively. Esterification of cholesterol reduces the solubility of the molecule 
and promotes storage within cytoplasmic lipid droplets. During normal physiology, 
cholesterol is subjected to cycles of esterification and ester hydrolysis to carefully 
regulate cholesterol levels within the cell (Ikonen 2006). Platelets, endothelial cells and 
inflammatory cells also secrete mediators that control the influx and egress of 
cholesterol (Hajjar and Pomerantz 1992). 
 
HDL particles are mainly made up of polar lipids (PLs) and apolipoproteins principally 
in the form of ApoA1, whereas CEs and TAGs are only minor components (Hamilton et 
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al. 1976). Nascent forms of HDL gain phospholipids and cholesterol during cellular 
efflux and through LPL-mediated lipolysis of chylomicrons and VLDLs (Lewis and 
Rader 2005). The involvement of these particles within atherosclerosis has received a 
great level of attention. Sufferers of Tangier disease contain mutations within the gene 
that encodes for ABCA-1 and display drastically low levels of HDL further to localised 
accumulation of CEs within different tissues of the body (Schaefer et al. 1978; Asztalos 
et al. 2001). People with the disease are also prone to developing premature 
atherosclerosis (Rust et al. 1999). The relationship between reduced HDL levels and 
incidences of CAD have long been established as one of the major risk factors for the 
disease (Gordon et al. 1977) and the concentration of HDL is negatively affected by 
many other atherosclerotic risk factors such as gender, smoking, obesity and lack of 
exercise (Vergeer et al. 2010).  
 
Promisingly, elevated levels of HDL are associated with reduced severity of the disease 
(Gordon et al. 1989). Transgenic mice expressing human ApoA-1 display raised levels 
of plasma HDL and are significantly protected from atherosclerotic development 
following feeding on a lipid-rich diet (Rubin et al. 1991). The anti-atherosclerotic 
effects are thought to mostly arise from the involvement of HDLs within RCT (Lewis 
and Rader 2005). However, the particle has additional protective properties and contains 
an esterase that can inhibit lipoprotein oxidation (Roheim 1986; Lusis 2000). In vitro 
experiments have shown that HDL particles reduce the expression of endothelial cell 
adhesion molecules and also inhibit the secretion of pro-inflammatory mediators such as 
tumour necrosis factor-α (TNF-α) (Cockerill et al. 1995). Furthermore, incubation of 
HDL with cocultures of human aortic wall cells reverses the pro-atherogenic effects of 
LDL including the up-regulation of monocyte chemotactic protein-1 (MCP-1) by 
endothelial cells and SMCs and accordingly attenuates monocyte adhesion (Navab et al. 
1991). The administration of HDL particles into rabbits fed on a high-cholesterol diet 
inhibits lesion progression and also stimulates the regression of aortic fatty streaks 
(Badimon et al. 1990).  
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1.3.3. The effects of dietary fatty acids in coronary artery disease (CAD) 
Early monumental studies such as the Seven Countries Study (Keys et al. 1965; Keys et 
al. 1986) and the Japanese NI HO SAN migration study (Kagan et al. 1974) described a 
relationship between diets containing high proportions of SFAs and raised plasma 
cholesterol in patients with cardiac disorders. It was observed that geographical 
discrepancies in coronary mortality existed which were related to the percentage of 
dietary SFAs as a proportion of caloric intake. Short chain fatty acids such as those 
containing 8-10 carbon atoms appear to have a neutral effect on cholesterol, whereas 
longer chain SFAs with 12, 14 and 16 carbon atoms have a hypercholesterolaemic 
impact in humans (Rhee et al. 1997).  
The effects of monounsaturated fatty acids (MUFAs) on atherosclerosis are often 
described as neutral; however, the geometric isomerisation of the double bond can 
influence the atherosclerotic potential of these fatty acids. Cardiac arrest patients 
contained higher levels of trans-fatty acids, particularly trans-LA, within erythrocyte 
membranes that served as a strong indicator of cardiac events (Lemaitre et al. 2002). In 
another study, subjects were given a rotation of six diets enriched with different fatty 
acids. Diets low in trans-fats and SFAs produced the most beneficial ratio of total and 
LDL cholesterol to total and HDL cholesterol. On the other hand, diets high in trans-
fats and SFAs had an adverse effect on these ratios. Trans-fat rich diets produced the 
most prominent reduction in levels of HDL and were also associated with increased 
levels of the atherosclerotic marker lipoprotein a (Lichtenstein et al. 1999).  
Studies comparing the diets of populations known to have reduced numbers of 
mortalities from CAD highlighted the potential athero-protective effects of n-3 PUFA-
enriched diets. Dyerberg et al. (1987) observed that incidences of MIs within 
Greenland’s Eskimo community were low and blood samples taken from these subjects 
were high in levels of the n-3 PUFA eicosapentaenoic acid (EPA), whilst levels of the 
n-6 PUFA arachidonic acid (AA) were considerably reduced compared to subjects fed a 
westernised diet. Interestingly, it was also noted that there was a greater tendency to 
bleed within this population. The study demonstrated that vessel-wall cyclo-oxygenases 
(COXs) utilise EPA for the synthesis of anti-aggregating agents and EPA itself exerts 
anti-thrombotic properties (Dyerberg et al. 1978). The beneficial effects of increased 
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dietary intake of fish have been attributed to n-3 PUFAs and their influence on n-6 
PUFAs. Mice fed a fish oil based diet or a low-fat diet exhibited changes in the fatty 
acid composition of peritoneal macrophages reflective of their dietary intake. The levels 
of the n-6 PUFAs LA and AA were significantly less in mice fed on the fish oil diet 
compared to the low-fat diet whereas the n-3 PUFAs EPA, docosapentaenoic acid (DPA) 
and docosahexaenoic acid (DHA) were raised in comparison (Miles et al. 2000). 
Several studies have also explored the effect of n-3 PUFA supplementation on survival 
rates following a previous cardiac arrest. In the diet and reinfarction trial, patients who 
had previously suffered a MI were put on either a beneficial fat, fibre or fish diet. The 
study showed that consumption of 2-3 portions of fish a week, in comparison to the 
other prescribed diets, significantly reduced cases of myocardial reinfarction by 29% 
(Burr et al. 1989).  
Where n-3 PUFAs are thought to have a protective impact within CAD, the role of n-6 
PUFAs within the disease state is less certain. Many advisory boards recommend 
replacing SFAs with PUFAs and analysis of pooled cohort studies indicate that such a 
change would be beneficial in the prevention of CHD (Jakobsen et al. 2009; Russo 
2009). However, due to the inflammatory nature of atherosclerosis, there are concerns 
over the potential adverse effects from n-6 PUFAs arising from the production of AA-
derived pro-inflammatory metabolites (Harris et al. 2009). AA-derived eicosanoids 
exhibit a range of actions that likely contribute towards atherogenesis (Lewis et al. 1980; 
Samuelsson 1983). However, AA can also be converted into lipoxins which have anti-
inflammatory effects (Kohli and Levy 2009). Also, several n-6 PUFAs have been 
shown to have little impact on inflammatory markers (Riemersma et al. 1986; Rallidis 
et al. 2003) and a number of studies have suggested that the actions of n-6 PUFAs on 
atherosclerotic markers are nullified in the presence of n-3 PUFAs (Pischon et al. 2003; 
Kusumoto et al. 2007). 
1.3.4. Fatty acid metabolism and atherosclerotic processes 
De novo lipogenesis is incapable of producing fatty acid chains exceeding 18 carbons 
(Cook and McMaster 2002). However, through a process of elongation and desaturation, 
eukaryotes have evolved a system to accommodate the fatty acid requirements of cells. 
Using pre-existing fatty acids the body can elongate the acyl chain by 2 carbons in 
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length. Elongation primarily occurs within the ER, with a smaller portion occurring 
within the mitochondrion and to some extent within peroxisomes (Cook and McMaster 
2002). Figure 3 provides a pictorial overview of fatty acid biosynthesis. 
 
 
 
Figure 3. Fatty acid biosynthesis 
The microsomal system lengthens saturated or unsaturated fatty acyl-CoA through sequential 
addition of 2-carbon groups from malonyl-CoA up to a length of 22-24 carbons. Elongation requires 
the malonyl-CoA donor and NADPH and is influenced by dietary fatty acid intake. The products 
from de novo synthesis are primarily 16 carbon fatty acids like palmitic acid, whilst small amounts 
of the 18 carbon stearic acid are also generated in addition to shorter chain fatty acids. Adapted from 
Schulze and Harris (2012) and Yecies and Manning (2010). 
 
 
The range of fatty acids obtained by de novo synthesis and through the diet is not 
always sufficient to match demand and therefore extensive metabolism and 
rearrangement of existing fatty acids may be necessary. Pre-formed long chain fatty 
acids are utilised as substrates for the generation of MUFAs and PUFAs by desaturases. 
Desaturases can be structurally identified by the existence of a N-terminal cytochrome 
b5-like domain fused to a desaturation domain (Meesapyodsuk and Qiu 2012). Within 
humans three types of desaturases exist: Stearoyl-CoA desaturase (SCD) (a Δ9-
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desaturase), Δ6-desaturases and Δ5-desaturases. Human desaturases are special oxidase 
enzymes capable of introducing double bonds between pre-existing double bonds and 
the carboxyl end of fatty acids and therefore belong to a group of ‘front-end’ 
desaturases. Other organisms are capable of introducing double bonds between a 
previous double bond and the methyl end through the actions of ‘methyl-end’ 
desaturases (Meesapyodsuk and Qiu 2012).  
1.3.5. Desaturases and CAD 
Due to the pivotal role of desaturases in regulating MUFA and PUFA formation, several 
studies have investigated the involvement of these enzymes within cardiovascular 
disease. Many studies have shown that enhanced Δ6-desaturase activity and reduced 
Δ5-desaturase activity are associated with increased CAD risk (Warensjoe et al. 2008; 
Lu et al. 2012). Within humans, the genes FADS1 and FADS2 encode for Δ5-desaturase 
and Δ6-desaturase respectively (Marquardt et al. 2000). In a population study of CAD 
and non-CAD sufferers, subjects containing single nucleotide polymorphisms in the 
FADS cluster of genes exhibited elevated Δ6-desaturase activity linked to high 
concentrations of C-reactive protein (CRP) and an increased risk of CAD. As such it 
was proposed that polymorphisms in the FADS cluster may promote a pro-inflammatory 
environment supporting atherogenesis (Martinelli et al. 2008). Conversely, 
polymorphisms in the promoter region of FADS2 that impair Δ6-desaturase reduce the 
peroxidation susceptibility of lipoproteins (Solakivi et al. 2013). Furthermore, patients 
with MI exhibit raised ratios of DGLA/AA; indicating that dysfunctional Δ5-desaturase 
activity occurs during the disease (Leng et al. 1999). An epidemiological study by 
Warensjoe et al. (2008) demonstrated that increased Δ6-desaturase and reduced Δ5-
desaturase activity were related to total and cardiac-related mortality. However, the 
strongest predictor of mortality was based on the SCD-1 index (Warensjoe et al. 2008). 
Much of the work within this field has focused on SCD-1 and as such the remaining 
content of this section will be on SCD-1.  
SCD-1 gene expression is carefully regulated by cellular levels of PUFAs, cholesterol, 
vitamin A, insulin, temperature, alcohol, phenol, metals and peroxisomal proliferators 
(Ntambi 1999). The enzyme is essential for normal lipid biosynthesis as mice lacking 
SCD-1 display impaired production of TAGs and CEs. However, supplementation with 
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MUFAs does not reverse these effects demonstrating that SCD-1 controls the de novo 
lipogenesis of MUFAs that is integral for TAG formation (Miyazaki et al. 2000). In the 
presence of saturated fats, mice deficient in SCD-1 favour β-oxidation over lipogenesis 
mediated through a reduction in the expression of lipogenic genes like sterol regulatory 
element binding protein-1c (SREBP-1c) and the up-regulation of genes involved in β-
oxidation such as CPT-1 (Sampath et al. 2007). Furthermore, subjects with 
polymorphisms in the gene for SCD-1 tend to have a lower body mass index, reduced 
waist circumference and improved insulin sensitivity (Warensjo et al. 2007). As such 
SCD-1 functions as a protector against saturated fat-induced obesity  
Although SCD-1 has been shown to prevent diet-induced obesity and significantly 
reduce fasting insulin levels, both risk factors for CAD, many studies have indicated 
that ablation of SCD-1 promotes atherosclerosis. LDLR
-/-
ApoB
100/100
 mice treated with 
SCD-1 antisense oligonucleotides have an enlarged total aortic lesion area and 
significantly raised free and esterified cholesterol (Brown et al. 2008). In another study, 
LDLR
-/-
 mice deficient in SCD-1 exhibit increased atherosclerosis characterised by 
greater lesion size, macrophage infiltration and increased levels of soluble ICAM-1 
(sICAM-1) and IL-6. Also, HDL particles from these mice had a composition 
resembling those present during inflammation e.g. reduced apoAII and plasma A-I 
content (MacDonald et al. 2009). On the other hand, other groups have shown that 
overexpression of SCD-1 in HEK 293 cells (Sun et al. 2003) and RAW264.7 
macrophages (Nakaya et al. 2013) promotes RCT to HDL particles independently of 
ABCA-1, ABCG-1 and SR-B1 (Sun et al. 2003; Nakaya et al. 2013).  
The role SCD-1 in atherosclerosis is unclear as both protective and pathogenic actions 
have been described for the enzyme. Overexpression of SCD-1 promotes fat 
accumulation and insulin resistance but also increases the efflux of cholesterol 
(Pinnamaneni et al. 2006). Conversely, inhibition of SCD-1 causes catabolism of fat 
stores accompanied with inflammation and cellular stress (Thorn et al. 2010; Liu et al. 
2011). Conflictingly, an absence of SCD-1 produces a beneficial lipid profile but also 
promotes the development of atherosclerosis that occurs independently of many of the 
well-established risk factors such as obesity and insulin resistance (Warensjoe et al. 
2008; Djousse et al. 2012). The disparity in these findings suggests that there is a fine 
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balance between beneficial metabolic effects and possible inflammatory consequences 
arising from SCD-1 activity. 
1.4. The development and progression of atherosclerosis 
1.4.1. Initiation of atherosclerosis 
The exact events that initiate atherogenesis are not fully understood. A number of 
theories have focused on different disease drives including intimal lipid accumulation, 
changes in haemodynamic forces and a response to injury of the endothelium (Tegos et 
al. 2001). Immune cells, cellular signalling and cytokines are pivotal to the pathogenesis 
of atherosclerosis and will be covered in greater detail in subsequent sections.  
 
Atherosclerotic lesions tends to develop within areas of curvature, such as branching 
points, that are prone to disturbed laminar flow within the large and medium-sized 
arteries (Moore and Tabas 2011). The arterial endothelium is a highly responsive 
system, functioning as a barrier to invading pathogens and maintenance of vascular wall 
tone. Whilst typically impermeable to large biomolecules such as LDL, physiological 
and pathophysiological changes can activate endothelial cells leading to an increase in 
the permeability of the endothelial cell layer. As a result the expression of adhesion 
molecules rises in addition to the production of extracellular matrix (ECM) proteins and 
the secretion of chemokines and growth factors (GFs) such as macrophage colony-
stimulating factor  (M-CSF) (McLaren and Ramji 2009).  
Within the plasma, circulating lipoproteins are protected from major chemically-
induced alterations but during atherosclerosis LDL particles containing ApoB diffuse 
between endothelial cell junctions and accumulate within the subendothelial space 
(Hansson and Hermansson 2011; Moore and Tabas 2011). The LDL particles associate 
with ECM components through interactions with ApoB and LPL, becoming trapped and 
susceptible to a range of enzymatic and non-enzymatic chemical modifications 
mediated through the activities of myeloperoxidases, lipoxygenases (LOX), reactive 
oxygen species (ROS), peroxynitrite and nitric oxide (Glass and Witztum 2001). 
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Modified LDL particles are immunogenic as the peroxidation of phospholipids, CEs 
and TAGs within the core creates reactive species capable of stimulating inflammatory 
processes that promote the activation of endothelial cells, platelets and macrophages 
(Matsuura et al. 2008; Frostegard 2013; Wraith et al. 2013). The presence of OxLDLs 
in the intima also aggravates surrounding cells and induces SMC mitogenesis (Paoletti 
et al. 2004). Prolonged oxidation of LDL alters several properties of the particle such as 
size and charge, dependent on the oxidising agent (Hansson and Hermansson 2011). 
The presence of small, dense LDL particles is associated with increased risk of CHD 
(Lamarche et al. 1997) and minimally modified LDL (mmLDL), which are not 
recognised by SRs, are major initiators of the immune response (Miller et al. 2003). 
Leukocytes including monocytes, neutrophils, T cells, B cells, dendritic cells and mast 
cells are recruited along a chemotactant gradient towards the lesion site. Activated 
endothelial cells and SMCs secrete chemokines, a family of structurally similar 
chemotactic cytokines that includes macrophage inflammatory protein (MIP)-1α/β and 
MCP-1 (Zernecke and Weber 2010). The number of monocytes adhering to the aortic 
intima rises approximately fifty times in response to a cholesterol-rich diet in rats (Joris 
et al. 1983) and the attachment of primary human monocytes has been shown to 
increase proportionally with levels of circulating LDL in a dose-dependent manner 
(Alderson et al. 1986). 
The leukocyte adhesion cascade is comprised of three main stages; rolling, activation 
and arrest (Moore et al. 2013). Circulating monocytes roll along the endothelium co-
ordinated by weak interactions between P-selectin glycoprotein ligand-1 found on the 
monocyte surface to P-selectin and E-selectin expressed by the endothelium (Ley et al. 
2007). The leukocytes are immobilised through associations between leukocyte 
integrins like β2 integrin, lymphocyte function associated molecule and very late 
antigen-4 to adhesion proteins such as vascular cell adhesion protein-1 (VCAM-1) and 
ICAM-1 on endothelial cells (Lawson and Wolf 2009; Michael et al. 2012a). 
Chemoattractant receptors on the leukocytes aid migration and also stimulate integrin-
mediated adhesiveness by inducing conformational changes in the integrins present at 
their cell surface (Springer 1994; Chan et al. 2001). 
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The leukocytes quickly migrate through the endothelial cell barrier in a process that 
typically takes between two to five minutes. Entry through the endothelial cell basement 
membrane lasts longer and can take over five to fifteen minutes (Ley et al. 2007). 
Following transdiapedesis into the intima, monocytes differentiate into macrophages 
under the influence of M-CSF or granulocyte-macrophage CSF (GM-CSF) (Gui et al. 
2012). Key processes involving macrophages within atherosclerosis are summarised in 
Figure 4. 
 
 
 
Figure 4. Overview of the role of macrophages within the disease state 
Adhesion molecules are up-regulated in response to endothelial cell activation facilitating the 
adhesion of circulating monocytes. Following diapedesis, the monocytes differentiate into 
macrophages. The presence of immune cells within the plaque also up-regulates the expression of 
genes involved in the oxidation of LDL and its subsequent uptake, such as SRs, promoting 
transformation of macrophages into macrophage foam cells. Unregulated accumulation of lipids into 
the plaque produces a distinct fatty streak that progresses into an atherosclerotic lesion. Macrophage 
foam cells secrete pro-inflammatory mediators promoting the inflammatory state and contributing to 
destabilisation and eventual rupture of the plaque. 
 
Macrophages are professional bone marrow-derived phagocytes, present in almost all 
tissues within the body (Lucas and Greaves 2001; Swirski et al. 2006). During normal 
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physiology, macrophages utilise a variety of pattern-recognition receptors, including 
SRs and members from the Toll-like receptor (TLR) family, to elicit rapid responses 
against foreign particles without the need for prior priming (Libby et al. 2009). 
Observations that patients with familial hypercholesterolaemia develop atherosclerosis 
in the absence of functional LDLRs indicate that additional cellular mechanisms exist 
that facilitate LDL uptake. In 1979, Goldstein and Brown demonstrated that chemically 
synthesised acetylated LDL (AcLDL) was readily taken up by macrophages and 
contributed towards foam cell formation (Goldstein et al. 1979). The participating 
receptor has since been identified and exists as two isoforms; scavenger receptor-A1 
(SR-A1) and -A2. Other members of the SR family, including cluster of differentiation 
36 (CD36) and SR-B1, have a role in the innate immune system but also participate in 
pathogenesis through the recognition of modified lipoproteins (Libby et al. 2009). The 
oxidation of PUFAs leads to the formation of aldehydes that modify lysine residues in 
apoB100 and gives the particle a net negative charge. The modified LDL can then bind 
with high affinity to SRs (Stocker and Keaney 2004).  
 
Within early atherosclerotic lesions, macrophages are the prevalent cell type and during 
the disease the cells accumulate LDL, VLDL and modified LDL through several 
processes including macropinocytosis, phagocytosis and SR-mediated uptake thereby 
facilitating the transformation of these cells into macrophage foam cells (Moore et al. 
2013). Non-oxidised LDL is also likely taken up by macrophages where it may be 
subjected to oxidation and subsequent aggregation within lysosomes (Wen and Leake 
2007; Satchell and Leake 2012). In vitro experiments have shown that accumulated 
LDL is oxidised by redox-active iron at lysosomal pH (pH 4.5). The oxidation event 
promotes rapid aggregation of the particles which could potentially hinder degradation 
by lysosomal enzymes during the atherosclerotic state (Satchell and Leake 2012). SMCs 
within the plaque are also capable of foam cell transformation mediated through the 
uptake of modified LDLs by SRs expressed at the cell surface (Yan et al. 2011; 
Allahverdian et al. 2012). Small, asymptomatic lesions are comprised of macrophage 
and SMC foam cells and T cells and are referred to as fatty streaks due to the 
concentration of foam cells (Ross 1999). The fatty streak may regress or progress into a 
clinically relevant plaque (George and Johnson 2010).  
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1.4.2. Disease progression 
The formation of an intermediate lesion arises due to enhanced migration and 
proliferation of vascular SMCs from the tunica media into the inflamed area in response 
to platelet-derived GFs released from plaque-resident cells (George and Johnson 2010; 
Michael et al. 2012a). The SMCs proliferate and release ECM proteins contributing 
towards the production of a fibrotic cap (Packard and Libby 2008). Stable plaques are 
associated with the presence of a fibrous cap, containing a matrix enriched with type I 
and III collagen, and the absence of a necrotic core (Lucas and Greaves 2001).  
Histologic sections of human atherosclerotic lesions demonstrate that the area of the 
lumen is maintained despite the presence of a large developing plaque (Glagov et al. 
1987). The artery is capable of remodelling itself via gradual dilation (Ross 1999) and 
angiographs taken at constant intervals highlight that progression of the disease is 
phasic and does not follow a strict linear timescale (Mann and Davies 1999). However, 
once the lesion occupies approximately 40% of the internal elastic lamina region, the 
artery is incapable of maintaining its integrity through dilation and protrudes into the 
lumen affecting blood flow (Glagov et al. 1987; Ross 1999). The growing plaque may 
result in narrowing of the artery (stenosis) and/or the restriction of blood flow to 
surrounding tissues (ischaemia) (Hansson and Hermansson 2011).  
During earlier stages of the disease effective engulfment of apoptosing cells by 
neighbouring phagocytes (efferocytosis) helps to resolve pro-inflammatory processes 
and maintain stability within the plaque (Li et al. 2006; Tabas 2010; Van Vre et al. 
2012). Dying cells produce ‘find me’ signals comprised of unique combinations of 
surface molecules such as PS which recruit phagocytosing cells to the site (Fadok et al. 
1992). Phagocytes bind to the apoptosing cell, eliciting an anti-inflammatory response 
and engulf the dying cell. However dysfunctional efferocytosis is a key feature of 
advanced lesions and as the disease progresses the rate of apoptosis within the necrotic 
core likely overwhelms the phagocytic capabilities of residing phagocytes. Furthermore, 
dying macrophages are thought to function as poor substrates for neighbouring 
phagocytes and therefore contribute towards necrotic core formation (Tabas 2010). 
Interestingly, in vitro experiments have demonstrated that modified LDL serves as a 
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substrate for phagocytes so may competitively hinder the efferocytosis of dying cells 
(Bird et al. 1999). 
Ineffective efferocytosis also stimulates secondary necrosis of lesion-resident cells and, 
in the case of macrophages, leads to the release of oxidised lipids and pro-inflammatory 
propagators (Liu et al. 2005). Intracellular free cholesterol released from dying foam 
cells builds up within the lesion triggering further apoptosis (Ball et al. 1995; Liu et al. 
2005). The underlying mechanisms for this response are unclear and may involve the 
unfolded protein response within the ER and initiation of apoptotic pathways or could 
arise from the incorporation and accumulation of cholesterol within the plasma 
membrane (Kellner-Weibel et al. 1999; Feng et al. 2003). Plaque development is 
thought to occur in ‘bursts’ consisting of periods of rupturing and repair. However as 
the disease continues, the plaque becomes increasingly unstable and vulnerable as a 
result of reduced efferocytosis, chronic inflammation and ineffective egress of immune 
cells (Li et al. 2006). When residing within the plaque, the migration of macrophages is 
limited and therefore compromises potential resolution of inflammation favouring 
pathogenic processes (Moore et al. 2013). Lesion-resident macrophages contribute 
towards the inflammatory state through the secretion of protease enzymes and pro-
inflammatory cytokines (Libby et al. 2009). 
1.4.3. Advanced plaque formation and rupture 
Towards the later stages of the disease, the atherosclerotic lesion is characterised by an 
abundance of disorganised cells, lipids, matrix components and minerals. Clinical 
symptoms may occur during this phase of the disease as the intimal region is thickened 
and the area of the arterial lumen may be reduced in size (Stary et al. 1995). Unstable 
plaques are associated with a high proportion of macrophages to SMCs and a lipid-rich 
necrotic core (Vanderwal et al. 1994). The activation of lesion-resident mast cells 
augments SMC apoptosis by the induction of caspases and through the attenuation of 
signalling pathways that promote cell survival (Leskinen et al. 2006). The necrotic core 
is often described as a ‘graveyard of dead macrophages’ (Li et al. 2006). The dying 
foam cells release their cytoplasmic contents causing a build-up of extracellular lipids 
and GFs that exacerbates inflammation and triggers secondary necrosis (Ross 1999). 
Excessive levels of cholesterol can also promote the formation of solid crystals that are 
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toxic to cells (Brown and Goldstein 1997). The growing necrotic core exerts physical 
pressure on the fibrous cap and compromises its integrity (Thorp and Tabas 2009). 
Shah et al. (1995) performed studies with primary monocyte-derived macrophages 
incubated with ex vivo fibrous caps that indicated that macrophages induce the 
expression of matrix metalloproteinases (MMPs); several of which promote the 
degradation of collagen such as MMP-9 (Lubos et al. 2006). However, in the presence 
of MMP inhibitors the breakdown of collagen does not occur highlighting the key role 
of these enzymes during late events within the disease (Shah et al. 1995). The MMP 
family encompasses a range of proteolytic enzymes including collagenases, gelatinases, 
matrilysins and membrane-type MMPs (Raffetto and Khalil 2008). In the healthy state, 
MMPs are carefully regulated through the production of precursor zymogens, the 
activities of endogenous tissue inhibitors of metalloproteinases (TIMPs) and 
associations with the ECM. However, an imbalance in the ratio of MMPs to TIMPs is 
thought to support excessive ECM breakdown (Raffetto and Khalil 2008). MMPs are 
overexpressed within unstable lesions and localise to vulnerable regions within the 
plaque that are prone to rupture and inhabited by macrophage foam cells (Galis et al. 
1994). The degradation of  the connective tissue is detrimental to plaque stability and 
the resulting products are deposited within the arterial intima where they promote 
vasculitis (Chinetti-Gbaguidi and Staels 2009).  
Locally produced cytokines, such as interferon-γ (IFN-γ) secreted by T cells, reduce the 
proliferation of SMCs and also inhibit the synthesis of integral ECM components like 
collagen types I and III (Amento et al. 1991). The fibrous cap undergoes thinning prior 
to rupture which undermines the stability of the structure (Libby et al. 1998). At this 
stage of the disease, the plaque contains depleted levels of fibrous material and may 
show signs of calcification, ulceration and haemorrhaging from small vessels (Lusis 
2000; Packard and Libby 2008).  
A number of factors contribute towards the disruption of the cap including the presence 
of inflammatory cells, building toxicity, the activities of proteolytic enzymes released 
from macrophages, coronary spasms and physical vulnerabilities and stresses arising 
from the altered composition of the lesion (Stary et al. 1995). The exposure of tissue 
factor from the plaque with the arterial lumen promotes coagulation and the formation 
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of a thrombus (Paoletti et al. 2004; McLaren and Ramji 2009). The thrombus may 
instantly obstruct the lumen or may detach in the form of an embolus and block blood 
flow at an independent site (Hansson and Hermansson 2011). Immunohistochemical 
staining has shown that some plaques have residual deposits associated with fibrin 
degradation representing the occurrence of multiple thrombi responsible for narrowing 
of the lumen (Stary et al. 1995). On the other hand, several case studies have also 
shown that occlusion of the arteries can arise as a result from haemorrhaging of small 
vessels within the plaque (Wartman 1938). Figure 5 provides an overview of key events 
within atherosclerosis. 
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Figure 5. Atherosclerotic 
development 
Successive rounds of immune cell 
infiltration, proliferation and 
fibrous material production causes 
restructuring of the plaque and 
formation of a fibrotic cap 
surrounding the necrotic core. 
Plaque rupture is an attribute of cap 
disruption due to VSMC apoptosis 
and depleted ECM, in addition to 
the death of lesion-resident cells 
and protease activity. T cells and 
macrophages produce angiogenic 
factors that cause leakage of 
erythrocytes into the plaque leading 
to inflammation and blood vessel 
formation. Ultimately the fibrous 
cap is sufficiently destabilised 
leading to rupture of the plaque 
into the artery lumen and 
subsequent thrombosis. 
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1.5. Cellular signalling  
During atherosclerosis the dysregulation of key signalling pathways leads to altered 
gene expression that facilitates atherogenic processes. Signal transduction pathways 
mediate the transfer of information within the cell and mostly utilise membrane-bound 
receptors that respond to external stimuli such as hormones and neurotransmitters. The 
information is then communicated across the membrane through the use of different 
transducers and amplifiers that activate intracellular signalling pathways. Alternatively, 
intracellular signals such as metabolic messengers can also initiate signalling (Berridge 
2012). Several signalling pathways have been implicated within the atherosclerotic state. 
Extracellular signal-regulated kinase (ERK) mitogen-activated protein kinases (MAPKs) 
are involved in many essential processes including cell growth and differentiation, 
synaptic plasticity and the activation of other kinases like p90 ribosomal S6 kinases 
involved in the cell cycle (Ravandi et al. 2003). Mutations in the genes encoding for 
ERK1/2 result in developmental abnormalities highlighting the key role of these kinases 
in basic functionality (Rodriguez-Viciana et al. 2006).  
The exact roles of ERK1 and ERK2 in atherosclerosis are still not properly understood 
but studies have shown that pathways involving ERK regulate the proliferation and 
differentiation of SMCs in the lesion (Muslin 2008). OxLDL promotes the proliferation 
of cultured aortic SMCs in a signalling mechanism involving ERK1/2 (Auge et al. 
1998). A study by Zhou et al. (2010) demonstrated that inhibition of ERK1/2 activity 
led to increased efflux of cholesterol to ApoAI and HDL acceptors in macrophage-
derived foam cells associated with enhanced expression of ABCA-1 (Zhou et al. 2010). 
Furthermore, ERK1/2 are integral to IFN-γ-mediated activation of signal transducer and 
activator of transcription (STAT)-1; a key regulator of many genes implicated in 
atherosclerosis such as ICAM-1 and MCP-1 and the uptake of modified LDL by 
macrophages (Li et al. 2010). In addition to the pro-atherogenic actions described, 
ERK1/2 are also involved in protective effects. A disintegrin and metalloproteinase with 
thrombospondin motifs (ADAMTS) are structurally related to MMPs and involved in 
remodelling of the ECM within the plaque (Ashlin et al. 2013). The anti-atherogenic 
cytokine interleukin-33 (IL-33) down-regulates the expression of ADAMTS-1 and -4 in 
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human macrophages through a signalling mechanism dependent on ERK1/2 (Ashlin et 
al. 2014). 
Another MAPK, p38, is also integral to atherosclerotic development as the kinase is 
activated in response to elevated intracellular cholesterol and MCP-1, whilst chemical 
inhibition of p38 reduces cholesterol accumulation by macrophages (Werle et al. 2002; 
Mei et al. 2012). In response to the accumulation of free cholesterol within the ER, p38 
co-ordinates signalling events that induce cellular apoptosis (DeVries-Seimon et al. 
2005). However, ApoE
-/-
 mice deficient in p38α display increased levels of apoptosing 
macrophages and enhanced necrosis within the plaque. Lesions from these mice are also 
characterised by a reduced content of collagen and a thin fibrous cap. The MAPK is 
thought to inhibit ER-stress-induced apoptosis; as the amount of apoptosis arising in 
response to ER stressors is enhanced following knock down of p38 in primary mouse 
macrophages (Seimon et al. 2009). These studies demonstrate that p38 can exert pro- or 
anti-apoptotic effects dependent on the cellular conditions. However it seems likely that 
during atherosclerosis the MAPK is involved in protective signalling pathways against 
ER-stress responses and apoptosis in advanced plaques. The activation of G-protein-
coupled receptors, receptor tyrosine kinases (RTKs) and factors related to stress such as 
ischaemia also initiate the p38 MAPK signalling cascade (Liang and Molkentin 2003). 
Interestingly a study by Kardakaris et al. (2011) indicated that ablation of p38α in 
macrophages and endothelial cells did not affect atherosclerotic plaque formation in 
ApoE
-/- 
mice following feeding on a high cholesterol diet. Although p38α deficiency 
disrupted the recruitment of monocytes in response to modified LDL in in vitro cultures 
of endothelial cells (Kardakaris et al. 2011). 
c-Jun N terminal kinases (JNKs) also belong to the MAPK superfamily. These proteins 
regulate the maturation and activity of T cells and the synthesis of pro-inflammatory 
cytokines such as IL-2, IL-6 and TNF-α (Rincon et al. 2000). Within ApoE-/- mice, JNK 
is activated in response to a high cholesterol diet. Interestingly, JNK2
-/-
 mice crossed 
with ApoE
-/-
 mice contain smaller plaques, whereas ablation of JNK1 has little effect on 
the size of the lesions in ApoE
-/-
 mice. These differences highlight the differential roles 
of JNK isoforms within the atherosclerotic disease state. The lack of JNK2 within these 
mice is also associated with a halved number of macrophage foam cells despite 
enhanced uptake of fluorescently labelled AcLDL in peritoneal macrophages from 
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ApoE
-/-
/JNK2
-/-
 mice. Additionally, although levels of SR-A were raised, the efflux of 
cholesterol to apoA1 acceptors was enhanced and levels of phosphorylated, activated 
SR-A were reduced indicating that the knock down of JNK2 in macrophages 
compromises the production of foam cells through defective uptake and degradation of 
modified lipoproteins by SR-A (Ricci et al. 2004). The signalling component has also 
been implicated in later events within the disease. Within cultured primary rat aortic 
SMCs JNK is activated in response to oxidative stresses and induces the expression of 
matrix degrading MMPs whilst down-regulating the expression of genes involved in 
ECM biosynthesis such as lysyl hydroxylase (Yoshimura et al. 2005). The results 
indicate that the signalling component exerts destabilising effects on the architecture of 
aortic tissue which could compromise the integrity of the atherosclerotic plaque 
(Yoshimura et al. 2005). The MAPK likely plays a complex role in atherogenesis as 
transient activation of JNK promotes cell survival whereas a more sustained activation 
is linked to apoptosis (Chang et al. 2006).  
The role of the nuclear factor-κB (NF-κB) signalling cascade in atherosclerosis is also 
well-established. The pathway regulates a number of genes implicated in atherosclerosis 
including TNF-α, IL-6, MCP-1 and ICAM-1 (Baker et al. 2011). Furthermore, the 
pathway is activated by several factors associated with the disease such as minimally 
OxLDL (Liao et al. 1994) and haemodynamic forces (Hajra et al. 2000). High levels of 
activated NF-κB subunits are found within the nuclei of intima-resident SMCs, 
macrophages and endothelial cells within human atheromas (Brand et al. 1996; 
Bourcier et al. 1997). Furthermore, inhibition of NF-κB, arising from the deletion of 
NF-κB essential modifier (NEMO) or inhibitor of NF-κB (IκBα), reduces the size of 
atherosclerotic plaques in ApoE
-/-
 mice and is accompanied with impaired macrophage 
recruitment and reduced adhesion molecule expression (Gareus et al. 2008). 
Experiments utilising the transfer of bone marrow from p50-deficient mice to LDLR
-/-
 
mice have shown that the decrease in plaque size obtained by the ablation of NF-κB is 
associated with a fall in the number of lesional macrophage foam cells and expression 
of SR-A (Kanters et al. 2004). The resulting lesion displays an inflammatory phenotype 
characterised by increased numbers of macrophages and T cells (Kanters et al. 2004). 
Interestingly, overexpression of the NF-κB subunit p65 also inhibits atherosclerotic 
development in ApoE
-/-
 mice associated with a drop in foam cell numbers and SR-A 
expression (Ye et al. 2013). 
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The phosphoinositide-3-kinase (PI3K) signalling cascade is responsible for the 
regulation of many cellular functions including glycogen and lipid metabolism, cell 
growth, calcium signalling, inflammation and apoptosis (Berridge 2012). Due to the 
diverse role of these proteins, the pathway has been implicated in many atherosclerotic 
processes. Ablation of the PI3K catalytic subunit, p110γ, decreases atherosclerotic 
development in genetically prone mice. The resulting lesions are characterised by a 
reduced number of proliferating plaque-resident macrophages (Chang et al. 2007; Zotes 
et al. 2013). Furthermore, atherosclerotic lesions within humans and mice display raised 
levels of the PI3K isoform; PI3K-γ, and transplantation of bone marrow from PI3K-γ-/- 
mice into irradiated LDLR
-/-
 mice demonstrates that the expression of PI3K-γ by 
immune cells is integral for atherosclerotic development (Fougerat et al. 2008). PI3K-γ 
is also a key regulator of reparative neovascularisation and infarction size following a 
MI event within mice. As such inhibition of PI3K-γ impairs the angiogenic properties of 
endothelial cells and compromises cardiac function (Siragusa et al. 2010). However, 
several studies have also described anti-atherogenic roles for PI3K. The 
atheroprotective lipoprotein HDL activates endothelial nitric oxide leading to the uptake 
of HDL particles to SR-B1 and induction of the PI3K signalling cascade (Mineo and 
Shaul 2011; Zhang et al. 2011b; Wang and Peng 2012).  
The PI3K family utilise membrane-residing lipids as substrates, and signalling through 
these pathways gives rise to the production of intracellular lipids that mediate a range of 
biological effects (Morello et al. 2009; Vanhaesebroeck et al. 2012). During 
atherosclerosis a vast array of lipid-derived compounds play a major role in initiating 
and directing pathological processes that augment the disease state. An imbalance 
between pro- and anti- lipid-derived inflammatory mediators dictates the inflammatory 
environment and will be discussed in further detail. 
1.5.1. Lipid signalling and disease 
Inflammation is a feature of the host’s response to external threats and injury. However, 
dysregulation of this response can result in pathologies such as atherosclerosis. The 
cellular environment is characterised by the generation of pro-inflammatory cytokines, 
inflammatory mediators such as adhesion molecules and fatty acid-derived eicosanoids 
(Calder 2006). Eicosanoids, taken from the Greek for twenty, are formed from twenty 
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carbon PUFAs like AA, EPA and eicosatetraenoic acid (ETA) and are produced by all 
vascular tissues (Hajjar and Pomerantz 1992). In response to mechanical stress or 
inflammatory mediators, PUFAs are released from membrane-residing phospholipids by 
phospholipase A2 (PLA2). The liberated fatty acids are then oxygenated through the 
LOX-dependent pathway or COX-pathway giving rise to the production of different 
eicosanoid family members: prostaglandins (PGs), thromboxanes (TXs) and 
leukotrienes (LTs) (Rustan and Drevon 2001; Wymann and Schneiter 2008). 
Prostacyclins, PGs and TXs derived from ETA, AA and EPA are formed from the 
actions of membrane-bound COX enzymes; COX-1 and -2 (Gil 2002). On the other 
hand, 5-LOX activity generates 3, 4 and 5 series LTs from ETA, AA and EPA (Gil 
2002). An overview of eicosanoid synthesis is shown in Figure 6. 
 
PGs are the most potent biologically active substances within the body (Vasudevan 
2013) and are therefore rapidly formed and degraded (Wymann and Schneiter 2008). 
Due to the potent nature of eicosanoids, their synthetic processes are the targets of 
pharmacological intervention (Vasudevan 2013). A key discovery in the treatment of 
inflammation was the characterisation of aspirin in targeting the COX enzymes 
responsible for PG synthesis (Vane 1971). COX-1 is constitutively expressed in many 
tissues and is involved in gastric protection and renal water balance (Capra et al. 2013). 
In contrast, COX-2 expression is usually absent but inducible in response to 
inflammatory stimuli (Capra et al. 2013). Several modern non-steroidal anti-
inflammatory drugs specifically target COX-2; as inhibition of COX-1 can have adverse 
gastric and renal effects (Tapiero et al. 2002). However, several studies have indicated 
that selective targeting of COX-2 may be linked to a greater chance of thrombotic 
events and a higher incidence of cardiovascular risk (Kearney et al. 2006; Antman et al. 
2007). However, definitive proof that COX-2 inhibition promotes thrombosis is 
currently lacking. Armstrong et al. (2011) trialled a range of inhibitors including the 
non-specific COX inhibitors aspirin and diclofenac and a selective COX-2 inhibitor; 
parecoxib, in mice that had been subjected to platelet-driven thromboembolism. 
Samples from ex vivo tissue showed that general inhibition of COX enzymes had anti-
thrombotic effects, whereas selective inhibition of COX-2 had little effect on 
thrombosis (Armstrong et al. 2011). 
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AA is a crucial fatty acid in the synthesis of pro-inflammatory eicosanoids. 
Inflammatory cells contain a high proportion of the fatty acid and only modest 
proportions of other twenty-carbon PUFAs (Calder 2006; Vasudevan 2013). 
Eicosanoids formed from AA are involved in a vast array of cellular activities that are 
associated with atherogenic processes including the activation of platelets and 
leukocytes. These species function in an autocrine and paracrine fashion and are 
therefore referred to as local hormones (Rustan and Drevon 2001). The 4-series LTs 
derived from AA are potent bronchoconstrictors, enhancers of vascular permeability 
and promoters of mucous secretion. LTB4 is also a potent chemoattractant for 
leukocytes (Lewis et al. 1980; Samuelsson 1983). In contrast, the respective 5-series 
derived from EPA display weak chemotactic and vasoconstricting properties (Gil 2002). 
However, not all AA derivatives are involved in pro-inflammatory activities as 15-oxo-
eicosatetraenoic acid is thought to inhibit endothelial cell proliferation indicating a 
potential anti-atherogenic role for the lipid (Wei et al. 2009). The effects of eicosanoids 
can also differ dependent on the cell type, the initial stimulus, the presence of other 
eicosanoids and the sensitivity of the target cell (Calder 2006).  
 
Interestingly, several risk factors of atherosclerosis have been shown to directly 
influence eicosanoid production. A study by Fauler and Frölich (1997) demonstrated 
that the production of LTE4 followed a dose-responsive relationship with the number of 
cigarettes smoked per day (Fauler and Frolich 1997). Furthermore, levels of AA-derived 
metabolites are elevated in hypercholesterolaemic patients and increased amounts of 
TXA2 was linked to the activation of platelets and the action of platelet-derived PLAs 
(Davi et al. 1992). CRP is an acute phase protein and elevated levels within the plasma 
function as an independent risk factor for adverse cardiac events (Pepys and Baltz 1983; 
Capra et al. 2013). Also, treatment of porcine coronary arterioles with CRP inhibits 
nitric oxide production and restricts the secretion of the vasodilator PGI2 thereby 
compromising cardiovascular homeostatic mechanisms (Hein et al. 2009). These studies 
lend some explanation to the underlying causes of well-established risk factors.  
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Figure 6. Lipid metabolism and eicosanoid biosynthesis 
The Δ5- and Δ6-desaturases catalyse the formation of n-3 and n-6 PUFAs from essential fatty acids LA and ALA. Adapted from Merino et al. (2010) and Larsson et al. 
(2004). Red denotes pro-inflammatory mediators whilst blue denotes anti-inflammatory mediators. Abbreviations: 15-HETE; 15-hydroxyeicosatetraenoic acid 
 LA  
(18:2 n-6) 
ALA  
(18:3 n-3) 
ω-6 pathway ω-3 pathway 
(18:4 n-3) 
(20:4 n-3) 
EPA  
(20:5 n-3) 
GLA  
(18:3 n-6) 
DGLA  
(20:3 n-6) 
AA  
(20:4 n-6) 
(22:4 n-6) (22:5 n-3) 
(24:5 n-3) 
(24:6 n-3) 
DHA 
 (22:6 n-3) 
(24:4 n-6) 
(24:5 n-6) 
DPA 
(22:5 n-6) 
 
 
SERIES 2 
Prostaglandins 
SERIES 4 
Leukotrienes 
SERIES 3 
Prostaglandins 
SERIES 5 
Leukotrienes 
 
Essential Fatty 
Acids 
 
SERIES 1 
Prostaglandins 
COX 
15-HETE 
LOX 
Lipoxins 
COX 
LOX 
 
D-series 
Resolvins 
COX 
LOX 
E-series 
Resolvins 
LOX 
Membrane 
phospholipids 
PLA2 and PLC 
 INTRODUCTION  Melanie Buckley 
 
 
34 
 
Enzymatic conversion of the essential fatty acids LA and ALA gives rise to two groups 
of lipid-derived messengers belonging to either the n-6 family or n-3 family 
respectively (Tapiero et al. 2002). n-6 and n-3 PUFAs are subjected to distinct 
metabolic routes and exhibit antagonistic actions. The consumption of EPA and DHA 
from fish sources causes a range of effects such as the reduction of PGE2 derivatives, a 
decrease in the platelet aggregating agent TXA2 and lowered production of LTB4 which 
is involved in vasoconstriction and the recruitment and adherence of leukocytes. n-3 
PUFAs are also modified to TXA3 and PGI3 which exert platelet aggregating and 
vasodilating effects (Simopoulos 2008).  
n-3 PUFAs exert direct and indirect actions on other eicosanoids. For example n-3 fatty 
acids compete with n-6 members for COXs, therefore high levels of n-3 fatty acids 
negatively affect the formation of n-6 fatty acid derivatives (Arab 2003). n-3 PUFAs 
also indirectly influence the activities of n-6 PUFAs by regulating the expression of 
inflammatory genes (Calder 2006; Russo 2009). Furthermore, EPA and DHA function 
as precursors for the production of anti-inflammatory molecules such as resolvins and 
protectins. Resolvins were appropriately termed by Serhan and colleagues as these 
endogenous molecules are produced during the resolution phase and promote 
proresolution during inflammation (Serhan et al. 2000; Serhan et al. 2002; Hersberger 
2010). Resolvins are either derived from EPA, giving rise to E-resolvins, or from DHA 
producing D-series resolvins, by COX-2. The E-series of resolvins have a range of 
actions and mediate a reduction in leukocyte rolling, enhance L-selectin shedding and 
block platelet aggregation (Dona et al. 2008). D-series resolvins also exert anti-
inflammatory actions and inhibit the transendothelial migration of human neutrophils 
(Sun et al. 2007b). 
The production and secretion of eicosanoids are modulated by cells within the plaque 
through the generation of inflammatory mediators including cytokines that target 
membrane precursor lipids or metabolic enzymes like COX (Hajjar and Pomerantz 
1992).  
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1.6. The role of immune cells in atherogenesis 
Atherosclerosis was initially thought to solely arise due to the passive accumulation of 
cholesterol in the arterial wall as early lesions are distinguishable by the build-up of 
lipids within the arterial intima (Hansson and Hermansson 2011). However, 
pathogenesis is complex and the disease is now recognised as a chronic inflammatory 
disorder that involves both innate and adaptive immune responses (Mallat et al. 2009). 
Prior to the disease, immunohistochemical staining has revealed that regions of the 
intima prone to atherosclerotic development are marked by an accumulation of 
macrophages, dendritic cells and activated T cells (Millonig et al. 2002). As the disease 
progresses a range of additional immune cells are recruited and reside within the plaque 
including B lymphocytes, mast cells and natural killer cells. The role of immune cells 
during the disease is vast and varied. For example, mast cells amass at sites prone to 
rupture and are persistently activated during the disease aiding plaque development 
within mice (Bot et al. 2007). The actions of these cells destabilises the plaque by 
inducing intraplaque haemorrhaging, macrophage apoptosis and vascular damage (Bot 
et al. 2007; Sun et al. 2007a).  The following sections will focus on some of the key 
immune cells involved in atherogenesis. 
1.6.1. Macrophage heterogeneity within the plaque 
During the early stages of atherosclerosis, monocytes are the primary group of 
leukocytes recruited to the lesion. Monocytes develop within the bone marrow before 
entering the circulation as a heterogeneous non-differentiated population of cells 
(Randolph 2014). There are two categories of monocytes referred to as CD14
hi
CD16
-
 
and CD14
+
CD16
+
 in humans and respectively termed Ly6C
hi
 (inflammatory) and 
Ly6C
lo
 (patrolling) within mice (Swirski et al. 2007). Hypercholesterolaemic ApoE
-/- 
mice fed on a high-fat diet exhibit raised levels of Ly6C
hi
 monocytes that adhere to the 
activated endothelium and enter the atherosclerotic lesion. Interestingly, within these 
mice the conversion of Ly6C
hi
 to the Ly6C
lo
 phenotype is impaired and migration of 
Ly6C
lo
 monocytes into the plaque is also reduced (Swirski et al. 2007; Tacke et al. 
2007). Following recruitment to the lesion, the monocytes differentiate into either 
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macrophages or myeloid dendritic cells under the influence of M-CSF and other 
differentiating agents (Imhof and Aurrand-Lions 2004; Gui et al. 2012).  
Macrophages were the first immune cells identified within the plaque (Gerrity et al. 
1979). Different subsets of macrophages arise due to the exposure of the circulating 
monocytes to specific priming agents and are generally classified as either M1 or M2 
(Wolfs et al. 2011). Ly6C
hi
 monocytes are thought to function as the precursors for M1 
macrophages whereas Ly6C
lo
 monocytes give rise to M2 macrophages (Moore et al. 
2013). Monocyte differentiation into macrophages is accompanied by an increase in the 
expression of pattern recognition receptors such as SRs that facilitate the uptake of 
endotoxins, microbial products, apoptotic bodies and LDL particles (Libby et al. 2013). 
Classically activated M1 macrophages are stimulated by microbial products including 
LPS and cytokines like IFN-γ. Within the disease state, M1 macrophages are pro-
atherosclerotic and release ROS and pro-inflammatory cytokines including TNF (Tabas 
2010). Conversely, alternatively activated M2 macrophages aid the resolution of 
inflammatory responses through the synthesis of ECM components and anti-
inflammatory cytokines like IL-13 (Tabas 2010). M2 macrophages are induced by T 
Helper (Th) 2 cytokines like IL-4 and are abundant in regressing plaques. In contrast, 
advanced lesions display an imbalanced ratio of M1 to M2 macrophages supporting 
defective resolution and augmentation of the chronic inflammatory state (Tabas 2010; 
Ogawa et al. 2012; Moore et al. 2013).  
The M1 and M2 macrophage categories are not absolute as the population of infiltrating 
monocytes seen during the disease state contain a combination of M1 and M2 markers  
and, although macrophages are mainly categorised under these two broad labels, 
additional subclassifications and macrophage phenotypes exist (Gratchev et al. 2012). 
For example M2 macrophages are further subdivided based upon function and the 
polarising cytokine. Exposure to IL-4 or IL-13 gives rise to M2a macrophages involved 
in homeostasis and tissue repair, whereas IL-10 primed macrophages are referred to 
M2c and modulate the immune response (Wolfs et al. 2011). Other macrophage 
subtypes have been also detected within the plaque. Stimulation of monocytes with the 
platelet factor CXCL4 produces M4 macrophages which express a mixture of M1 and 
M2-associated genes, display limited phagocytic capabilities and express a 
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transcriptome distinct from M1 and M2 macrophages (Gleissner et al. 2010; Gleissner 
2012). Although M4 markers are found within human atherosclerotic coronary arteries, 
the exact contribution of this subtype is not clear as M4 macrophages express both pro- 
and anti-atherogenic genes (Gleissner et al. 2010). However, the deletion of the gene 
encoding CXCL4 decreases the size of lesions within atherosclerotic prone mice 
(Sachais et al. 2007). 
1.6.2. Dendritic cells  
The exposure of circulating monocytes to inflammatory stimuli like GM-CSF promotes  
dendritic cell formation (Niessner and Weyand 2010). Ablation of GM-CSF in LDLR
-/-
 
mice causes a substantial fall in the number of plaque-residing dendritic cells in addition 
to a significant reduction in lesion size (Shaposhnik et al. 2007). Although macrophages 
and dendritic cells share common origins, the cells can be distinguished by differences 
in functionality. Macrophages are mainly involved in responding to injury whereas 
dendritic cells favour the presentation of antigens on major histocompatibility complex 
(MHC) molecules to direct the T cell response (Randolph 2014). The presence of 
dendritic cells within the plaque was initially described in 1995 through the use of 
electron microscopy (Bobryshev and Lord 1995). The accumulation of these cells, 
although not as abundant as macrophages and T cells, into areas prone to atherosclerosis 
correlates with disease progression and inflammation (Liu et al. 2008; Frostegard 2013).  
 
Dendritic cells belong to the group of professional antigen presenting cells and also 
function as primers of T cell responses and modulators of immune tolerance (Steinman 
et al. 2003b; Van Vre et al. 2011). The maturation state of dendritic cells dictates their 
function (Menges et al. 2002). Immature dendritic cells within peripheral tissues drive 
tolerance through the deletion of autoreactive T cells (Steinman et al. 2003a). Yet, in 
response to inflammatory stimuli, dendritic cells undergo phenotypic and functional 
changes, mature and migrate to T cell-rich areas to activate naïve T- and B- cells (Link 
and Bohm 2002). The change is also accompanied with enhanced expression of 
costimulatory molecules, chemokine receptors, adhesion molecules and the release of 
cytokines that influence the formation of different T cell subtypes (Dhodapkar et al. 
2001; Frostegard 2013).  
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A range of receptors including SRs are expressed at the surface of dendritic cells that 
facilitate the uptake of antigens. The antigen peptides are then trans located onto MHC 
molecules in preparation for T cell presentation (Frostegard 2013). Danger-associated 
molecular patterns released during atherosclerosis are recognised through receptors such 
as SRs present at the surface of dendritic cells and promotes a shift to adaptive immune 
responses (Niessner and Weyand 2010; Hansson and Hermansson 2011). Alderman and 
colleagues demonstrated that the exposure of mildly OxLDL to monocyte-derived 
dendritic cells triggers the activation and maturation of these cells and consequently 
leads to the activation and proliferation of T cells. However, continued exposure to 
highly OxLDL causes apoptosis of dendritic cells (Alderman et al. 2002). Inflammatory 
species such as ROS and denatured material from the plaque may potentially injure 
dendritic cells and in doing so support tolerance or suppression of the immune response 
instead of T cell activation (Rutault et al. 1999; Link and Bohm 2002).  
1.6.3. T cells 
Monocytes and T cells are recruited along a chemotactic gradient and enter the plaque 
through interactions with cell-surface adhesion molecules during initial stages of the 
disease. The mass of macrophages and T cells constitutes the major component of the 
fatty streak (Paulsson et al. 2000; Hansson and Libby 2006). The number of T cells 
present within the plaque are far fewer than that of macrophages but have an important 
modulating role during pathology (Libby et al. 2011). Antigen presenting cells such as 
macrophages and dendritic cells interact with T cells to activate the adaptive immune 
system. These cells also influence the activities of T cells through the secretion of 
cytokines like IL-12 that modulates the infiltration of T cells into the plaque (Niessner 
et al. 2006). As such the function of T cells are closely tied to that of dendritic cells and 
macrophages (Baidya and Zeng 2005).  
The cytokine repertoire of T cells is dictated by their phenotype. The production of 
cytokines from naïve T cells is limited to IL-2, whereas memory T cells, that have had 
prior exposure to antigens, secrete a range of cytokines including IFN-γ, IL-3, IL-4, IL-
5, IL-6, GM-CSF and M-CSF (Stemme et al. 1992). The cells are then activated in 
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response to specific antigens presented on MHC complexes of antigen presenting cells 
such as dendritic cells, macrophages and B cells triggering the proliferation of antigen-
specific T cells (Baidya and Zeng 2005).  
Samples from human plaques have demonstrated that the majority of T cells are 
memory T cells positive for the T cell antigen receptor and CD4
+
; although CD8
+
 T 
cells are also present (Hansson and Hermansson 2011). Several studies have shown that 
atherosclerotic plaques contain oxidative lipoproteins and heat shock protein-specific T 
cells therefore indicating that local activation and clonal expansion occurs during the 
disease (Paulsson et al. 2000; Rossmann et al. 2008). Many of the cells show signs of 
late or chronic activation and are distinctly different from the circulating population 
(Stemme et al. 1992). T cells promote inflammation through the production of 
cytokines like IFN-γ and TNF that activate VSMCs and endothelial cells (Hui 2007). 
Within the plaque CD4
+
 T cells propagate the disease state by promoting the apoptosis 
of VSMCs through death receptors on those cells (Sato et al. 2006), in addition to the 
activation of macrophages through the secretion of IFN-γ (Liuzzo et al. 2001) and the 
release of perforin which lyses endothelial cells (Nakajima et al. 2002).  
Subsets of Th cells are generalised under the Th1 and Th2 categories based upon 
cytokine expression (Lohning et al. 1998). The balance between Th1 and Th2 responses 
is carefully modulated by regulatory T cells (Tregs) (Galkina and Ley 2009). Tregs are 
specialised T cells that suppress pathogenic responses by the immune system towards 
foreign and self-antigens (Sakaguchi et al. 2006). Activated Tregs can suppress the 
actions of T cells and other immune cells and atherosclerotic mice deficient in Tregs 
display increased plaque development (Ait-Oufella et al. 2006). However the disease is 
characterised by an abundance of T cells supporting an imbalance in Th1 to Th2 
cytokines (Libby et al. 2013).  
The Th1 response is associated with the release of pro-inflammatory cytokines such as 
the classical Th1 cytokine IFN-γ (Libby et al. 2009). The cytokine exerts a major 
impact on disease progression and injections of IFN-γ into ApoE-/- mice increases the 
size of the atherosclerotic lesion by approximately two-fold (Whitman et al. 2000). On 
the other hand, ApoE
-/-
 mice crossed with IFN-γ receptor (IFN-γR)-/- mice exhibit 
attenuated atherosclerotic development accompanied by a substantial reduction in 
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accumulated lipids within the lesion (Gupta et al. 1997). The Th2 response is 
conversely associated with attenuated atherosclerotic formation, however its exact 
contribution in the disease state is unknown (Libby et al. 2009). Th2 cell cytokines, 
including IL-4, and the transcription factor peroxisome proliferator-activated receptor-γ 
(PPAR-γ) bias macrophage differentiation towards the M2 phenotype (Tabas 2010). 
However, the abundances of Th2 cytokines such as IL-4 and IL-5 are markedly under-
represented in comparison to Th1 cytokines within the plaque (Frostegard et al. 1999). 
1.7. Cytokine involvement in the atherosclerotic state  
Cytokines are soluble low molecular weight proteins involved in immune and 
inflammatory responses (Ross 1993). Most are composed of a single polypeptide chain 
and travel short distances to bind with high affinity to their specific receptors typically 
located on lymphoid organs or inflamed tissues (Ait-Oufella et al. 2011). Based upon 
the structural homology of their receptors, cytokines are classified as class I or class II 
owing to the presence of either four conserved cysteine residues or two cysteine 
doublets in the extracellular region (Bazan 1990). The cytokine family is a large group 
of over 100 proteins encompassing lymphokines, monokines, chemokines, interferons, 
TNFs and interleukins (George and Johnson 2010) and cytokines from the same family 
regularly share receptor subunits (Parrish-Novak et al. 2002). Members of these 
families have common characteristics and are frequently pleiotrophic whereby 
cytokines exert different effects dependent on the type of cell and time they were 
produced. A key difference between cytokines and GFs is that cytokine production is 
strictly regulated and the main targets are immune cells (Tedgui and Mallat 2006). 
Cytokines are important mediators of the innate and adaptive immune system and play a 
key role at every stage of atherosclerosis, from early events involving dysfunction of the 
endothelium, lipid metabolism and later phase actions such as enhancing MMP 
secretion (Ait-Oufella et al. 2011). Within the disease state, the production of many 
cytokines is auto-inducible through autocrine and paracrine signalling, which helps to 
augment and sustain inflammation (Panousis and Zuckerman 2000). Extracellular GFs 
and cytokines are highly expressed during atherosclerosis and mediate the proliferation 
and survival of cells involved in plaque formation (McLaren and Ramji 2009). 
 INTRODUCTION  Melanie Buckley 
 
 
41 
 
Furthermore, the synergistic actions of cytokines and GFs can function to amplify their 
responses. For example, the effects of IL-1α and TNF-α on MMP activation is enhanced 
through costimulation with platelet-derived GF and fibroblast GF-2 in rabbit VSMCs 
and human SMCs (Bond et al. 2001).  
Cytokines exert a dual role during atherosclerosis and a complex interplay between pro- 
and anti-inflammatory cytokines arises which influences the development and stability 
of the plaque. Table 3 gives a description of prominent pro- and anti-atherogenic 
cytokines. The prevalence of pro-inflammatory cytokines within the plaque drives Th1-
related processes and augments disease progression (McLaren et al. 2011a). A variety 
of pro-inflammatory cytokines such as IFN-γ, TNF-α and TNF-like protein-1A support 
Th1 responses and promote foam cell formation (McLaren et al. 2010a). Conversely, 
anti-inflammatory cytokines predominately promote Th2-type responses that function to 
resolve inflammation (McLaren et al. 2011a). The anti-inflammatory cytokine 
transforming growth factor-beta (TGF-β) inhibits SR activity and reduces foam cell 
production (Michael et al. 2012b). Interestingly, Th1 and Th2 cytokines are capable of 
cross-regulation, for example, pro-inflammatory IL-12 inhibits Th2 responses and may 
restrict Th2 activities during atherosclerosis (Hansson et al. 2002).  
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Table 3. Cytokines involved in atherosclerosis 
 
Cytokine Role in atherosclerosis Reference 
Pro-atherogenic 
IFN-γ 
ApoE
-/-
 knockout mice crossed with IFN-γR -/- 
knockout mice display smaller atherosclerotic 
lesions and decreased lipid accumulation. 
(Gupta et al. 1997) 
TNF-α 
Size of atherosclerotic plaque significantly 
reduced in TNF-α and ApoE double knockout 
mice. Also, ICAM-1 and MCP-1 expression 
down-regulated. 
(Ohta et al. 2005) 
IL-1-β 
IL-1 receptor antagonist decreases the production 
of fatty streak in ApoE
-/-
 mice. 
(Elhage et al. 1998) 
IL-6 
Injection of recombinant IL-6 into wild type and 
ApoE
-/-
 mice promotes atherosclerotic 
development and elevates the release of pro-
inflammatory cytokines like IL-1β and TNF-α. 
(Huber et al. 1999) 
IL-18 
Raised levels of serum IL-18 in patients with 
CAD. 
(Blankenberg et al. 
2002) 
Anti-atherogenic 
IL-10 
Overexpression of IL-10 in LDLR
-/-
 mice reduces 
atherosclerotic plaque formation and promotes 
the Th2 phenotype. 
(Pinderski et al. 2002) 
IL-33 
Reduces foam cell formation in vitro and the 
development of atherosclerosis in ApoE
-/-
 mice. 
(Miller et al. 2008; 
McLaren et al. 2010b) 
TGF-β 
Neutralising antibodies against TGF-β isoforms 
augments atherosclerosis and promotes instability 
within the lesion associated with decreased 
collagen content. 
(Mallat et al. 2001) 
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1.7.1. Interleukin-33 (IL-33) 
In 1989 ST2 was identified as an orphan receptor that shared close homology to the 
extracellular portion of murine interleukin-1 receptor (IL-1R) and IL-18α (Tominaga 
1989). Toll-like/IL-1R family members are characterised by the presence of a shared 
Toll/interleukin-1 receptor (TIR) domain consisting of a central five-stranded β-sheet 
surrounded by five α-helices (Xu et al. 2000). The ST2 receptor was later shown to play 
a role in supporting anti-inflammatory processes such as enhanced differentiation of 
Th2 cells and polarisation of M2 macrophages (Kakkar and Lee 2008; Ogawa et al. 
2012). ST2 is expressed on the surface of immune cells including mast cells, dendritic 
cells, Th2 cells and macrophages but is not expressed on naïve T cells or Th1 cells 
(Lohning et al. 1998; Lefrancais et al. 2012).  
Alternative splicing of the gene that encodes ST2 gives rise to at least eight isoforms of 
the receptor including ST2L (functional full-length transmembrane form), ST2V 
(variant), ST2LV and sST2 (secreted, soluble decoy receptor) (Joshi et al. 2010; Miller 
and Liew 2011). ST2L has an extracellular domain containing three immunoglobulin-
like motifs, a transmembrane portion and a TIR domain (Kakkar and Lee 2008). ST2V 
lacks the third immunoglobulin motif and instead contains a novel hydrophobic tail in 
the C-terminal region (Tominaga et al. 1999). In contrast, ST2LV is characterised by an 
absence of the transmembrane portion found in ST2L (Kakkar and Lee 2008) and the 
soluble decoy receptor sST2 does not contain the transmembrane or intracellular 
domains (Iwahana et al. 1999). 
The gene for IL-33 was initially discovered by Baekkevold et al. (2003) in high 
endothelial venule (HEV) endothelial cells and was termed nuclear factor from HEV’s 
(Baekkevold et al. 2003). It was not until 2005 that the gene was identified as a ligand 
for ST2 following a computational search for members of the IL-1R family (Schmitz et 
al. 2005). The human gene for IL-33 contains seven exons and is located on 
chromosome 9p24.1 and on chromosome 19qC1 in mice. The cytokine is formed of 270 
and 266 amino acids in human and mouse respectively and share 55% identity to one 
another (Schmitz et al. 2005). Within mice, levels of IL-33 mRNA are high within the 
stomach, lung, spinal cord, brain and skin but less prevalent in lymph tissue, spleen, 
pancreas, kidney and the heart. IL-33 mRNA is also found in resting mouse dendritic 
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cells and activated macrophages. The cytokine is not expressed by the majority of 
human haematopoietic cells; with the exception of activated dendritic cells and 
macrophages where it is expressed at low levels. However, it is constitutively expressed 
by human SMCs and bronchial epithelial cells. Furthermore, the expression of IL-33 is 
induced by TNF-α and IL-1β in primary lung and dermal fibroblasts and keratinocytes 
(Schmitz et al. 2005).  
Family members such as IL-1 and IL-18 contain prodomains that are proteolytically 
cleaved to produce the mature form (Chackerian et al. 2007). Interestingly, IL-33 is also 
secreted containing a prodomain and in vitro studies have shown that the cytokine is 
susceptible to cleavage by caspase-1 yielding a 18kDa peptide product (Schmitz et al. 
2005). Initial theories proposed that IL-33 may be processed in a fashion similar to 
other IL-1β members and that caspase activity may be a prerequisite for activation 
(Kakkar and Lee 2008). However, although caspase-1 is capable of cleaving IL-33; the 
cytokine is preferentially cleaved by the caspases-3 and -7 (Schmitz et al. 2005; Luethi 
et al. 2009; Talabot-Ayer et al. 2009). Furthermore, recent studies have demonstrated 
that cleavage after residue 178 (aspartic acid) in the IL-1-like domain functions to 
inactivate the cytokine (Cayrol and Girard 2009).  
A recent study by Luzina et al. (2012) found that full-length, unprocessed IL-33 was the 
major form found in the lungs of healthy and pulmonary disease sufferers. Interestingly, 
the full length and mature forms display slightly different activities in mouse model 
systems. Both forms trigger the infiltration of lymphocytes and neutrophils, but only the 
mature form promotes pulmonary eosinophilia, goblet cell hyperplasia and increases the 
expression of IL-4, IL-5, IL-13, IL-17 and MCP-1. Also, in the absence of the ST2 
receptor the response from full-length IL-33 is not lost (Luzina et al. 2012). IL-33 can 
directly interact with heterochromatin and could therefore participate in the regulation 
of gene expression through repressing gene transcription in a receptor-independent 
method (Ali et al. 2011). It is thought that full-length IL-33 may also serve as an 
alarmin; an endogenous molecule released in response to tissue and cellular injury and 
has been hypothesised that caspase-mediated inactivation of IL-33 acts to limit pro-
inflammatory responses mediated by the cytokine during apoptosis (Bianchi 2007; 
Miller 2011).  
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spIL-33 is a novel short splice variant which lacks the caspase-1 cleavage site and is 
therefore constitutively expressed. Recombinant spIL-33 induces the phosphorylation of 
IL-1R-associated kinase 1 (IRAK1), NF-κB, ERK1, ERK2, p38 and JNK in a dose- and 
time-responsive fashion (Hong et al. 2011). The presence of new splice variants 
indicates that different forms of IL-33 may be released in response to a variety of 
stimuli (Hong et al. 2011). 
1.7.2. The IL-33 signalling axis 
Under normal physiological conditions, IL-33 is associated with chromatin within the 
nucleus through an N-terminal bipartite homeo-domain-like helix-turn-helix motif DNA 
binding domain (Ali et al. 2011). The role of IL-33 as an intracellular factor is poorly 
understood but is thought to function as a nuclear repressor (Choi et al. 2012). 
Interestingly, the mechanisms giving rise to extracellular IL-33 have not been fully 
defined and are further complicated by the absence of a signal sequence within IL-33 
mRNA (Shao et al. 2014). However, in response to certain stimuli, extracellular IL-33 
binds to the ST2L receptor triggering the formation of a trimeric complex with the IL-
1R accessory protein (IL-1RaP) (Ali et al. 2011). IL-1RAcP functions as a co-receptor 
which associates with ST2 in a ligand-dependent fashion and is necessary for ST2 
activity (Arend et al. 2008). Both ST2 and IL-1RAcP are widely expressed and 
prevalent in many cells from the innate immune system and Th2 cells (Miller 2011). 
The presence of IL-1RAcP increases the affinity of IL-33 for ST2 (Palmer et al. 2008). 
Mice deficient in IL-1RAcP do not respond to IL-33 treatment and other members of 
the IL-1 family such as IL-1F6, IL-1F8 and IL-1F9, also utilise IL-1RAcP for signal 
transduction (Chackerian et al. 2007). IL-33-mediated activity through the ST2-IL-
1RAcP complex triggers the recruitment of IRAK, IRAK4, the E3 ubiquitin ligase TNF 
receptor associated factor (TRAF6) and the adaptor protein myeloid differentiation 
primary-response protein 88 (MyD88) (Schmitz et al. 2005; Chackerian et al. 2007). 
Signalling occurs through the TIR domain of the ST2 receptor and leads to the 
activation of additional signalling pathways. An overview of IL-33 signalling is given in 
Figure 7.  
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Figure 7. Canonical IL-33/ST2 signalling 
Nuclear IL-33 is thought to function as a nuclear repressor however the mechanisms leading to 
release and eventual processing to the mature form of the cytokine are not known. Binding of 
extracellular IL-33 to ST2 is enhanced in the presence of IL-RAcP. The trimeric complex recruits 
the adaptor proteins MyD88, IRAK and IRAK4 leading to the activation of signalling components. 
Signalling by IL-33 is attenuated by the decoy receptor sST2 that reduces the availability of IL-33 
and the presence of SIGIRR also negatively impacts IL-33 signalling. Abbreviations: SIGIRR; 
single Ig IL-1R-related molecule. Adapted from Liew et al. (2010) and Palmer and Gabay (2011).  
 
The IL-33/ST2 axis, like other members from the IL-1 family, utilises members from 
the NF-κB and the MAPK superfamilies (Schmitz et al. 2005). An overview of studies 
exploring IL-33 signalling is provided in Table 4. The cytokine is thought to negatively 
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regulate gene transcription in an intracrine receptor-independent manner. For example, 
the full-length form associates with the p65 subunit of NF-κB and impairs the ability of 
NF-κB to bind to DNA (Ali et al. 2011). There are also a number of regulatory 
mechanisms that attenuates ST2-IL-33-mediated signalling. The decoy receptor sST2 
binds to IL-33 and therefore reduces its availability for ST2L. On the other hand, a 
single immunoglobulin IL-1R-related molecule (SIGIRR) binds to ST2L so the receptor 
is unable to complex with IL-RAcP thereby terminating further signal transduction 
(Bulek et al. 2009). Additionally, a splice variant for IL-1RaP also exists that enhances 
the binding affinity of IL-33 to sST2 (Palmer et al. 2008). For clarity ST2L will be 
referred to as ST2 henceforth within this thesis. 
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Table 4. Studies investigating IL-33 signalling 
 
IL-33 Signalling Reference 
Full length IL-33 constitutively interacts with the NF-κB subunit 
p50. Interactions between IL-33 and NF-κB reduce and delay the 
binding of NF-κB to DNA and decreases NF-κB triggered 
transactivation in HEK293R1 embryonic kidney cells. 
(Ali et al. 2011) 
IL-33 activates endothelial cells and increases vascular permeability 
and several processes associated with angiogenesis; these actions 
are ST2-dependent and mediated through PI3K and Akt. 
(Choi et al. 2009) 
IL-33 promotes the survival and adhesion of human umbilical cord 
blood-derived mast cells to fibronectin. Signalling through IL-33 
also leads to the activation of ERK, p38 and JNK and induces IL-8 
and IL-13 production within these cells. 
(Iikura et al. 2007) 
IL-33 inhibits the induction of NF-κB in wild-type mice but not in 
ST2
-/-
 mice. 
(Sanada et al. 
2007) 
IL-33 stimulation results in the recruitment of MyD88, IRAK, 
IRAK4 and TRAF6. Treatment of ST2-transfected HEK293 cells 
with IL-33 leads to the activation of ERK1/2, p38, IκBα and JNK. A 
similar result is seen in HEK293 cells transfected with IL-1R1 
following treatment with IL-1β. IL-33 stimulation of murine mast 
cells results in the phosphorylation of NF-κB, ERK1/2, p38 and 
JNK. 
(Schmitz et al. 
2005) 
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1.7.3. The involvement of IL-33 in disease  
IL-33 mainly promotes Th2 responses unlike other IL-1 family proteins and also acts as 
a chemoattractant for Th2 cells (Komai-Koma et al. 2007). The cytokine has been 
implicated in a number of inflammatory disorders including asthma, rheumatoid 
arthritis and ulcerative colitis (Lefrancais et al. 2012). IL-33 promotes M1 chemokine 
production in naïve human macrophages but also increases the expression of M2 
chemokine markers within mature polarised macrophages (Joshi et al. 2010). 
Furthermore, IL-33 amplifies the polarisation of alternatively activated macrophages 
during airway inflammation and levels of the cytokine are elevated in epithelial cells 
from asthmatic sufferers (Kurowska-Stolarska et al. 2009). A summary of studies 
describing the role of IL-33 in different disease states is provided in Table 5. 
 
There is a great level of interest in understanding the actions and mechanisms behind 
IL-33 signalling as the cytokine displays conflicting activities in different disease states. 
Several studies have demonstrated that IL-33 has an adverse role in mast-cell mediated 
inflammatory diseases (Liew et al. 2010). A study by Xu et al. (2008) established that 
IL-33 was expressed in synovial fibroblasts of patients with rheumatoid arthritis and its 
expression was increased by the inflammatory cytokines TNF-α and IL-1β in vitro. In 
murine models of arthritis, ST2 knockout mice exhibited less severe collagen-induced 
arthritis, whereas the wild-type displayed increased signs of arthritis as a result of 
enhanced secretions of pro-inflammatory cytokines and anti-collagen antibodies (Xu et 
al. 2008). Mice injected with IL-33 develop splenomegaly accompanied with elevated 
amounts of eosinophils, mononuclear cells, and plasma cells. Furthermore, levels of 
circulating immunoglobulin (Ig) E and IgA, which are associated with hypersensitivity, 
were raised (Polmar et al. 1972; Schmitz et al. 2005).  
 
IL-33 is thought to function as an ‘alarmin’ capable of amplifying immune responses 
following injury to tissues. Oboki et al. (2010) proposed that IL-33 is an important 
amplifier of mucosal and systemic innate responses as the cytokine was crucial for T 
cell-independent protease allergen-mediated airway inflammation and mice deficient in 
IL-33 displayed a compromised response to LPS-induced systemic inflammation 
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(Oboki et al. 2010). These studies implicate IL-33 as a potent inducer of the pro-
inflammatory response. 
 
Several studies have, however, also demonstrated that IL-33 can have a protective role 
in certain disease states. Neill et al. (2010) identified a novel innate type 2 immune 
leukocyte which they termed the nuocyte. IL-33 and IL-25 stimulation caused the 
expansion of nuocytes in vivo which were the primary source of IL-13; a type 2 
cytokine vital for countering the immune response against helminth infection and 
allergic responses. However, in the absence of IL-33 and IL-25 nuocytes were unable to 
expand leading to compromised expulsion of worms (Neill et al. 2010).  
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Table 5. Studies investigating the role of IL-33 in inflammatory disorders  
 
Organ/ disease Role of cytokine Reference 
Cancer 
 
Mice with mammary tumours lacking the ST2 receptor 
display reduced metastasis and raised numbers of natural 
killer cells expressing IFN-γ. IL-33 treatment promotes 
vascular permeability and proliferation, migration and 
differentiation of endothelial cells. 
(Choi et al. 2009; 
Jovanovic et al. 
2011) 
Central nervous 
system 
Polymorphism in the gene for IL-33 is associated with 
Alzheimer’s disease and reduced amounts of IL-33 are 
found in the brains of Alzheimer patients. 
(Chapuis et al. 
2009) 
Crohn’s disease 
and rheumatoid 
arthritis 
High levels of IL-33 expression in endothelial cells from 
patients with rheumatoid arthritis and Crohn’s disease. 
(Carriere et al. 
2007) 
Immune system 
 
IL-33 injections increase amounts of eosinophils, 
mononuclear cells and plasma cells, and levels of IgE 
and IgA. IL-33 induces expression of IL-4, IL-5 and IL-
13 in thymus, spleen, liver and lung but no changes in 
levels of IL-1α, IL-2, IL-10, IL-12, TNFα, or IFN-γ, 
accompanied by increased size of duodenum and spleen. 
Arteries within lung tissue display hypertrophy and 
infiltration of myeloid cells in the lumen and eosinophils 
and/or mononuclear cells within the subendothelium. IL-
33 has a protective effect in mice infected with intestinal 
nematodes by inducing a Th2 response. 
(Schmitz et al. 
2005; Humphreys 
et al. 2008) 
Respiratory 
High levels of IL-33 expression in asthmatic patients, 
particularly in bronchial epithelial cells. ST2 knockout 
mice have reduced inflammation in the airways and 
lungs in comparison to wild-type mice subjected to 
ovalbumin-induced inflammation. 
(Kurowska-
Stolarska et al. 
2008; Kurowska-
Stolarska et al. 
2009; Prefontaine 
et al. 2009) 
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1.7.4. The role of IL-33 in CAD 
In addition to the well-documented pro-inflammatory actions of the cytokine in certain 
disease states, IL-33 can also attenuate inflammatory responses. Several studies have 
described a protective role for IL-33 within atherosclerosis and cardiovascular diseases. 
In experiments undertaken by Miller et al. (2008), injections of recombinant IL-33 into 
ApoE
-/- 
mice decreased the generation of atherosclerotic lesions. Additionally, the 
cytokine reduced the number of lesional macrophages and promoted a Th1 to Th2 
phenotypic switch within the plaque accompanied with enhanced production of the Th2 
cytokines IL-4 and IL-13 and secretion of antibodies against OxLDL. Treatment with 
the decoy receptor reversed the protective effects of IL-33 and also increased the size of 
the lesion (Miller et al. 2008).  
Studies by Mclaren et al. (2010) demonstrated that IL-33 acts through the ST2 receptor 
to decrease foam cell formation in vivo. Also, treatment of THP-1 macrophages with IL-
33 reduced the uptake of AcLDL and OxLDL (McLaren et al. 2010b). The authors also 
identified several genes involved with mediating the reduction in foam cell 
accumulation. The cytokine decreased the expression of genes implicated in lipid uptake 
and storage such as SR-A, SR-B1 and CD36, and cholesterol esterification like ACAT-
1. In contrast, the expression of the cholesterol efflux transporters; ABCA-1 and 
ABCG-1 were up-regulated by the cytokine (McLaren et al. 2010b). Within THP-1 
macrophages, IL-33 also inhibited the uptake of Lucifer yellow, a fluorescent dye used 
as an indicator of macropinocytosis (Michael et al. 2013). As macropinocytosis is 
attributed as a contributor to plaque formation through constitutive and passive uptake 
of LDL particles, the study demonstrates a novel mechanism by which IL-33 may 
reduce macrophage foam cell formation in vitro.  
The cytokine has a wide range of effects on different cell types that reside within the 
atherosclerotic plaque. A study by Wasserman et al. (2012) showed that IL-33 increases 
the number of Tregs. During normal physiological conditions Tregs promote the switch 
from Th1 to Th2 but during atherosclerosis the number of Tregs within the plaque is 
reduced. Interestingly, within ApoE
-/-
 mice, IL-33 treatment had no effect on the 
number of Tregs. However, levels of the decoy receptor sST2 were elevated within 
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these animals whilst the amount of ST2 was reduced. The authors suggest that 
attenuation of signalling through the IL-33/ST2 axis contributes to the repressed number 
of regulatory T cells observed during the atherosclerotic state and therefore promotes 
the Th1 state (Wasserman et al. 2012).  
The IL-33/ST2 axis enhances angiogenesis and endothelial cell permeability in vitro 
and in vivo by increasing the production of nitric oxide (Choi et al. 2009). However, IL-
33 reduces the damage incurred from oxidative stress in cultured cardiomyocytes and in 
mice with ischaemia by promoting the expression of anti-apoptotic mediators. The 
cytokine also protects against cardiomyocyte apoptosis in in vitro and in vivo systems 
(Seki et al. 2009). These effects were shown to be ST2-dependent as ischemic mice 
displayed reduced infarction volume and improved ventricular function when treated 
with IL-33 but the same effects were not observed in ST2
-/-
 mice (Seki et al. 2009). The 
cytokine also defends cells against mechanical stresses. In response to mechanical 
stretch cardiomyocytes undergo hypertrophy characterised by the enlargement of cells 
in the absence of cell division (Sadoshima et al. 1993). Sustained hypertrophy can lead 
to compromised contractile functionality and arrhythmia and therefore often serves as a 
precursor to heart disease. However, IL-33 is released by cardiomyocytes in response to 
biomechanical stress and inhibits the actions of hypertrophic effectors such as 
angiotension II and phenylephrine. The cytokine functions as a protector against 
mechanical overload by reducing cardiac fibrosis and cardiomyocyte hypertrophy in 
vivo. These responses were shown to be dependent on ST2 as administration of sST2 
reversed the effects of IL-33 (Sanada et al. 2007). 
Epidemiological studies have also described the relationship between the cytokine and 
cardiac disorders. Levels of IL-33 are raised in the serum of patients who suffer from 
acute coronary syndrome and stable angina pectoris (Liu et al. 2013). Another study 
found that serum levels of IL-33 were elevated in patients with chronic heart failure 
(CHF) and were positively associated with several markers of oxidative stress such as 
erythrocyte superoxide dismutase activity (Zhang et al. 2012). Interestingly, levels of 
sST2 were also high and contributed to a depressed ratio of IL-33/sST2. Furthermore, 
the full-length and cleaved versions of IL-33 were detected in patients with CHF, 
whereas only the cleaved form was found in healthy subjects. The results suggest that 
full-length IL-33 may be released in response to heart failure (HF) but the cardio-
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protective effects of IL-33 are negated by an increased presence of the decoy receptor 
(Zhang et al. 2012).  
 
The soluble decoy receptor sST2 has also attracted a lot of attention as the receptor 
negates the cardioprotective actions of the IL-33/ST2 axis. As such levels of sST2 have 
been proposed to function as an accurate prognostic tool for predicting cardiovascular 
risk. Circulating sST2 is transiently boosted following a MI event within human patients 
and in mice with experimental MI (Weinberg et al. 2002). Furthermore, levels of sST2 
correlate with other inflammatory markers, total mortality and cardiovascular mortality 
in low risk populations and in patients with acute MI (Shimpo et al. 2004; Rehman et al. 
2008; Chen et al. 2013). HF is the most frequent reason for hospital admissions and 
readmissions, and arises due to compromised contractibility of the heart (Avery et al. 
2012). Levels of sST2 are elevated in sufferers of HF and there is a relationship between 
levels of serum sST2 and the extent and volume of infarctions within MI patients (Weir 
et al. 2010). Additionally, sST2 has been proposed to function as a reliable biomarker of 
HF in patients with breathing difficulties indicating that circulating sST2 could function 
as a robust marker for different manifestations of cardiovascular disease (Januzzi et al. 
2007). 
1.8. Aims of the study 
Atherosclerosis is the primary contributor to CHD; the leading cause of global death. 
Due to the inflammatory nature of atherosclerosis much attention has fallen on the 
critical role that cytokines play in orchestrating and augmenting the disease state. The 
imbalance between pro-inflammatory and anti-inflammatory cytokines within the 
plaque supports pathogenesis. Furthermore cytokines are involved in all key events; 
from the recruitment of leukocytes, foam cell generation, secretion of MMPs to eventual 
rupture of the plaque. Many of these atherogenic processes are mediated through the 
modulation of signalling pathways and the dysregulation of gene expression. As such it 
is of crucial importance to understand the underlying mechanisms that dictate the 
activities of cytokines implicated within the disease.  
 
INTRODUCTION  Melanie Buckley 
 
 
55 
 
IL-33 is a novel member of the IL-1 superfamily of cytokines and a number of studies 
have described the anti-atherosclerotic effects of the cytokine. Administration of IL-33 
into murine models of atherosclerosis reduces the size of atherosclerotic plaques and 
promotes the secretion of Th2 cytokines. Furthermore the cytokine reduces macrophage 
foam cell accumulation in ApoE
-/-
 mice and studies in THP-1 macrophage-derived foam 
cells have demonstrated that IL-33 down-regulates the expression of genes involved in 
cholesterol uptake and esterification whilst up-regulating those involved in cholesterol 
efflux. In addition to the anti-atherosclerotic effects of the cytokine, IL-33 also plays a 
role in other related cardiovascular disorders.  
 
Atherosclerosis is characterised by two important factors: lipid accumulation and 
inflammation therefore the main aims of these studies were: 
 
 To explore the effects of IL-33 on the gene expression of well-characterised 
atherosclerotic markers through the use of real time-quantitative polymerase 
chain reaction (RT-qPCR) within murine and human macrophages (chapter 3) 
 The identification of key signalling pathways responsible for the IL-33-mediated 
down-regulation of pro-atherogenic genes within human macrophages. For this 
purpose a combination of small interfering RNA (siRNA) and short hairpin 
RNA (shRNA) was used to knock down the expression of signalling 
components implicated in atherosclerosis. The knock down was then validated 
by RT-qPCR and western blotting before RT-qPCR analysis was used to assess 
the effect on gene expression following stimulation by IL-33 (chapter 4). 
 To determine the influence of IL-33 on the lipid composition of murine and 
human macrophages (chapter 5) using thin layer chromatography (TLC) and gas 
chromatography (GC). 
 
Even with a growing awareness of the key contributors of cardiovascular disease, 
current risk prevention methods are lacking; as the majority of CHD events occur in 
individuals placed within the “low” and “intermediate” risk groups (Nambi et al. 2010; 
Balagopal et al. 2011). Improving our knowledge of the disease could aid future 
discovery of novel markers and therefore improve clinical risk stratification through 
better prediction and categorisation of the disease. Furthermore, a greater understanding 
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of the underlying mechanisms which give rise to pathogenesis is essential for the 
identification and development of new therapeutic targets to help combat the disease 
state. 
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CHAPTER 2.  
MATERIALS AND METHODS 
 
2.1. Chemicals and reagents 
 
Reagent Supplier Location 
10X NH4 reaction buffer, 
magnesium chloride, Taq 
polymerase 
Bioline London, UK 
Microplate reader, PTC-200 Peltier 
thermal cycler, Opticon 2 PCR 
machine 
Bio-Rad Hertfordshire, UK 
15ml and 50ml Falcon 
polypropylene tubes, black 96-well 
plate 
Corning Costar 
Amsterdam, 
Netherlands 
THP-1 cells, RAW264.7 cells, T-
Rex-293 cells 
European Collection of 
Animal Cell Cultures 
Salisbury, UK 
Chloroform, ethanol, methanol, 
potassium chloride, sodium dodecyl 
sulphate (SDS) 
Fisher Scientific Loughborough, UK 
Foetal calf serum (FCS), RPMI 
1640 tissue culture medium, 
trypsin-ethylenediaminetetraacetic 
acid (EDTA) 
Gibco BRL Paisley, UK 
6-well plates, 10ml stripettes, 12-
well plates, 25ml stripettes, 50ml 
Falcon tubes, Cell-star cell culture 
flasks, cell scrapers 
Greiner Bio-One Stonehouse, UK 
1kb DNA molecular weight 
markers, 2-mercaptoethanol, 
Invitrogen Paisley, UK 
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Dulbecco’s modified Eagle’s 
medium (DMEM) high glucose 
media, FCS, I-BLOCK, 
MagicMark™ XP western protein 
standard, MOPS running buffer, 
NuPAGE™ Novex gel tank system, 
NuPAGE™, penicillin and 
streptomycin, RPMI1640 with 
GlutaMAX™ liquid, SDS- 
polyacrylamide gel, See Blue Plus 
2, transfer buffer, Tropix® CDP-
Star® detection reagent 
Sterile 0.22μm filters, 
polyvinylidene difluoride (PVDF) 
membrane 
Millipore Watford, UK 
Spin column RNA miniprep kit NBS Biologicals 
Cambridgeshire, UK 
Anti-phospho p44/p42 
Thr202/Tyr204 (9101), anti-total 
p38 (9212), anti-total p44/p42 
(9102) 
Cell Signaling 
Technology 
Hertfordshire, UK 
LymphoprepTM 
Nycomed 
Pharmaceuticals 
Zurich, Switzerland 
Recombinant human IL-33, 
recombinant murine IL-33 
Peprotech London, UK 
Deoxyribonucleotide triphosphates 
(dNTPs), MMLV 10X buffer, 
MMLV reverse transcriptase 
(RNase H minus, point mutant), 
RNasin ribonuclease inhibitor 
Promega Southampton, UK 
Interferin™, RNeasy plus minikit, 
validated siRNAs 
Qiagen Manchester, UK 
Chicken anti-goat (sc-2961) horse Santa Cruz Texas, USA 
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radish peroxidase (HRP) conjugate, 
donkey anti-goat HRP (sc02056), 
goat anti-rabbit alkaline 
phosphatase (AP) conjugate, goat 
anti-mouse AP 
Biotechnology 
10X tris borate EDTA (TBE) 
buffer, Accuspin tubes
TM
, anti-β-
actin antibody (A2228), DAPI 
mounting media, dimethyl 
sulfoxide, ethidium bromide, RIPA 
buffer, phosphate buffered saline 
(PBS) tablets, PCR primers, 
penicillin, phorbol 12-myristate 13-
acetate (PMA), protease inhibitor 
cocktail, streptomycin, SYBR
® 
Green JumpStart
TM 
Taq ReadyMix, 
Tween 20, X-ray Film 
Sigma-Aldrich Poole, UK 
Interferin™ 
Source Bioscience Life 
Sciences 
Nottingham, UK 
96-well plates, PCR tubes, PCR 
plates, PCR seals  
Star Labs Lahore, Pakistan 
Bicinchoninic acid (BCA) protein 
assay reagents, cryovials, Restore™ 
PLUS western blot stripping buffer 
Thermo Scientific New York, USA 
Buffy Coats Welsh Blood Service Pontyclun, UK 
 
 
 
2.2. Preparation of solutions and glassware 
Solutions and glassware were autoclaved for 20-30 minutes at 121°C (975kPa) as 
necessary. 
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2.3. Cell culture techniques 
2.3.1. Cell lines 
2.3.1.1. THP-1 cells 
THP-1 is a human monocytic leukaemia cell line. The cells grow within suspension and 
following differentiation with phorbol esters become adherent and display many 
features of human monocyte-derived macrophages (HMDMs). Due to this characteristic, 
the cell line is a useful model for the study of human macrophages (Auwerx 1991; 
Kohro et al. 2004). 
2.3.1.2. RAW264.7 cells 
RAW264.7 is an adherent murine macrophage cell line derived from tumours induced 
with the  Abelson leukaemia virus (Raschke et al. 1978). The adherent cells share many 
properties of macrophages such as expression of the macrophage markers CD36 and 
CD11b, phagocytosis and production of nitric oxide (Shen et al. 2008b). 
2.3.1.3. T-REx293 cells 
T-REx293 is an adherent human cell line derived from embryonic kidney cells exposed 
to adenovirus type 5 DNA. T-REx293 cells stably express the tetracycline repressor 
protein and are capable of superinfection with other adenoviruses, therefore serving as a 
good system for growing and proliferating adenoviruses for experiments (Graham et al. 
1977). 
2.3.2. Maintenance of cell lines 
The THP-1 and RAW264.7 cell lines were cultured in RPMI1640 medium with stable 
glutamine supplemented with 10% (v/v) heat-inactivated (56ºC, 30 minutes) FCS (HI-
FCS), penicillin (100U/ml) and streptomycin (100µg/ml) (complete medium). The HI-
FCS, penicillin and streptomycin were sterilised by passing through a 0.2µm sterile 
filter. The T-REx293 kidney cell line was grown in DMEM with 4.5g/l glucose 
supplemented with 10% (v/v) HI-FCS, penicillin (100U/ml) and streptomycin 
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(100µg/ml) (complete medium). The cells were maintained at 37ºC in a humidified 
atmosphere containing 5% (v/v) CO2 and used within their 2
nd
 to 7
th
 Passage.  
2.3.3. Subculturing of cells 
2.3.3.1. THP-1 cells 
The THP-1 cells were transferred into a 50ml polypropylene tube upon reaching 
approximately 60% confluency and centrifuged at 800g for 5 minutes. The cellular 
pellet was resuspended in an appropriate volume of pre-warmed complete RPMI1640 
medium and seeded into new tissue culture flasks typically at a ratio of 1:30. The cells 
were grown up at 37ºC in a humidified incubator containing 5% (v/v) CO2. 
2.3.3.2. RAW264.7 cells 
The adherent RAW264.7 cells were subcultured until they were 80% confluent. The 
cells were liberated from the flasks using sterile disposable cell scrapers and pelleted by 
centrifugation at 800g for 5 minutes. The resulting pellet was resuspended into pre-
warmed complete RPMI1640 medium and transferred into new dishes at a ratio of 1:25. 
The cells were grown up at 37ºC in a humidified incubator containing 5% (v/v) CO2. 
2.3.3.3. T-REx293 cells 
Approximately 70% confluent T-REx293 cells were trypsinised by adding 0.25% (v/v) 
trypsin/EDTA to cover the cell monolayer. The cells were then incubated at 37ºC, 5% 
(v/v) CO2 until they became visibly detached from the flask. Complete DMEM medium 
was added to the flask in order to collect the detached cells before centrifuging at 800g 
for 5 minutes. The resulting pellet was then resuspended in pre-warmed complete 
DMEM medium to remove residual trypsin solution before seeding into new tissue 
culture flasks at a ratio of 1:12. The cells were grown up at 37ºC in a humidified 
incubator containing 5% (v/v) CO2. 
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2.3.4. Preserving and storing of cell lines  
Early passage cells (between passages 1-3) were stored at -80°C or in liquid nitrogen for 
longer storage. Prior to freezing, cells were centrifuged at 800g for 5 minutes and 
resuspended in HI-FCS containing 10% (v/v) DMSO. Cellular suspensions were 
divided into 1ml aliquots and stored in sterile cryovials. The cryovials were frozen 
overnight in a Cryo 1°C freezing container at -80°C before being transferred into liquid 
nitrogen (Nalgene). 
2.3.5. Thawing frozen cells 
The cryovials were taken from liquid nitrogen and incubated at 37°C in a water bath 
until the contents were thawed. The cells were transferred to a 50ml polypropylene tube 
containing 10ml HI-FCS and centrifuged at 800g for 5 minutes. The pellet was then 
resuspended with the appropriate pre-warmed medium containing 20% (v/v) HI-FCS, 
penicillin (100U/ml) and streptomycin (100µg/ml) before the cells were seeded into 
tissue culture flasks and cultured as described above. 
2.3.6. Counting cells 
The cells were counted using a haemocytometer (Neubaurer chamber). In preparation 
for counting, the cells were centrifuged at 800g for 5 minutes and resuspended in 3-5ml 
of the appropriate complete medium depending on an estimate of the numbers of cells. 
The haemocytometer was then covered with a precision ground coverslip and 7µl of the 
cell suspension was added, forming a monolayer of cells across the 5 x 5 counting grid. 
The total number of cells per ml was calculated by multiplying the number counted by 
10
4
. 
2.3.7. Cytokine stimulation of cells 
For RT-qPCR analysis, 500,000 cells were plated into 12-well plates and supplemented 
with 1ml of complete medium. For THP-1 monocytes, 0.16µM of PMA was added to 
the cells to promote macrophage differentiation. The cells were then incubated at 37°C 
in 5% (v/v) CO2 for 24 hours prior to cytokine treatment to facilitate adherence of cells 
to the plate. For western blot analysis, 1x10
6
 cells were plated into 6-well plates with 
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2ml of complete medium whereas 3x10
6– 6x106 cells in 2ml of complete medium were 
used for lipid analysis experiments. IL-33 (10ng/ml or 25ng/ml) was directly added to 
the culture medium for 12 or 24 hours and the treated cells were kept at 37ºC in a 
humidified incubator containing 5% (v/v) CO2.  
2.3.8. Human monocyte-derived macrophage (HMDM) cell culture 
HMDMs were isolated from monocytes obtained from buffy coats (supplied from the 
National Blood Service Wales). Lymphoprep solution was warmed to room temperature 
prior to use and added to the Accuspin centrifuge tubes. The tubes were centrifuged at 
1000g for 1 minute in order to place the Lymphoprep below the filter. The buffy coat 
was under-layered 2:1 (v/v) with Lymphoprep in the Accuspin tube and centrifuged at 
1000g for 30 minutes at room temperature. Lymphoprep contains the high molecular 
weight polysaccharide dextran and sodium diatrizoate that establishes a density gradient 
promoting the isolation of mononuclear cells due to a lower buoyant density. Higher 
density cells such as granulocytes and erythrocytes aggregated and were removed 
through centrifugation. The resulting mononuclear cell interface was collected and 
washed with an equal volume of ice-cold PBS-0.4% (w/v) tri-sodium citrate and 
centrifuged at 1000g for 5 minutes at 4°C. The pellet was resuspended in 10ml of 0.2% 
(w/v) sodium chloride solution and incubated on ice for 30 seconds. An equal volume of 
1.6% (w/v) sodium chloride solution was added before immediate centrifugation at 
1000g for 5 minutes at 4°C. Repeating this step increased the removal of erythrocytes. 
The pellet was then washed five to six times with ice-cold PBS-0.4% (v/v) tri-sodium 
citrate to remove platelets. The monocytes were isolated and plated into 12-well plates 
in RPMI1640 medium containing 5% (v/v) HI-FCS, penicillin (100U/ml) and 
streptomycin (100µg/ml). The culture medium was replaced after 7 days or more 
depending on confluency of the cells. After 7-10 days the cells differentiated into 
macrophages and were ready for use in experiments.  
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2.4. RNA/ DNA related techniques 
2.4.1. RNA isolation from cells  
Total RNA was extracted using the RNeasy Plus Mini kit (Qiagen) or the Spin Column 
RNA Miniprep kit (NBS Biologicals) according to the manufacturer’s instructions 
(information on the buffers used is included in Table 6). The kit purifies RNA 
molecules exceeding 200 nucleotides including mRNA. Briefly, the medium was 
aspirated and the cells washed once with PBS to remove traces of the growing medium 
before addition of 300μl of buffer RLT plus (provided in the kit) supplemented with 10% 
(v/v) β-mercaptoethanol to liberate the cells from the plate. Following lysis, the cells 
were either stored at -80ºC for extended storage or used immediately for RNA 
extraction. The lysate was homogenised by passing through a QIAshredder column and 
then transferred to a genomic DNA Eliminator spin column to remove genomic DNA 
from the sample. The resulting lysate was passed through an RNeasy spin column to 
concentrate the RNA on the silica-based membrane and washed with Buffer RW1 and 
RPE (both supplied in kits) to remove possible contaminants such as DNA.  
 
The resulting RNA was eluted in nuclease-free water and the concentration and purity 
was determined using a NanoDrop spectrophotometer ND-1000 (ThermoFisher) by 
measuring the absorbance of light at 260nm and 280nm. The quality of the RNA was 
 
Table 6. Buffers used in RNA extraction process 
 
Buffer Function 
Buffer RLT plus 
Disrupts plasma membranes of cells and organelles releasing 
RNA and contains guanidine thiocyanate which inactivates 
RNases to ensure isolation of intact RNA. 
Buffer RW1 Provides appropriate binding conditions for RNA. 
Buffer RPE Promotes RNA binding to the spin column. 
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also analysed by size-fractionating an aliquot on a 1.5% (w/v) agarose gel (section 
2.4.3). 
2.4.2. Reverse transcriptase-polymerase chain reaction (RT-PCR) 
Reverse transcriptase polymerase chain reaction (RT-PCR) involves two stages:  
1. cDNA synthesis from an RNA template through a reverse transcriptase-mediated 
reaction; 
2. PCR reaction of the resulting cDNA using gene specific primers to amplify a 
product of interest. 
2.4.2.1. Reverse transcriptase generation of cDNA 
RNA (1/0.5µg depending on the concentration of the isolated RNA) was incubated at 
72ºC for 5 minutes on a Biometra thermoblock with random hexamer primers (200pmol, 
PdN6) and nuclease-free water to a total volume of 13.5µl. Samples were immediately 
placed on ice. Then, 1µl of deoxyribonucleotide triphosphate (dNTP) mix (10mM each 
of deoxyadenosine triphosphate, deoxycytidine triphosphate, deoxyguanosine 
triphosphate and deoxythymidine triphosphate), 4µl of 5X Molony Murine Leukaemia 
Virus (MMLV) buffer [(50mM Tris-HCl (pH 8.3 at 25°C), 75mM KCl, 3mM MgCl2 
and 10mM DTT)], 0.5µl of Recombinant RNasin Plus inhibitor (50U/µl), 0.5µl of 
MMLV reverse transcriptase (200U/µl) were added to a final volume of 20µl and the 
mixture was incubated for 1 hour at 37ºC. The reaction was terminated by a temperature 
increase to 92ºC for 2 minutes. The mixture was then diluted with 80µl (or 30µl if 0.5µg 
RNA was used as starting material) nuclease-free water and stored at -20ºC for future 
use.  
2.4.2.2. PCR 
PCR reactions were setup containing 10x buffer [(670mM Tris-HCl (pH 8.8 at 25°C), 
160mM (NH4)2SO4, 0.1% stabilizer)] (Bioline), dNTP mix (100µM), Taq polymerase 
(1U) and forward and reverse primers (1µM), and concentration of cDNA depending on 
initial optimisation experiments. Nuclease-free water was included to give a final 
volume of 25μl. The optimised conditions ensured that the products were formed during 
the exponential phase of amplification and thus provided a direct correlation between 
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the forming product and the starting cDNA template. The PCR reactions were 
performed on a PTC-200 Peltier thermal cycler.  
2.4.3. Resolving RNA/ DNA by gel electrophoresis 
The PCR products were size-fractionated by agarose gel electrophoresis and analysed 
using a Syngene gel documentation system. The gels were made using 1.5% (w/v) 
agarose containing 0.5μg/ml ethidium bromide using the stock solutions included in 
Table 7.  
 
RNA/DNA (1µg) was prepared with loading dye to a final volume of 20µl. The samples 
were size-fractionated at 100V for 30 minutes in a Fisherbrand horizontal gel unit in 1x 
TBE buffer. The resulting bands were visualised under a UV light using a Syngene gel 
documentation system and the images were analysed by the GeneScan computer 
package (Biosoft, Cambridge, UK). Product size was compared to standard molecular 
weight markers.  
2.4.4. Real-time quantitative PCR (RT-qPCR) 
The mRNA expression of a number of genes was analysed using the SYBR
®
 Green 
JumpStart
TM
 Taq ReadyMix kit (Sigma). RT-qPCR reactions were set up with the 
reagents provided in Table 8 within a 96 well plate using gene specific primers. 
Information on primer annealing temperatures and sequences are provided in Table 9. 
The mRNA levels were measured by fold changes in expression in an Opticon 2
®
 real- 
time PCR detection system (MJ Research). The comparative ΔΔCt method was used to 
represent relative expression over absolute expression and then normalised to levels of 
the house-keeping gene glyceraldehyde 3-phosphate dehydrogenase (GAPDH) for 
 
Table 7. Composition of reagents for agarose gel electrophoresis  
 
Reagent Composition 
10x Tris Borate EDTA 0.98M Tris borate, 890mM boric acid, 20mM EDTA, pH 8. 
5x loading dye 1x TBE, 50% (v/v) glycerol, 2.25% (w/v) bromophenol blue. 
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human cells.  β-actin was used as the reference gene for mouse cells. All PCRs were 
performed at least in duplicate. 
 
During the PCR reaction copies of the DNA template are generated exponentially. 
Traditional end-point quantification assesses the PCR signal relative to a standard curve; 
however this “end-point” may fall outside of the exponential phase and thus produce 
unreliable results. However, the “real-time” method quantifies the amount of PCR 
product produced during the exponential phase of the reaction so the amount of product 
formed is directly proportional to the amount of DNA template used and allows for the 
comparison of multiple samples (Livak and Schmittgen 2001). A detectable output such 
as fluorescence is produced which relates to the level of PCR product produced after 
each cycle of the reaction. In the comparative Ct method of analysis, the fluorescence of 
a gene is required to surpass a predetermined threshold (Ct) value within the 
exponential phase and can be compared against the Ct value of a control gene to 
normalise the data (Ginzinger 2002). GAPDH and β-actin were chosen as suitable 
control genes as they have both been frequently used for this purpose by other studies 
(Mori et al. 2008; McLaren et al. 2010a; McLaren et al. 2010b) and are stably 
expressed independent of the experimental conditions. 
SYBR Green is an intercalating dye similar to ethidium bromide which fluoresces when 
bound to double-stranded DNA. During PCR, multiple molecules of the dye bind to the 
product producing a detectable fluorescent signal. The dye is non-specific and can 
therefore be used in different PCR reactions (VanGuilder et al. 2008). 
 
Table 8. Reagents for RT-qPCR 
 
 
Reagent Volume (µl) 
cDNA 1.1 
Forward primer (100µM) 0.5 
Reverse primer (100µM) 0.5 
SYBR Green JumpStart™ Taq ReadyMix 13.75 
RNase-free water 11.55 
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Table 9. Primers used during study 
Gene Forward Primer (5’ - 3’) Reverse primer (5’ - 3’) Reference 
Initial 
melting 
5 minutes 
Annealing 
60 seconds 
Extension 
60 
seconds 
Melting 
30 
seconds 
Final 
extension 
10 minutes 
Human CD36 GAGAACTGTTATGGGGCTAT TTCAACTGGAGAGGCAAAGG 
(Draude and 
Lorenz 2000) 
95°C 58°C 72°C 94°C 72°C 
Human c-Jun TCCAAGTGCCGAAAAAGGAAG CGAGTTCTGAGCTTTCAAGGT Primer Bank 95°C 60°C 72°C 94°C 72°C 
Human CPT-1 ACAGTCGGTGAGGCCTCTTATGAA TCTTGCTGCCTGAATGTGAGTTGG 
(Chinetti et al. 
2003) 
95°C 65°C 72°C 94°C 72°C 
Human ERK1 GCAGGACCTGATGGAGACTGAC CCAGAATGCAGCCCACAGAC QPCR Database 95°C 63°C 72°C 94°C 72°C 
Human ERK2 GCGCTACACCAACCTCTCGT CACGGTGCAGAACGTTAGCTG QPCR Database 95°C 63°C 72°C 94°C 72°C 
Human  GAPDH GAAGGTGAAGGTCGGAGTC GAAGATGGTGATGGGATTTC 
(Yamanishi et al. 
2002) 
95°C 60°C 72°C 94°C 72°C 
Human ICAM-1 ACGCTGAGCTCCTCTGCTACTC GGGCAGGATGACTTTTGAGG 
(Sabatakos et al. 
1998) 
95°C 63°C 72°C 94°C 72°C 
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Human JNK1 TCTGGTATGATCCTTCTGAAGCA TCCTCCAAGTCCATAACTTCCTT Primer Bank 95°C 60°C 72°C 94°C 72°C 
Human JNK2 GAAACTAAGCCGTCCTTTTCAGA TCCAGCTCCATGTGAATAACCT Primer Bank 95°C 60°C 72°C 94°C 72°C 
Human LPL GAGATTTCTCTGTATGGCACC CTGCAAATGAGACACTTTCTC (Irvine et al. 2005) 95°C 60°C 72°C 94°C 72°C 
Human MCP-1 CATTGTGGCCAAGGAGATCTG CTTCGGAGTTTGGGTTTGCTT (Locati et al. 2002) 95°C 62°C 72°C 94°C 72°C 
Human p38 GTGGTACAGGGCTCCTGAGA TATGCATCCCACTGACCAAA 
(Ashlin et al. 
2014) 
95°C 63°C 72°C 94°C 72°C 
Human PI3K-γ TCTGATGGATATTCCCGAAAGCC CTCACCCACTGGAAGTTTTTGAT Primer Bank 95°C 63°C 72°C 94°C 72°C 
Human RPL3a CCTGGAGGAGAAGAGGAAAGAG TTGAGGACCTCTGTGTATTTGT 
(Vandesompele et 
al. 2002) 
95°C 60°C 72°C 94°C 72°C 
Human SCD-1 TGCAGGACGATATCTCTAGC ACGATGAGCTCCTGCTGTTA (Peter et al. 2009) 95°C 58°C 72°C 94°C 72°C 
Human SR-A CCAGGGACATGGAATGCAA CCAGTGGGACCTCGATCTCC 
(Draude and 
Lorenz 2000) 
95°C 60°C 72°C 94°C 72°C 
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All primers were purchased from Sigma Aldrich and each reaction was subjected to 35 cycles 
 
Human SR-B1 TGATGATGGAGAATAAGCCCAT TGACCGGGTGGATGTCCAGGAAC 
(Eguchi et al. 
2006) 
95°C 60°C 72°C 94°C 72°C 
Mouse β-actin TGGAGAAGAGCTATGAGCTGCCTG GTGCCACCAGACAGCACTGTGTTG 
(Harvey et al. 
2007) 
95°C 60°C 72°C 94°C 72°C 
Mouse CD36 GAACCACTGCTTTCAAAAACTGG TGCTGTTCTTTGCCACGTCA 
(Hickman et al. 
2008) 
95°C 60°C 72°C 94°C 72°C 
Mouse ICAM-1 CAGTCCGCTGTGCTTTGAGA CGGAAACGAATACACGGTGA Primer Bank 95°C 60°C 72°C 94°C 72°C 
Mouse MCP-1 CTGGATCGGAACCAAATGAG CGGGTCAACTTCACATTCAA Primer Bank 95°C 60°C 72°C 94°C 72°C 
Mouse SCD-1 CTTCTTGCGATACACTCTGG TGAATGTTCTTGTCGTAGGG 
(Thorn et al. 
2010) 
95°C 65°C 72°C 94°C 72°C 
Mouse SR-A TGAACGAGAGGATGCTGACTG GGAGGGGCCATTTTTAGTGC 
(Hickman et al. 
2008) 
95°C 60°C 72°C 94°C 72°C 
Mouse SR-B1 TTTGGAGTGGTAGTAAAAAGGGC TGACATCAGGGACTCAGAGTAG 
(Hickman et al. 
2008) 
95°C 60°C 72°C 94°C 72°C 
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2.5. Small interfering RNA (siRNA) transfections with Interferin™ 
siRNA transfections were performed using validated siRNAs against target mRNA 
sequences (Table 10). Stock solutions of lyophilised siRNA were prepared in nuclease-
free water according to the manufacturer’s instructions (Qiagen and Invitrogen). 
 
Table 10. siRNAs used in study 
 
Target mRNA transcript NCBI accession 
number(s) of target 
SI reference number/ 
catalogue number 
Negative control N/A AM4611 
GAPDH 
NM_002046 NM_002046 
ERK2 
NM_002745 SI00300755 
JNK1 
NM_002750 SI02758637 
JNK2 
NM_001135044 SI02222920 
p50 
NM_001165412, 
NM_003998 
SI02654932 
p65 
NM_001145138, 
NM_001243984, 
NM_001243985, 
NM_021975 
SI00301672 
 
siRNA transfections were carried out before the addition of PMA. THP-1 cells were 
harvested upon reaching approximately 60% confluency and centrifuged at 800g for 5 
minutes. The resulting pellet was then resuspended in an appropriate volume of pre-
warmed RPMI1640 medium supplemented with 10% (v/v) HI-FCS without any 
antibiotics. Then, 500,000 THP-1 cells were seeded into 12-well plates and incubated at 
37ºC in a humidified incubator containing 5% (v/v) CO2 for 4 hours prior to 
MATERIALS AND METHODS  Melanie Buckley 
 
 
72 
 
transfections. siRNA transfections were performed according to the manufacturer’s 
instructions (Polyplus Transfection) with a few minor modifications. Briefly, 100µl of 
transfection mix was made in HI-FCS-free and antibiotic-free RPMI1640 medium 
consisting of 7.5nM siRNA and 9µl of Interferin and then quickly vortexed. The 
mixture was left to incubate for 20 minutes at room temperature before addition to the 
cells in a drop-wise manner. The cells were then placed at 37ºC in a humidified 
incubator containing 5% (v/v) CO2 for 24 hours. PMA (0.16µM) was added to 
differentiate the cells for 24 hours before IL-33 stimulation for 12 hours. For analysis by 
western blotting, the same procedure was used but 1x10
6
 cells were plated and a 200µl 
transfection mixture was made with twice the amount of siRNA and Interferin. 
Following IL-33 stimulation, the RNA was harvested following the procedure described 
in section 2.4.1. or the protein was extracted for western blot analysis following the 
protocol in section 2.7. 
2.6. Adenoviral delivery of short hairpin RNA (shRNA)  
2.6.1. Generating recombinant adenoviral vectors 
TREx-293 cells (2x10
6
) were plated into a small culture flask in complete DMEM 
medium for 2 days to allow attachment to the flask’s surface before infection. 
Adenoviral type 5 recombinant vector DNA (4µg) was prepared in pre-warmed DMEM 
medium without HI-FCS or antibiotics and left at room temperature for 10 minutes. The 
medium on the TREx-293 cells was aspirated and replaced with fresh complete DMEM 
medium before addition of the DNA mixture. Thereafter the flasks were incubated at 
37ºC in a humidified incubator containing 5% (v/v) CO2 for 24 hours before the 
medium was changed with fresh complete DMEM medium. Viral plaques formed after 
7-10 days which constituted the initial viral stock was added to a larger flask containing 
6x10
6
 TREx-293 cells to generate a useable amount of virus. These flasks were cultured 
for 3-10 days until viral plaques were produced. The virus was then extracted in PBS. 
Briefly, the cells were centrifuged at 1000g for 5 minutes and the pellet was 
resuspended in PBS to wash the pellet. The cells were centrifuged once more and then 
resuspended in a 1:1 (v/v) ratio of PBS to tetrachloroethylene to lyse the cells. The 
mixture was then shaken vigorously and centrifuged at 1000g for 20 minutes. The top 
layer of PBS containing the virus was carefully removed and stored at -80ºC. DNA 
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sequencing of the recombinant vector DNA used in the experiments was previously 
performed by the Molecular biology support unit, School of Biosciences at Cardiff 
University to ensure specific targeting by the virus. 
2.6.2. Titering of the adenoviruses 
To determine the titre of the adenovirus generated, 5x10
5
 TREx-293 cells were seeded 
in 1ml of compete DMEM medium in a 12-well plate and incubated overnight at 37ºC 
in a humidified incubator containing 5% (v/v) CO2. Serial dilutions were then prepared 
of the viral stock, of which 100μl of the 10-4 and 10-5 dilutions were added to the cells 
before incubation for 48 hours at 37ºC in a humidified incubator containing 5% (v/v) 
CO2. Afterwards, the medium was aspirated and the wells left to air-dry at room 
temperature. Then 1ml of ice cold 50%:50% (v/v) acetone/methanol was added to the 
wells for 10 minutes at -20ºC to fix the cells to the surface of the plate. The 
acetone/methanol layer was aspirated and the cells were washed three times with PBS 
containing 1% (w/v) bovine serum albumin (BSA). The cells were then incubated at 
37ºC on a rocker with a goat anti-adenovirus primary antibody (Chemicon) made up in 
a 1:5000 dilution in PBS containing 1% (w/v) BSA. After 1 hour, the primary antibody 
was aspirated and the cells were washed three times with PBS containing 1% (w/v) 
BSA. The cells were then incubated with two secondary antibodies; chicken anti-goat 
and donkey anti-goat (Abcam) made up at a 1:1000 dilution in PBS with 1% (w/v) BSA 
for 1 hour before washing with PBS containing 1% (w/v) BSA three times. 3,3’-
diaminobenzidine tetrahydrochloride (DAB) was added to the cells for 10 minutes to 
stain cells containing the antibody. The DAB was removed and the cells washed for a 
final time with PBS. The cells were then counted on a light microscope (Leica) as the 
number of infected cells per field of view at a 10X magnification. The number of plaque 
forming units/ml was calculated by: 
 
(Infected cells by field X 150) 
[(Virus volume (ml) X dilution factor)] 
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2.6.3. Adenoviral transfection of THP-1 cells 
Following the procedure described in section 2.3.6, 5x10
5
 THP-1 cells were plated in a 
12-well plate. The adenovirus was then added at a multiplicity of infection previously 
optimised in our laboratory of 100. The cells were left for 2.5 hours at 37ºC in a 
humidified incubator containing 5% (v/v) CO2 before the addition of 0.16µM PMA (for 
THP-1 cells). The cells were then incubated at 37ºC in a humidified incubator 
containing 5% (v/v) CO2 for 48 hours before IL-33 stimulation. 
2.6.4. Efficiency of adenoviral-mediated knock down  
The knock down efficiencies of adenoviral-delivered shRNAs were assessed by qPCR 
(section 2.4) using gene-specific primers and western blot analysis (section 2.7). 
2.7. Protein analysis  
2.7.1. Cellular lysis 
For analysis by western blotting, 1x10
6 
THP-1 cells were plated in a 6-well plate. 
Following cytokine stimulation for the prerequisite amount of time, the medium was 
aspirated and the cells were washed with ice cold PBS. The PBS was removed and the 
samples were lysed in an appropriate volume of RIPA buffer [(150 mM NaCl, 1.0% 
(v/v) IGEPAL® CA-630, 0.5% (w/v) sodium deoxycholate, 0.1% (w/v) SDS and 
50mM Tris (pH 8.0)] (Sigma) (typically 80µl). The cells were then scraped from the 
well and micro-centrifuged at 1000g for 5 minutes. The supernatant was transferred to a 
1.5ml micro-centrifuge tube and stored at -80ºC, or used immediately for protein 
quantification or sodium dodecyl-sulphate-polyacrylamide gel electrophoresis (SDS-
PAGE) followed by western blotting. 
2.7.2. BCA protein assay 
The concentration of total protein within the samples was determined using the Micro 
BCA protein assay reagent kit (Pierce). A standard curve was prepared using a range of 
concentrations of BSA: 0, 5, 10, 15, 20 and 25μg/ml. The BCA cocktail was prepared 
following manufacturer’s instructions and 150μl of this mix was added to 150μl of 
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standards and samples (diluted 1 in 50 in RIPA buffer) in a 96-well plate. The plate was 
covered, incubated for 2 hours at 37°C and the absorbance of each sample read at 
570nm on a 680-microplate reader (Bio-Rad Laboratories). The protein concentration of 
the samples was calculated from the resulting standard curve. 
2.7.3. Sodium dodecyl-sulphate-polyacrylamide gel electrophoresis (SDS-
PAGE) 
The protein samples were mixed with an equal volume of gel sample buffer (Table 11), 
boiled at 100°C for 5 minutes and then cooled on ice. The samples were loaded onto a 
pre-cast NuPAGE 4-12% Bis-Tris gel (1.0mm thick, 10-well) designed to separate 
small- to medium-sized proteins under denaturing conditions. NuPAGE gels provide a 
near neutral pH to minimise protein modifications. Proteins become denatured when 
boiled in the presence of SDS and form a rod-like complex with the SDS molecules. 
The SDS also masks the protein’s charge and therefore enables fractionation based 
solely upon size (Dennison 1999). SDS-PAGE was performed on the Novex NuPAGE 
gel electrophoresis system (Invitrogen) filled with NuPAGE MOPS SDS running buffer 
(Invitrogen). The See Blue Plus 2 marker (Invitrogen) was included to form a 4-250kDa 
ladder and the gel was subjected to electrophoresis at 150-200V, 400mA for 1-2 hours.  
MATERIALS AND METHODS  Melanie Buckley 
 
 
76 
 
Table 11. Stock solutions of reagents used in SDS-PAGE and western blotting 
 
Reagent Composition 
Gel sample buffer 
63mM Tris HCl pH 6.8, 10% (v/v) glycerol, 5% (v/v) β-
mercaptoethanol, 2% (w/v) SDS, 0.0025% (w/v) bromophenol 
blue. 
NuPAGE
® 
MOPS 
SDS running buffer 
(20X) 
50mM 3-(N-morpholino) propane sulphonic acid (MOPS), 
50mM Tris Base, 0.1% (w/v) SDS, 1mM EDTA, pH 7.7. 
NuPAGE
® 
transfer 
buffer 
50mM bis-tris propane, 50mM Bicine, 20% (v/v) methanol. 
PBS-Tween 10L ddH20, 100 PBS tablets, 20ml Tween20. 
I-BT solution 
500ml PBS-Tween, 1g Tropix I-BLOCK, 500μl of 5% (v/v) 
sodium azide. 
Ponceau S 0.1% (w/v) Ponceau S, 5% (v/v) acetic acid, ddH20. 
 
2.7.4. Western blotting  
Following electrophoresis, the gel was removed and arranged into an Xcell II™ Blot 
Module (Invitrogen) prepared in NuPAGE transfer buffer. The proteins were transferred 
onto a methanol-activated Immobulin-P polyvinylidene difluoride (PVDF) membrane 
(Millipore) by electrophoresis, at 150V for 2 hours. The efficiency of the transfer was 
assessed by Ponceau S staining of the PVDF membrane. 
2.7.5. Immunodetection of proteins 
The blotted PVDF membranes were washed in PBS-Tween for 5 minutes before 
blocking in I-BT for 1 hour with continuous shaking. The membrane was incubated 
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with the primary antibody diluted in I-BT (details of the antibodies used are given in 
Table 12) and left overnight at 4°C. Afterwards the membrane was washed three times 
with PBS-Tween for 5 minutes before incubation with the secondary antibody. After 1 
hour, the membrane was washed three times in PBS-Tween.  
 
Table 12. Antibodies used for immunodetection in western blot analysis 
 
Protein Primary 
Antibody 
Dilution Secondary Antibody Dilution Protein Size 
β-actin 
Polyclonal 
Mouse 
1:10,000 
Goat Anti-Mouse 
Alkaline phosphatase 
(AP) 
1:5000 42kDa 
Phospho
ERK1/2 
Rabbit 1:1000 Goat Anti-Rabbit (AP) 1:5000 
44kDa ERK1 
42kDa ERK2 
Total 
ERK1/2 
Rabbit 1:1000 Goat Anti-Rabbit (AP) 1:5000 
44kDa ERK1 
42kDa ERK2 
Total 
JNK1/2 
Rabbit 1:1000 Goat Anti-Rabbit (AP) 1:5000 
46kDa JNK1 
54kDa JNK2 
Total 
p38 
Rabbit 1:1000 Goat Anti-Rabbit (AP) 1:5000 43kDa 
Total 
p50 
Rabbit 1:1000 Goat Anti-Rabbit (AP) 1:5000 
50kDa, 120kDa 
precursor 
Total 
p65 
Rabbit 1:1000 Goat Anti-Rabbit (AP) 1:5000 65kDa 
 
2.7.6. Detection of chemiluminescence  
Membrane-bound proteins were then detected by incubation with 0.25mM of Tropix 
CDP-Star
®
 (Applied Biosystems). The chemiluminescence detection reagent is cleaved 
by the AP linked to the secondary antibody producing luminescence correlating with the 
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amount of protein present. The membrane was exposed to Kodak XAR sensitive film 
(Sigma) in a light resistant X-ray cassette (Genetic Research Instrumentation) for 
different exposure times and developed using an Agfa developing machine.  
2.7.7. Densitometric analysis of western blots 
Semi-quantitative measurement of signals on the blots was performed by densitometric 
analysis using the Gene Tools software (GRI, Braintree, UK). The values for the test 
protein was normalised to the β-actin housekeeping protein.  
2.8. Lipid analysis of cells 
2.8.1. Lipid extraction  
Lipids from THP-1 and RAW264.7 cells were extracted using a modified version of the 
method first described by Garbus and colleagues (Garbus et al. 1963). The cells were 
subcultured in a 6-well plate following the procedure described in section 2.3.3 to 
obtain 3x10
6– 6x106 cells per well. The cells were then stimulated with vehicle or IL-33 
for either 12 or 24 hours. The medium was replaced with PBS and the cells scraped 
from the plate and transferred into a 1.5ml micro-centrifuge tube. The samples were 
centrifuged at 1700g for 5 minutes at room temperature and the resulting pellet was 
resuspended in 1ml of distilled water and 2.5ml of chloroform: methanol (1:2 v/v) to 
stop any cellular activities and to extract lipids. The lysate was transferred to a glass 
tube and vortexed. Samples were then either stored at -20ºC for short-term storage or 
kept at room temperature for 15 minutes. Then, 1ml of chloroform and 1ml of Garbus 
solution (2M potassium chloride in 0.5M potassium phosphate buffer, pH 7.6) was 
added and the samples were centrifuged at 1000g for 3 minutes (Baird  and Tatlock 
Auto Bench centrifuge) producing a chloroform-rich lower phase, aqueous layer and 
cellular debris present at the interface. The saline upper layer contained much of the 
non-lipid contaminants such as sugars and amino acids. The chloroform portion, 
containing the total lipid extract, was dried under a stream of nitrogen and reconstituted 
in chloroform for storage at -20°C. Samples were dried under nitrogen before storage to 
reduce autoxidation of PUFAs. 
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2.8.2. One-dimensional thin layer chromatography (TLC) 
The samples were prepared on 10x10cm Silica gel G plates to pre-fractionate into 
individual classes prior to GC. Total lipids were separated using one-dimensional TLC 
due to differences in partitioning behaviour between the mobile liquid phase and 
stationary phase (Hajjar and Pomerantz 1992; Perona and Ruiz-Gutierrez 2004). The 
mobile phase consisted of a mixture of hexane:diethyl ether:acetic acid (80:20:1 v/v) 
and permitted migration of free fatty acids (FFAs) whilst more complex lipids such as 
phospholipids remained at the origin. The plates were then dried and sprayed with 0.05% 
(v/v) 8-anilino-4-naphthosulphonic acid in methanol, a non-destructive method of 
detection in comparison to sulphuric acid, and visualised by UV using a Syngene Gel 
Documentation System. PLs, TAGs and sterols were scraped from the plates for further 
analysis.  
2.8.3. Fatty acid analysis by gas chromatography (GC) 
TAGs cannot be directly analysed by GC and require conversion to a more apolar and 
volatile species. The lipid samples were prepared by transmethylation to fatty acid 
methyl esters (FAMEs) by the addition of 1ml of 2.5% H2SO4 (v/v) in dry methanol: 
toluene (2:1 v/v) at 70°C. Then 2ml of 5% sodium chloride (w/v) was added and the 
samples were washed twice with 3ml of HPLC grade hexane and centrifuged at 1000g 
for 3 minutes at room temperature to separate the aqueous and hexane layers. The 
hexane layer was evaporated under nitrogen and reconstituted with a small volume of 
hexane. 
Heptadecanoic acid (C17:0) was included as an internal standard to produce peaks for 
reference and to test if the system was functional. The FAMEs were separated and 
analysed on a 30m x 0.25mm i.d capillary column at 170°C for 3 minutes and 220°C for 
30 minutes (Clarus 500 gas chromatograph, Perkin-Elmer). The column partitions the 
sample between the mobile (gaseous) and stationary (liquid) phase and individual fatty 
acids display different retention times based upon their relative affinities providing a 
fatty acid profile of the sample. A G411 standard mixture (Nu-Chek Prep) was used to 
identify FAMEs based upon retention times. 
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2.9. Statistical analysis  
Data was tested for normality using the Shapiro-Wilk test and represented as mean ± 
standard deviation and single comparisons were carried out using the Student’s t test 
(two-tailed, paired) in Excel (Microsoft Inc, USA). For multiple comparisons one-way 
ANOVA was mostly employed accompanied with Tukey’s post-hoc test, where 
homogeneity of variance was met; otherwise Welch’s test of equality of means with 
Games-Howell post-hoc analysis was performed using SPSS software (IBM, USA). The 
results were regarded as significant where *p<0.05, **p<0.01, ***p<0.001.  
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CHAPTER 3.  
THE REGULATION OF EXPRESSION OF KEY 
GENES IMPLICATED IN ATHEROSCLEROSIS  
 
3. Introduction 
3.1. Markers of atherosclerosis  
Strategies to tackle the disease are often introduced too late to prevent cardiac events as 
clinical manifestations of atherosclerosis can arise decades after original disease 
initiation (Ross 1993). However, a number of molecules are integral to the development 
of atherosclerosis and may therefore serve as functional biomarkers of the disease, some 
of which can be measured and potentially used to predict future cardiac events (Koenig 
and Khuseyinova 2007). 
3.1.1. Leukocyte recruitment and attachment 
During atherosclerosis circulating leukocytes travel along a chemotactic gradient 
towards the lesion site. In response to pro-inflammatory stimuli such as LPS, elevated 
levels of mmLDL (Berliner et al. 1990), shear stress (Shyy et al. 1994) and 
inflammatory cytokines; arterial cells including SMCs and endothelial cells release the 
chemokine MCP-1 (Strieter et al. 1989; Rollins et al. 1990). MCP-1 becomes tethered 
to proteoglycans within the arterial lumen and interacts with CCR2 present on the 
surface of the rolling leukocytes (Niu and Kolattukudy 2009). Plaque-resident cells 
amplify levels of MCP-1 and studies exploring the effects of MCP-1 overexpression 
within atherosclerotic models have shown that elevated MCP-1 promotes the 
accumulation of modified LDL and increases the number of leukocytes within the 
plaque (Aiello et al. 1999). In contrast, MCP-1 knockout mice crossed with ApoE
-/-
 
mice contain reduced quantities of lipids within their aortas and display a diminished 
number of macrophages within the aortic wall (Gu et al. 1998). Another chemokine 
MIP-1β, also known as CCL4, also supports leukocyte recruitment and is secreted by T 
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cells within the plaque (Wilcox et al. 1994). Levels of MIP-1β are significantly elevated 
within human plaques and in peripheral blood mononuclear cells from patients with 
familial hypercholesterolaemia (Reape and Groot 1999; Holven et al. 2003).  
IFN-γ–inducible protein–10 (IP-10) is another chemoattractant glycoprotein that 
participates in the adhesion of T cells and monocytes to endothelial cells. Mice deficient 
in IP-10 exhibit a compromised T cell response associated with a decreased number of 
cells and reduced secretion of IFN-γ (Dufour et al. 2002). During atherosclerosis, 
activated monocytes, endothelial cells and T cells secrete IP-10 in response to low shear 
stress and IFN-γ. Levels of the glycoprotein are raised in patients with CAD (Taub et al. 
1996) and are also elevated in complicated atherosclerotic plaques (Cheng et al. 2007; 
Profumo et al. 2010).  
Activated endothelial cells express surface molecules that facilitate the attachment and 
infiltration of circulating leukocytes into the subendothelial space (Springer 1994). The 
process is mediated by an array of adhesion molecules including VCAM-1, P-selectin, 
E-selectin and ICAM-1 expressed at the surface of the endothelium (Albelda et al. 
1994). Disturbed laminar flow causes the up-regulation of ICAM-1 at the surface of 
endothelial cells and in vitro studies have demonstrated that increased expression of 
ICAM-1 directly relates to enhanced adhesion of lymphocytes (Nagel et al. 1994). 
Levels of circulating ICAM-1 are raised in patients with CHD and during carotid artery 
atherosclerosis (Hwang et al. 1997).  
3.1.2. Scavenger receptors (SRs) 
During normal physiology, cellular levels of cholesterol are carefully regulated through 
homeostatic mechanisms that influence the expression of LDLRs thereby modulating 
the uptake of LDL into the cell (Podrez et al. 2000). However, chemical modification of 
LDL facilitates the uptake of these particles through alternative receptors that are not 
subjected to typical feedback mechanisms. SRs form part of the innate immune system 
tasked with the recognition of a wide range of ligands associated with pathogenic 
classes of molecular patterns and support the elimination of foreign agents (Silverstein 
and Febbraio 2009). Several SRs contain multiple LDL binding sites that facilitate the 
uptake of modified forms of LDL (Freeman et al. 1991; Pearce et al. 1998). SR-
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mediated uptake of lipoproteins promotes the formation of lipid-engorged foam cells 
associated with the disease state (Goldstein et al. 1979).  
The integral membrane receptor SR-A is expressed by an array of cells such as 
monocytes, macrophages, SMCs and endothelial cells and recognises a broad range of 
ligands. Studies in SR-A
-/-
 mice have identified that SR-A promotes the differentiation 
of monocytes into macrophages and is the principle route for AcLDL uptake (Gough et 
al. 1999). The multi-ligand SR CD36 is also expressed by many lesion-resident cells 
including platelets, macrophages, endothelial cells and SMCs (Demers et al. 2004; 
Collot-Teixeira et al. 2007) and is a class B SR that mediates the uptake of advanced 
glycation end products (Ohgami et al. 2001), thrombospondin-1 (Pearce et al. 1998), 
growth hormone-releasing peptides (Demers et al. 2004) and various lipid derivatives 
(Hoebe et al. 2005). Interestingly, ablation of both CD36 and SR-A in ApoE
-/-
 mice 
does not affect the size of atherosclerotic lesions (Manning-Tobin et al. 2009). However, 
the absence of these SRs disturbs the evolution of the plaque by limiting macrophage 
apoptosis and reducing the expression of pro-inflammatory and apoptotic genes 
resulting in decreased necrosis within the plaque (Manning-Tobin et al. 2009). In 
contrast, targeted down-regulation of either CD36 or SR-A hinders atherosclerotic 
development and silencing of one receptor results in the up-regulation of the other due 
to compensatory mechanisms (Makinen et al. 2010).  
Although the expression of many SRs are up-regulated during atherosclerosis and exert 
atherogenic effects, the results from many studies have described conflicting actions for 
SR-B1. SR-B1 is a highly conserved surface glycoprotein and is widely expressed in 
different tissues and cell types including macrophages, endothelial cells and SMCs (Van 
Eck et al. 2005). SR-B1 functions as a high affinity receptor of native and modified 
LDL and displays similar binding preferences as CD36 (Acton et al. 1994). However, 
the receptor also binds HDL particles with high affinity, facilitating the selective uptake 
of CEs in the absence of HDL internalisation (Liu and Krieger 2002) and also mediates 
the efflux of unesterified cholesterol to HDL (Ji et al. 1997). Interestingly, 
overexpression of SR-B1 causes a drastic reduction in HDL, LDL and VLDL levels 
accompanied with enhanced amounts of biliary cholesterol (Kozarsky et al. 1997; Wang 
et al. 1998). In contrast, attenuation of SR-B1 elevates levels of HDL (Varban et al. 
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1998) and a complete absence of the receptor raises plasma cholesterol levels and 
results in the formation of enlarged HDL particles (Rigotti et al. 1997). 
3.1.3. Metabolic enzymes 
LPL resides within the luminal surface of capillary endothelial cells but is released and 
synthesised from a range of tissues including adipose, skeletal, muscle, heart and 
mammary gland (Benavram et al. 1986). LPL is a rate-determining enzyme responsible 
for the catabolism of TAGs to FFAs and 2-monoacylglycerol from TAG-enriched 
circulating lipoproteins including VLDLs and chylomicrons (Tsutsumi 2003). The 
resulting FFAs and 2-monoacylglycerol are assimilated into tissues whilst the remnant 
particles are taken up by the liver and residual surface matter is incorporated into HDLs 
(Peterson et al. 1992). Complete knockout of LPL in mice is fatal, the newly born mice 
exhibit elevated levels of TAGs and VLDLs, and hypertriglyceridemia is the eventual 
cause of death for these animals (Weinstock et al. 1995).  
The enzyme is expressed within human and rabbit atherosclerotic plaques by 
macrophages and SMCs (Ylaherttuala et al. 1991a; Obrien et al. 1992). Interestingly, 
LPL expressed by muscle and adipose tissue is regarded as anti-atherogenic as the 
enzyme aids the clearance of circulating lipoproteins such as VLDL and chylomicrons 
(Mead et al. 2002). However, LPL expressed by macrophages has a pro-atherogenic 
role. Bone marrow transplantation experiments by Babaev et al. (1999) demonstrated 
that these actions arise due to a bridging effect whereby the enzyme binds lipoproteins 
and the cell surface through separate domains, thereby promoting the accumulation of 
lipoproteins and aiding subsequent uptake by receptor- and non-receptor-mediated 
mechanisms (Babaev et al. 1999). 
3.2. Experimental aims 
Due to the growing interest in the protective actions of IL-33, the studies presented in 
this chapter attempted to further establish the role of the cytokine within atherosclerosis. 
The primary aims of this chapter were to validate the use of THP-1 cells as a suitable in 
vitro human model system that could be used to test the regulatory role of IL-33 and 
secondly to confirm the effects of IL-33 stimulation on atherosclerotic markers (shown 
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in Table 13) previously employed by the laboratory such as SR-A and SR-B1. These 
experiments additionally aimed to evaluate the effects of IL-33 on previously untested 
genes, like ICAM-1 and MCP-1, within the validated system.  
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Table 13. Experimental atherosclerotic markers 
 
Gene Role in atherosclerosis Reference 
CD36 
Transmembrane SR facilitates modified LDL uptake in macrophages.  
Mice deficient in ApoE and CD36 display increased atherogenic 
lipoprotein profile. 
(Febbraio et al. 2000; 
McLaren et al. 
2010a) 
ICAM-1 
Transmembrane adhesion protein that mediates firm adhesion of 
inflammatory cells to the endothelium. Increased levels of circulating 
ICAM-1 present in patients with CHD and atherosclerosis, and 
functions as a robust marker of inflammation. 
(Hwang et al. 1997; 
Blankenberg et al. 
2003) 
IP-10 
Chemokine expressed by lesion-resident endothelial cells and 
macrophages. Biomarker of ischemic stroke risk. 
(Lucas and Greaves 
2001; Prugger et al. 
2013) 
LPL 
Mediates hydrolysis of TAGs in chylomicrons and VLDL resulting in 
release of FFAs and 2-monoacylglycerol. Facilitates modified 
lipoprotein uptake by macrophages through bridging effect. Bone 
marrow transplantation from LPL
-/- 
mice into irradiated C57BL/6 
mice fed on a high fat diet reduces lesion size. 
(Van Eck et al. 2000; 
Mead et al. 2002; 
Mead and Ramji 
2002; Lusis et al. 
2004) 
MCP-1 
Primary chemokine responsible for recruitment of circulating 
monocytes to lesion site, secreted by cellular components of the 
arterial wall. Elevated in cases of experimental and clinical HF. 
Robust marker for pro-inflammatory cytokine action. 
(Hayashidani et al. 
2003; Deo et al. 
2004) 
MIP-1β 
Chemokine promotes macrophage and T cell recruitment to plaque. 
Stimulation by MIP-1β increases ROS generation and adhesion of 
THP-1 cells to inflamed human umbilical vein endothelial cells 
(HUVECs). 
(Lucas and Greaves 
2001; Tatara et al. 
2009) 
SR-A 
Facilitates unregulated uptake of modified LDL in macrophages. SR-
A deficient mice crossed with ApoE
-/-
 mice develop less 
atherosclerotic lesions than ApoE
-/-
 mice. 
(Suzuki et al. 1997; 
McLaren and Ramji 
2009) 
SR-B1 
Promotes RCT by HDLs and increases uptake of modified 
lipoproteins. Role in atherosclerosis uncertain. Irradiated ApoE
-/-
 mice 
transplanted with bone marrow from SR-B1
-/-
 mice display increased 
atherosclerosis. Transient overexpression of SR-B1 in LDLR
-/-
 mice 
results in reduced size of atherosclerotic plaques. 
(Kozarsky et al. 
2000; Zhang et al. 
2003; Zhao et al. 
2007; Chinetti-
Gbaguidi and Staels 
2009) 
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By characterising the responses of previously studied genes, the optimal concentration 
and time point for cytokine treatment could be identified for subsequent studies. The 
experimental strategy is outlined in Figure 8. 
 
 
 
                                 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PHASE ONE   System optimisation 
 
 
 
 
 
 
 
PHASE TWO Confirmation of findings 
THP-1 
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Establish THP-1 as 
suitable in vitro system 
THP-1 
macrophages 
RNA 
extraction 
 
RT-qPCR 
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Figure 8. Experimental strategy 
The strategy employed to analyse the effects of IL-33 on the expression of key atherosclerotic 
markers. Early studies were performed in the well-studied THP-1 cell line and then expanded into 
HMDMs and RAW 264.7 macrophages to gain a further understanding of the respective physiological 
and species-specific role of IL-33.   
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3.3. Experimental design  
3.3.1. The THP-1 cell line  
The THP-1 cell line is a well-established cellular system isolated by Tsuchiya in 1980 
from a patient with leukaemia (Tsuchiya et al. 1980). THP-1 cells are round suspension 
cells that mimic many aspects of native monocytes. In response to specific reagents like 
PMA and 1,25-dihydroxyvitamin D-3 (VD3) the monocytic cells differentiate into 
macrophages. The change is associated with alterations in cellular morphology 
identifiable by irregularity of the nucleus and the presence of phagocytic vacuoles 
within the cytoplasm (Auwerx 1991; Qin 2012). This transformation is also 
accompanied by increased adherence to culture plates and induced expression of 
macrophage markers such as SRs, LPL and ApoE within 3 hours of PMA treatment 
(Tsuchiya et al. 1982). 
There are a number of monocytic-macrophage cell lines available such as HL-60, U937, 
KG-1 and HEL that provide effective in vitro systems to study atherosclerotic processes. 
Cell lines have several advantages over primary cells, such as primary HMDMs, that 
tend to have reduced cell counts arising from low rates of proliferation. The population 
of primary cells can also be heterogeneous due to donor-specific variation (Maess et al. 
2010; Qin 2012). Additionally, the cells are notoriously difficult to transfect with 
siRNA and have a limited lifespan. For these reasons THP-1 cells are frequently used in 
atherosclerotic studies and several groups have shown that these cells share a greater 
conservation of responses with primary cells than other available monocytic cell lines 
(Auwerx 1991; Qin 2012).  
During the study PMA was used to differentiate the cells (see Figure 9) as our 
laboratory (Harvey et al. 2007; McLaren et al. 2010b; Salter et al. 2011) and a 
multitude of other studies (Kohro et al. 2004; Daigneault et al. 2010; Maess et al. 2010) 
have previously used the reagent for this purpose. Treatment with the phorbol ester 
produces a more differentiated phenotype based upon adherence, phagocytic capabilities 
and the expression of macrophage surface markers CD11b and CD14 in comparison to 
alternative reagents like VD3 (Schwende et al. 1996).  
 
 
B 
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Figure 9. Differentiation of THP-1 monocytes to macrophages 
THP-1 monocytes (1 x 10
6
 cells) were plated in a 12-well plate (A) and differentiated into 
macrophages following incubation with PMA (0.16µM) for 24 hours (B). The maturation of the 
cells was accompanied with alterations in morphology and cellular characteristics. Photos are 
taken at 10X magnification on a light microscope and the scale bar represents 100µm. 
A 
B 
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3.4. Results  
3.4.1. Optimisation of PCR conditions 
Initial experiments were performed in THP-1 macrophages following a 24 hour 
differentiation period with PMA with the concentration and incubation time point 
previously used by our laboratory (McLaren et al. 2010a; McLaren et al. 2010b) to 
select important IL-33-regulated genes for further mechanistic studies and optimisation 
of experimental conditions. RT-qPCR was performed using gene-specific primers with 
conditions designed to obtain a single product of the expected size. Primer sequences 
were sourced from published literature and primer-Blast searches were performed to 
confirm that the primer sequence was specific for the intended product (Figure 10). 
 
 
 
 
The amounts of reagents used for each reaction were well established in our laboratory, 
but the annealing temperatures between the different primer sets differed. As such a 
range of annealing temperatures were tested for each chosen primer set and the resulting 
PCR products were size-fractionated by agarose gel electrophoresis (Figure 11); 
amplification of the correct product was verified by expected size and sequence analysis. 
Furthermore, the absence of a band in samples lacking reverse transcriptase indicated 
that any product generated was due to amplification of the relative mRNA and not due 
to possible contamination of the samples with genomic DNA.  
Figure 10. MCP-1 primer homology 
Primer-Blast search details identifying that the primer sequence is 100% specific for human MCP-1. 
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In studies designed to analyse the actions of IL-33, the cells were stimulated by IL-33, 
harvested and the RNA was isolated in order to perform RT-qPCR. The integrity of the 
RNA was evaluated by resolving an aliquot of these preparations on a 1.5% (w/v) 
agarose gel and the quality of the RNA was assessed by the presence of the 28S rRNA 
band at a relative intensity approximately twice that of the 18S rRNA band for each 
sample (an example is provided in Figure 12). RNA of this quality was generated 
throughout the study. Also, only RNA with an OD260/OD280 ratio of 1.9-2.1 was used 
for experiments as an additional indicator of high RNA purity.  
 
 
 
 
Figure 11. MCP-1 primer optimisation 
cDNA was taken from the same experiment and subjected to a range of annealing temperatures 
(62- 64ºC shown). The products from RT-PCR were assessed on a 1.5% (w/v) agarose gel. As a 
result an annealing temperature of 62ºC was chosen. The expected product size for MCP-1 
=91bp. The position of the 100 bp marker is shown. Abbreviations: -RT, minus reverse 
transcriptase. 
62ºC -RT 
100bp 
63ºC 64ºC Marker 
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RT-qPCR was subsequently performed with the DNA-binding dye SYBR Green I 
which interacts with double stranded DNA and emits a fluorescent signal upon 
excitation by a light source (Ginzinger 2002). Data analysis was carried out using the 
comparative Ct method as described by Livak and Schmittgen (Livak and Schmittgen 
2001). Briefly, successive rounds of amplification are performed during which the 
fluorescent output of a gene surpasses a pre-set threshold value (the Ct value) within the 
exponential phase that directly correlates to the amount of starting template. The 
method provides a comparative difference between the investigated gene and a 
reference gene; for these experiments GAPDH was used, to enable relative quantitative 
comparisons between the samples (VanGuilder et al. 2008).  
Melting curve analysis was performed following completion of the PCR reaction 
whereby the annealed products were melted by small increases in temperature and the 
reduction in fluorescence was measured as the strands dissociate to ensure the 
production of a single peak in each experiment. Plotting the temperature against the rate 
of change in fluorescence provides a distinct peak corresponding to the melting 
temperature of a product (Pryor and Wittwer 2006). The melting curves for MCP-1 and 
GAPDH are given as an example in Figure 13. 
 
Figure 12. Gel electrophoresis of RNA 
Total RNA extracted from PMA-treated THP-1 macrophages. RNA preparations from five 
separate samples were subjected to gel electrophoresis to check integrity.  
 
 
       Samples        1           2           3          4          5 
            28S rRNA          
 
18S rRNA   
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Figure 13. Melting curve analysis 
RT-qPCR was performed for GAPDH and MCP-1. The graph is representative of the sigmoidal 
curves (A and C) obtained over the duration of the PCR cycles. Samples shown are from 
unstimulated THP-1 macrophages and the annealing temperatures for GAPDH were 60°C (A and 
B), and 62°C for MCP-1 (C and D). The formation of possible primer dimers would be identified 
by the presence of major additional peaks prior to the single peak that represents the specific 
product formed during melting curve analysis (B and D).  
A B 
D C 
Threshold 
Threshold 
A B 
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The housekeeping gene GAPDH has been routinely used by our laboratory and many 
others as a reference in RT-qPCR analysis (Irvine et al. 2005; McLaren et al. 2010a; 
McLaren et al. 2010b; Salter et al. 2011; Tan et al. 2012). GAPDH and other frequently 
used housekeeping genes such as RPL37a (Pombo-Suarez et al. 2008; Strube et al. 2008; 
Pfister et al. 2011) and β-actin (Greer et al. 2010; Tan et al. 2012) exhibit stable levels 
of expression independent of the experimental conditions and are therefore used to 
facilitate accurate quantification of the expression of investigated genes. The 60S 
ribosomal protein RPL37a was used to compare the reliability of GAPDH (Figure 14) 
as it is also commonly used as an alternative house-keeping gene and had been recently 
recommended as a suitable gene of reference for THP-1 cells in a report by Maess 
(Maess et al. 2010).  
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Experiments in THP-1 and primary HMDMs (Figure 14) indicate that variances in the 
gene expression of GAPDH and RPL37a were comparable and that both genes 
Figure 14. Comparison of Ct values using GAPDH and RPL37a as 
housekeeping genes  
RT-qPCR for GAPDH and RPL37a was performed using cDNA from THP-1 macrophages (A) 
and HMDMs (B) that were treated for 12 or 24 hours with either vehicle (control) or IL-33 
(10ng/ml or 25ng/ml) as indicated. The graph displays the Ct values for GAPDH or RPL37a. 
Data represents the mean from a single experiment carried out in triplicate. 
A 
B 
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displayed similar patterns of expression. GAPDH was shown to be a suitable gene of 
reference for qPCR quantification and was therefore used over the course of the study. 
3.4.2. The effect of IL-33 on the expression of pro-atherosclerotic genes  
To understand the functions of the novel anti-inflammatory cytokine IL-33 on 
atherosclerotic processes within macrophages, RT-qPCR was performed to evaluate the 
effect of the cytokine on the mRNA expression of well-characterised genes implicated 
in the control of foam cell formation and monocyte recruitment. These experiments 
would function as a positive control to confirm that recombinant IL-33 was 
physiologically active and also served to validate the system used. THP-1 cells were 
seeded into 12-well plates, stimulated with PMA (0.16µM) for 24 hours and then 
incubated with or without IL-33 (10ng/ml) for 24 hours, replicating the concentration 
and duration previously used by our laboratory in these cells (McLaren et al. 2010a) 
The expression of a number of chosen markers (described in Table 13) were then 
examined by RT-qPCR. 
3.4.2.1. Cholesterol uptake genes  
SRs play an important role in the transformation of lesion-resident macrophages into 
lipid-loaded foam cells. Under normal physiological conditions, cholesterol uptake and 
efflux is carefully regulated. However during the disease state, macrophages and other 
cells in the lesion release factors that up-regulate the expression of SRs facilitating 
excessive unregulated internalisation of modified LDL and promoting macrophage 
foam cell formation (Bultel et al. 2008). Due to the significance of SRs in augmenting 
atherosclerosis and the anti-atherogenic actions of IL-33, the effects on SR expression 
was investigated.  
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IL-33 produced a statistically significant reduction in the expression of SR-A and SR-
B1 (Figure 15). In addition, a trend for suppressed CD36 expression was seen although 
this failed to reach statistical significance thereby suggesting that additional 
experiments were required.  
Figure 15. Effect of IL-33 stimulation on the mRNA expression of SRs 
RT-qPCR for SR-A, SR-B1 and CD36 was performed using cDNA from PMA differentiated 
THP-1 macrophages and incubated in the presence or absence (control) of IL-33 (10ng/ml) for 24 
hours. The mRNA levels were calculated using the comparative Ct method and normalised to the 
house-keeping gene, GAPDH, with values from control cells given an arbitrary value of 1. Data 
represents mean ± SD from four (SR-B1, CD36) or six (SR-A) independent experiments. The 
Student t test was used to determine the statistical significance of the results *p<0.05, **p<0.01.  
* ** 
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3.4.2.2. Cholesterol metabolism 
During atherosclerosis the metabolic pathways responsible for regulating cholesterol 
homeostasis within macrophages become dysfunctional, promoting the excessive uptake 
and storage of lipids. LPL is a critical metabolic enzyme responsible for the hydrolysis 
of TAGs in circulating lipoproteins resulting in the production of FFAs and 2-
monoacylglycerol (George and Johnson 2010). Additionally, within macrophages LPL 
increases the uptake of modified lipoproteins via a bridging action (Mead and Ramji 
2002).  
 
 
 
 
Following 24 hours of stimulation by IL-33 (10ng/ml) LPL mRNA expression was 
significantly down-regulated in THP-1 macrophages (Figure 16). 
Figure 16. Effect of IL-33 stimulation on the mRNA expression of LPL 
RT-qPCR for LPL was performed using cDNA from PMA differentiated THP-1 macrophages and 
incubated in the presence or absence (control) of IL-33 (10ng/ml) for 24 hours. The mRNA levels 
were calculated using the comparative Ct method and normalised to the house-keeping gene, 
GAPDH, with values from control samples given an arbitrary value of 1. Data represents mean ± 
SD from four independent experiments. The Student t test was used to determine the statistical 
significance of the results *p<0.05. 
* 
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3.4.2.3. Monocyte recruitment and attachment 
The study next investigated the role of IL-33 on the expression of genes implicated in 
the initial development of atherosclerosis. ICAM-1 is an adhesion molecule expressed 
on the endothelial cell wall and functions as a robust marker of inflammation in cells 
such as macrophages. ICAM-1 is involved in the attachment of circulating immune cells 
to the lesion site (Blankenberg et al. 2003).  
 
 
  
 
 
 
Figure 17 shows that IL-33 significantly reduced the expression of the adhesion 
molecule ICAM-1.  
 
Figure 17. Effects of IL-33 stimulation on the mRNA expression of ICAM-1 
RT-qPCR for ICAM-1 was performed using cDNA from PMA differentiated THP-1 
macrophages and incubated in the presence or absence (control) of IL-33 (10ng/ml) for 24 hours. 
The mRNA levels were calculated using the comparative Ct method and normalised to the 
house-keeping gene, GAPDH, with values from control cells given an arbitrary value of 1. Data 
represents mean ± SD from six independent experiments. The Student t test was used to 
determine the statistical significance of the results *p<0.05. 
* 
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IP-10, MCP-1 and MIP-1β are chemokines implicated in plaque initiation and the 
development of atherosclerosis. The expression of these genes are induced in several 
cell types, including macrophages, during inflammation and therefore acts as a robust 
marker for this process.  
 
 
  
 
 
 
 
Similar to the findings for ICAM-1, IL-33 produced a significant decrease in the 
expression of the chemokines IP-10, MCP-1 and MIP-1β (Figure 18).  
Figure 18. Effects of IL-33 stimulation on the mRNA expression of chemokines 
RT-qPCR for IP-10, MCP-1 and MIP-1β was performed using cDNA from PMA differentiated 
THP-1 macrophages and incubated in the presence or absence (control) of IL-33 (10ng/ml) for 24 
hours. The mRNA levels were calculated using the comparative Ct method and normalised to the 
house-keeping gene, GAPDH, with values from control cells given an arbitrary value of 1. Data 
represents mean ± SD from six (IP-10 and MIP-1β) and seven (MCP-1) independent experiments. 
The Student t test was used to determine the statistical significance of the results *p<0.05. 
* * 
* 
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3.4.3. IL-33 time-course and dose-response in THP-1 cells 
Initial studies were performed using a concentration of 10ng/ml and a 24 hour time 
point for IL-33 stimulation based upon previous experiments within the laboratory 
(McLaren et al. 2010b). The present study confirmed that at this concentration and time 
point IL-33 causes a reduction in previously studied pro-atherosclerotic genes (CD36, 
SR-A, SR-B1) and shows for the first time a decrease in ICAM-1, IP-10, LPL, MIP-1β 
and MCP-1 mRNA expression within THP-1 macrophages.  
However, a number of groups use higher concentrations of IL-33 and different time 
points for their experiments (Demyanets et al. 2011; Ogawa et al. 2012). Therefore to 
determine whether the optimal concentration and time point were being used in the 
study, the effects of IL-33 on the expression of pro-atherosclerotic genes at different 
concentrations and time points were investigated. THP-1 macrophages were incubated 
in the presence of IL-33 over a range of concentrations (10ng/ml-100ng/ml) for 24 
hours and 48 hours to assess changes in the mRNA expression of LPL and SR-A by 
RT-qPCR. Unstimulated cells at these time points were included for comparison. 
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This initial, preliminary study suggested that IL-33 had little effect on SR-A or LPL 
mRNA expression at 48 hours (Figure 19). On the other hand, a decreased expression of 
both SR-A and LPL mRNA expression was obtained with IL-33 at 24 hours. However, 
in contrast to earlier studies (Figure 16) no reduction in LPL mRNA expression was 
seen at 10ng/ml of IL-33 but a decrease was obtained using 25ng/ml and 50ng/ml of the 
cytokine. In addition, the decrease in SR-A mRNA expression with 25ng/ml was greater 
than that achieved with 10ng/ml of IL-33. Based upon these results, it was decided to 
focus on new IL-33 regulated genes such as ICAM-1 and MCP-1 which were used for 
subsequent studies.  
Figure 19. Effects of IL-33 concentration and incubation time on SR-A and 
LPL mRNA expression  
RT-qPCR for LPL and SR-A was performed using cDNA from PMA differentiated THP-1 
macrophages and incubated in the presence or absence (control) of IL-33 at a range of 
concentrations (10ng/ml-100ng/ml) for 24 hours (A) and 48 hours (B). The mRNA levels were 
calculated using the comparative Ct method and normalised to the house-keeping gene, 
GAPDH, with values from control cells given an arbitrary value of 1. Data represents mean 
from a single experiment performed in triplicate. 
B 
A 
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Preliminary studies were performed to establish the optimum time point for incubation 
with IL-33. An initial study assessed the effects of IL-33 at a concentration of 10ng/ml 
and 25ng/ml after 6, 12 and 24 hours of stimulation (Figure 20).  
 
 
 
Figure 20. IL-33 time-course and dose-response experiment 
RT-qPCR for ICAM-1 and MCP-1 was performed using cDNA from PMA differentiated THP-1 
macrophages and incubated in the presence or absence (control) of IL-33 at 10ng/ml and 25/ml 
for 6, 12 and 24 hours. The mRNA levels were calculated using the comparative Ct method and 
normalised to the housekeeping gene, GAPDH, with values from control cells given an arbitrary 
value of 1. Data represents mean from a single experiment performed in triplicate. 
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The expression of ICAM-1 mRNA was reduced by IL-33 (10ng/ml or 25ng/ml) 
following 12 and 24 hours but not after 6 hours of stimulation. Likewise, the expression 
of MCP-1 was decreased following IL-33 treatment at 10ng/ml and 25ng/ml after 12 
and 24 hours.  
As a result, PMA-differentiated THP-1 cells were then stimulated with IL-33 at 
concentrations of 10ng/ml and 25ng/ml for 12 and 24 hours to determine which time 
point and concentration gave the most statistically significant results from four 
independent experiments (Figure 21). 
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Figure 21. Effects of IL-33 concentration and period of stimulation on ICAM-1 
and MCP-1 expression  
RT-qPCR for ICAM-1 and MCP-1 was performed using cDNA from PMA-differentiated THP-1 
macrophages and incubated in the presence or absence (control) of IL-33 at 10ng/ml and 25/ml 
for 12 and 24 hours. The mRNA levels were calculated using the comparative Ct method and 
normalised to the housekeeping gene, GAPDH, with values from control cells given an arbitrary 
value of 1. Data represents mean ± SD from four independent experiments. ANOVA were used 
to determine statistical significance of the results between untreated control and samples at 
different concentration and time-points in combination with Tukey’s post hoc test for ICAM-1 
**p<0.01. For MCP-1 Homogeneity of variances were not met so the Games-Howell and 
Dunnett’s T3 post hoc tests were used ***p<0.001. 
** 
*** 
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The studies confirmed the results from the preliminary experiments and showed that the 
expression of ICAM-1 and MCP-1 was most responsive to IL-33 following 12 hours of 
stimulation at 25ng/ml. In addition, the inhibitory effect of 25ng/ml IL-33 on MCP-1 
and ICAM-1 expression at 12 hours reached significance from four independent 
experiments. In contrast, six to seven independent experiments were required to observe 
the significant action of 10ng/ml IL-33 at 24 hours (Figures 17-18). Based on these 
experiments, it was decided to use this concentration and duration in subsequent studies. 
3.4.4. IL-33 stimulation of HMDMs 
Experiments were completed in HMDMs at the concentrations and time points 
previously identified to determine whether the results obtained were not peculiar to the 
cell line. HMDMs were incubated for 12 or 24 hours with IL-33 at a concentration of 
10ng/ml or 25ng/ml. RT-qPCR was then performed to determine the effect of IL-33 on 
the mRNA expression of ICAM-1 and MCP-1.  
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Figure 22. The effect of IL-33 on gene expression in primary macrophages 
RT-qPCR for ICAM-1 and MCP-1 was performed using cDNA from 12 and 24 hour IL-33-
stimulated HMDMs at 10ng/ml and 25ng/ml (control). The mRNA levels were calculated 
using the comparative Ct method and normalised to the housekeeping gene, GAPDH, with 
values from untreated cells given an arbitrary value of 1. Data represents mean ± SD from 
four independent experiments for ICAM-1 and MCP-1. ANOVA was used to determine 
statistical significance between control and samples at different concentrations and time 
points in combination with Tukey’s post hoc test **p<0.01. 
** 
** 
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Following 12 hours of IL-33 stimulation at 25ng/ml there was a noticeable reduction in 
the expression of each of the genes tested; this decrease was significant for ICAM-1 and 
MCP-1 (Figure 22). The overall trend was therefore consistent with the results found in 
THP-1 cells.  
3.4.5. IL-33 stimulation in RAW264.7 cells   
The time-course experiments showed variation in the form of larger SD between 
experiments. The murine RAW264.7 cell line was therefore included as a model system 
for the study, as the cells are fully differentiated adherent macrophages and do not 
require PMA activation. In addition, studies in this cell line would provide an indication 
of conserved IL-33 actions in human and mouse macrophages. β-actin was chosen as 
the gene of reference for RT-qPCR analysis as this has been previously used by several 
laboratories for studies in mouse tissues and cell lines (Smith and Wickstrom 1998; 
Irvine et al. 2005; Svensson et al. 2006; Harvey et al. 2007; McLaren et al. 2010a; 
McLaren et al. 2010b). 
3.4.5.1. SRs 
RAW264.7 macrophages were either incubated in the presence of murine IL-33 at 10 or 
25ng/ml for 12 or 24 hours, or left unstimulated for use as a control. The mRNA 
expression of the SRs CD36, SR-A and SR-B1 were then analysed by RT-qPCR. 
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IL-33 caused a reduction in CD36 mRNA expression at both concentrations (10ng/ml 
and 25ng/ml) and at both time points, although statistical significance was seen with 
25ng/ml of cytokine at 12 hours (Figure 23). A similar pattern was obtained with SR-B1 
mRNA expression with statistical significance seen with 25ng/ml of cytokine at 12 
hours. In contrast, IL-33 had no significant effect on SR-A mRNA expression, 
potentially because of relatively large SD, though a trend of reduction was obtained at 
24 hours at both concentrations of the cytokine.  
Figure 23. The effect of IL-33 on SR expression in RAW264.7 macrophages 
RT-qPCR for murine CD36, SR-A and SR-B1 was performed using cDNA from RAW264.7 
macrophages incubated in the presence or absence (control) of IL-33 at 10ng/ml and 25ng/ml for 
12 and 24 hours. The mRNA levels were calculated using the comparative Ct method and 
normalised to the housekeeping gene, β-actin, with values from untreated cells given an arbitrary 
value of 1. Data represents mean ± SD from three (CD36, SR-B1) or five (SR-A) independent 
experiments. Statistical analysis by ANOVA was performed to determine whether the means 
between different concentrations and time points were significant in combination with Tukey’s 
post hoc test *p<0.05. 
* 
* 
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3.4.5.2. Monocyte recruitment and attachment 
To investigate the effects of IL-33 on the regulation of genes involved in early 
atherosclerotic events; RAW264.7 cells were stimulated with murine IL-33 for 12 or 24 
hours with 10 or 25ng/ml of the cytokine and the mRNA expression of murine ICAM-1 
and MCP-1 were assessed. 
 
 
 
 
 
IL-33 reduced ICAM-1 mRNA expression with both 10ng/ml and 25ng/ml 
concentrations and at both time points; though a statistically significant reduction was 
obtained with 25ng/ml at 12 hours (Figure 24). For MCP-1, the variation between 
experiments was large and hence no statistically significant differences were obtained. 
However, a trend of reduction of MCP-1 mRNA expression was observed with 25ng/ml 
IL-33 at both the 12 and 24 hour time points.  
Overall, there was a consistent trend for IL-33-mediated down-regulation of the genes 
analysed and these reductions were most significant following 12 hours incubation with 
IL-33 at a concentration of 25ng/ml. 
Figure 24. IL-33 time-course and dose-response in RAW264.7 cells 
RT-qPCR for ICAM-1 and MCP-1 was performed using cDNA from 12 and 24 hour IL-33 
stimulated RAW264.7 cells incubated in the presence or absence (control) of IL-33 at 10ng/ml and 
25ng/ml. The mRNA levels were calculated using the comparative Ct method and normalised to 
the housekeeping gene, β-actin, with values from untreated cells given an arbitrary value of 1. 
Data represents mean ± SD from five independent experiments. ANOVA was used to determine 
statistical significance between untreated control and samples at different concentrations and time 
points in combination with Tukey’s post hoc test **p<0.01. 
** 
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3.5. Discussion 
Macrophages have a critical role in initiating and augmenting the disease state during 
atherosclerosis. IL-33 is a recently discovered member of the IL-1 family and has been 
implicated in a number of inflammatory disorders such as rheumatoid arthritis and 
asthma where the cytokine aggravates the disease state (Carriere et al. 2007; Kondo et 
al. 2008; Funakoshi-Tago et al. 2011). The monocytic THP-1 cell line was chosen to 
study the effects of IL-33 on the expression of a number of pro-atherogenic markers. 
These genes were chosen as their roles in atherosclerosis are well-characterised and 
many have been previously studied within our laboratory (McLaren et al. 2010a; 
Michael et al. 2012b). Although several of these genes have been analysed by other 
groups, a detailed study of the effects of IL-33 in the THP-1 system has not been 
performed. 
3.5.1. IL-33 stimulation of THP-1 cells 
There is a great deal of interest in the anti-atherosclerotic actions of IL-33 as the 
cytokine has been implicated in many aspects of the disease ranging from leukocyte 
recruitment (Demyanets et al. 2011), macrophage foam cell formation (McLaren et al. 
2010b) to plaque progression (Miller et al. 2008). As a result initial experiments were 
conducted using conditions previously employed by our group (McLaren et al. 2010b) 
to establish whether the recombinant IL-33 used within these experiments was 
physiologically active. The monocytic THP-1 cell line was used to study the actions of 
IL-33 within macrophages and to facilitate initial optimisation of experimental 
conditions.  
The study investigated the effects of IL-33 stimulation on a number genes implicated in 
atherosclerosis and other inflammatory disorders. Chemokines are small proteins which 
interact with G-protein-coupled receptors and form part of the larger cytokine 
superfamily (van Buul and Hordijk 2004). IP-10, MIP-1β and MCP-1 direct circulating 
leukocytes to the lesion where adhesion molecules, including ICAM-1, aid 
transdiapedesis into the subendothelium (Nagel et al. 1994; Wilcox et al. 1994; Taub et 
al. 1996; Niu and Kolattukudy 2009).  
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SRs promote macrophage foam cell formation by mediating excessive uptake of 
cholesterol during the disease. A study by Kunjathoor et al. (2002) demonstrated that 
CD36 and SR-A are major contributors to the uptake of modified LDL as mice deficient 
in these SRs exhibit approximately 75-90% decreased degradation of modified LDLs. 
Also macrophages from these animals are unable to accumulate CEs (Kunjathoor et al. 
2002).  The metabolic enzyme LPL regulates the storage of lipids within macrophages 
and mutations within the LPL gene are associated with an increased risk of CHD, 
accompanied by raised plasma TAGs and reduced levels of HDL cholesterol (Wittrup et 
al. 1999).  
Interestingly, in alternative disease states IL-33 increases the expression of many of 
these genes (Table 14) and therefore promotes the inflammatory state. However within 
the context of atherosclerosis IL-33 is believed to have a protective role and these 
experiments demonstrated that IL-33 reduces the mRNA expression of ICAM-1, IP-10, 
LPL, MIP-1β, SR-A, SR-B1, CD36 and MCP-1. A number of studies have investigated 
the effects of IL-33 on ICAM-1 expression within the plaque (Demyanets et al. 2011) 
and in endothelial cells (Choi et al. 2012) but experiments within human macrophages 
had not been performed. Likewise, the studies presented in this thesis demonstrated the 
novel down-regulation of IP-10, LPL, MIP-1β and MCP-1 by IL-33 in the THP-1 
cellular system. This is also the first study to demonstrate the involvement of IL-33 in 
the regulation of LPL mRNA expression. Overall, the data supports the hypothesis that 
IL-33 is a key mediator of anti-atherosclerotic events and also validates the use of the 
THP-1 as a useful system for studying atherosclerosis.  
The regulation of expression of key genes implicated in atherosclerosis       Melanie Buckley 
 
113 
 
     Table 14. Studies of IL-33 on the expression of genes tested within the study  
Gene Cellular system Effect of IL-33 Reference 
CD36 Human THP-1 macrophages, HMDMs, bone marrow-derived macrophages from 
WT and ST2
-/-
 mice. 
↓ (McLaren et al. 2010b) 
ICAM-1 HUVECs and human explanted atherosclerotic plaques. ↑ 
(Pecaric-Petkovic et al. 2009; Chow et al. 
2010; Demyanets et al. 2011; Choi et al. 2012) 
IP-10 
Synovial tissue from rheumatoid arthritis patients. Human eosinophils. ↑ (So et al. 2012; Wong et al. 2012) 
LPL 
Not previously tested. - - 
MCP-1 Human pancreatic myofibroblasts, human eosinophils, human basophils, murine 
embryonic fibroblasts. 
↑ 
(Funakoshi-Tago et al. 2008; Kondo et al. 
2008; Nishida et al. 2010; Wong et al. 2012) 
MIP-1β 
Human basophils. ↑ (Kondo et al. 2008) 
SR-A Human THP-1 macrophages, HMDMs, bone marrow-derived macrophages from 
WT and ST2
-/-
 mice. 
↓ (McLaren et al. 2010b) 
SR-B1 Human THP-1 macrophages, HMDMs, bone marrow-derived macrophages from 
ST2
-/-
 mice. 
↓ (McLaren et al. 2010b) 
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Anti-inflammatory cytokines like TGF-β have been shown to down-regulate the 
expression of genes associated with cholesterol uptake and metabolism (Michael et al. 
2012b). The cytokine also up-regulates the expression of genes involved in 
atheroprotective processes such as cholesterol trafficking and efflux (Singh and Ramji 
2006a). Previous work in our group has shown that TGF-β and IL-33 up-regulate the 
expression of ApoE, ABCA-1, ABCG-1, NCP1, NPC2 and CPT-1 (Singh and Ramji 
2006b; McLaren et al. 2010b). The studies presented here demonstrate that IL-33 
decreases the expression of a number of well-characterised markers associated with 
augmentation of the disease state, including CD36, ICAM-1, MCP-1 and SR-B1. 
However, due to the small nature of the response, potential trends within the data may 
have not been shown in some cases. As a result, ICAM-1 and MCP-1 were chosen to 
further optimise the experimental system. 
3.5.2. Optimising IL-33 stimulation of THP-1 cells  
After validating that the IL-33 response was present at concentrations and time points 
previously used (McLaren et al. 2010b), a range of concentrations (10ng/ml-100ng/ml) 
and incubation periods (6-48 hours) were trialled to address the variability seen within 
the results and to validate the findings. The experiments highlighted that IL-33 exerted 
the strongest response after 12 hours and at a concentration of 25ng/ml (Figures 20 and 
21). An array of different time-courses and doses of IL-33 have been used in previous 
studies and the conditions tested in these initial experiments are within the range used 
by other groups (Funakoshi-Tago et al. 2008; Kondo et al. 2008; Joshi et al. 2010; 
Funakoshi-Tago et al. 2011). For example, Kaieda et al. (2012) treated murine mast 
cells with 10ng/ml of IL-33 for 10 hours (Kaieda et al. 2012) and Kempuraj et al. (2013) 
stimulated human pancreatic samples for 6 hours with IL-33 (100ng/ml) (Kempuraj et 
al. 2013). On the other hand, Turnquist et al. (2011) administered 25ng/ml of IL-33 into 
mice over a course of 8 days (Turnquist et al. 2011). 
3.5.3. IL-33 stimulation in HMDMs 
Experiments were also conducted in HMDMs to determine whether the response from 
IL-33 was not peculiar to the THP-1 cell line and to establish the physiological 
relevance of results. The expression of ICAM-1 and MCP-1 was analysed using RT-
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qPCR and the greatest reduction in mRNA expression occurred after 12 hours of 
stimulation using 25ng/ml of IL-33.  
Cell lines are frequently used as model systems for studying disease, as culturing 
primary cells can be difficult to establish and maintain due to heterogeneous 
populations of cells. However, monocytic cell lines may not give a fully accurate 
representation of differentiated tissue macrophages. For example, the responses 
produced by the promyelocytic leukemia cell line HL-60 can vary depending on the 
type of reagent used to induce cellular differentiation (Daigneault et al. 2010).  The cells 
display a monocytic phenotype following stimulation by VD3 but the addition of 
phorbol esters promotes a more mature macrophage phenotype (Daigneault et al. 2010). 
Furthermore, the effects of passaging in cell lines are not completely understood. 
Wenger et al. (2004) found that maintaining cell cultures over a long time-period led to 
the appearance of mutations that altered the characteristics of the breast cancer MCF-7 
and endometrial tumour Ishikawa cell lines. These mutations introduced heterogeneity 
between cells within the same culture (Wenger et al. 2004). Also, studies in Syrian 
hamster embryo cells found that cell passage affected doubling time and plating 
efficiency. At later passages, the cells reached a ‘crisis’ point where growing conditions 
needed to be altered to facilitate growth, and coincided with changes in sensitivity to 
experimental treatments (ChangLiu and Woloschak 1997). The use of cells at different 
passages could introduce variation between experiments and the passage number of 
THP-1 cells used in previous atherosclerotic studies greatly varies between groups. 
During these studies experiments were completed using cells between passages 2-7 but 
there are examples of groups using THP-1 cells up to passage 20 (Kritharides et al. 
1998; Chanput et al. 2010) and many studies do not state the passage number. HMDMs 
are not subjected to passaging and the inclusion of RAW264.7 macrophages allows for 
comparison between the two cell lines.  
3.5.4. Optimising IL-33 stimulation in RAW264.7 cells 
PMA is commonly used to differentiate THP-1 monocytes into macrophages for 
experimental use. However, PMA also activates several signalling pathways and could 
therefore introduce variability in the data. Several studies have shown that the 
expression of several genes are induced by PMA in a variety of cell lines including 
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HeLa, primary human T cells, primary rabbit cardiac fibroblasts (Kronke et al. 1985; 
Eghbali et al. 1991; Ma et al. 2004), in addition to THP-1 cells (Kohro et al. 2004; 
Daigneault et al. 2010). Additionally, PMA can induce the secretion of IL-33 and sST2 
in cardiac fibroblasts in a dose-dependent manner which could impact the data (Sanada 
et al. 2007). The phorbol ester interrupts the cellular cycle by modulating the expression 
of cell cycle regulators through the production of ROS and also activates signalling 
pathways including MAPK and PKC (Traore et al. 2005). This may lend some 
explanation to some of the inconsistency exhibited in samples taken at 24 hours (Nile et 
al. 2010).  
Murine RAW264.7 macrophages were included as a model system in the study as these 
cells are frequently used in atherosclerotic studies and are mature adherent cells so 
PMA is not required. Experiments were conducted using the same conditions as the 
human THP-1 system, only without the inclusion of PMA. Following incubation with 
the cytokine, RT-qPCR was performed to evaluate the effects on the mRNA expression 
of CD36, SR-A, SR-B1, ICAM-1 and MCP-1. The majority of genes tested, with the 
exception of SR-A, displayed a reduction in mRNA expression following IL-33 
treatment. The reduction in expression was significant at 25ng/ml of IL-33 after 12 
hours for both SR-B1 and ICAM-1. Overall the results from the murine RAW264.7 cell 
line confirmed those seen in human macrophages, indicating a well-conserved role of 
IL-33 in the regulation of key atherosclerotic makers. This is important as species-
specific differences have been seen by other groups.  
Mice and humans share many features but key discrepancies exist such as differences in 
metabolic enzymes (Martignoni et al. 2006), ionic channels (Martignoni et al. 2006; 
Bianchi et al. 2012), innate and adaptive immune systems including Th1/Th2 
differentiation, leukocyte subsets; whereby humans display a more neutrophilic profile 
and rodents have greater proportions of circulating lymphocytes (Haley 2003). However, 
the use of mice has greatly aided our understanding of atherosclerosis and significant 
parallels can be drawn between murine and human forms of the disease. Combining the 
findings from both organisms has enabled the identification and validation of many 
major players involved in the pathogenesis of atherosclerosis (Stylianou et al. 2012). 
The studies presented here demonstrate that IL-33 exerts a consistent atheroprotective 
effect on the expression of genes implicated in atherogenesis. These initial experiments 
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were performed in the THP-1 and mouse RAW264.7 cell lines and verified in HMDMs. 
Future studies performed within this thesis will use the conditions optimised within this 
chapter as they produced the strongest response from the cytokine. 
3.6. Future perspective 
Due to the growing prevalence of CHD within westernised societies, and an increasing 
trend in incidences globally, there is a pressing need to identify and examine novel 
contributors to the disease. Cytokines are involved at every stage of the disease, from 
recruitment of circulating immune cells and activation of the endothelium, to 
propagating dysfunctional metabolism and eventual plaque rupture. The disease state 
arises through an imbalance in the activities of pro- and anti-inflammatory cytokines. 
Therefore it is of crucial importance to explore the role of novel cytokines implicated in 
the disease state such as IL-33. Analysing the mechanisms through which IL-33 
operates may aid the development of potential therapies and also identify side-effects 
which could arise. 
The study provides evidence for the anti-atherosclerotic role of IL-33 in THP-1 and 
RAW264.7 macrophages in addition to primary HMDMs and demonstrates the novel 
down-regulation of the mRNA expression of ICAM-1, IP-10, MCP-1, MIP-1β and LPL 
by IL-33 within macrophages. Interestingly, studies have also shown that IL-33 
increases the expression of many of the pro-atherogenic genes used in the study within 
the context of other inflammatory diseases (Table 14). Therefore it is of great interest to 
understand the potential signalling pathways that contribute towards the IL-33-mediated 
reduction of these genes. The next step will attempt to elucidate the mechanisms 
underlying IL-33 actions through the use of RNA interference (RNAi) whereby a 
combination of siRNA and shRNA will be used to knock down the expression of key 
signalling components. The effects on the expression of atherosclerotic markers will 
then be assessed through a combination of RT-qPCR and western blotting.  
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CHAPTER 4. 
THE SIGNALLING PATHWAYS UNDERLYING IL-
33-REGULATION OF ICAM-1 AND MCP-1 
EXPRESSION 
 
4.1. Introduction 
4.1.1. Mitogen-activated protein kinases (MAPKs) 
The MAPK signalling network encompasses a variety of pathways responsible for the 
regulation of key cellular functions including gene transcription, cell cycle and 
apoptosis. This network utilises a series of proteins, often referred to as a “toolkit”, from 
which signalling cascades are assembled. The activation of several protein kinases prior 
to the MAPK is required for activity. MAPKKK’s act as transducers which transmit the 
signal by dual phosphorylation of serine and threonine present within MAPKK’s, the 
activated MAPKKs then phosphorylate tyrosine and threonine residues of MAPK’s 
which in turn phosphorylate selected serine and threonine residues of their target 
proteins (Figure 25) (Lawrence et al. 2008; Berridge 2012).  
MAPKs share evolutionary conserved modules and are classified under three main 
pathways: ERK, p38 and JNK. The MAPK network is tightly regulated through the use 
of scaffolding proteins that mediate interactions and localisation of MAPKs. Also, the 
antagonistic actions of MAPK phosphatases inactivate MAPKs by the removal of 
necessary phosphate groups (Ravandi et al. 2003). Aberrant MAPK signalling is 
observed in a number of disease states such as cancer (White et al. 1995; Roberts and 
Der 2007) and Alzheimer’s disease (Puig et al. 2004; Muresan and Muresan 2007).  
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4.1.1.1. Extracellular signal-regulated kinase (ERK) 1/2 signalling  
The ERK family contains a number of isoforms named ERK1-8 (Kim and Choi 2010). 
ERK1 (also known as p44
ERK1
) and ERK2 (p42
ERK2
) are ubiquitously expressed in all 
mammalian cells (Hu et al. 2000) and function as serine-threonine protein kinases. 
ERK1/2 are integral components of the Ras-Raf-MAPK/ERK kinase (MEK)-ERK 
MAPK pathway (Zhou et al. 2010). The kinases undergo cyclic rounds of 
phosphorylation and dephosphorylation associated with nuclear-cytoplasmic shuttling. 
ERK1/2 phosphorylation induces translocation of the kinase from the cytoplasm into the 
nucleus, where ERK1/2 either directly activate target proteins or trigger alternative 
signalling cascades  (Costa et al. 2006).  
Figure 25. MAPK signal transduction pathway 
MAPK signalling is formed of a hierarchical cascade. Components within the cascade often share 
common modules. The activation of MAPKKKs by extracellular stimuli or cell surface receptors 
triggers sequential phosphorylation of a series of kinases ending with a terminal MAPK such as 
the ERKs, p38s and JNKs which elicit a biological response. Taken from Roberts and Der 2007. 
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ERK1 and ERK2 share similar sequences and were previously thought to play an 
interchangeable role in signalling cascades. However experimental evidence indicates 
that both kinases may facilitate different activities within the cell. A study by 
Vantaggiato et al. (2006) demonstrated that ERK2 mediates normal and Ras-mediated 
cell proliferation whereas ERK1 functions as a negative regulator of cell proliferation 
under certain conditions. The authors proposed that ERK1 competes for the upstream 
kinase MEK and affects the overall signalling outcome by antagonising ERK2 activity 
(Vantaggiato et al. 2006). Furthermore, although both kinases are present in most 
tissues, cellular levels of the proteins differ and mice deficient in ERK2 die during 
embryonic development (Saba-El-Leil et al. 2003). 
4.1.1.2. p38 signalling  
The second group of MAPKs are the p38 MAPKs consisting of four splice variants; α, β, 
γ and δ in mammals (Ravandi et al. 2003). p38 kinases share a Thr-Gly-Tyr dual 
phosphorylation motif (Zarubin and Han 2005) and members of the family are activated 
through receptor-dependent routes e.g. TLRs, or by environmental factors such as UV 
irradiation. JNK and p38 share a number of common upstream activators such as the 
MAPKKKs Apoptosis signal-regulating kinase 1 and TGF-β-activated kinase 1. 
Although distinct MAPKKs also exist like MAPKK-3 and -6 that are solely responsible 
for the activation of p38s (Kim and Choi 2010).  
p38 members are involved in inflammation and cell cycle progression along with the 
regulation of apoptotic activities and the secretion of cytokines from neutrophils and 
macrophages (Berridge 2012). p38 isoforms display both overlapping and distinct 
activities (Nemoto et al. 1998) which may arise due to the production of complexes 
between MAPKKs and selected p38 isoforms (Enslen et al. 2000). Interestingly, several 
phosphatases target p38α and p38β but there are no known effective phosphatases 
against p38γ and p38δ (Zarubin and Han 2005). Complete ablation of p38α in mice 
causes embryonic lethality (Adams et al. 2000). 
4.1.1.3. c-Jun N-terminal kinase (JNK) signalling  
The third group of MAPKs comprises the JNKs proteins. Members of this group share 
many responses with the p38 MAPKs and the family was initially found due to their 
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ability to phosphorylate the transcription factor c-Jun (Cui et al. 2007). Alternative 
splicing of the three JNK genes produces at least ten isoforms ranging from 46 kDa to 
54 kDa in size (Derijard et al. 1994). The isoforms display different expression patterns; 
JNK1 and JNK2 are ubiquitously expressed whilst JNK3 expression is restricted to the 
central nervous system, neurons, testis and cardiac SMCs (Cui et al. 2007). 
The canonical JNK cascade is activated in response to environmental stresses like UV 
irradiation, hyperosmolarity and heat shock, as such the family was initially known as 
stress-activated protein kinases (Guma and Firestein 2012). It is thought that 13 
MAPKKKs interact with upstream activators of JNKs giving rise to a complex and 
intricate array of potential activation routes for the MAPK. JNK members 
phosphorylate and activate a range of transcription factors including c-Jun, p53 and c-
myc, in addition to other cellular targets such as Bcl-2 family members (Guma and 
Firestein 2012). As such negative feedback mechanisms are necessary to regulate JNK 
members. For example the scaffolding protein JNK-interacting protein-1 physically 
limits the mobility of JNKs hindering activity (Berridge 2012).  
4.1.2. Phosphoinositide-3-kinase (PI3K)/ Protein kinase B (Akt) signalling  
Members of the PI3K family catalyse the phosphorylation of D3 hydroxyl groups 
within membrane PIs (Morello et al. 2009). There are three general classifications of 
PI3K members. Class I proteins are formed of catalytic (p110α, β, δ and γ) and 
adaptor/regulatory (p85 or p101) heterodimers. These members are solely responsible 
for the phosphorylation of phosphatidylinositol 4,5-bisphosphate [(PtdIns(4,5)P2)] to 
PtdIns(3,4,5)P3 and are further subdivided based on their route of activation (Vara et al. 
2004). Subclass 1A proteins are primarily activated through RTKs or non-RTKs in the 
cytoplasm. These members associate with phosphotyrosine consensus motifs in the 
cytoplasmic tail of RTKs through Src-homology 2 (SH2) domains within their adaptor 
subunit. This interaction results in allosteric activation of the catalytic subunit. In 
contrast, members from subclass IB interact with receptors coupled with G proteins 
(Cooray 2004; Vara et al. 2004). The Class II group is comprised of three monomers: 
PI3K-C2α, PI3K-C2β and PI3K-C2γ. Vascuolar protein sorting 34 is the only member 
of Class III (Morello et al. 2009). An overview of PI3K signalling is provided below in 
Figure 26. 
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The main products from PI3K activity are 3-phosphorylated lipids that function as 
primary effectors within the plane of the plasma membrane. 3-phosphorylated lipids 
recruit target proteins to the plasma membrane through lipid-binding domains like 
pleckstrin homology (PH), Phox homology and C2 (Berridge 2012). These domains 
also serve as targets for PI3K-mediated phosphorylation (Morello et al. 2009). A major 
downstream effector is the serine-threonine kinase, protein kinase B (Akt). There are 
Figure 26. PI3K signalling 
Class I PI3Ks phosphorylate PI(4,5)P2 producing the secondary effector PI(3,4,5)P3. Regulatory 
subunits like p85 of PI3Ks facilitate the interaction of their catalytic subunits; such as p110, 
with phosphorylated tyrosine residues of activated GF receptors. G protein-coupled receptors 
activate Class 1B PI3Ks which translocate to the plasma membrane through associations with 
the Gβγ subunit. PI3Ks produce PI(3,4,5)P3 which associate with other signalling mediators 
such as PKCs and PLCγ. PLCγ cleaves PI(3,4,5)P3 to IP3 and DAG which participate in 
potassium and calcium signalling and in the regulation of transient receptor potential channels. 
Monomeric G proteins (Rac, Rho and Cdc42) activated through the cascade facilitate 
rearrangement of the cytoskeleton and superoxide production. The activation of 3-
phosphoinositide-dependent kinase-1 (PDK1/2) and Akt (PKB) triggers downstream signalling 
components involved in a range of cellular processes. Taken from Berridge (2012). 
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three Akt isoforms which all contain PH domains. The phosphorylation of a specific 
threonine switches the enzyme into an active state, whilst multiple phosphorylation 
ensures maximal activity (Vara et al. 2004). Other downstream targets of PI3Ks include 
the serine/threonine PDK1, glycogen synthase kinase B, Raf, forkhead box transcription 
factor (FOXO), RhoA and PLC (Morello et al. 2009). Due to the extensive scope of 
PI3K signalling, the pathway is tightly controlled through the action of three main 
phosphatases. Phosphatase and tensin homologue deleted on chromosome 10 (PTEN) 
and myotubularin are responsible for the removal of phosphate groups from PI(3,4,5)P3 
and PI(3)P respectively, whereas SH2-containing inositol phosphatase acts as a 5-
phosphatase (Morello et al. 2009). 
4.1.3. Nuclear factor-κB (NF-κB) signalling  
Stimulation of cell-surface receptors like TLRs by pathogen-associated molecular 
patterns and inflammatory cytokines results in the activation of NF-κB members (Baker 
et al. 2011). NF-κB signalling is involved in the control of cell differentiation, 
proliferation, survival and apoptosis (Oeckinghaus et al. 2011). Dysregulation of this 
pathway is implicated in cancer (Pikarsky et al. 2004), insulin resistance (Cai et al. 
2005), ectodermal dysplasia (Doffinger et al. 2001) and many other disease states.  
The NF-κB family is formed of five members within mammals: the precursor proteins 
NF-κB-1 (p105) and NF-κB-2 (p100) which are processed to p50 and p52 respectively, 
RelA (p65), RelB and c-Rel (Oeckinghaus et al. 2011). Members of the NF-κB family 
contain a conserved Rel homology domain responsible for DNA binding and 
dimerisation (Oeckinghaus et al. 2011). Under normal physiological conditions, NF-κB 
dimers are sequestered within the cytoplasm due to their association with inhibitory IκB 
proteins; IκBα, IκBβ and IκBε (Smahi et al. 2002; Oeckinghaus et al. 2011). 
Extracellular stimuli trigger cellular cascades which converge leading to the activation 
of the inhibitor of κB kinase complex (IKK) consisting of catalytically active kinases 
IKKα (IKK1), IKKβ (IKK2) and the regulatory subunit NF-κB essential modifier 
(NEMO) also known as IKKγ (Baker et al. 2011). Phosphorylation of two specific 
serine residues within the IκB proteins by the IKK complex targets the protein for 
polyubiquitination and subsequent degradation by the proteasome (Smahi et al. 2002; 
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Oeckinghaus et al. 2011). The unbound NF-κB dimers are then free to translocate to the 
nucleus and function as transcription factors (Oeckinghaus et al. 2011).  
There are two main NF-κB pathways (Figure 27); the classical route involves IKKβ and 
NEMO-mediated phosphorylation of IκBα. The phosphorylated IκBα unit is tagged for 
degradation facilitating the translocation of NF-κB dimers, mainly consisting of p50 and 
p65 heterodimers. Alternatively, the non-canonical pathway is activated in response to 
selected TNF members such as CD40 ligand and lymphotoxin-β. IKKα is responsible 
for the phosphorylation of p100 which is bound to RelB. Degradation of p100 then 
gives rise to the formation of functional p52-RelB dimers (Oeckinghaus et al. 2011). 
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Figure 27. Canonical and non-canonical NF-κB signalling 
The canonical pathway is activated by ligand binding to cell surface receptors like TNFR and utilises 
p50-p65 to mediate its effects. Cytokines such as lymphotoxin-β trigger non-canonical signalling 
involving p52-RelB family members. Inactivation of NF-κB signalling is achieved through the use 
of inhibitory IκB proteins. Inducible processing of the p52 precursor p100 functions as an inhibitor 
for RelB. Phosphorylation of these inhibitory proteins leads to their degradation thus facilitating 
translocation of p50-p65 and p52-RelB dimers where the proteins function as transcription factors. 
Taken from Oeckinghaus et al. (2001). 
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4.1.4. RNA interference (RNAi) 
The body contains a controlled system through which genes can be systematically 
switched on and off. RNAi is an ATP-dependent process initiated by the presence of 
exogenous or endogenously produced double stranded RNA (dsRNA) (Hammond et al. 
2001; Milhavet et al. 2003; Whitehead et al. 2009). RNAi has been observed in many 
organisms including plants, fungi, nematodes, insects and mammals and is thought to 
have evolved in order to protect the genome from undesired foreign DNA sequences 
such as viruses and transposons. The system is also involved in tightly regulated 
processes such as embryonic development (Elbashir et al. 2001; Milhavet et al. 2003).  
A pivotal paper by Fire et al. (1998) demonstrated that injection of small amounts of 
dsRNA into mice produced potent, specific and inheritable interference of gene function 
which was greater than that achieved by the presence of single strands of sense or 
antisense RNA (Fire et al. 1998). Tuschl et al. (1999) later replicated these effects in an 
in vitro system, thus providing the basis for a key tool in the study of RNAi. It was 
noted that dsRNA targeted to intronic sequences were ineffective and as such the 
system was postulated to inhibit protein production at the post transcriptional level 
(Tuschl et al. 1999). The discovery of the RNA-induced silencing complex (RISC) by 
Hammond et al. (2000) a year later was a crucial step in clarifying events underlying 
RNAi (Hammond et al. 2001). During RNAi, dsRNA is processed into 21-23 nucleotide 
fragments called siRNAs which bind to their complementary mRNA sequence. This 
triggers the formation of RISC and the recruitment of RNases that mediate the cleavage 
of target mRNA at 21-23 nucleotide intervals (Zamore et al. 2000; Hammond et al. 
2001). Several key components involved in RNAi have since been identified including 
Dicer, an RNase III family nuclease responsible for processing dsRNA into siRNAs 
(Bernstein et al. 2001), and Argonaute2 which guides RNAs to RISC (Hammond et al. 
2001). It is now known that RISC is a ribonucleoproteic complex with an Argonaute 
family member at its core that binds small RNA and facilitates target recognition (Pratt 
and MacRae 2009). RISC also contains RNases responsible for degradation of the 
targeted mRNA (Milhavet et al. 2003). An overview of events is shown in Figure 28. 
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Figure 28. RNAi processing pathways 
During RNAi four main steps take place: the formation of RISC, activation of RISC, binding to the target and subsequent cleavage. RNAi is instigated by the 
presence of dsRNA within the cell from endogenous or exogenous sources such as transposons and microRNA or virus and plasmid vectors respectively. Pre-
miRNA and pre-shRNA are transcribed and transported to the cytoplasm through Exportin-5. The RNase III enzymes Dicer and Drosha cleave the dsRNA into 21-
23 nucleotide fragments. These small dsRNA fragments function as a guide for selective recognition and degradation of the target mRNA by RISC. 
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RNAi technology is routinely used in many laboratories to knock down the expression 
of specific genes and represents a useful tool for reverse genetics. There are 2 main 
routes used for the introduction of dsRNA into the cell: 
1) siRNA: dsRNAs of 20-23 nucleotides in length can be purchased 
commercially to assess the effects of knocking down the expression of genes 
of interest (Milhavet et al. 2003). Liposomes are also commonly employed to 
achieve short-term suppression, in addition to electroporation and 
microinjection (Milhavet et al. 2003).  
2) shRNA: DNA-vector based technology utilises intrinsic RNA Polymerase III 
activity within the cell to synthesise shRNAs in vivo or in vitro from a DNA 
template (Sui et al. 2002; Milhavet et al. 2003). Lentivirus, herpes simplex 
virus, adenovirus, adeno-associated virus and retrovirus vectors are frequently 
used (Smith and Romero 1999). The shRNA vector is transported to the 
nucleus and processed through similar mechanisms as seen during miRNA 
processing. The primary transcript termed pre-shRNA contains a hairpin like 
stem-loop structure which is processed by RNase III enzyme Drosha within the 
nucleus (Rao et al. 2009) and then transported into the cytoplasm through 
Exportin-5 (Yi et al. 2003). Within the cytoplasm, Dicer activity results in the 
removal of the hairpin loop and the molecule is thought to thereafter follow the 
same processing pathway as siRNA (Rao et al. 2009). 
Although siRNA and shRNA have similar effects within the cell, the molecules differ 
and are subjected to different RNAi processing routes (Rao et al. 2009). As a result 
siRNA-mediated suppression is typically a transient process, with normal gene 
expression recovering after 96-120 hours or 3-5 cycle of cell division. In contrast, 
gene suppression achieved by virally-delivered shRNA lasts longer and is lost after 
approximately 21 days potentially due to the host’s immune response (Smith and 
Romero 1999). Furthermore, vector-based methods have a greater transfection 
efficiency in certain cell lines, especially post-mitotic and primary-derived cells 
(Milhavet et al. 2003).  
A major advantage of the siRNA system is the ease of synthesis which allows fast 
production of numerous siRNAs. Furthermore, the technique has been widely used by 
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numerous studies and holds great therapeutic potential. Different methods of 
transfection have been shown to have varying degrees of success in different cell types 
and it is therefore important to optimise transfection techniques depending on cell 
culture conditions, the transfection reagents chosen, amount of dsRNA used and the 
length of exposure time to dsRNA (Milhavet et al. 2003). A combination of siRNA 
and shRNA was used for the studies outlined below. 
4.2. Experimental aims 
The previous chapter demonstrated that stimulation by IL-33 modulates the mRNA 
expression of the pro-atherosclerotic genes ICAM-1 and MCP-1 (several studies 
investigating their role in atherosclerosis are summarised in Tables 15 and 16). The 
strongest response was observed after 12 hours of IL-33 (25ng/ml) stimulation in three 
separate cellular systems; human THP-1 macrophages and HMDMs and also within 
the murine RAW264.7 macrophage cell line. Previous studies have investigated the 
activation of genes and proteins by IL-33. However analysis of the signalling 
pathways underlying IL-33-mediated regulation of ICAM-1 and MCP-1 in THP-1 
macrophages and primary HMDMs has not been undertaken.  
The principal aim of this chapter was to discern the signalling pathways used by IL-33 
to regulate ICAM-1 and MCP-1 expression. The signalling components; ERK1, ERK2, 
p38α, JNK1, JNK2, PI3K-γ, p50 and p65 were chosen due to the well-established role 
of these proteins in atherosclerotic processes. In order to determine which signalling 
cascades were involved in this response, a combination of siRNA and shRNA was 
utilised to knock down the expression of signalling components and to assess the 
effect on IL-33 signalling using the well-established THP-1 cell line. Several of these 
shRNAs were then used in primary HMDMs to validate the response. RNAi is a 
frequently used technique and can be employed to explore functional studies within 
different cell lines (Kamath et al. 2003; Scherr and Eder 2004; Salter et al. 2011). Our 
group has previously optimised conditions for siRNA and shRNA-mediated knock 
down for the purpose of analysing signalling pathways. Cells were transfected with 
siRNA against scramble sequences or infected with viruses encoding scramble 
sequences to allow for direct comparison with cells transfected/infected with gene-
specific siRNA or shRNA respectively. Additional cells were treated with these 
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scramble sequences and stimulated by IL-33 to enable comparison with cells subjected 
to gene-specific silencing and IL-33 stimulation. 
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Table 15. Role of ICAM-1 in atherosclerosis and related pathologies 
Gene Role in Atherosclerosis Reference 
ICAM-1 
Treatment with atorvastatin reduced levels of sICAM-1 in patients at risk of cardiovascular 
disease. 
(Blanco-Colio et al. 2007) 
 
ICAM-1 was expressed on the endothelium and functioned as a ligand for β2 integrins such as 
lymphocyte function-associated antigen 1 and macrophage-1 antigen. 
(Kadono et al. 2002) 
 
Ablation of ICAM-1 significantly reduced lesion size within ApoE
-/-
 mice. (Kitagawa et al. 2002) 
 A polymorphism in the ICAM-1 gene, K469E, caused greater expression of the gene and was 
associated with increased incidences of cardiovascular disease. The genotype was significantly 
higher in sufferers of atherosclerosis. 
(Motawi et al. 2012) 
 ICAM-1 was strongly expressed in regions of the lesion site associated with irregular blood flow. 
(Nakashima et al. 1998) 
 Immunohistochemical staining revealed increased expression of ICAM-1 within all subtypes of the 
plaque with the exception of the fibrous cap. Furthermore, ICAM-1 was expressed by a number of 
plaque-resident cells including endothelial cells, macrophages and SMCs. 
(Poston et al. 1992) 
 sICAM-1 is a well-established marker of atherosclerosis and increased concentrations are linked to 
MI risk. Levels of the protein are increased in relation to disease progression in ApoE
-/-
 mice. 
(Ridker et al. 1998) 
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Table 16. Role of MCP-1 in atherosclerosis and related pathologies 
Gene Role in Atherosclerosis Reference 
MCP-1 
In ApoE
-/-
 mice, overexpression of MCP-1 promoted atherosclerosis and was associated with 
increased numbers of macrophages and accumulation of oxidised lipids. 
(Aiello et al. 1999) 
 
Treatment with atorvastatin reduced levels of sMCP-1 in patients at risk of cardiovascular disease. (Blanco-Colio et al. 2007) 
 
mmLDL increased the secretion of MCP-1 in cultured endothelial and SMCs and subsequent 
chemotactic activity was primarily driven by MCP-1. 
(Cushing et al. 1990) 
 
Knocking out the MCP-1 gene in LDLR
-/- 
mice caused a large reduction in the size of 
atherosclerotic plaques. 
(Gu et al. 1998) 
 
sMCP-1 is a recognised marker of cardiovascular disease. Mice deficient in MCP-1 were 
specifically unable to recruit circulating monocytes. 
(Lucas and Greaves 2001) 
 
MCP-1 mRNA was present in atherosclerotic lesions but absent from the intima media of animals 
without the disease. MCP-1 mRNA was observed in macrophage foam cells of atherosclerotic 
rabbits but missing from alveolar macrophages. The presence of the MCP-1 protein correlated with 
macrophage-rich areas of human plaques. 
(Ylaherttuala et al. 1991b) 
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The principal aims of this chapter were:  
1) To determine whether IL-33 affected the mRNA levels of the signalling 
components tested. 
2) To assess whether the siRNA and/or shRNA-mediated knock down was 
achieved at the mRNA and protein level through the use of RT-qPCR and 
western blot analysis. 
3) To analyse the effects on IL-33-regulation of ICAM-1 and MCP-1 following 
siRNA/ shRNA-mediated knock down of key signalling components 
previously implicated in IL-33 signalling using RT-qPCR. 
4) To validate the findings observed in THP-1 macrophages in primary cultures 
of HMDMs through a combination of RT-qPCR and western blotting. 
A schematic of the experimental strategy employed to achieve these aims is provided 
in Figure 29. 
 
  
The signalling pathways underlying IL-33-regulation of ICAM-1 and MCP-1 expression Melanie Buckley 
 
134 
 
 
 
 
 
 
                                 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 29. Schematic of experimental procedure 
THP-1 cells were treated with shRNA or siRNA and the expression of targeted genes was then 
measured by RT-qPCR to determine whether knock down of gene expression had been achieved. 
Samples with confirmed knock down were assessed by RT-qPCR and western blotting to analyse the 
effects of reduced expression of key signalling components on IL-33-mediated regulation of ICAM-
1 and MCP-1 expression. RNAi was then completed in HMDMs to assess whether the results were 
replicable in primary macrophages.  
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4.3. Results 
4.3.1. The effect of IL-33 on the expression of key components of signal 
transduction pathways in THP-1 macrophages 
Studies were performed to determine the effect of IL-33 stimulation on the mRNA 
expression of key genes involved in signal transduction. In accordance with the 
conditions optimised in the previous chapter, THP-1 cells were plated into 12-well 
plates and differentiated by PMA. The cells were then left untreated or were 
stimulated for 12 hours with IL-33 (25ng/ml). RT-qPCR was performed on the 
resulting cDNA using gene specific primers for the MAPKs ERK1, ERK2, p38α, 
JNK1 and JNK2; PI3K-γ; and the NF-κB subunits p50 and p65. 
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Figure 30. Action of IL-33 on the expression of key components of signal 
transduction pathways in THP-1 macrophages 
RT-qPCR was performed using cDNA from PMA differentiated THP-1 macrophages incubated 
in the presence or absence (Control) of IL-33 (25ng/ml) for 12 hours. Gene specific primers for: 
Panel A= ERK1, B= ERK2, C= p38α, D= JNK1, E= JNK2, F= PI3K-γ, G= p50 and H= p65 
were used. The mRNA levels were calculated using the comparative Ct method and normalised 
to the house-keeping gene, GAPDH, with values from control samples given an arbitrary value 
of 1. Data represents mean ± SD from four independent experiments. The Student t test was 
used to determine the statistical significance of the results *p<0.05, **p<0.01. 
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IL-33 stimulation did not have a significant effect on the mRNA expression of ERK1, 
ERK2 and JNK1 or the NF-κB subunits p50 and p65. However, IL-33 did cause a 
slight but significant reduction in the mRNA expression of the MAPKs p38α and 
JNK2 in addition to PI3K-γ (Figure 30).  
4.3.2. The effects of IL-33 in ERK1/2 activation  
The effect of IL-33 on levels of ERK1 and ERK2 protein was next analysed. Studies 
have shown that ERK pathways regulate the proliferation and differentiation of SMCs 
in the lesion (Muslin 2008) and inhibition of ERK1/2 leads to increased cholesterol 
efflux from macrophage-derived foam cells (Zhou et al. 2010). Two isoforms of ERK; 
ERK1 and ERK2 are ubiquitously expressed in all mammalian cells (Hu and Ivashkiv 
2009). The pathway can be activated by various stimuli resulting in the 
phosphorylation and activation of ERK1/2 (Zhou et al. 2010). Phosphorylation of 
ERK1/2 induces translocation of the kinase from the cytoplasm into the nucleus, 
where the proteins activate target proteins or trigger alternative signalling cascades 
(Costa et al. 2006).  
An experiment under conditions previously used by our group (i.e. 10ng/ml IL-33 for 
24 hours) was performed to investigate the mechanisms underlying IL-33 signalling 
and was performed with participation from another laboratory member, Timothy 
Ashlin, to aid studies towards his thesis. The experiment also served to validate the 
western blotting system previously optimised by our laboratory (McLaren et al. 
2010b). Western blots were performed for total and phospho-ERK1/2 to determine 
whether IL-33 activated these proteins. Cellular lysates were taken from THP-1 
macrophages incubated in the presence or absence of IL-33 (10ng/ml) and analysed by 
SDS-PAGE.  The samples were then incubated with phospho-ERK1/2 and total 
ERK1/2 antibodies before membrane blotting. The membranes were exposed to X-ray 
film and densitometric analysis was completed using SynGene computer software.  
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The data showed that stimulation of THP-1s with IL-33 (10ng/ml) for 24 hours 
significantly increased the phosphorylation of ERK1/2 compared to the control 
(Figure 31) indicating that the active phosphorylated forms are involved in IL-33 
signalling. On the other hand, the total ERK1/2 levels were unchanged by IL-33 
stimulation.  
 
4.3.3. The role of key signalling components in the IL-33-mediated 
regulation of ICAM-1 and MCP-1 expression in THP-1 macrophages 
Experiments were performed to determine the extent of knock down achieved through 
the use of siRNA and/or shRNA targeting key signalling components implicated in 
atherosclerosis. The use of siRNA (Salter et al. 2011; Horiguchi et al. 2012; Michael 
et al. 2012b; Volante et al. 2012) and shRNA (Li et al. 2010; Wang et al. 2011; 
Michael et al. 2012b) has been extensively applied by research groups for mechanistic 
and functional studies (Kamath et al. 2003; Scherr and Eder 2004). To accommodate 
Figure 31. The effect of IL-33 on ERK1/2 phosphorylation in THP-1 
macrophages 
Western blotting was performed on samples from differentiated THP-1 macrophages that were 
left untreated (control) or stimulated with IL-33 (10ng/ml) for 24 hours. Equal amounts of 
protein from the samples were analysed using phospho ERK1/2 and total ERK1/2 antibodies. 
The signals of the bands for phospho-ERK1/2 were normalised to that for total ERK1/2 with 
values from control samples given an arbitrary value of 1. Bands correspond with the molecular 
weight of both proteins. Semi-quantitative analysis was performed using the Gene Tools 
software. Data represents mean ± SD from three independent experiments. The Student t test 
was used to determine the statistical significance of the results *p<0.05. 
* 
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potential changes in gene expression induced by the presence/ method of delivery of 
shRNA or siRNA which could bias results, shRNA and siRNA targeted towards a 
scramble sequence was also included as a control for each experiment.   
4.3.3.1. Effects of ERK1/2 knock down  
Due to the well-established role of the MAPKs ERK1 and ERK2 in atherosclerosis, 
RT-qPCR was conducted following RNAi-mediated knock down of these genes to 
validate the effectiveness of the siRNA and shRNA used. THP-1 cells were 
transfected with siRNA or infected with shRNA targeted towards ERK1 or ERK2 and 
then stimulated with IL-33 (25ng/ml) for 12 hours before RT-qPCR was performed to 
validate the level of gene silencing.  
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The use of ERK1 and ERK2 shRNA and ERK2 siRNA produced a significant 
reduction in mRNA levels of the targeted genes in the presence and absence of IL-33 
(Figure 32). Incubation with ERK1 shRNA achieved an average decrease in the 
corresponding mRNA levels of 78% and 93% in the absence and presence of IL-33 
respectively. There was a 40% and 33% reduction in nonstimulated and stimulated 
Figure 32. shRNA/siRNA-mediated knock down of ERK1/2 gene expression in 
THP-1 macrophages 
RT-qPCR was performed using cDNA from PMA differentiated THP-1 macrophages treated 
with ERK1 or ERK2 shRNA or ERK2 siRNA and incubated in the presence or absence of IL-33 
(25ng/ml) for 12 hours. Cells expressing shRNA targeting a scramble sequence were used as a 
control for shRNA experiments (Scr), whilst siRNA targeting a scramble sequence was used as a 
control for siRNA experiments (NEG). Gene-specific primers for: Panel A= ERK1, B= ERK2 
and C= ERK2 were used. The mRNA levels were calculated using the comparative Ct method 
and normalised to the house-keeping gene, GAPDH, with values from control samples 
(unstimulated and stimulated Scr and Neg) given an arbitrary value of 1. Data represents mean ± 
SD from five (A), six (B) or three (C) independent experiments. The Student t test was used to 
determine the statistical significance of the results *p<0.05, **p<0.01, ***p<0.001. 
 
*** *** *** * 
* ** 
A B 
C 
The signalling pathways underlying IL-33-regulation of ICAM-1 and MCP-1 expression Melanie Buckley 
 
141 
 
cells respectively mediated by ERK2 shRNA and a decrease of  52% and 42% was 
attained by ERK2 siRNA in untreated and IL-33 treated cells respectively.  
Western blot anaysis was then performed to assess whether the use of RNAi also 
affected  protein expression. Prior to IL-33 addition, THP-1 cells were infected with 
shRNA or transfected with siRNA targeted towards ERK1 or ERK2. Cellular lysates 
were then size-fractionated by SDS-PAGE for analysis by western blotting. 
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Figure 33. RNAi-mediated knock down of ERK1/2 protein levels in THP-1 cells 
Western blot analysis was performed using cellular lysates from PMA-differentiated THP-1 
macrophages treated with ERK1 or ERK2 shRNA, or ERK2 siRNA and incubated in the 
presence or absence of IL-33 (25ng/ml) for 12 hours. Cells expressing shRNA targeting a 
scramble sequence were used as a control for shRNA experiments (Scr), whilst siRNA targeting 
a scramble sequence was used as a control for siRNA experiments (NEG). Equal amounts of 
protein from the samples were analysed using total ERK1/2 and β-actin antibodies. The signals 
for ERK 1/2 were normalised to that for β-actin with values from control samples (unstimulated 
and stimulated Scr and NEG) given an arbitrary value of 1. Bands correspond with the 
molecular weight of both proteins. Panel A= ERK1 shRNA, B= ERK2 shRNA and C= ERK2 
siRNA. Semi-quantitative analysis was performed using the Gene Tools software. Data 
represents mean ± SD from four (A), two (B) and three (C) independent experiments. The 
Student t test was used to determine the statistical significance of the results *p<0.05. 
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Figure 33 shows that the use of ERK1 shRNA significantly decreased protein levels of 
ERK1 by 55% and 47% in untreated cells or those stimulated with IL-33 respectively. 
Because of time restraints that restricted the number of repeats, it was not possible to 
carry out statistical analysis for ERK2 shRNA. However, a trend of reduced ERK2 
protein levels was observed (72% and 17% reduction in untreated cells and those 
stimulated with IL-33 respectively). The use of ERK2 siRNA resulted in a significant 
decrease of 67% in untreated cells and a reduction of 64% was achieved in IL-33 
treated cells that failed to reach significance.  
RT-qPCR was performed on the two ERK isoforms to determine whether these 
reductions were specific to the targeted protein and did not produce off-target effects.  
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The data in Figure 34 demonstrates that the shRNA and siRNA used in the study 
specifically knocked down the expression of the targeted gene without causing a 
significant reduction in the other isoforms tested. The mRNA levels of these 
alternative isoforms was comparable to the levels seen in the control cells. 
  
Figure 34. Specificity of shRNA/siRNA-mediated knock down of ERK1/2 gene 
expression in THP-1 macrophages 
RT-qPCR was performed using cDNA from differentiated THP-1 macrophages treated with 
ERK1 or ERK2 shRNA, or ERK2 siRNA and incubated in the presence or absence of IL-33 
(25ng/ml) for 12 hours as described for Figure 32. Cells expressing shRNA targeting a 
scramble sequence were used as a control for shRNA experiments (Scr), whilst siRNA 
targeting a scramble sequence was used as a control for siRNA experiments (NEG). Gene-
specific primers for: Panel A= ERK1, B= ERK2 and C= ERK2 were used. The mRNA levels 
were calculated using the comparative Ct method and normalised to the house-keeping gene, 
GAPDH, with values from control samples (unstimulated and stimulated Scr and NEG) given 
an arbitrary value of 1. Data represents mean ± SD from five (A), six (B) or three (C) 
independent experiments. The Student t test was used to determine the statistical significance 
of the results. 
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Western blot analysis using specific antibodies for alternative isoforms was then 
performed to determine whether RNAi was isoform specific at the protein level.  
 
  
 
The data of Figure 35 combined with Figure 34 demonstrates specificity and shows 
that both methods of RNAi produced significant levels of gene silencing of the 
Figure 35. Specificity of shRNA/siRNA-mediated knock down of ERK1/2 
proteins in THP-1 macrophages 
Western blot analysis was performed using cellular lysates from PMA-differentiated THP-1 
macrophages treated with ERK1 or ERK2 shRNA, or ERK2 siRNA and incubated in the 
presence or absence of IL-33 (25ng/ml) for 12 hours. Cells expressing shRNA targeting a 
scramble sequence were used as a control for shRNA experiments (Scr), whilst siRNA 
targeting a scramble sequence was used as a control for siRNA experiments (NEG). Equal 
amounts of protein from the samples were analysed using total ERK1/2 and β-actin antibodies. 
The signals for total ERK 1/2 was normalised to that for β-actin with values from control 
samples (unstimulated and stimulated Scr and NEG) given an arbitrary value of 1. Bands 
correspond with the molecular weight of both proteins. Panel A= ERK1 shRNA, B= ERK2 
shRNA and C= ERK2 siRNA. Semi-quantitative analysis was performed using the Gene Tools 
software. Data represents mean ± SD from four (A), two (B) and three (C) independent 
experiments. 
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targeted isoform. The knock down achieved through the use of shRNA was greater 
than with siRNA. Following the validation of these shRNAs and siRNAs, they were 
then used to assess the effects of reduced levels of ERK1 and ERK2 on IL-33-
mediated regulation of ICAM-1 and MCP-1 mRNA expression. 
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Figure 36. ERK-1 and -2 are involved in the IL-33-mediated regulation of ICAM-
1 and MCP-1 expression in THP-1 macrophages 
RT-qPCR was performed using cDNA from differentiated THP-1 macrophages treated with ERK1 
or ERK2 shRNA, or ERK2 siRNA and incubated in the presence or absence of IL-33 (25ng/ml) 
for 12 hours. Cells expressing shRNA targeting a scramble sequence were used as a control for 
shRNA experiments (Scr), whilst siRNA targeting a scramble sequence was used as a control for 
siRNA experiments (NEG). The mRNA levels were calculated using the comparative Ct method 
and normalised to the house-keeping gene, GAPDH, with values from control samples 
(unstimulated and stimulated Scr and NEG) given an arbitrary value of 1. Panel A= ERK1 shRNA, 
B= ERK2 shRNA and C= ERK2 siRNA. Data represents mean ± SD of five (A), six (B) and three 
(C) independent experiments. The Student t test was used to determine the statistical significance 
of the results *p<0.05, **p<0.01. 
** 
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In accordance with the findings from chapter 1, IL-33 reduced the expression of 
ICAM-1 and MCP-1 mRNA in cells expressing scramble sequence (Figure 36). 
However the knock down of ERK-1 and -2 attenuated the IL-33-mediated down-
regulation of mRNA expression for both genes. Figure 36 shows a significant 
induction of ICAM-1 mRNA expression occurs following ERK2 shRNA infection and 
ERK2 siRNA transfection in the presence of IL-33. A similar trend in ICAM-1 
expression is observed following the addition of ERK1 shRNA and IL-33, although 
not significant. 
4.3.3.2. Effects of p38α knock down  
There are four mammalian p38 isoforms: α, β, γ and δ, of which p38α and p38β are 
ubiquitously expressed. Most studies and experimental data focuses on p38α which is 
a key regulator of inflammation and is commonly referred to as p38 MAPK (Risco 
and Cuenda 2012). The p38α isoform is of particular relevance to this study as it is 
activated in vivo during atherosclerotic development (Seimon et al. 2009) and 
silencing of the gene reduces the ratio of CEs to free cholesterol in THP-1 cells (Mei 
et al. 2012).  
THP-1 cells were infected with shRNA for p38α and then stimulated with IL-33 
(25ng/ml) for 12 hours before RT-qPCR analysis was used to assess the extent of 
knock down in mRNA levels for p38α. 
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Figure 37 shows that infection with shRNA resulted in a significant 55% and 50% 
reduction in the average mRNA levels of p38α in the absence and presence of IL-33 
respectively.  
To further discern the effects of p38α shRNA, western blot analysis was conducted on 
cellular lysates to determine the potential reduction in total p38 protein levels. 
Figure 37. shRNA-mediated knock down of p38α gene expression in THP-1 
macrophages 
RT-qPCR was performed using cDNA from differentiated THP-1 macrophages infected with 
p38α shRNA and incubated in the presence or absence of IL-33 (25ng/ml) for 12 hours. Cells 
expressing shRNA targeting a scramble sequence were used as a control (Scr). The mRNA 
levels were calculated using the comparative Ct method and normalised to the house-keeping 
gene, GAPDH, with values from control samples (unstimulated and stimulated Scr) given an 
arbitrary value of 1. Data represents mean ± SD from six independent experiments. The 
Student t test was used to determine the statistical significance of the results ***p<0.001. 
*** *** 
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Figure 38. shRNA-mediated knock down of p38α protein in THP-1 
macrophages 
Western blot analysis was performed using cellular lysates from differentiated THP-1 
macrophages infected with p38α shRNA and incubated in the presence or absence of IL-33 
(25ng/ml) for 12 hours. Cells expressing shRNA targeting a scramble sequence were used as a 
control (Scr). Equal amounts of protein from the samples were analysed using total p38 and β-
actin antibodies. The signals for total p38 were normalised to that for β-actin with values from 
control samples (unstimulated and stimulated Scr) given an arbitrary value of 1. Bands 
correspond with the molecular weight of both proteins. Semi-quantitative analysis was 
performed using the Gene Tools software. Data represents mean ± SD from three independent 
experiments. The Student t test was used to determine the statistical significance of the results 
*p<0.05, **p<0.01. 
Total p38 38kDa 
β-actin 42kDa 
** 
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Western blot analysis demonstrated that expression of p38α shRNA resulted in a 
significant decrease of 86% (Unstimulated) and 72% (IL-33 stimulated) in total p38 
protein (Figure 38).  
Thus, the use of p38α shRNA produced a significant reduction in p38α mRNA and 
total p38 protein levels. Therefore the shRNA was used to determine the involvement 
of p38α in IL-33 regulation of ICAM-1 and MCP-1 gene expression.  
 
 
 
Figure 39 shows that p38α was involved in IL-33-mediated reduction of ICAM-1 and 
MCP-1 mRNA expression. In cells expressing the scramble sequence, IL-33 produced 
a significant decrease in mRNA levels for both of these genes. However, the presence 
of p38α shRNA negated this response.  
4.3.3.3. Effects of JNK1/2 knock down  
The role of JNK1/2 within IL-33 signalling was next explored due to the well 
established involvement of these MAPKs in atherosclerosis (Yoshimura et al. 2005; 
 
Figure 39. p38α is involved in the IL-33-mediated regulation of ICAM-1 and 
MCP-1 expression in THP-1 macrophages 
RT-qPCR was performed using cDNA from differentiated THP-1 macrophages infected with 
p38α shRNA and incubated in the presence or absence of IL-33 (25ng/ml) for 12 hours. Cells 
expressing shRNA targeting a scramble sequence were used as a control (Scr). The mRNA 
levels were calculated using the comparative Ct method and normalised to the house-keeping 
gene, GAPDH, with values from control samples (unstimulated and stimulated Scr) given an 
arbitrary value of 1. Data represents the mean ± SD of six independent experiments. The 
Student t test was used to determine the statistical significance of the results *p<0.05. 
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Hui 2007). The presence of LDL and OxLDL induces the activation of JNK-1 and -2 
within atherosclerotic plaques (Metzler et al. 2000). Also inhibition of JNK reduces 
the size of the atherosclerotic plaque and JNK2 may have an important role in 
facilitating the uptake of lipoproteins and, as a result, promote foam cell production 
(Ricci et al. 2004).  
To validate the use of JNK1 and JNK2 siRNA, the siRNAs were co-transfected into 
differentiated THP-1 cells to achieve a decrease in the expression of both JNK 
isoforms prior to stimulation by IL-33. RT-qPCR was then performed to assess the 
level of reduction at the mRNA level. 
 
 
 
Co-transfection of siRNAs targeting JNK1 and JNK2 produced a significant reduction 
of 71% in the mRNA levels of JNK1 in the absence of IL-33 (Figure 37). A marked 
reduction in JNK1 mRNA was also present in THP-1 cells stimulated by IL-33 (34%) 
though this failed to reach significance. JNK2 mRNA was significantly decreased by 
 
Figure 40. siRNA-mediated knock down of JNK1/2 gene expression in THP-1 
macrophages 
RT-qPCR was performed using cDNA from differentiated THP-1 macrophages co-transfected 
with JNK1 and JNK2 siRNAs and incubated in the presence or absence of IL-33 (25ng/ml) for 
12 hours. Samples transfected with siRNA targeting a scramble sequence were used as a control 
(NEG). Gene specific primers for JNK1 (Panel A) and JNK2 (B) were used. The mRNA levels 
were calculated using the comparative Ct method and normalised to the house-keeping gene, 
GAPDH, with values from control samples (unstimulated and stimulated NEG) given an 
arbitrary value of 1. Data represents mean ± SD from five independent experiments. The 
Student t test was used to determine the statistical significance of the results *p<0.05, 
**p<0.01. 
* ** ** 
A B 
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siRNA co-transfection by 75% and 31% in cells untreated and treated by IL-33 
respectively. 
To confirm whether knock down was also present at the protein level, western blot 
analysis was performed on cellular lysates from siRNA transfected THP-1 
macrophages.  
 
 
 
   
 
  
 
Figure 41. siRNA-mediated knock down of JNK1/2 proteins in THP-1 
macrophages 
Western blot analysis was performed using cellular lysates from differentiated THP-1 
macrophages co-transfected with JNK1/2 siRNAs and incubated in the presence or absence of IL-
33 (25ng/ml) for 12 hours. Samples transfected with siRNA targeting a scramble sequence were 
used as a control (NEG). Equal amounts of protein from the samples were analysed using total 
JNK and β-actin antibodies. The signals for total JNK was normalised to that for β-actin with 
values from control samples (unstimulated and stimulated NEG) given an arbitrary value of 1. 
Bands correspond with the molecular weight of both proteins. Semi-quantitative analysis was 
performed using the Gene Tools software. Data represents mean from two independent 
experiments.  
β-actin 42kDa 
JNK2 54kDa 
JNK1 46kDa 
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Co-tranfection of JNK-1 and -2 siRNAs in THP-1 macrophages resulted in a decrease 
in the levels of JNK-1 and -2 proteins (Figure 41). An average decrease of 36% and 70% 
was seen in unstimulated and IL-33 stimulated macrophages, respectively. Following 
incubation with JNK1/2 siRNAs the levels of JNK2 protein were reduced by 37% in 
untreated cells and 51% in IL-33-treated cells. 
The combination of JNK1 and JNK2 siRNAs were then used to investigate whether 
the MAPKs were involved in IL-33-mediated regulation of ICAM-1 and MCP-1 
expression. Following co-transfection of JNK1/2 siRNAs, RT-qPCR was used to 
determine the effects on the mRNA levels of ICAM-1 and MCP-1 after IL-33 
stimulation. 
 
  
 
Figure 42 shows that the MAPKs JNK1/2 were involved in IL-33 signalling. 
Stimulation with IL-33 significantly decreased levels of ICAM-1 and MCP-1 mRNA 
in cells expressing the scramble sequence. However with reduced levels of JNK1/2 
this response was lost. Furthermore the RNAi-mediated reduction of JNK1/2 resulted 
Figure 42. JNK1/2 are involved in IL-33-mediated regulation of ICAM-1 and 
MCP-1 expression in THP-1 macrophages 
RT-qPCR was performed using cDNA from differentiated THP-1 macrophages co-transfected 
with JNK1 and JNK2 siRNAs and incubated in the presence or absence of IL-33 (25ng/ml) for 
12 hours. Samples transfected with siRNA targeting a scramble sequence were used as a control 
for siRNA experiments (NEG). The mRNA levels were calculated using the comparative Ct 
method and normalised to the house-keeping gene, GAPDH, with values from control samples  
(unstimulated and stimulated NEG) given an arbitrary value of 1. Data represents the mean ± 
SD of five independent experiments. The Student t test was used to determine the statistical 
significance of the results *p<0.05. 
 
 
 
 * * * 
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in a significant induction in MCP-1 mRNA levels following IL-33 treatment. A 
similar trend occured for ICAM-1, although the induction in mRNA expression was 
not significant. 
4.3.3.4. Effects of PI3K-γ knock down  
In addition to the MAPK signalling cascades other signal transduction pathways are 
implicated in atherogenesis. The exact role of PI3K-γ, a PI3K family member, in 
atherosclerosis is not fully understood. The isoform is expressed by haematopoietic 
cells, endothelial cells and cardiomyocytes (Siragusa et al. 2010) and appears to 
participate in a number of pro-atherogenic processes (Chang et al. 2007). Levels of 
PI3K-γ are high within human and mouse atherosclerotic plaques and use of the PI3K-
γ inhibitor AS605240 improves plaque stability and reduces the infiltration of 
macrophages and T cells (Fougerat et al. 2008). Also, mice deficient in PI3K-γ display 
impaired platelet aggregation (Hirsch et al. 2001). 
Due to time constraints, the study focused on the PI3K isoform PI3K-γ due to its 
involvement in pro-atherosclerotic processes and sought to investigate the role of this 
kinase in IL-33 activity. To determine the extent of knock down achieved by RNAi, 
differentiated THP-1 cells were infected with adenovirus encoding PI3K-γ shRNA and 
RT-qPCR was performed.  
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Figure 43 shows that expression of PI3K-γ shRNA resulted in a significant reduction 
of PI3K-γ mRNA levels in untreated cells (48%) and IL-33 stimulated cells (62%).  
 
Unfortunately an antibody for PI3K-γ was not available to validate the use of PI3K-γ 
shRNA at the protein level. However, as a significant reduction had been achieved at 
the mRNA level, PI3K-γ shRNA was used to assess whether the kinase was involved 
in IL-33 signalling. RT-qPCR using gene-specific primers for ICAM-1 and MCP-1 
was performed on mRNA from THP-1 cells expressing PI3K-γ shRNA. 
 
Figure 43. shRNA-mediated knock down of PI3K-γ gene expression in THP-1 
macrophages 
RT-qPCR was performed using cDNA from differentiated THP-1 macrophages infected with 
PI3K-γ shRNA and incubated in the presence or absence of IL-33 (25ng/ml) for 12 hours. Cells 
expressing shRNA targeting a scramble sequence were used as a control for shRNA (Scr). The 
mRNA levels were calculated using the comparative Ct method and normalised to the house-
keeping gene, GAPDH, with values from control samples (unstimulated and stimulated Scr) 
given an arbitrary value of 1. Data represents mean ± SD from six independent experiments. 
The Student t test was used to determine the statistical significance of the results ***p<0.001. 
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IL-33 stimulation significantly reduced mRNA levels of ICAM-1 and MCP-1 (Figure 
44). However, following shRNA-mediated reduction of PI3K-γ, the decrease in 
ICAM-1 and MCP-1 mRNA expression by IL-33 was lost. Also, ICAM-1 and MCP-1 
displayed a trend for increased mRNA expression following IL-33 stimulation in cells 
transfected with PI3K-γ shRNA.  
  
Figure 44. PI3K-γ is involved in IL-33-mediated regulation of ICAM-1 and 
MCP-1 expression in THP-1 macrophages 
RT-qPCR was performed using cDNA from differentiated THP-1 macrophages infected with 
PI3K-γ shRNA and incubated in the presence or absence of IL-33 (25ng/ml) for 12 hours. Cells 
expressing shRNA targeting a scramble sequence were used as a control (Scr). The mRNA 
levels were calculated using the comparative Ct method and normalised to the house-keeping 
gene, GAPDH, with values from control samples (unstimulated and stimulated Scr) given an 
arbitrary value of 1. Data represents the mean ± SD of three (ICAM-1) and five (MCP-1) 
independent experiments. The Student t test was used to determine the statistical significance of 
the results *p<0.05. 
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4.3.3.5. Effects of p50/p65 knock down  
The final signalling components investigated were the NF-κB members p50 and p65. 
This signalling cascade has been implicated in the disease as activated NF-κB is found 
localised in fibrotic-enriched intima/media and atheromateous regions of the plaque 
and colocalises with plaque-resident SMCs, macrophages and endothelial cells (Brand 
et al. 1996; Bourcier et al. 1997). Also, a number of genes implicated in 
atherosclerosis are regulated by NF-κB including ICAM-1, M-CSF, MCP-1 and TNF-
α (Brand et al. 1997).  
The involvement of NF-κB signalling components in the IL-33-mediated regulation of 
ICAM-1 and MCP-1 expression was explored by co-transfection of THP-1 
macrophages with p50 and p65 siRNAs.  
 
   
Figure 45 shows that co-transfection of p50 and p65 siRNAs produced a significant 
Figure 45. siRNA-mediated knock down of p50/p65 gene expression in THP-1 
macrophages 
RT-qPCR was performed using cDNA from differentiated THP-1 macrophages co-transfected 
with p50 and p65 siRNAs and incubated in the presence or absence of IL-33 (25ng/ml) for 12 
hours. Samples transfected with siRNA targeting a scramble sequence were used as a control 
(NEG). Gene specific primers for p50 (Panel A) and p65 (B) were used. The mRNA levels were 
calculated using the comparative Ct method and normalised to the house-keeping gene, 
GAPDH, with values from control samples (unstimulated and stimulated NEG) given an 
arbitrary value of 1. Data represents mean ± SD from four (NEG and p65/p50) and two 
independent experiments (NEG+IL-33 and p65/p50+IL-33). The Student t test was used to 
determine the statistical significance of the results for NEG and p65/p50 **p<0.01. Insufficient 
replicates of IL-33 treated cells meant that statistical tests were not performed for these samples. 
 
 
 
** 
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decrease of 60% in the mRNA levels of p50 in unstimulated cells. In the presence of 
IL-33 there was an average decrease of 48%. The mRNA expression of p65 was 
significantly reduced by 53% in cells absent of IL-33 and a reduction of 53% was 
achieved in cells treated with IL-33.  
To further validate the use of p50 and p65 siRNAs in this system, the effects of these 
siRNAs on protein expression was assessed using western blot analysis. 
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Figure 46. siRNA-mediated knock down of p50/p65 protein in THP-1 
macrophages 
Western blot analysis was performed using cellular lysates from differentiated THP-1 
macrophages co-transfected with p50 and p65 siRNAs and incubated in the presence or absence 
of IL-33 (25ng/ml) for 12 hours. Samples transfected with siRNA targeting a scramble 
sequence were used as a control (NEG). Equal amounts of protein from the samples were 
analysed using p50 (Panel A), p65 (Panel B) and β-actin antibodies. The signals for p50 and 
p65 were normalised to that for β-actin with values from control samples (unstimulated and 
stimulated NEG) given an arbitrary value of 1. Bands correspond with the molecular weight of 
both proteins. Semi-quantitative analysis was performed using the Gene Tools software. Data 
represents mean ± SD from four independent experiments. The Student t test was used to 
determine the statistical significance of the results *p<0.05. 
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Co-transfection of p50 and p65 siRNAs produced a marked reduction in p50 and p65 
protein levels (Figure 46). The decrease in p50 protein (45%) following IL-33 
stimulation was significant and a similar trend was present in other samples subjected 
to p50/p65-mediated RNAi, although not significant, possibly due to large variation. 
In the absence of IL-33, the siRNAs mediated a 42% decrease in the levels of p50 
protein. The levels of p65 protein exhibited a 24% and 45% reduction in unstimulated 
and IL-33 stimulated cells respectively. 
The p50 and p65 siRNAs reduced the mRNA and protein expression of p50 and p65 
and were therefore used to determine the effect on IL-33 signalling. THP-1 cells were 
co-transfected with p50 and p65 siRNAs in the absence and presence of IL-33 before 
RT-qPCR analysis using primers for ICAM-1 and MCP-1. 
 
 
 
IL-33 stimulation significantly reduced levels of ICAM-1 (Figure 47). Silencing of 
p50 and p65 negated the response from IL-33 and led to a non-significant increase in 
the mRNA expression of this gene. Due to time constraints further repeats were not 
Figure 47. p50/p65 are involved in the IL-33-mediated regulation of ICAM-1 
expression in THP-1 cells 
RT-qPCR was performed using cDNA from differentiated THP-1 macrophages co-transfected 
with p50 and p65 siRNAs and incubated in the presence or absence of IL-33 (25ng/ml) for 12 
hours. Samples transfected with siRNA targeting a scramble sequence were used as a control 
(NEG). The mRNA levels were calculated using the comparative Ct method and normalised to 
the house-keeping gene, GAPDH, with values from control samples (unstimulated and 
stimulated NEG) given an arbitrary value of 1. Data represents the mean ± SD of three 
independent experiments. The Student t test was used to determine the statistical significance of 
the results *p<0.05. 
* 
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performed for MCP-1, although the cytokine caused a possible modest reduction in 
MCP-1 mRNA expression in the absence and presence of p50/p65 siRNAs indicating 
that these signalling components do not have an integral role in IL-33 signalling for 
this gene. 
The studies presented here demonstrate that the MAPKs ERK1, ERK2, p38α and 
JNK1/2 along with the PI3K isoform PI3K-γ and the NF-κB subunits p50 and p65 
play an essential role in the regulation of ICAM-1 expression by IL-33 in THP-1 
macrophages. The same signalling components were also utilised for MCP-1 with the 
exception of p50 and p65.  
4.3.4. The role of key signalling components in the IL-33-mediated 
regulation of ICAM-1 and MCP-1 expression in primary cells 
Within THP-1 macrophages, the use of siRNAs and shRNAs achieved effective knock 
down of targeted gene expression. A similar approach was adopted to explore the role 
of key signalling components within primary HMDMs. However, due to the known 
issues with the use of siRNA in primary cells; such as low efficiency of transfection, 
RNAi was mediated with shRNAs within these cells. Technical difficulties with 
attaining a knock down by ERK2 and PI3K-γ shRNA meant that only shRNAs for 
ERK1 and p38α were used. 
4.3.4.1. Effects of ERK1 knock down  
Primary HMDMs were infected with shRNA for ERK1 using the same protocol as the 
THP-1 cells. The gene expression of ERK1 and ERK2 was then analysed by RT-
qPCR. However, due to issues with cell viability and time restraints, western blots 
were not performed to assess the effects on ERK1 protein levels. 
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Figure 48A shows that ERK1 shRNA mediated a significant decrease of 32% in 
untreated cells and levels of ERK1 mRNA fell by 33% in IL-33 treated cells. Figure 
48B demonstrates that the effects of ERK1 shRNA in primary cells were specific to 
ERK1 and did not cause a reduction in mRNA levels of the ERK2 isoform. An 
increase in the levels of ERK2 mRNA was observed, although the raise was not 
significant and may indicate that compensatory mechanisms were induced through the 
use of ERK1 shRNA. 
Following validation of the use of these shRNAs for gene silencing in primary cells, 
ERK1 shRNA was then used to knock down the mRNA expression of ERK1 to assess 
the effects on IL-33-mediated regulation of ICAM-1 and MCP-1 mRNA expression 
by RT-qPCR. 
 
 
Figure 48. ERK1 shRNA mediated specific knock down of ERK1 gene 
expression in primary cells 
RT-qPCR was performed using cDNA from primary macrophages expressing ERK1 shRNA 
and incubated in the presence or absence of IL-33 (25ng/ml) for 12 hours. Cells expressing 
shRNA targeting a scramble sequence were used as a control (Scr). Gene specific primers for 
ERK1 (Panel A) and ERK2 (Panel B) were used. The mRNA levels were calculated using the 
comparative Ct method and normalised to the house-keeping gene, GAPDH, with values from 
control samples (unstimulated and stimulated Scr) given an arbitrary value of 1. Data 
represents mean ± SD from three experiments. The Student t test was used to determine the 
statistical significance of the results *p<0.05. 
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Experiments in chapter one demonstrated that IL-33 down-regulates the expression of 
ICAM-1 and MCP-1 mRNA within primary HMDMs (Figure 22). However, in the 
presence of scramble shRNA, treatment with IL-33 caused a non-signficant but 
noticeable induction in ICAM-1 and MCP-1 mRNA levels (Figure 49). The 
experiments performed in THP-1 macrophages indicated that IL-33 uses ERK1 to 
mediate the reduction in ICAM-1 and MCP-1 (Figure 36A). In one of the HMDM 
experiments, IL-33 treatment caused a reduction in ICAM-1 and MCP-1 mRNA 
expression (Appendix Figure 67). Further experiments will be required to delineate the 
role of ERK1 in the IL-33-mediated expression of these genes in primary cultures.   
4.3.4.2. Effects of p38α knock down  
Primary HMDMs were infected with p38α shRNA and RT-qPCR was used to analyse 
the effect on p38α gene expression.  
 
Figure 49. The effect of ERK1 knock down in regulation of ICAM-1 and MCP-
1 by IL-33 
RT-qPCR was performed using cDNA from primary macrophages expressing ERK1 shRNA 
and incubated in the presence or absence of IL-33 (25ng/ml) for 12 hours. Cells expressing 
shRNA targeting a scramble sequence were used as a control (Scr). The mRNA levels were 
calculated using the comparative Ct method and normalised to the house-keeping gene, 
GAPDH, with values from control samples (unstimulated and stimulated Scr) given an arbitrary 
value of 1. Data represents mean ± SD from three experiments. The Student t test was used to 
determine the statistical significance of the results. 
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The use of p38α shRNA mediated a significant reduction of 38% in untreated cells and 
levels of p38α mRNA fell by 34% in IL-33-stimulated cells (Figure 50). 
To determine whether these reductions were present at the protein level, western blot 
analysis was performed on cellular lysates following infection by p38α shRNA in 
primary HMDMs.  
  
 
Figure 50. p38α shRNA-mediated knock down of p38α gene expression in 
primary cells 
RT-qPCR was performed using cDNA from primary macrophages expressing p38α shRNA 
and incubated in the presence or absence of IL-33 (25ng/ml) for 12 hours. Cells expressing 
shRNA targeting a scramble sequence were used as a control (Scr). Gene specific primers for 
p38α were used. The mRNA levels were calculated using the comparative Ct method and 
normalised to the house-keeping gene, GAPDH, with values from control samples 
(unstimulated and stimulated Scr) given an arbitrary value of 1. Data represents mean ± SD 
from three experiments. The Student t test was used to determine the statistical significance of 
the results *p<0.05. 
 
** 
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Figure 51 shows that p38α shRNA caused a substantial decrease in the levels of total 
p38 protein in primary cells left untreated or treated with IL-33.  
 
Figure 51. shRNA-mediated knock down of p38α protein in primary human 
macrophages 
Western blot analysis was performed using cellular lysates from primary macrophages 
expressing p38α shRNA and incubated in the presence or absence of IL-33 (25ng/ml) for 12 
hours. Cells expressing shRNA targeting a scramble sequence were used as a control (Scr). 
Equal amounts of protein from the samples were analysed using total p38 and β-actin 
antibodies. The signal for p38 was normalised to that for β-actin with the values from control 
samples (unstimulated and stimulated Scr) given an arbitrary value of 1. Bands correspond with 
the molecular weight of both proteins. Semi-quantitative analysis was performed using the 
Gene Tools software. Data represents mean from two experiments. 
Total p38 38kDa 
β-actin 42kDa 
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Following validation of p38α shRNA in reducing the mRNA and protein expression of   
p38α in primary cells, the shRNA was then used to examine the role of p38α in the 
regulation of ICAM-1 and MCP-1 gene expression by IL-33 using RT-qPCR. 
 
  
 
The use of scramble shRNA caused a non-significant induction in the mRNA 
expression of ICAM-1 and MCP-1 following IL-33 stimulation (Figure 52), as was 
also seen in Figure 49. The induction in ICAM-1 and MCP-1 was particular to 
primary cells as THP-1 macrophages displayed a reduction in the expression of these 
genes in the presence of scramble shRNA (Figures 36A, 36B, 39 and 44). Interestingly, 
in a single experiment from Figure 52 IL-33 treatment caused a reduction in MCP-1 
mRNA expression (Appendix Figure 68). Within these samples p38α was not integral 
in the IL-33 down-regulation of MCP-1.  
The responses seen in THP-1 cells in cells expressing scramble shRNA and from 
normal HMDMs were mostly not conserved in HMDMs expressing scramble shRNA. 
The primary HMDM experiments were associated with a high variability likely due to 
Figure 52. The effects of p38α knock down in IL-33 regulation of ICAM-1 and 
MCP-1  
RT-qPCR was performed using cDNA from primary macrophages expressing p38α shRNA and 
incubated in the presence or absence of IL-33 (25ng/ml) for 12 hours. Cells expressing shRNA 
targeting a scramble sequence were used as a control (Scr). The mRNA levels were calculated 
using the comparative Ct method and normalised to the house-keeping gene, GAPDH, with 
values from control samples (unstimulated and stimulated Scr) given an arbitrary value of 1. 
Data represents mean ± SD from three experiments.  The Student t test was used to determine 
the statistical significance of the results. 
 
The signalling pathways underlying IL-33-regulation of ICAM-1 and MCP-1 expression Melanie Buckley 
 
168 
 
the heterogenous nature of these cells and further repeats would be needed to perform 
further statistical analysis. 
4.4. Discussion 
The use of ERK1, ERK2, p38α and PI3K-γ shRNAs, and ERK2, JNK1, JNK2, p50 
and p65 siRNAs were validated within the THP-1 cellular system, in addition to 
ERK1 and p38α shRNAs within primary HMDMs. The data demonstrated that these 
RNAi methods produced substantial reductions in the mRNA levels of the genes 
tested. Also where analysed (ERK1, ERK2 and p38α shRNA and ERK2, JNK1, JNK2, 
p50 and p65 siRNAs) there was a corresponding decrease at the protein level. The 
studies presented within this chapter have reaffirmed the findings found in the 
previous chapter; that stimulation by IL-33 (25ng/ml) for 12 hours produces a 
reduction in the mRNA expression of ICAM-1 and MCP-1 in THP-1 macrophages. 
The use of RNAi then demonstrated that the MAPKs ERK1, ERK2, p38α, JNK1 and 
JNK2; the PI3K component PI3K-γ and NF-κB members p50 and p65 were involved 
in some of these responses. A reduction in the mRNA expression of these signalling 
modules attenuated or reversed the previously described effects of IL-33 on ICAM-1 
and MCP-1 mRNA.  
A number of studies have reported that IL-33 activates multiple signalling cascades 
(see Table 4 for further details) including those tested in this chapter. The cytokine 
activates PI3K in endothelial cells to increase vascular permeability (Choi et al. 2009). 
In contrast, NF-κB is inhibited by treatment of IL-33 in embryonic kidney cells (Ali et 
al. 2011). Interestingly following 12 hours of IL-33 stimulation there were no 
significant change in the levels of ERK1, ERK2, JNK1, p50 and p65 mRNA but a 
significant decrease was seen in the expression and activation of p38α, JNK2 and 
PI3K-γ mRNA (Figure 30).  However, to discern the biological relevance of IL-33 
treatment, these studies should be extended to explore the effects of IL-33 on the 
expression and activation of the protein forms of these components. For example, 
although IL-33 stimulation had no effect on the mRNA expression of ERK1 and 
ERK2, the cytokine induced the levels of phosphorylated ERK1/2 protein (Figure 31).  
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The western blot was performed with participation from another laboratory member to 
aid studies towards their thesis and also served to test western blot conditions and 
assess the effect of IL-33 on ERK1/2 activation. For this purpose western blot analysis 
was performed using conditions previously optimised by our laboratory (McLaren et 
al. 2010b) to determine the change in levels of phosphorylated ERK1/2 to total 
ERK1/2 following IL-33 stimulation. The activation of ERK1/2 by IL-33 has been 
demonstrated by many groups in a variety of cell types including mouse pancreatic 
cells (Kempuraj et al. 2013), embryonic fibroblasts (Funakoshi-Tago et al. 2008), 
mast cells (Schmitz et al. 2005) and peritoneal macrophages (Funakoshi-Tago et al. 
2011), in addition to human umbilical cord blood-derived mast cells (Iikura et al. 2007) 
and human lung epithelial and endothelial cells (Aoki et al. 2010; Yagami et al. 2010). 
In accordance with the findings from other studies, IL-33 promoted the 
phosphorylation of ERK1 and ERK2 indicating that these signalling components are 
involved in IL-33 activity. 
The primary aim of this chapter was to analyse the signalling pathways utilised by IL-
33 to regulate ICAM-1 and MCP-1 expression. RNAi was utilised to silence the gene 
expression of signalling molecules implicated in atherosclerosis. To validate the use of 
these siRNAs and shRNAs, THP-1 cells were transfected/infected and the extent of 
knock down quantitatively assessed by RT-qPCR. The shRNAs and siRNAs tested 
exerted a significant level of gene silencing for each of the signalling targets in the 
absence of IL-33. A significant level of reduction was also achieved following IL-33 
stimulation by ERK1, ERK2, p38α, PI3K-γ shRNA and ERK2 and JNK2 siRNA. The 
mRNA expression of JNK1, p50 and p65 was not significantly affected by their 
corresponding siRNAs in the presence of IL-33, although a trend for decreased 
expression was present in all cases and therefore additional repeats should be 
undertaken. Analysis by western blotting was conducted following the infection of 
shRNAs for ERK1, ERK2 and p38α and also transfection of ERK2, JNK1 and JNK2 
siRNAs to determine the level of protein reduction. Trends seen in mRNA expression 
following siRNA and shRNA-mediated RNAi correlated with changes in protein 
levels. A significant decrease in protein levels occurred following incubation with 
ERK1 and p38α shRNA, in addition to ERK2 and JNK2 siRNA in cells not treated 
with IL-33.  
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The use of certain siRNAs following IL-33 stimulation did not achieve a significant 
reduction possibly due to issues with transfection efficiency. Gene silencing with 
siRNAs is sometimes not as robust as shRNA-mediated RNAi and there are many 
factors which can affect siRNA efficiency including the presence of internal structures 
such as hairpins and substances within the media (Reynolds et al. 2004). An 
alternative to the methods employed would be the use of pharmacological inhibitors, 
however many inhibitors are not as specific as siRNA and shRNA and can exert off-
target effects (Milhavet et al. 2003). The shRNAs and siRNAs used were readily 
available and have been previously optimised and used by the laboratory. Additional 
experiments should be performed as a significant decrease was not achieved under all 
tested conditions, although all siRNAs and shRNAs produced substantial reductions at 
the mRNA and protein level and therefore a trend was seen in all cases. 
Following validation of the shRNAs and siRNAs, the effects on the IL-33-mediated 
regulation of ICAM-1 and MCP-1 following RNAi was explored. IL-33 was 
previously shown to reduce the gene expression of ICAM-1 and MCP-1 and this was 
once more demonstrated in the presence of scramble sequences of siRNA and shRNA 
within THP-1 macrophages. Previous studies investigating signalling pathways 
regulated by IL-33 in primary cells such as trophoblasts (Fock et al. 2013), nasal 
epithelial cells (Kamekura et al. 2012) and hepatocytes (Sakai et al. 2012) have also 
demonstrated the involvement of ERK, p38, JNK and NF-κB. Furthermore, our 
laboratory recently showed that IL-33 utilises ERK1/2, JNK1/2, c-Jun, PI3K-γ and 
PI3K-δ in the regulation of ADAMTS-1, -4 and -5 within the THP-1 system and the 
involvement of ERK1/2, PI3K-γ and PI3K-δ were also confirmed in primary HMDMs 
(Ashlin et al. 2014).  
In accordance with other groups, the experiments within this chapter showed that gene 
silencing of key signalling modules; the MAPKs ERK1, ERK2, p38α, JNK1/2; the 
PI3K component PI3K-γ and the NF-κB subunits p50 and p65 resulted in a loss of 
response from the cytokine within THP-1 macrophages. Furthermore, the studies 
demonstrated that these signalling components are involved in the IL-33-mediated 
down-regulation of ICAM-1 and MCP-1. A summary of the results is provided in 
Table 17.  
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Table 17. Summary of results 
 
Effect of IL-33 on gene expression following knock down 
RNAi mediator ICAM-1 MCP-1  
THP-1 macrophages 
ERK1 shRNA Induction  N/S Induction   N/S 
ERK2 shRNA Induction  * Induction  N/S 
P38α shRNA Induction  N/S 
Ablation of 
response  
N/S 
PI3K-γ shRNA Induction  N/S Induction  N/S 
ERK2 siRNA Induction  * 
Ablation of 
response 
N/S 
JNK1/2 siRNA Induction  N/S Induction  * 
p50/p65 siRNA Induction  N/S Reduction  N/S 
The Student t test was used to determine the statistical significance of the results for the THP-1 
macrophages: *p<0.05, N/S = not significant. 
The involvement of these signalling cascades in the regulation of ICAM-1 and MCP-1 
expression are well documented (Table 18). However, this is the first study to 
characterise the signalling pathways involved in the IL-33 mediated-reduction of 
ICAM-1 and MCP-1 mRNA expression in THP-1 macrophages.  
The experiments within primary HMDMs produced several interesting results. 
Primary cells are notoriously difficult to transfect with siRNA so an approach utilising 
shRNA was undertaken. A marked reduction was achieved through the use of ERK1 
and p38α shRNAs in ERK1 and p38α mRNA expression respectively, and was also 
shown at the protein level of p38α in primary HMDMs. However, within a subset of 
primary cells, treatment with IL-33 caused a non-significant up-regulation in the 
mRNA expression of ICAM-1 and MCP-1 in the presence of scramble shRNA. The 
inclusion of scramble shRNA did not induce levels of ICAM-1 and MCP-1 mRNA 
following IL-33 treatment within THP-1 cells (Figures 36A, 36B, 39 and 44). 
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Additionally, the experiments within chapter three demonstrated that IL-33 reduces 
the expression of ICAM-1 and MCP-1 within THP-1 macrophages, RAW264.7 
macrophages and HMDMs. Interestingly, in certain experiments IL-33 down-
regulated ICAM-1 or MCP-1 expression and within these cells the response to ERK1 
or p38α shRNAs varied in comparison to cells where an up-regulation occurred. Such 
differences in response may indicate the occurrence of donor-specific variation within 
HMDMs (Maess et al. 2010; Qin 2012) and the presence of a heterogeneous 
population of cells that respond differently to IL-33 in the presence of shRNA. The 
experiments within HMDMs displayed a high level of variation in comparison to 
THP-1 macrophages subjected to the same experimental procedure and were not 
significant, further repeats would be required to perform meaningful statistical 
analysis. 
The up-regulation of ICAM-1 and MCP-1 gene expression in response to shRNA 
within certain cells could have arisen due to an anti-viral response. IL-33 expression 
can be induced by the presence of viruses and drives an anti-viral immune response 
(Le Goffic et al. 2011; Bonilla et al. 2012) associated with the production of pro-
inflammatory cytokines (Le Goffic et al. 2011) such as IFN-γ and TNF-α which are 
also known to exert pro-atherogenic effects (Gupta et al. 1997; Ohta et al. 2005). The 
disparity in results could arise due to a reaction to the viral delivery of shRNAs 
resulting in the up-regulation of ICAM-1 and MCP-1, or to the shRNA itself. 
Interestingly, the change in response to cytokine stimulation in the presence of 
shRNAs has not been previously noted by our laboratory. Many studies have utilised 
shRNAs for characterising signalling pathways involved in cytokine-mediated 
regulation of atherosclerotic markers within primary cultures such as bone marrow 
derived macrophages from knockout animals and HMDMs (McLaren et al. 2010a; 
Michael et al. 2012b; Ashlin et al. 2014). However, these studies explored the effects 
on the expression of genes involved in ECM degradation (Ashlin et al. 2014) and 
foam cell formation (McLaren et al. 2010a; Michael et al. 2012b). The altered 
response to IL-33 stimulation, seen in section 4.3.4, could be peculiar to ICAM-1 and 
MCP-1 due to their role within immune reactions and cell recruitment. To determine 
whether the virus or scramble shRNA had an influence, a different approach could be 
adopted to knock down the expression of signalling components such as plasmid 
transfection of shRNA (Stopeck et al. 1998; Hunt et al. 2010; Park et al. 2011) or the 
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use of bone marrow-derived macrophages from ERK1 or p38 knockout mice. 
Scramble shRNA is frequently used as an experimental control (Shih et al. 2005; Li et 
al. 2010; Moore et al. 2010) and different methods could be utilised to determine 
whether targeting the scramble sequence had an effect on ICAM-1 and MCP-1 
expression such as the use of an empty vector lacking an shRNA insert.  
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Table 18. Studies of signalling pathways regulating ICAM-1 and MCP-1 expression 
Gene Stimulus Signalling pathways Cell line Reference 
ICAM-1 Vascular endothelial 
growth factor 
PI3K, Akt, nitric oxide Rat primary brain microvascular endothelial cells (Radisavljevic et al. 2000) 
ICAM-1 Thrombin NF-κB HUVECs (Xue et al. 2009) 
ICAM-1 mAb ligation ERK1/2, p38 Rat primary astrocytes (Lee et al. 2000) 
ICAM-1 LPS  JNK, p38 Rat schwann cells (Shen et al. 2008a) 
ICAM-1 IL-1β, TNF-α PKC Rat neonatal astrocytes (Ballestas and Benveniste 1995) 
MCP-1 Lysophosphatidic acid p38, JNK, NF-κB, Rho kinase HUVECs (Shimada and Rajagopalan 2010) 
MCP-1 IFN-γ PI3K, Casein Kinase 2, JAK-
STAT, Akt 
Murine J774.2 macrophages, HMDMs, human Hep3B 
hepatomas HUVECs and human endothelial EA.hy926 
(Harvey et al. 2007) 
MCP-1 TNF-α JNK Primary astrocytes (Gao et al. 2009) 
MCP-1 Diabetic nephropathy NF-κB Renal biopsies of patients with diabetic nephropathy (Mezzano et al. 2004) 
MCP-1 NiCl2 p38 Primary human endothelial cells (Goebeler et al. 2001) 
ICAM-1 & MCP-1 IFN-γ ERK1/2 THP-1 macrophages (Li et al. 2010). 
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Future investigations should be undertaken to assess whether IL-33-mediated down-
regulation of ICAM-1 and MCP-1 expression is ST2 dependent (wild type control) or 
mediated independently of the receptor. The use of bone marrow-derived macrophages 
from ST2 deficient mice could be used for this purpose. Also, the components involved 
in upstream signalling like IRAK, IRAK4, and TRAF6 in addition to downstream 
mediators implicated in IL-33 signalling could also be explored through the use of 
siRNA or shRNA (Schmitz et al. 2005; Chackerian et al. 2007; Sun et al. 2013). 
Furthermore, these experiments were performed using recombinant mature IL-33 but 
several studies have shown that the unprocessed form is also active and it would 
therefore be interesting to see whether the same results arise through the use of full-
length IL-33. 
Several studies have previously shown that IL-33 increases levels of ICAM-1 and 
MCP-1 (Table 14). Choi et al. (2012) demonstrated that stimulation by IL-33 raises the 
amount of ICAM-1 mRNA and protein in HUVECs and that the use of IL-33 siRNA 
reduces mRNA and protein levels of ICAM-1 mediated through the NF-κB pathway. 
Demyanets et al. (2011) found that IL-33 raised levels of ICAM-1 and MCP-1 mRNA 
and protein in human coronary arteries and HUVECs in vitro and within explanted 
atherosclerotic plaques ex vivo. The study also reported that IL-33 promoted human 
leukocyte binding to human endothelial monolayers and caused nuclear translocation of 
p50 and p65 (Demyanets et al. 2011). However, these studies were performed in 
different cell types and within different systems so the effects could be cell- or species-
specific. Furthermore, it is difficult to draw a direct comparison to other studies as other 
groups use different doses and time-courses to perform their experiments. For example, 
Chow et al. (2010) uses a range of concentrations (10-100ng/ml) and stimulate human 
eosinophils for 16 hours with IL-33 to determine the effects on ICAM-1 expression 
(Chow et al. 2010). Funakoshi-Tago et al. (2008) explored the effects on MCP-1 using 
10ng/ml of IL-33 over a time course of 12 hours in murine embryonic fibroblasts 
(Funakoshi-Tago et al. 2008). 
Although these studies mentioned above support a pro-atherogenic role for IL-33, there 
is a wealth of data provided by our group and many others such as those described in 
section 1.7.4. that demonstrate the anti-atherogenic properties of IL-33. The cytokine 
reduces macrophage foam cell production (McLaren et al. 2010b), decreases 
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macropinocytosis by macrophages (Michael et al. 2013) and inhibits ADAMTS-1, -4 
and -5 expression (Ashlin et al. 2014). The data within this thesis has shown that IL-33 
exerts a number of anti-inflammatory effects within both human and murine systems 
and supports the emerging anti-atherogenic role of the cytokine demonstrated in studies 
in mouse model systems. 
Interestingly, following the knock down of ERK2 by shRNA or siRNA, IL-33 
stimulation caused a significant increase in the expression of ICAM-1. This indicates 
that ERK2 holds a key role in IL-33-mediated down-regulation of ICAM-1 and suggests 
that the MAPK could potentially act as a repressor of IL-33 activity. Also, the reduction 
of JNK1/2 by siRNA did not just negate the anti-atherosclerotic effects of IL-33 but led 
to an induction of MCP-1 mRNA following IL-33 stimulation which indicates that IL-
33 could exert pro-atherosclerotic actions in the absence of ERK2 or JNK1/2. IL-33 is 
known to promote several pro-inflammatory disease states such as asthma and 
rheumatoid arthritis (see Table 5) but within atherosclerosis the cytokine exerts an anti-
inflammatory role. A study by Joshi et al. (2010) describes an interesting switch in IL-
33 actions. Stimulation of naïve human bone marrow-derived macrophages by IL-33 
produces a M1 profile characterised by increased expression of CCL13. However, 
following 24 hours exposure to M1 or M2 mediators, primary macrophages were then 
further exposed to these mediators in addition to IL-33. The combination of IL-33 and 
M1 agents raised the expression of the M2 marker CCL18, whereas exposure of IL-33 
and M2 mediators to previously M2 polarised cells increased the expression of the M2 
mannose receptor (Joshi et al. 2010). These results suggest that in macrophages 
activated by M1 or M2 stimuli IL-33 promotes the expression of M2 markers but within 
naïve macrophages IL-33 supports the M1 profile.  
The observed changes in IL-33 activity could explain how IL-33 is implicated in both 
pro- and anti-inflammatory processes. It is possible that dysregulation and atypical 
signalling exhibited during disease states could induce a switch in the activities of 
plaque-resident cells and cytokines. It is already known that macrophages are capable of 
switching classes even after exposure to initial activating stimuli and can therefore 
participate in both the propagation and resolution of inflammation (Lake et al. 1994; 
Porcheray et al. 2005). It would be useful to explore whether alternative pathways are 
activated following the knock down of ERK2 and JNK1/2 that facilitate the change in 
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response by IL-33 and whether these components are associated with pro-
atherosclerotic processes. Further investigations should also explore whether the 
increase in MCP-1 mRNA following JNK1/2 gene silencing was isoform specific as a 
combination of JNK1 and JNK2 siRNAs were used for the knock down due to 
limitations with time. Differences in the roles of JNK1 and JNK2 have previously been 
described. For example, absence of JNK2 but not JNK1 in ApoE
-/-
 mice imparts 
resistance to diet-induced atherosclerosis (Ricci et al. 2004). Also, although JNK1 and 
JNK2 regulate cellular proliferation, the isoforms regulate different phases of the cell 
cycle and exhibit differential binding preferences to c-Jun (Sabapathy et al. 2004).   
In conclusion, the data presented within this chapter has demonstrated that multiple 
signalling cascades such as MAPKs, PI3K and NF-κB were involved in the regulation 
of ICAM-1 and MCP-1 gene expression by IL-33. A reduction in mRNA and protein 
levels of these signalling components resulted in a loss of response from IL-33 and in 
the case of ERK2 and JNK1/2 caused a reversal of the previously described effects in 
THP-1 macrophages. Figure 53 displays a schematic of the ICAM-1 and MCP-1 
promoters. Interestingly, flanking regions within these genes contain a number of shared 
regulatory elements such as AP-1, NF-κB and SP1 (Roebuck and Finnegan 1999; 
Kanda and Watanabe 2003) which may explain the involvement of common signal 
transduction pathways by IL-33. For example, AP-1 can be activated as a result of either 
NF-κB and MAPK signalling and c-Jun, a key downstream target of JNK1/2, is a 
component of the AP-1 family (Xie 2013).  
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Figure 53. Promoter region of ICAM-1 and MCP-1 
Structure of the ICAM-1 and MCP-1 promoters. The nucleotide positions displayed are in relation to 
the translational start site. Figures are taken from Roebuck and Finnegan (1999) and Kanda and 
Watanabe (2003) respectively. 
  
Atherosclerosis is a complex disease and numerous signalling components have been 
implicated in its pathogenesis. Due to the anti-atherogenic nature of IL-33 it would be 
useful to fully define the signalling mechanisms which give rise to its activity, the use 
of mice lacking upstream and downstream elements could be utilised. Alternatively, 
gene-specific reporter constructs containing 5’ regions upstream of the gene of interest 
in front of a luciferase gene could be used to determine the integral regulatory elements 
required for gene expression in response to cytokine treatment (Mehl et al. 2001; Kanda 
and Watanabe 2003). Mutational analysis along with DNA-protein interaction studies 
could also be performed to further delineate regulatory sequences. The experiments 
presented within this chapter have implicated the involvement of key signalling 
molecules in the regulation of ICAM-1 and MCP-1 gene expression by IL-33 and it 
would be useful to also investigate the effects on ICAM-1 and MCP-1 proteins. 
4.5. Future Aims 
The experimental chapters have so far investigated the effects of IL-33 on the 
expression of atherosclerotic markers and signalling components using a combination of 
RT-qPCR, western blotting and RNAi. The data has shown that IL-33 exerts an anti-
atherogenic effect on the expression of several genes investigated and has discerned that 
several signalling pathways already implicated in atherosclerotic events are involved.  
 
MCP-1 promoter 
ICAM-1 promoter 
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However, it is also important to determine whether IL-33 is involved in other cellular 
processes that contribute towards the disease state. Atherosclerosis is a chronic 
inflammatory disorder that is characterised by the excessive build-up of lipids within 
the arterial subendothelium. The next chapter will explore the actions of IL-33 on the 
lipid profile of human and murine macrophages. During the disease, macrophages 
amass lipids and transform into macrophage-derived foam cells; the major component 
of the fatty streak. These cells are also key orchestrators of the inflammatory state 
through the expression and secretion of cytokines and fatty-acid derived mediators. This 
will be the first study to utilise GC and TLC to determine the impact of IL-33 on 
individual fatty acids and major lipid groups within macrophages. Additionally, the 
effects of IL-33 on the expression of enzymes involved in lipid metabolism will be 
assessed by RT-qPCR to elucidate the novel mechanisms through which IL-33 exerts its 
actions. 
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CHAPTER 5. 
THE EFFECTS OF IL-33 ON THE LIPID PROFILE 
OF MACROPHAGES 
 
5.1. Introduction 
5.1.1 Desaturation of fatty acids 
Desaturases are either soluble or membrane-bound and mammals contain acyl-CoA 
desaturases located within the ER membrane (Nakamura and Nara 2004). The major 
enzyme responsible for desaturation is SCD (Sampath and Ntambi 2014). Mice have 
four known isoforms of SCD, whereas humans have two genes; SCD-1 and SCD-5, 
encoding for two highly homologous (87%) isoforms: SCD-1 and SCD-2 (Wang et al. 
2005). Both SCD isoforms are expressed in the lung, adipose tissue and kidneys. SCD-1 
is additionally expressed within the liver and SCD-2 is expressed in the brain, spleen, 
heart and placenta (Sampath and Ntambi 2014). The main substrates for SCD are 16 and 
18 carbon fatty acids and predominately stearic acid (Cook and McMaster 2002). SCD 
directs the rate limiting step in MUFA synthesis, catalysing the formation of a cis-
double bond at the Δ-9 position from the carboxyl end of palmitic acid and stearic acid 
to palmitoleic acid and oleic acid respectively (Attie et al. 2002; MacDonald et al. 
2009).  
Within humans and other animals there is limited conversion of essential fatty acids to 
very long chain PUFAs like AA and eicosapentaenoic acid (EPA) (Meesapyodsuk and 
Qiu 2012). A combination of Δ6- and Δ5-desaturase activity and the elongation of fatty 
acids from the n-6 and n-3 series produces a diverse array of PUFAs (de Antueno et al. 
2001). Figure 54 summarises the elongation and desaturation reactions responsible for 
MUFA and PUFA generation. Dysregulation or abnormal desaturase activity is linked 
to disease and as such the expression and activity of these enzymes is carefully 
modulated through feedback loops and signalling pathways (Cook and McMaster 2002). 
SCD activity is reliant on the proportion of dietary SFAs, especially palmitic acid, and 
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is accordingly negatively regulated by elevated PUFA levels (Vessby et al. 2001; 
Vessby et al. 2002). The activities and expression of Δ6- and Δ5-desaturases are 
likewise modulated by the presence of fatty acid substrates and products (Vessby et al. 
2002). As such Δ6-desaturase and Δ5-desaturase activity increases in the absence of 
dietary PUFAs and in response to refeeding after a fasting state (Cook and McMaster 
2002), although Δ5-desaturase is less active than Δ6-desaturase (Dias and Parsons 1995; 
Vessby et al. 2013). 
THE EFFECTS OF IL-33 ON THE LIPID PROFILE OF MACROPHAGES       Melanie Buckley 
182 
 
 
LINOLEIC ACID 
LA (18:2 n-6) 
α-LINOLENIC ACID 
ALA (18:3 n-3) 
ω-6 pathway ω-3 pathway 
(18:4 n-3) 
(20:4 n-3) 
EICOSAPENTAENOIC 
EPA (20:5 n-3) 
Δ6-desaturase 
γ-LINOLENIC ACID 
GLA (18:3 n-6) 
Elongase 
DIHOMO γ-LINOLENIC ACID 
DGLA (20:3 n-6) 
Δ5-desaturase 
ARACHIDONIC ACID 
AA (20:4 n-6) 
(22:4 n-6) (22:5 n-3) 
Elongase 
(24:5 n-3) 
(24:6 n-3) 
DOCOSAHEXAENOIC 
(22:6 n-3) 
(24:4 n-6) 
Elongase 
(24:5 n-6) 
Δ6-desaturase 
DOCOSAPENTAENOIC 
(22:5 n-6) 
 
Essential Fatty 
Acids 
Peroxisomal partial 
β-oxidation 
Figure 54. Fatty acid metabolic pathways 
The major product of fatty acid synthesis; palmitic acid and the essential fatty acids; LA and ALA are subjected to sequential elongation and desaturation to produce a range 
of MUFAs and PUFAs. The ER desaturation system additionally requires NAD, molecular oxygen and cytochrome b5. Adapted from Uauy et al. (2003), Voruganti et al. 
(2012), White et al. (2013), Wang et al. (2013). 
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5.1.2. The role of lipids in heart disease 
There are a wealth of epidemiological studies investigating the link between fatty 
acids and incidences of CAD and its complications. The roles of fatty acids in cardiac-
related pathologies are complex and further information is provided within the 
introduction. Although a number of studies have found conflicting results there are 
several general rules describing the cholesterolemic effects of fatty acids 
(KrisEtherton and Yu 1997): 
 SFAs are typically hypercholesterolaemic and myristic acid is the most potent 
whilst stearic acid appears to have a neutral effect.  
 MUFAs have a mostly neutral/ or mildly hypocholesterolaemic influence but 
are not as potent as PUFAs. 
 Trans-fatty acids are hypercholesterolaemic, produce an unfavourable LDL to 
HDL cholesterol ratio (Mensink and Katan 1990) and also up-regulate the 
expression of pro-atherosclerotic markers (Mozaffarian et al. 2004; Lopez-
Garcia et al. 2005). 
 n-3 PUFAs decrease the expression of pro-inflammatory cytokines (Caughey 
et al. 1996; Trebble et al. 2003). 
 n-6 PUFAs are potentially associated with inflammatory processes but may 
also exert some beneficial effects. 
Table 19 summarises the findings from several studies, where pro-atherosclerotic 
actions of fatty acids are denoted in red and anti-atherosclerotic processes are 
highlighted in blue. 
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Lipid class Fatty acid Role in CAD Testing medium Reference 
SFAs 
Meta-analysis of 60 studies determined that saturated fats increased LDL cholesterol 
but had no effect on HDL cholesterol. 
Dietary SFAs caused an increase in blood cholesterol two-times as much as PUFAs 
decreased blood cholesterol.  
Human serum 
Human serum 
(Mensink et al. 2003) 
(Hegsted et al. 1965; 
Keys et al. 1965). 
Myristic acid 14:0 
Raised plasma cholesterol. Thought to be most potent SFA. 
Increased LDL cholesterol and levels of ApoB and reduced 
HDL to LDL ratios. 
Promoted formation of dense LDL particles. 
Monkey plasma 
Human serum 
Human 
lipoproteins 
(Hayes and Khosla 
1992) 
(Zock et al. 1994) 
(Dreon et al. 1998) 
Palmitic acid 16:0 
Increased LDL cholesterol and levels of ApoB and reduced 
ratio of HDL to LDL. 
Promoted formation of dense LDL particles. 
Human serum 
Human 
lipoproteins 
(Zock et al. 1994) 
(Dreon et al. 1998) 
Stearic acid 18:0 
Neutral effect/ mild beneficial effects on LDL cholesterol. 
Human serum (Mensink et al. 2003) 
MUFAs 
Trans-MUFAs are associated with an unfavourable lipoprotein profile. 
Human serum 
(Lichtenstein et al. 
1999) 
Cis-palmitoleic acid 
Positive association with CAD risk. Human 
erythrocytes 
(Djousse et al. 2012) 
Table 19. Studies exploring the effects of fatty acids in CAD 
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16:1n-7 
Cis-vaccenic acid 
18:1n-7 
Negative association with CAD risk. Human 
erythrocytes 
(Djousse et al. 2012) 
Oleic acid 
18:1n-9 
Neutral effect on atherosclerotic markers. Rat serum 
Monkey plasma 
Human serum 
(Lee et al. 1989) 
(Hayes and Khosla 
1992) 
(Mensink and Katan 
1990) 
Trans-oleic acid 
18:1 
Produced an atherogenic lipoprotein profile. 
Unlike other trans-fatty acids was not prevalent in patients 
following cardiac arrest. 
Human serum 
Human 
erythrocytes 
(Mensink and Katan 
1990). 
(Lemaitre et al. 2002) 
n-3 PUFAs 
n-3 PUFAs inhibited TAG, apolipoprotein and VLDL synthesis. Competitively suppressed production of 
AA metabolites. 
Protective effect of n-3 supplements in patients who have previously suffered a MI after 3 months. 
Supplementation of n-3 PUFAs significantly increased survival following a previous MI, whereas the anti-
oxidant vitamin E had no effect on outcome. 
The expression of ICAM-1 and SRs were significantly reduced in fish oil fed mice. 
(Okuyama et al. 2000) 
(Marchioli et al. 2002) 
(Valagussa et al. 1999) 
(Miles et al. 2000) 
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α-linolenic acid 
(ALA) 18:3n-3 
Reduced levels of ALA in patients with stroke and lower 
limb disease. 
Reduced serum CRP, serum amyloid A and IL-6. 
Human 
erythrocytes 
Human serum and 
plasma 
(Leng et al. 1999) 
(Rallidis et al. 2003) 
Eicosapentaenoic 
acid (EPA) 20:5n-3 
EPA was a poor substrate for COX enzymes but binds with 
high affinity therefore reducing AA conversion. 
Reduced amounts in patients with stroke and lower limb 
disease. 
Post-MI patients displayed longer life expectancy when 
taking EPA and DHA supplements. 
Inhibited modified LDL uptake and macropinocytosis. 
Human platelets 
 
Human serum 
 
Human THP-1 and 
HMDMs 
(Needleman et al. 1979) 
 
(Leng et al. 1999) 
(Valagussa et al. 1999) 
(McLaren et al. 2011b) 
Docosahexaenoic 
acid (DHA) 22:6n-3 
DHA inversely affected levels of AA thus reducing 
production of pro-inflammatory mediators. 
Post-MI patients displayed longer life expectancy when 
taking EPA and DHA supplements. 
Inhibited modified LDL uptake and macropinocytosis. 
Human serum and 
plasma 
 
Human THP-1 and 
HMDMs 
(Rallidis et al. 2003) 
(Valagussa et al. 1999) 
(McLaren et al. 2011b) 
n-6 PUFAs 
Increased n-6/n-3 PUFA ratio, promoted oxidative stress and production of pro-inflammatory eicosanoid 
precursors. 
(Okuyama et al. 2000) 
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Linoleic acid (LA) 
18:2n-6 
Increased thromboxane A2/ PGI2 ratio and thrombosis. 
Levels of LA inversely associated with serum cholesterol 
and TAGs. 
Significantly raised amounts of LA in serum TAGs of 
patients with MI. 
Did not affect levels of CRP, serum amyloid A or IL-6 but 
reduced cholesterol. Reduction associated with increased 
synthesis of LDLR. 
Rat serum 
Human serum 
Human serum 
Human serum and 
plasma 
(Lee et al. 1989) 
(Renaud et al. 1986) 
(Leng et al. 1999) 
(Rallidis et al. 2003) 
Dihomo-γ-linolenic 
acid (DGLA)  
20:3n-6 
Raised levels of serum phospholipids and erythrocytes of 
MI sufferers. 
Levels inversely related to CAD. 
Human serum and 
erythrocytes 
Human adipose 
biopsies 
(Leng et al. 1999) 
(Riemersma et al. 
1986). 
Arachidonic acid 
(AA) 20:4n-6 
Increased thromboxane A2/ PGI2 ratio and thrombosis. 
Levels inversely related to CAD. 
Rat serum 
Human adipose 
biopsies 
(Lee et al. 1989) 
(Riemersma et al. 
1986). 
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5.2. Experimental aims 
The data presented within this thesis has so far supported the role of IL-33 as an anti-
atherogenic agent. The cytokine down-regulates the expression of several well-
characterised atherosclerotic markers within RAW264.7 and THP-1 macrophages and 
HMDMs. A combination of siRNA and shRNA was then utilised to elucidate the 
signalling pathways that underlie the IL-33-mediated regulation of ICAM-1 and MCP-1 
expression within human THP-1 macrophages and primary HMDMs. The study will 
next focus on the temporal and inter-species effects of IL-33 on the fatty acid 
composition of macrophages.  
The THP-1 and RAW264.7 macrophage cell lines were utilised to investigate the effects 
of IL-33 on the fatty acid composition of human and murine macrophages. The aim of 
this chapter was to determine whether IL-33 produces anti-atherogenic changes in fatty 
acids within TAGs, PLs and SEs. This was the first study to utilise TLC and GC to 
explore the changes in major lipid classes and individual fatty acid profiles caused by 
the cytokine. An outline of the experimental strategy employed is shown in Figure 55. 
Cells were prepared using a similar method to those in chapter three whereby THP-1 
and RAW264.7 macrophages were incubated with IL-33 (25ng/ml) for 12 and 24 hours. 
Total lipids were then extracted from these cells and separated into TAGs, PLs and SEs 
by TLC and subsequently analysed by GC to determine the fatty acid distribution of 
these groups. Another aim was to explore the effects of IL-33 on SCD-1, Δ5- and Δ6-
desaturase activity. Previous studies have used the ratio of product to substrate as an 
index of desaturase activity (Attie et al. 2002; Shiwaku et al. 2004; Warensjo et al. 
2007; Martinelli et al. 2008). The following indices were used to quantify enzymatic 
activity: 
 Δ5-desaturase = 20:4 n6/ 20:3 n6 
 Δ6-desaturase = 20:3n6/18:2n6 
 SCD-1 = 16:1n7/ 16:0 and 18:1n9/18:0 
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Previous studies have varied in the choice of SCD-1 product/precursor ratios therefore 
ratios of 16:1/16:0 and 18:1/18:0 were analysed both separately and together to provide 
a more comprehensive assessment. The expression of SCD-1 was then assessed by RT-
qPCR to determine whether changes in activity were reflected at the genetic level. 
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Figure 55. Schematic of experimental procedures 
Lipids were extracted from THP-1 and RAW264.7 macrophages and separated by TLC into TAGs, 
PLs and SEs. The fatty acids of individual fractions were then converted into FAMEs for GC 
analysis. Enzymatic activity was calculated based upon the ratio of product to precursor and the 
mRNA expression of SCD-1 was assessed by RT-qPCR analysis. 
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5.3. Results 
5.3.1. Analysis of individual lipid classes 
5.3.1.1. THP-1 macrophages 
Figure 56 displays the alterations in the concentrations and ratio of TAGs and PLs 
following incubation with IL-33 for 12 and 24 hours. TLC was performed to separate 
total lipids into TAGs and PLs. However, SEs were undetectable in THP-1 
macrophages.  
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Figure 56. The effect of IL-33 on major lipid classes in THP-1 macrophages 
PMA-differentiated THP-1 macrophages were incubated with IL-33 (25ng/ml) for 12 or 24 hours. 
An untreated control was included under the same conditions. TLC was used to separate lipids into 
different lipids groups; PLs (A) and TAGs (B). In graphs A and B, results were normalised to 
µg/million cells. The ratio of major lipid groups is shown in graph C. Data represents mean ± SD 
from three independent experiments. The Student t test was used to determine the statistical 
significance of the results *p<0.05. 
 
There was a general reduction in the levels of PLs following IL-33 treatment and this 
decrease was significant following 12 hours of IL-33 stimulation (Figure 56A). 
Conversely, there was a 24% increase in the levels of TAGs within these cells in the 
presence of IL-33 which was significant following 24 hours of IL-33 stimulation 
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(Figure 56B). Furthermore a trend was present for increased total fatty acids between 12 
and 24 hours which was not significant. PLs represented the largest lipid fraction 
followed by TAGs (Figure 56C). 
5.3.1.2. RAW 264.7 macrophages 
Lipids were also extracted from RAW 264.7 macrophages and analysed by TLC/GC to 
determine the inter-species effect of IL-33 on the lipid composition of murine 
macrophages.  
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Figure 57. The effect of IL-33 on major lipid classes in RAW 264.7 macrophages 
RAW264.7 macrophages were incubated with IL-33 (25ng/ml) for 12 or 24 hours. An untreated 
control was included under the same conditions. TLC was used to separate lipids into different lipids 
groups; PLs (A), TAGs (B) and SEs (C). In graphs A-C, results were normalised to µg/million cells. 
The ratio of major lipid groups is shown in graph D. Data represents mean ± SD from three 
independent experiments. The Student t test was used to determine the statistical significance of the 
results. 
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Figure 57 displays the concentration and ratio of TAGs, PLs and SEs within RAW 
264.7 macrophages following IL-33 stimulation for 12 and 24 hours. Unlike human 
THP-1 macrophages, murine RAW 264.7 macrophages also contained detectable SEs 
(Figure 57C). However, there were no significant alterations in the concentration of SEs 
over time or following incubation with IL-33. Furthermore, IL-33 did not have a 
significant effect on the concentrations of TAGs or PLs, although in accordance with 
the THP-1 cells, there was a trend for reduced concentrations of PLs (Figure 57A) and 
increased concentrations of TAGs (Figure 57B) following IL-33 stimulation, though 
these failed to reach significance. However, unlike THP-1 macrophages, there was a 
noticeable decrease in levels of total fatty acids between 12 and 24 hours especially in 
the amounts of PLs (Figure 57D). 
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5.3.2 Fatty acid analysis 
5.3.2.1 THP-1 macrophages 
After separation of the lipid extracts into major lipid groups by TLC, the fatty acids 
were then converted to FAMEs and analysed by GC to assess the effects of 12 and 24 
hours of IL-33 stimulation on the fatty acid composition of human THP-1 macrophages. 
The results are displayed as changes in the percentages of individual fatty acids within 
PLs and TAGs. This was deemed the most appropriate method to display the data as 
different amounts of cells were seeded for each experiment due to the large amount of 
material required for GC analysis. The data is also provided as concentrations in the 
appendices where a similar trend was seen. 
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Figure 58. Fatty acid composition of THP-1 macrophages in response to IL-33 
PMA-differentiated THP-1 macrophages were incubated with IL-33 (25ng/ml) for 12 or 24 hours. An untreated control was included under the same conditions. 
Following TLC, fatty acids from fractions for PLs (Panels A and B) and TAGs (Panels C and D) were converted to FAMEs for analysis by GC. Total fatty acids 
(Panels E and F) represent the summation of fatty acids from PLs and TAGs. The results are presented as percentage of PLs (A and B), TAGs (C and D) or total fatty 
acids (E and F). Fatty acids are indicated with the number before the colon showing the number of carbon atoms, after which denotes the number of double bonds 
followed by the position of the first double bond. Data represents mean ± SD from four independent experiments. The Student t test was used to determine the 
statistical significance of the results *p<0.05, **p<0.01, ***p<0.001.   
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Figure 59. Change in the percentages of fatty acids in THP-1 
macrophages 
PMA-differentiated THP-1 macrophages were incubated with IL-33 (25ng/ml) for 12 or 
24 hours. An untreated control was included under the same conditions. Lipids were 
separated by TLC into different lipids groups; PLs and TAGs, and then the individual 
fatty acid composition of these fractions was assessed by GC. Total fatty acids represent 
the summation of PLs and TAGs. Fatty acids are indicated with the number before the 
colon showing the number of carbon atoms, after which denotes the number of double 
bonds followed by the position of the first double bond. Changes in the percentages of 
individual fatty acids following IL-33 stimulation are presented for PLs, TAGs or total 
fatty acids. Data represents mean from four independent experiments.  
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Figures 58 and 59 show the changes in the percentages of fatty acids in THP-1 
macrophages following 12 and 24 hours of IL-33 stimulation and a summary is 
provided in Table 20. Within PLs IL-33 significantly increased the levels of C20:4n6 
(AA) and C22:5n3 (DPA) following 12 hours of stimulation. After 24 hours of IL-33 
treatment, there was a significant increase in C14:0 (myristic acid) and C18:0 (stearic 
acid). A significant reduction occurred after 12 hours of IL-33 stimulation in the 
percentages of C16:0 (palmitic acid), C16:1n7 and C16:1n9 and after 24 hours in 
C16:1n7, C16:1n9, C18:1n9 (oleic acid) and C18:1n7 (vaccenic acid). Within TAGs, 
IL-33 significantly decreased levels of C16:1n7 following 12 hours of IL-33 stimulation 
(Figure 58C). Within total fatty acids, taken as a combination of fatty acids from TAG 
and PL fractions; C16:1n7 was significantly reduced whereas levels of stearic acid and 
DPA significantly increased after 12 hours of IL-33 stimulation. Similar alterations in 
fatty acid composition were exhibited following 12 and 24 hours of incubation with IL-
33. Figure 59 demonstrates that the largest change in percentage occurred in myristic 
acid in the presence of IL-33 for 24 hours across fractions, although this change was not 
significant. A similar number of significant changes occurred at both time points with 
the majority taking place within the PL fraction.  
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Table 20. Changes in fatty acid composition following IL-33 stimulation in THP-1 macrophages 
THP-1 macrophages 
Fatty acid PL TAG TOTAL 
12 hours 24 hours 12 hours 24 hours 12 hours 24 hours 
Percentage 
change 
Ttest Percentage 
change 
Ttest Percentage 
change 
Ttest Percentage 
change 
Ttest Percentage 
change 
Ttest Percentage 
change 
Ttest 
C14:0 18.18 ↑N/S 53.42 ↑*** 14.66 ↑ N/S 136.46 ↑ N/S 16.20 ↑ N/S 106.59 ↑ N/S 
C16:0 -3.88 ↓** -0.89 ↓ N/S 0.07 ↑ N/S 9.41 ↑ N/S -1.65 ↓ N/S 4.91 ↑ N/S 
C16:1n7 -8.61 ↓* -9.21 ↓** -7.89 ↓* 10.30 ↑ N/S -8.34 ↓* -1.24 ↓ N/S 
C16:1n9 -8.42 ↓* -5.95 ↓*** 0.18 ↑ N/S 10.99 ↑ N/S -4.85 ↓ N/S 1.91 ↑ N/S 
C18:0 5.87 ↑ N/S 5.05 ↑** 10.62 ↑ N/S -2.24 ↓ N/S 8.00 ↑* 1.83 ↑ N/S 
C18:1n9 -0.49 ↓ N/S -3.66 ↓** 1.49 ↑ N/S -4.06 ↓ N/S 0.55 ↑ N/S -3.87 ↓ N/S 
C18:1n7 -0.72 ↓ N/S -2.94 ↓* -0.78 ↓ N/S -4.26 ↓ N/S -0.75 ↓ N/S -3.59 ↓ N/S 
C18:2n6 -4.22 ↓ N/S -3.94 ↓ N/S -4.11 ↓ N/S -12.71 ↓ N/S -4.17 ↓ N/S -8.33 ↓ N/S 
C18:3n3 -0.51   -5.03 ↓ N/S -26.22 ↓ N/S -34.74 ↓ N/S -22.06 ↓ N/S -28.99 ↓ N/S 
C20:1n9       2.63 ↑ N/S 8.91 ↑ N/S 2.63 ↑ N/S 8.91 ↑ N/S 
C20:3n6 3.04 ↑ N/S -1.55 ↓ N/S -7.75 ↓ N/S -27.47 ↓ N/S -2.91 ↓ N/S -16.27 ↓ N/S 
C20:4n6 6.45 ↑* 2.37 ↑ N/S -22.20 ↓ N/S -18.09 ↓ N/S -1.85 ↓ N/S -2.55 ↓ N/S 
C20:5n3 2.92 ↑ N/S -1.51 ↓ N/S -11.90 ↓ N/S -20.65 ↓ N/S -2.01 ↓ N/S -7.59 ↓ N/S 
C22:0 2.50 ↑ N/S 25.23 ↑ N/S       2.50 ↑ N/S 25.23 ↑ N/S 
C22:3n6 3.63 ↑ N/S -0.89 ↓ N/S -0.37 ↓ N/S -17.62 ↓ N/S 0.91 ↑ N/S -12.06 ↓ N/S 
C22:5n3 8.10 ↑* 10.02 ↑ N/S 7.25 ↑ N/S -10.19 ↓ N/S 7.59 ↑* -2.78 ↓ N/S 
C22:6n3 3.84 ↑ N/S 29.16 ↑ N/S 4.98 ↑ N/S -11.97 ↓ N/S 4.34 ↑ N/S 8.77 ↑ N/S 
C24:0 7.03 ↑ N/S 6.14 ↑ N/S       7.03 ↑ N/S 6.14 ↑ N/S 
C24:1n6 4.52 ↑ N/S -3.26 ↓ N/S         4.52 ↑ N/S -3.26 ↓ N/S 
The Student t test was used to determine the statistical significance of the results *p<0.05, **p<0.01, ***p<0.001, N/S not significant. Arrows depict 
direction of change following IL-33 stimulation. 
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5.3.2.2. RAW 264.7 macrophages 
GC analysis was performed on the PL, TAG and SE fractions to determine the effects of 
IL-33 on the fatty acid composition of murine macrophages after 12 and 24 hours.  
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Figure 60. Fatty acid composition of RAW 264.7 macrophages in response to IL-33 
RAW 264.7 macrophages were incubated with IL-33 (25ng/ml) for 12 or 24 hours. An untreated 
control was included under the same conditions. Following TLC, fatty acids from the fractions for 
PLs (Panels A and B), TAGs (Panels C and D) and SEs (Panels E and F) were converted to FAMEs 
for analysis by GC. Total fatty acids (Panels G and H) represent the summation of PLs, TAGs and 
SEs. The results are presented as percentage of PLs (A and B), TAGs (C and D), SEs (E and F) or 
total fatty acids (G and H). Fatty acids are indicated with the number before colon showing the 
number of carbon atoms, after which denotes the number of double bonds followed by the position 
of the first double bond. Data represents mean ± SD from four independent experiments. The 
Student t test was used to determine the statistical significance of the results *p<0.05, **p<0.01. 
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Figure 61. Change in percentages of fatty acids 
RAW 264.7 macrophages were incubated with IL-33 (25ng/ml) for 12 or 24 hours. An untreated 
control was included under the same conditions. Lipids were separated by TLC into different lipids 
groups for PLs, TAGs and SEs and then the individual fatty acid composition of these fractions was 
assessed by GC. Total fatty acids represent the summation of PLs, TAGs and SEs. Changes in the 
percentages of individual fatty acids following IL-33 stimulation are presented for PLs, TAGs, SEs 
or total fatty acids. Fatty acids are indicated with the number before the colon showing the number 
of carbon atoms, after which denotes the number of double bonds followed by the position of the 
first double bond. Data represents mean from four independent experiments.  
 
The changes in fatty acid percentages following IL-33 stimulation in RAW264.7 
macrophages are shown in Figures 60 and 61. IL-33 caused a significant reduction in 
palmitic acid (C16:0) at both time points and decreased levels of oleic acid (C18:1n9) 
and nervonic acid (C24:1n6) after 12 hours and C16:1n9 after 24 hours in PLs. There 
were also significant increases in the percentages of vaccenic acid (C18:1n7), LA 
(C18:2n6) and EPA (C20:5n3) following 24 hours of IL-33 stimulation in PLs. IL-33 
treatment caused a significant increase in the percentages of palmitic acid and vaccenic 
acid in TAGs after 24 hours of IL-33 treatment. Cytokine treatment resulted in a 
significant rise in stearic acid accompanied with a reduction in vaccenic acid in SEs 
after 24 hours of cytokine treatment. Total fatty acids were calculated as a summation of 
PLs, TAGs and SEs (Figures 60G and H). IL-33 significantly decreased the percentage 
of total DGLA (C20:3n6) after 12 hours. Figure 61 displays the extent of these changes 
in percentages. In accordance to THP-1 macrophages, the highest number of significant 
changes occurred in PLs and the greatest change in percentage occurred in myristic acid 
within each fraction but was not significant. The results are summarised in Table 21.
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Table 21. Changes in fatty acid composition following IL-33 stimulation in RAW264.7 macrophages 
RAW264.7 macrophages 
Fatty 
acid 
PL TAG SE TOTAL 
12 hours 
 
24 hours 
 
12 hours 
 
24 hours 
 
12 hours 
 
24 hours 
 
12 hours 
 
24 hours 
 
Percentage 
change 
Ttest Percentage 
change 
Ttest Percentage 
change 
Ttest Percentage 
change 
Ttest Percentage 
change 
Ttest Percentage 
change 
Ttest Percentage 
change 
Ttest Percentage 
change 
Ttest 
C14:0 66.45 ↑N/S 58.52 ↑ N/S 194.324 ↑ N/S 47.50 ↑ N/S 9.77 ↑ N/S 135.28 ↑ N/S 35.43 ↑ N/S 73.65 ↑ N/S 
C16:0 -3.46 ↓* -1.60 ↓* 4.471 ↑ N/S 8.77 ↑* 18.84 ↑ N/S 9.13 ↑ N/S 5.60 ↑ N/S 4.86 ↑ N/S 
C16:1n7 -11.45 ↓ N/S -2.21 ↓ N/S -23.743 ↓ N/S -21.60 ↓ N/S -3.53 ↓ N/S 11.93 ↑ N/S -15.27 ↓ N/S -10.92 ↓ N/S 
C16:1n9 -9.46 ↓ N/S -4.33 ↓* -3.232 ↓ N/S 12.85 ↑ N/S -8.87 ↓ N/S -0.32 ↓ N/S -7.22 ↓ N/S 4.70 ↑ N/S 
C18:0 2.21 ↑ N/S 1.57 ↑ N/S -7.464 ↓ N/S -4.19 ↓ N/S 24.29 ↑ N/S 15.70 ↑* 5.31 ↑ N/S 3.76 ↑ N/S 
C18:1n9 -2.68 ↓* -1.89 ↓ N/S 0.263 ↑ N/S -4.20 ↓ N/S -14.00 ↓ N/S -10.75 ↓ N/S -6.74 ↓ N/S -6.67 ↓ N/S 
C18:1n7 1.49 ↑ N/S 1.67 ↑* 8.301 ↑ N/S 1.13 ↑* -17.26 ↓ N/S -13.02 ↓* -4.10 ↓ N/S -4.50 ↓ N/S 
C18:2n6 1.17 ↑ N/S 2.53 ↑** -3.559 ↓ N/S -2.05 ↓ N/S 2.95 ↑ N/S -10.31 ↓ N/S -0.21 ↓ N/S -2.31 ↓ N/S 
C18:3n3 -0.36 ↓ N/S 5.00 ↑ N/S -6.378 ↓ N/S -18.13 ↓ N/S 10.03 ↑ N/S 1.61 ↑ N/S 3.30 ↑ N/S -5.16 ↓ N/S 
C20:1n9       -0.323 ↓ N/S -17.61 ↓ N/S        -0.32 ↓ N/S -17.61 ↓ N/S 
C20:3n6 2.66 ↑ N/S 1.43 ↑ N/S 3.005 ↑ N/S -18.01 ↓ N/S -10.95 ↓ N/S -16.31 ↓ N/S -1.39 ↓* -11.81 ↓ N/S 
C20:4n6 5.14 ↑ N/S 1.70 ↑ N/S -1.362 ↓ N/S -8.57 ↓ N/S 3.07 ↑ N/S -24.82 ↓ N/S 3.19 ↑ N/S -3.52 ↓ N/S 
C20:5n3 4.11 ↑ N/S 8.07 ↑* 8.540 ↑ N/S 10.81 ↑ N/S       7.10 ↑ N/S 10.06 ↑ N/S 
C22:0 -2.28 ↓ N/S -4.41 ↓ N/S             -2.28 ↓ N/S -4.41 ↓ N/S 
C22:3n6 1.77 ↑ N/S -3.67 ↓ N/S 5.068 ↑ N/S -23.52 ↓ N/S       3.04 ↑ N/S -13.97 ↓ N/S 
C22:5n3 4.42 ↑ N/S -0.74 ↓ N/S 11.844 ↑ N/S -16.04 ↓ N/S       7.34 ↑ N/S -7.23 ↓ N/S 
C22:6n3 6.08 ↑ N/S 1.52 ↑ N/S 5.456 ↑ N/S -11.62 ↓ N/S       5.87 ↑ N/S -1.82 ↓ N/S 
C24:0 -1.76 ↓ N/S -10.27 ↓ N/S             -1.76 ↓ N/S -10.27 ↓ N/S 
C24:1n6 -8.31 ↓* -6.09 ↓ N/S                 -8.31 ↓ N/S -6.09 ↓ N/S 
The Student t test was used to determine the statistical significance of the results *p<0.05, **p<0.01, ***p<0.001, N/S not significant. Arrows depict direction 
of change following IL-33 stimulation. 
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5.3.3. Distribution of fatty acids 
Using the results from GC, the data was analysed to determine the distribution of 
specific fatty acids within human THP-1 macrophages and murine RAW264.7 
macrophages. The data are presented both in terms of concentration to enable 
observation of relative abundances of fatty acids in each fraction, and also as 
percentages to demonstrate the changes in the proportions of specific fatty acids within 
each fraction. A similar trend within the data was seen using both analytical methods. 
5.3.3.1. THP-1 fatty acid distribution  
The concentration and percentages of fatty acids in PLs and TAGs within THP-1 
macrophages are shown in Figure 62.  
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Figure 62. Distribution of fatty acids in THP-1 macrophages 
PMA-differentiated THP-1 macrophages were incubated with IL-33 (25ng/ml) for 12 or 24 hours. 
An untreated control was included under the same conditions. Lipids were separated by TLC into 
different lipids groups; PLs and TAGs, and the individual fatty acid composition of these fractions 
was assessed by GC. The concentration was normalised to µg/million cells (Panels A and B), and 
percentages of total fatty acids (Panels C and D). Fatty acids are indicated with the number before 
the colon showing the number of carbon atoms, after which denotes the number of double bonds 
followed by the position of the first double bond. Data represents mean from three (A and B) and 
four (C and D) independent experiments.  
 
For both time points, PLs represented the largest fraction based upon fatty acid 
concentrations (Figures 62A and 62B). Interestingly, after 12 hours of IL-33 stimulation 
the concentrations of palmitic acid (C16:0), C16:1n7, C16:1n9, stearic acid (C18:0), 
oleic acid (C18:1n9), vaccenic acid (C18:1n7), EPA (C20:5n3), C22:3n6 and DHA 
(C22:6n3) in PLs were reduced which was accompanied by an increase of these fatty 
acids within TAGs (Figure 62A). There was also a reduction in both PL and TAG 
DGLA (C20:3n6) and AA (C20:4n6) after 12 hours of IL-33 treatment. Levels of 
myristic acid (C14:0) were increased in both fractions and at both time points in 
keeping with the overall rise in myristic acid seen in Figure 58. Figure 61B shows that 
IL-33 reduced the concentrations of palmitic acid, C16:1n7, C16:1n9, oleic acid, 
vaccenic acid and LA (C18:2n6) within PLs but the concentrations of these fatty acids 
were raised in TAGs after 24 hours. Levels of myristic acid, DPA (C22:5n3) and DHA 
in PLs and TAGs were also increased by IL-33. The changes in percentages (Figures 
62C and Figure 62D) reflected the trends exhibited in Figures 62A and 62B. 
Furthermore, IL-33 caused noteworthy rises in the percentages of myristic acid, palmitic 
acid, oleic acid and DPA in TAGs that exceeded the percentages of these fatty acids 
within PLs. The trends in the data were similar at both time points investigated and 
suggest that IL-33 may promote the redistribution of fatty acids from the larger PL pool 
to TAGs. 
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5.3.3.2. RAW264.7 fatty acid distribution  
Following the separation of murine fatty acids into TAGs, PLs and SEs by TLC, GC 
was performed to determine the distribution and amounts of fatty acids within each of 
these fractions.  
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Figure 63. Distribution of fatty acids in RAW264.7 macrophages 
RAW264.7 macrophages were incubated with IL-33 (25ng/ml) for 12 or 24 hours. An untreated 
control was included under the same conditions. Lipids were separated by TLC into different lipid 
groups; PLs, TAGs and SEs and then the individual fatty acid composition of these fractions was 
assessed by GC. The concentration was normalised to µg/million cells (Panels A and B) and 
percentages of total fatty acids (Panels C and D). Fatty acids are indicated with the number before 
the colon showing the number of carbon atoms, after which denotes the number of double bonds 
followed by the position of the first double bond. Data represents mean from three (A and B) and 
four (C and D) independent experiments.  
 
IL-33 stimulation of RAW 264.7 macrophages caused an increase in the concentrations 
of myristic acid (C14:0), stearic acid (C18:0) and LA (C18:2n6) in PLs, TAGs and SEs 
(Figure 63A) after 12 hours. There was also an increase in AA (C20:4n6), C22:3n6, 
DPA (C22:5n3) and DHA (C22:6n3) within PLs and TAGs after 12 hours but these 
fatty acids were absent in SEs. In accordance with the results found in THP-1 
macrophages, there was a reduction in the concentrations of palmitic acid (C16:0) and 
C16:1n9 in PLs but an increase of these fatty acids in TAGs and SEs. Palmitic acid, 
stearic acid and oleic acid (C18:1n9) were abundant in PLs, TAGs and SEs (Figures 
63A and 63C). Figures 63B and 63D display the changes in concentration and 
percentages of specific fatty acids from PLs, TAGs and SEs after 24 hours. IL-33 
increased the concentration of myristic acid and EPA (C20:5n3) in each fraction. In 
accordance with the pattern exhibited at 12 hours of IL-33 treatment, after 24 hours IL-
33 reduced palmitic acid in PLs and increased levels of the fatty acid in TAGs and SEs. 
However, in comparison to the THP-1 macrophage data set, there were less consistent 
trends and the relationship between different fractions was more complex. For example, 
IL-33 stimulation caused an increase in stearic acid in all lipid groups after 12 hours but 
after 24 hours of treatment; the cytokine decreased concentrations of stearic acid within 
SEs. Overall, the alterations in fatty acids were similar at both time points and mutual 
changes were seen in THP-1 macrophages. 
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5.3.4. The effect of IL-33 on desaturases 
5.3.4.1. Desaturase activity 
The studies presented within this chapter have demonstrated that IL-33 elicits 
significant alterations in the fatty acid composition of macrophages, some of which are 
specific to particular lipid fractions (Figures 56-61). A number of significant changes 
occurred in accordance to the fatty acid substrate–product relationships associated with 
certain desaturase enzymes (Figures 58 and 60). To gain some understanding of the 
molecular mechanisms responsible for these changes, experiments were performed to 
assess the impact of IL-33 on desaturase activity. Numerous studies have used the ratio 
of product to precursor as a measure of desaturase activity (Attie et al. 2002; Shiwaku et 
al. 2004; Martinelli et al. 2008; Ebbesson et al. 2012). In accordance with previous 
studies the following indices were used: 
  
   
 
  
  
 
 
To determine SCD activity; the ratio of C16:1n7/C16:0 and C18:1n9/C18:0 were 
assessed individually and together to determine the effects of IL-33 on specific and total 
Δ9-desaturation. Although the ratio of C18:3n6/C18:2n6 is frequently used as an 
indicator of Δ6-desaturase function, this was not possible due to the lack of C18:3n6 
(GLA) within the fractions and a ratio of the downstream Δ6-desaturation product 
C20:3n6 to C18:2n6 was therefore used in accordance with other studies (Raghallaigh 
et al. 2012; Pender-Cudlip et al. 2013). 
Δ6-desaturase: C20:3n-6 
C18:2n6 
Δ5-desaturase: C20:4n6 
C20:3n6 
SCD-1: C16:1n7 
C16:0 
C18:1n9 
C18:0 
and 
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Figure 64. Fatty acid ratios in THP-1 macrophages 
PMA-differentiated THP-1 macrophages were incubated with IL-33 (25ng/ml) for 12 or 24 hours. An untreated control was included under the same 
conditions. Lipids were separated by TLC into different lipids groups; PLs and TAGs and then the individual fatty acid composition of these fractions 
was assessed by GC. Enzymatic activity was analysed for SCD (Panels A-C), Δ6-desaturase (Panel D) and Δ5-desaturase (Panel E) whereby the ratio 
of product to precursor was measured: Panel A= C16:1n7/C16:0; Panel B= C18:1n9/C18:0; Panel C= [(C16:1n7+C18:1n9)/(C16:0+C18:0)]; Panel 
D= C20:3n6/C18:2n6 and Panel E= C20:4n6/C20:3n6. Data represents mean ± SD from four independent experiments. The Student t test was used to 
determine the statistical significance of the results *p<0.05, **p<0.01.   
E 
* 
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Figure 64 displays the changes in the ratio of desaturase products to precursors in THP-
1 macrophages in response to IL-33 stimulation for 12 and 24 hours. Stimulation of the 
cells with IL-33 caused a consistent reduction in the ratio of C16:1n7/C16:0; a measure 
of SCD activity, at both time points and in each fraction (Figure 64A). This decrease 
was significant after 12 and 24 hours of IL-33 treatment in PLs and desaturase activity 
was also greatest within this fraction. Another indicator of SCD activity is the ratio of 
C18:1n9/C18:0 (Figure 64B), IL-33 reduced this ratio across all lipid groups and at each 
time point tested. Furthermore, the reduction in C18:1n9/C18:0 was significant 
following 24 hours of IL-33 stimulation within PLs. The level of desaturation of 18-
carbon species was greater than that for 16-carbon species and SCD activity was highest 
within the TAG fraction. Interestingly, the results were non-significant when using a 
combination of the two ratios of SCD activity (Figure 64C). As such totalling these 
indices may not be the most appropriate method to assess SCD activity. The ratio of 
C20:3n6/C18:2n6 was used to measure Δ6-desaturase activity (Figure 64D). 
Interestingly, within PLs IL-33 increased Δ6-desaturase activity, which was significant 
following 24 hours of IL-33 stimulation. However, within TAGs and total fatty acids 
IL-33 caused a general reduction in enzymatic activity. The TAG fraction displayed the 
highest levels of Δ6-desaturase activity. Figure 64E displays the changes in the ratio of 
C20:4n6/C20:3n6, an indicator of Δ5-desaturase activity, following incubation with IL-
33 for 12 and 24 hours. IL-33 increased Δ5-desaturase activity within PLs at both time 
points. However, within TAGs, IL-33 exerted time-specific effects; after 12 hours the 
cytokine reduced Δ5-desaturase activity but after 24 hours IL-33 significantly increased 
enzymatic activity. The cytokine also increased Δ5-desaturase activity in total fatty 
acids.  
The effects of 12 and 24 hours of IL-33 stimulation on desaturase indices in RAW264.7 
macrophages were next investigated to determine the temporal and potential 
interspecies effect of the cytokine. 
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Figure 65. Fatty acid ratios in RAW264.7 macrophages 
RAW264.7 macrophages were incubated with IL-33 (25ng/ml) for 12 or 24 hours. An untreated control was included under the same conditions. Lipids were 
separated by TLC into different lipids groups; PLs, TAGs and SEs, and then the individual fatty acid composition of these fractions were assessed by GC. 
Enzymatic activity was analysed for SCD (Panels A-C), Δ6-desaturase (Panel D) and Δ5-desaturase (Panel E) whereby the ratio of product to precursor was 
measured: Panel A= C16:1n7/C16:0; Panel B= C18:1n9/C18:0; Panel C= [(C16:1n7+C18:1n9)/(C16:0+C18:0)]; Panel D= C20:3n6/C18:2n6 and Panel E= 
C20:4n6/C20:3n6. Data represents mean ± SD from four independent experiments. The Student t test was used to determine the statistical significance of the 
results *p<0.05. 
E 
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Desaturase activity within RAW264.7 macrophages was assessed using the same ratios 
as THP-1 macrophages. SCD activity (C16:1n7/ C16:0) was reduced following 12 and 
24 hours of IL-33 stimulation in PLs, TAGs, SEs and total fatty acids, except in SEs 
after 24 hours (Figure 65A). Enzymatic desaturation of C16:0 was greatest in TAGs. A 
similar trend was exhibited in the ratio of C18:1n9/C18:0, whereby IL-33 reduced 
activity within PLs, SEs and total fatty acids (Figure 65B). This decrease was 
significant within PLs following 24 hours of IL-33 stimulation. SCD-mediated 
desaturation of C18:0 was highest within SEs. Furthermore, the desaturation of C18:0 
was much greater than that of C16:0. Combining these ratios (Figure 65C) produced a 
trend for IL-33-induced reduction of SCD activity across the fractions at both time 
points with the exception of PLs. There was an increase in Δ6-desaturase activity 
(C20:3n6/C18:2n6) between the time points and following IL-33 treatment within PLs, 
whereas a reduction was exhibited in SEs and total fatty acids (Figure 65D). 
Interestingly IL-33 produced a time-specific effect; inducing Δ6-desaturase activity 
within TAGs after 12 hours of stimulation but reducing activity after 24 hours. The ratio 
of C20:4n6/C20:3n6 was used as a measurement of Δ5-desaturase activity (Figure 65E). 
There were less consistent trends across the fractions and between different time points. 
IL-33 increased Δ5-desaturase activity in PLs and total fatty acids after 12 and 24 hours 
which was significant after 24 hours in total fatty acids. However, IL-33 also decreased 
the activity of Δ5-desaturase in TAGs after 12 hours of treatment but after 24 hours of 
IL-33 treatment there was an increase. Within SEs, 12 hours of IL-33 stimulation 
increased activity but after 24 hours activity was reduced.  
5.3.4.2. Stearoyl-CoA desaturase (SCD)-1 gene expression 
Within human THP-1 and murine RAW264.7 macrophages there was a trend for 
reduced SCD activity following IL-33 treatment based upon the ratios of SCD product 
to precursors (C16:1n7/ C16:0 and C18:1n9/C18:0). Therefore RT-qPCR was 
performed to determine the effects of IL-33 on SCD-1 mRNA expression. THP-1 and 
RAW264.7 macrophages were incubated with IL-33 (25ng/ml) for 12 and 24 hours and 
RT-qPCR was performed on the resulting cDNA using the procedures from chapter 3. 
Further information on the optimisation of these primers are included in the appendix. 
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Figure 66. SCD-1 gene expression 
RT-qPCR was performed using cDNA from RAW264.7 and PMA-differentiated THP-1 
macrophages incubated in the presence or absence (control) of IL-33 (25ng/ml) for 12 hours and 
24 hours. Gene specific primers for: Panel A= human SCD-1 and B= murine SCD-1 were used. 
The mRNA levels were calculated using the comparative Ct method and normalised to the house-
keeping gene, GAPDH, with values from control samples given an arbitrary value of 1. Data 
represents mean ± SD from seven (A) and four (B) independent experiments. The Student t test 
was used to determine the statistical significance of the results *p<0.05, **p<0.01. 
A 
B 
** ** 
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Within THP-1 cells there were no significant changes in the level of SCD-1 mRNA 
following IL-33 treatment for both time points (Figure 66A). However, IL-33 
stimulation caused a significant reduction in SCD-1 mRNA expression after 12 and 24 
hours in murine RAW264.7 macrophages (Figure 66B).  
5.4. Discussion 
This is the first study to investigate the actions of IL-33 on the lipid and fatty acid 
composition of macrophages. Additionally, the involvement of desaturase enzymes, 
responsible for the production of MUFAs and PUFAs, has also been linked to CAD but 
the potential interactions between IL-33 and desaturases have not yet been investigated. 
The study explored the effects of IL-33 on desaturase activity and the mRNA 
expression of SCD-1.  
5.4.1. Major lipid classes 
TLC was used to analyse the effects of 12 and 24 hours of IL-33 stimulation on 
different lipid groups within human and murine macrophages. TLC analysis showed 
that RAW264.7 macrophages contained bands for TAGs, PLs and SEs (Figure 57), 
whereas THP-1 macrophages only contained bands corresponding to TAGs and PLs 
(Figure 56). Previous groups have noted that intracellular concentrations of SEs within 
THP-1 macrophages are low (Persson et al. 2008; Wang et al. 2009; Rajamaki et al. 
2010) and a study by Lada et al. (2002) could not detect CEs by gas-liquid 
chromatography prior to lipid loading (Lada et al. 2002). As such many groups initially 
expose THP-1 macrophages to LDL (Banka et al. 1991), modified LDL (e.g. AcLDL, 
OxLDL) (Rodriguez et al. 1994; Lada et al. 2003; McLaren et al. 2010b), radiolabelled 
cholesterol (Kritharides et al. 1998), 25-hydroxycholesterol (Hassall and Graham 1995; 
Graham et al. 1996), cholesterol crystals (Rajamaki et al. 2010) and mevalonic acid 
(Hassall and Graham 1995) prior to experiments. Pre-incubation with these molecules 
promotes the formation of macrophage ‘foam cells’ and also enriches the cholesterol 
pool. Although TLC analysis did not detect SEs within THP-1 macrophages, other 
studies have shown that these cells contain SEs. Radiolabelling experiments have 
observed the incorporation of precursors into cholesterol within untreated THP-1 
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macrophages (Hassall and Graham 1995; Rise et al. 2003). Rise et al. (2003) 
investigated the incorporation of radiolabelled acetate in THP-1 macrophages. The 
group performed one-dimensional TLC which revealed bands for PLs, TAGs, DAGs, 
FFAs and CEs. However, during the study, 2 day-differentiated cells were used to carry 
out stimulation experiments.  
A key difference between the experimental setup of RAW264.7 and THP-1 
macrophages was the inclusion of PMA in experiments involving THP-1 cells. 
Incubation of THP-1 monocytes with PMA promotes differentiation of the cells into 
macrophages which quickly acquire attributes associated with mature macrophages. 
Morphological differentiation of THP-1 cells has been reported within 15 minutes of 
phorbol ester treatment (Mehta and Lopezberestein 1986) and after 24 hours of PMA 
stimulation, THP-1 cells display an increase in phagocytic activity (Schwende et al. 
1996). Auwerx et al (1989) reported that the mRNA expression of LDLR was induced 
by PMA after only 15 minutes and levels peaked after 1-2 hours. Also, the mRNA 
expression of HMG-CoA reductase, a key enzyme in cholesterol biosynthesis, was 
maximally induced after 2 hours of PMA exposure. The exposure time and PMA 
concentration chosen for the experiments within this chapter have been frequently used 
by other groups in lipid and cholesterol-related studies (Yang et al. 2004; McLaren et al. 
2010b; McLaren et al. 2011b).  Interestingly, several groups have used longer exposure 
times with PMA e.g. 72 hours (Rajamaki et al. 2010) or 7 days (Via et al. 1989; Hassall 
and Graham 1995) in lipid-related studies. During our experiments the THP-1 cells 
were incubated with PMA for 36 hours (12 hours IL-33 treatment) and 48 hours (24 
hours IL-33) and both sets of cells did not contain SEs.  
A greater amount of starting material was used in RAW264.7 experiments; between 3-6 
million compared to the 2-4 million cells in THP-1 macrophage experiments which may 
have aided detection after TLC separation. The data suggests that RAW264.7 
macrophages contain a greater or more detectable amount of SEs compared to THP-1 
macrophages. The lack of SEs detected by TLC in our work may be due to low 
abundance as suggested by previous studies. Therefore future experiments could be 
performed over a longer time scale and HMDMs could be used for comparison. 
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For both THP-1 and RAW264.7 macrophages PLs represented the largest lipid fraction 
(Figures 56 and 57). IL-33 stimulation caused a reduction in the concentration and 
percentages of PLs after 12 and 24 hours and was accompanied by an increase in the 
concentration of TAGs in both cells. The concentration and percentages of SEs within 
RAW264.7 macrophages was relatively constant following IL-33 treatment. The 
increase in TAGs (Figures 56 and 57) in THP-1 and RAW264.7 cells may suggest IL-
33 enhances lipid accumulation within these cells, however due to the fall in PLs there 
were no significant net change in total fatty acid levels. Miller et al (2010) previously 
showed that injections of IL-33 into genetically obese diabetic mice significantly 
reduced adipose mass and although total serum cholesterol was decreased, there was no 
effect on serum TAGs (Miller et al. 2010). Also, a previous study by our laboratory 
demonstrated that IL-33 decreases macrophage foam cell formation in THP-1 
macrophages and HMDMs (McLaren et al. 2010b). Figures 62 and 63 suggest that IL-
33 promotes the redistribution of fatty acids from PLs to TAGs. The analysis of 
individual PLs such as PC, PE, PI, PS and sphingomyelin by two-dimensional TLC 
would reveal more detailed changes (Garrett and Grisham 2012). 
5.4.2. Fatty acid analysis 
The use of THP-1 and RAW264.7 cells provided an isolated system to assess the effects 
of IL-33 on the fatty acid profile of macrophages. A summary of results are provided in 
Tables 20 and 21 and the fatty acid profile of untreated THP-1 macrophages (Galli et al. 
1992; Zhao et al. 2005) and RAW264.7 macrophages (Rouzer et al. 2006; Schumann et 
al. 2011) were similar to those previously described in other studies.  Many of the 
changes initiated by IL-33 were conserved between the two species (Table 22). 
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Table 22. Comparison of responses in THP-1 and RAW264.7 macrophages  
Conservation of responses denoted as Y and differences shown as N. 
5.4.2.1. Saturated fatty acids (SFAs) 
Numerous epidemiological studies link the prevalence of dietary SFAs with incidences 
of CAD (Hayes and Khosla 1992; Zock et al. 1994; Dreon et al. 1998). In particular, the 
12, 14 and 16 carbon SFAs have been shown to exert hypercholesterolaemic effects, 
whereas shorter chain fatty acids and stearic acid are thought to have a neutral impact 
(Rhee et al. 1997; Mensink et al. 2003). IL-33 significantly increased levels of the 14 
carbon fatty acid myristic acid after 24 hours in PLs from THP-1 macrophages. Myristic 
acid is often attributed as the most hypercholesterolaemic SFA (Hayes and Khosla 1992; 
Hughes et al. 1996) due to the adverse effect of this fatty acid on the ratio of LDL 
cholesterol to HDL cholesterol (Zock et al. 1994; Dreon et al. 1998). In contrast, the 
cytokine significantly reduced levels of palmitic acid after 12 hours in THP-1 
THP-1 and RAW264.7 macrophage  
Conservation of responses 
Fatty 
acid 
PLs TAGs  TOTAL 
12 hours 24 hours 12 hours 24 hours 12 hours 24 hours 
C14:0 Y Y Y Y Y Y 
C16:0 Y Y Y Y N Y 
C16:1n7 Y Y Y N Y Y 
C16:1n9 Y Y N Y Y Y 
C18:0 Y Y N Y Y Y 
C18:1n9 Y Y Y Y N Y 
C18:1n7 N N N N Y Y 
C18:2n6 N N Y Y Y Y 
C18:3n3 Y N Y Y N Y 
C20:1n9   N N N N 
C20:3n6 Y N N Y Y Y 
C20:4n6 Y Y Y Y N Y 
C20:5n3 Y N N N N N 
C22:0 N N   N N 
C22:3n6 Y Y N Y Y Y 
C22:5n3 Y N Y Y Y Y 
C22:6n3 Y Y Y Y Y N 
C24:0 N N   N N 
C24:1n6 N Y   N Y 
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macrophages, and within RAW264.7 macrophages after 12 and 24 hours in PLs 
(Figures 58 and 60) but significantly increased palmitic acid levels in TAGs after 24 
hours in murine macrophages. The cytokine significantly increased the amount of 
stearic acid in PLs after 24 hours. Stearic acid is described as a neutral fatty acid within 
the context of CAD and may exert small beneficial effects on LDL cholesterol 
(Mensink et al. 2003). The perceived neutrality of this fatty acid has been attributed to 
the high rate of conversion to oleic acid (Bonanome et al. 1992; Garg 1992). Our data 
also demonstrated that human and murine macrophages have a greater abundance of 
oleic acid to stearic acid (Figures 58 and 60).  
The potential effects of these changes within an atherosclerotic context are unclear as 
IL-33 produced a number of significant changes in specific SFAs but did not exert a 
consistent trend across the group. IL-33 promoted the formation of pro-atherosclerotic 
myristic acid but had mixed effects on levels of palmitic acid within different lipid 
fractions. Alterations in palmitic acid may potentially represent changes in the de novo 
synthesis of fatty acids, as palmitic acid is the primary product of these biosynthetic 
reactions (Cook and McMaster 2002). The effects of IL-33 on biosynthetic enzymes 
such as fatty acid synthase (Lin et al. 2002) could be explored to assess whether the 
cytokine influences fatty acid production. The changes in SFAs were consistent 
between species. 
Interestingly, the greatest number of significant changes occurred within the PL fraction. 
Phospholipids primarily reside within the membrane where they influence structure and 
fluidity and can function as substrates for the production of signalling molecules 
(Calder and Yaqoob 2003). Alterations in the membrane composition of macrophages 
can have a significant impact on their characteristics and properties. Experiments 
involving exogenous enrichment of specific fatty acids within macrophage membranes 
have shown that there is a positive correlation between the level of fatty acid 
unsaturation and the phagocytic ability of macrophages (Schroit and Gallily 1979; 
Calder et al. 1990). Accordingly, increased proportions of SFAs in phospholipids 
reduces receptor-mediated phagocytosis and also decreases the rate of fluid-phase 
pinocytosis within primary murine peritoneal macrophages (Mahoney et al. 1977). The 
use of phagocytic inhibitors such as cytochalasin B (Axline and Reaven 1974; 
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Schrijvers et al. 2007) could be meaningful in future in vitro studies examining the 
influence of IL-33 on macrophage phagocytosis.  
Previous studies have shown that raised levels of SFAs within macrophage membranes 
enhances the adhesiveness of the cells (Calder et al. 1990). In vivo studies of mice have 
demonstrated that IL-33 decreases the accumulation of macrophages within the lesion 
thereby indicating that the migration and adhesion of these cells is compromised 
(McLaren et al. 2010b). A macrophage adhesion assay could be performed within 
RAW264.7 and THP-1 macrophages to assess the impact of IL-33 on monocyte 
adhesion. Saturated fats may exert pro-atherosclerotic effects through a combination of 
raising levels of plasma LDL-cholesterol and influencing the phagocytic properties and 
adhesiveness of macrophages. As such it would be interesting to determine whether the 
changes instigated by IL-33 influenced these characteristics. 
5.4.2.2. Monounsaturated fatty acids (MUFAs) 
MUFAs are generally ascribed as having a neutral atherogenic profile and are thought to 
be less potent than PUFAs (Lee et al. 1989; Hayes and Khosla 1992; Lemaitre et al. 
2002). The beneficial effects of MUFAs are mainly derived from observations that 
populations that consume a Mediterranean-type diet high in MUFAs have lower 
incidences of CHD. Dietary intervention strategies recommend the replacement of 
dietary SFAs with MUFAs and PUFAs (Degirolamo and Rudel 2010). However, recent 
studies have questioned this strategy (Jakobsen et al. 2009). The production of MUFAs 
are reflective of SCD-1 activity which has been positively associated with CAD and 
may implicate a pathological role for these fatty acids (Warensjoe et al. 2008). IL-33 
stimulation caused a significant reduction in the percentages of C16:1n7, C16:1n9 and 
oleic acid after 12 and 24 hours in THP-1 and RAW 264.7 macrophages. The reduction 
in 16 carbon-MUFAs was likely linked to the IL-33-mediated decrease of the precursor 
palmitic acid.  
5.4.2.3. Polyunsaturated fatty acids (PUFAs) 
PUFAs belong to either the n-3 or n-6 family depending on the position of their first 
double bond. The n-3 group of PUFAs are associated with protective effects against 
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heart disease, whereas the role of n-6 PUFAs within CAD is less clear due to the 
production of AA-derived inflammatory mediators. Western diets have a bias in the 
ratio of n-6 fatty acids to n-3 fatty acids which is thought to contribute to the 
development of heart disease (Simopoulos 2008).  
The abundances of fatty acids (Figures 62 and 63) were similar to those from other 
studies, although, in accordance with the findings from other studies, the levels of long 
chain PUFAs were relatively low within these cells (Galli et al. 1992; Zhao et al. 2005; 
Rouzer et al. 2006; Schumann et al. 2011). Interestingly, Agha-Jaffar et al (2013) 
showed that PMA-mediated differentiation of THP-1 macrophages was associated with 
changes in fatty acid composition including a reduction in PUFAs, in particular EPA, 
C22:5n6 and DHA. These changes were also accompanied with reduced FADS1 and 
FADS2 mRNA expression and associated with a fall in PUFA synthesis (Agha-Jaffar et 
al. 2013). It would be interesting to compare changes in fatty acid composition and 
desaturase expression in the absence and presence of PMA with the experimental 
conditions used within this study. 
IL-33 caused several significant changes within macrophage PUFAs. Overall the 
cytokine increased n-3 PUFA production but the effects on n-6 PUFAs were more 
mixed. Interestingly, within RAW264.7 macrophages levels of both LA and EPA in PLs 
were significantly increased by IL-33. The mutual increase was unexpected as LA, the 
precursor to n-6 PUFAs, shares an antagonistic relationship with the precursor ALA 
over competition for Δ6-desaturase (Emken et al. 1999) and as such increased levels of 
LA should reduce the formation of n-3 long chain fatty acid metabolites derived from 
ALA such as EPA and DHA. Within the study both EPA and DHA were increased, 
although the rise was not significant for DHA. Increased amounts of EPA and DHA 
within the cells should have an anti-atherogenic effect as enhanced dietary intake of 
EPA and DHA have been shown to cause a 39% reduction in AA and its metabolites 
and a 54% fall in LTB4 production (Lee et al. 1985). In previous studies by our group, 
incubation of THP-1 macrophages and primary HMDMs with DHA and EPA reduced 
the uptake of modified LDL and inhibited macropinocytosis (McLaren et al. 2011b; 
Michael et al. 2013). In this study IL-33 also significantly increased the n-3 PUFA DPA. 
Enhanced levels of serum DPA and supplementation of DPA have been shown to 
reduce the risk of cardiovascular disease (Rissanen et al. 2000; Oda et al. 2005). 
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Several complications arise when trying to interpret data based solely on n-3 and n-6 
PUFA categories. Although several studies support the notion that n-3 PUFAs are anti-
atherogenic and n-6 PUFAs are pro-atherogenic, the effects of individual fatty acids can 
sometimes contradict these classifications. Figure 58 shows that IL-33 significantly 
increased levels of AA and EPA in THP-1 macrophages. In a study by Wang et al. 
(2009) the growth medium of lipoprotein-incubated THP-1 macrophages was 
supplemented with AA and EPA. Both fatty acids reduced the expression of TNF-α and 
MCP-1 and also down-regulated ABCA-1 and SR-B1 expression. Furthermore, these 
fatty acids promoted CE accumulation without influencing total cholesterol content 
(Wang et al. 2009). Although the fatty acids originate from different PUFA families 
they exhibit the same actions. Interestingly, IL-33 also reduces the expression of SR-B1 
and MCP-1 (chapter 3). As such it would be useful to determine whether alterations in 
the production of specific fatty acids are responsible for changes in gene expression. 
However, it seems likely that other mechanisms are also in place as IL-33 also increases 
ABCA-1 expression and reduces CE accumulation (McLaren et al. 2010b). 
Monocytes and macrophages are major sources of eicosanoids (Calder and Yaqoob 
2003; Hansson and Hermansson 2011). During atherosclerosis LOX enzymes colocalise 
with modified LDL particles and macrophages within the plaque and are thought to 
assist the oxidative modification of LDL particles (Ylaherttuala et al. 1990; Ylaherttuala 
et al. 1991c; Benz et al. 1995). However, the current literature on the relationship 
between IL-33 and eicosanoids is conflicting and mainly focused on the role of the 
cytokine in mast cells (Allakhverdi et al. 2007; Iikura et al. 2007; Moulin et al. 2007). 
Figures 58 and 60 show that IL-33 significantly affected a number of fatty acids 
involved in eicosanoid production. Eicosanoids are not stored but are synthesised in situ 
and their production is reflected by the fatty acid membrane composition (Makheja 
1992; Mason et al. 2012). IL-33 reduced the production of murine DGLA in total fatty 
acids (Figure 60G); an n-6 PUFA responsible for the formation of the anti-inflammatory 
series 1 PGs via the COX pathway and or 15-HETeE by 15-LOX. These metabolites 
exert a range of anti-inflammatory effects including the reduction of blood pressure and 
inhibition of SMC proliferation (Wang et al. 2012). Supplementation with DGLA also 
reduces the expression of ICAM-1 and VCAM-1 and decreases atherosclerotic 
development in ApoE
-/-
 mice (Takai et al. 2009). 
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As was previously discussed, IL-33 significantly increased EPA production (Figure 60B) 
and a trend for raised EPA levels was present in both set of cells. The metabolism of 
EPA gives rise to weakly pro-inflammatory series-3 PGs and series-5 LTs. However, 
EPA is thought to exert anti-inflammatory actions through competition for the same 
acylation enzymes as AA within similar membrane pools therefore diluting the presence 
of AA and reducing the production of AA-derived eicosanoids (Shoenfeld Y et al. 
2001). Additionally, the production of mildly inflammatory mediators like TXA3 
derived from EPA may reduce the synthesis of more potent AA-derived mediators like 
TXA2 which promote platelet aggregation and vasoconstriction (Hulín and Simko 1997). 
However, it is interesting that AA levels were also raised by IL-33. AA is enriched in 
macrophage membranes and is the major precursor of eicosanoids, such as the pro-
inflammatory series 2 PGs and series 4 LTs  (Calder and Yaqoob 2003). Within the 
study, levels of AA were high within the PL fraction and exceeded those of EPA. 
However, as both EPA and AA were increased, it is possible that the actions of AA 
would be reduced due to the inhibitory effects of EPA and several studies have shown 
that the detrimental actions of n-6 PUFAs are nullified in the presence of n-3 PUFAs 
(Pischon et al. 2003; Kusumoto et al. 2007). As both fatty acids can produce a wide 
array of eicosanoids with differing properties it is difficult to assess the overall impact 
within the cell. For example, EPA and AA are also modified to the prostacyclins PGI3 
and PGI2, respectively, which exert anti-aggregating and vasodilating properties on the 
arterial wall.  
Inflammation can be limited by promoting pro-resolving mechanisms such as 
modulation of adhesion molecule expression and regulation of signalling pathways 
controlling the expression of genes responsible for pro-inflammatory actions (Kohli and 
Levy 2009). Within the thesis the anti-inflammatory effects of IL-33 have been 
consistently demonstrated (chapters 3 and 4); therefore it is likely that these actions may 
be accompanied by an increase in the production of anti-inflammatory molecules such 
as lipoxins, protectins and resolvins. Cellular processing of EPA and DHA gives rise to 
E- and D-series of resolvins respectively. E-resolvins attenuate the effects of the potent 
chemoattractant LTB4 derived from AA and reduce inflammation (Arita et al. 2005; 
Arita et al. 2007). Also, resolvin production utilises the same COX and LOX enzymes 
responsible for the conversion of AA to PGs and LTs. Therefore, a switch to resolvin 
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formation occurs at the expense of AA-derived PG and LT production. However, AA-
derived mediators like lipoxins formed by LOX enzymes can also exhibit anti-
inflammatory properties (Kohli and Levy 2009). Lipoxins exert a range of effects 
including reduced transmigration of polymorphonuclear leukocytes, regulation of 
endothelial cell adhesiveness and decreased polymorphonuclear leukocyte and 
eosinophil chemotaxis (Claria and Serhan 1995). Although IL-33 did not have a 
significant effect on DHA, the cytokine caused a general increase in levels of the fatty 
acid within human and murine PLs. In addition to D-series resolvins, DHA can also be 
converted into protectins that reduce kidney damage and decrease leukocyte infiltration 
and macrophage activation (Duffield et al. 2006). 
The study demonstrated that IL-33 produced a number of changes in macrophage fatty 
acids (Tables 20 and 21). The cytokine reduced the production of MUFAs but this was 
accompanied by a general increase in PUFA formation; particularly n-3 family 
members. Further studies should explore the effects of IL-33 on eicosanoid production 
as a number of significant changes occurred in eicosanoid-precursor fatty acids. The 
expression of metabolic enzymes like LOXs and COXs following IL-33 stimulation 
may provide some insight in combination with extensive analysis by GC/ mass 
spectrometry (MS) of the metabolites formed during IL-33 treatment. 
5.4.3. Desaturases 
The formation of MUFAs and PUFAs are dependent on the actions of desaturase and 
elongase enzymes. As such these enzymes also control the production of eicosanoid 
precursors like AA, EPA and DHA (Cho et al. 1999). The study has so far investigated 
the effects of IL-33 on the composition and distribution of fatty acids within human and 
murine macrophages. Due to the range of actions exhibited by individual fatty acids, 
there are difficulties in determining the overall impact of these changes within the 
context of atherosclerosis. However, the activities of desaturases reflect the metabolic 
changes in fatty acids and are directly associated with CAD and markers of the disease 
(Ebbesson et al. 2012).  
The effects of IL-33 on the ratio of products and substrates for SCD were next 
investigated arising from observations that the cytokine induced significant changes in 
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16 and 18 carbon fatty acids (Figures 58 and 60). SCD activity has been linked to 
various cardiovascular risk factors and other pathologies such as adiposity, hepatic 
steatosis, glucose intolerance (Sampath and Ntambi 2014), cholesterol metabolism and 
efflux (Sun et al. 2003; Nakaya et al. 2013) and CAD (Warensjoe et al. 2008). IL-33 
significantly reduced SCD activity within PLs (based on a ratio of C16:1n7/C16:0 and 
C18:1n9/C18:0) in THP-1 and RAW264.7 macrophages (Figures 64 and 65) and a fall 
in SCD activity was also observed in other fractions.  
The metabolic syndrome is a myriad of risk factors including abdominal obesity, 
hypertension, dyslipidaemia and insulin resistance and is linked to the development of 
CAD. Patients developing this syndrome display a characteristic fatty acid profile 
defined by increased amounts of myristic acid, palmitic acid, palmitoleic acid, oleic acid, 
GLA and DGLA and decreased LA which are indicative of increased SCD activity 
(Warensjo et al. 2005). Within the study palmitic acid, palmitoleic acid and oleic acid 
were significantly reduced in THP-1 and RAW264.7 macrophages PLs by IL-33. These 
results, in combination with the reduction in SCD activity indices, indicate that IL-33 
produces a protective fatty acid profile against CAD and related disorders.  
The effects of IL-33 stimulation on the activities of other desaturases were also 
investigated. Reduced or impaired Δ5-desaturase activity and raised Δ6-desaturase 
activity are associated with MI and cardiac-related mortality (Leng et al. 1999; 
Warensjoe et al. 2008) and have also been linked to other CAD-related disorders such 
as diabetes, obesity and the metabolic syndrome (Warensjo et al. 2005; Petersson et al. 
2008). Δ6-desaturase is responsible for the conversion of LA and ALA to GLA and 
C18:4n3 (STA) respectively, whilst Δ5-desaturase catalyses the desaturation of DGLA 
and ETA (Cho et al. 1999). Within the study, due to the absence of GLA, a ratio of 
C18:2n6/C20:3n6 was used to calculate Δ6-desaturase activity in accordance with other 
studies (Raghallaigh et al. 2012; Pender-Cudlip et al. 2013). Within THP-1 
macrophages, IL-33 significantly increased Δ6-desaturase activity within PLs. However, 
the response in other fractions and in murine macrophages was mixed which may be 
related to the alternative choice of ratio. The activity of Δ5-desaturase was predicted by 
a ratio of C20:4n6/C20:3n6. IL-33 significantly increased Δ5-desaturase activity within 
THP-1 TAGs and total fatty acids in RAW264.7 macrophages. Overall, increased Δ6-
desaturase activity is associated with adverse cardiac events but raised Δ5-activity is 
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thought to have a protective effect. The rise in these indices is likely linked to increased 
PUFA production observed within these macrophages. As the trends for Δ6-desaturase 
and Δ5-desaturase were less consistent across the fractions, experiments focused on the 
better characterised SCD which is thought to be a stronger indicator of CAD. 
The effects of 12 and 24 hours of IL-33 stimulation on the mRNA expression of SCD-1; 
the major isoform of SCD, was assessed by RT-qPCR. In accordance with the data 
shown in Figure 65, IL-33 significantly reduced SCD-1 expression within RAW264.7 
macrophages (Figure 66B). However, within THP-1 macrophages the cytokine did not 
have a significant effect on SCD-1 mRNA levels (Figure 66A). The reduction in SCD-1 
activity and expression exhibited within RAW264.7 macrophages was also in 
agreement with the IL-33-mediated increase in PUFA production (Figures 58 and 60) as 
PUFAs negatively regulate the expression of the SCD-1 gene (Liu et al. 2011).  
The role of SCD-1 in atherosclerosis is complex. Many studies have shown that SCD-1 
exerts protective effects against obesity and diabetes (Warensjo et al. 2005; Sampath 
and Ntambi 2014) and elevated levels of SCD-1 are associated with adverse cardiac 
events (Warensjoe et al. 2008). Also, within certain contexts ablation of SCD-1 is 
detrimental to atherosclerotic development; for example in mice with chronic 
intermittent hypoxia-induced atherosclerosis (Savransky et al. 2008). Yet, several 
groups have shown that complete ablation or knock down of SCD-1 promotes 
atherosclerosis (Brown et al. 2008; MacDonald et al. 2009).  
In light of the beneficial effects of IL-33 described in atherosclerosis it seems likely that 
the IL-33-mediated reduction of SCD-1 would have a protective influence. Although, 
IL-33 increased the expression of several SFAs (Figures 58 and 60), a study by Sampath 
et. al (2007) demonstrated that saturated fats induce the expression of SCD-1 ahead of 
lipogenic genes like SREBP-1c. However, in the absence of SCD-1, SFAs instead 
promote the expression of genes associated with β-oxidation instead of lipogenesis. As 
such the authors proposed that the desaturation of SFAs was required to promote lipid 
accumulation (Sampath et al. 2007). Previous studies have also shown that IL-33 
reduces the expression of lipogenic genes including SREBP-1c (Miller et al. 2010). 
Additionally, administration of IL-33 into genetically obese diabetic mice decreases 
adiposity and fasting glucose, and is accompanied with improved glucose and insulin 
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tolerance (Miller et al. 2010). Many of the actions associated with reduced SCD activity 
or expression are similar to those arising from IL-33 stimulation. IL-33 could 
potentially regulate SCD-1 to exert beneficial effects on lipid metabolism. RNAi or 
pharmacological inhibitors targeting SCD-1 such as TOFA, Abbott #7 and Abbott #28c 
(Mason et al. 2012) could be utilised to discern whether SCD-1 is involved in any of 
these actions. 
This was the first study to investigate the activities of SCD, Δ6- and Δ5-desaturases in 
response to IL-33 stimulation. Numerous studies have used indices of product to 
precursors to estimate desaturase activity and the activities of these enzymes may be a 
stronger predictor of disease than the assessment of individual fatty acids (Warensjo et 
al. 2005). However, there are some limitations in using product/precursor indices to 
assess activity. For example, the choices of product/precursor ratios are inconsistent 
between studies. Li et al (2013) used three indices to predict SCD-1 activity (Li et al. 
2013) whereas some studies only utilise a single ratio for assessment (Shiwaku et al. 
2004; Maria Martin-Nunez et al. 2013). Therefore, the use of radiolabelled fatty acid 
precursors could provide a more in-depth analysis and also give additional information 
on conversion rates of precursor to product (Narce et al. 1994).  
5.5. Future aims 
The experiments presented within this chapter have shown that IL-33 instigates a 
number of interesting changes within macrophage fatty acid composition and further 
studies should be performed to characterise the genes responsible for these responses. 
There are a limited number of studies that have investigated the effects of IL-33 on the 
expression of genes involved in lipid and cholesterol metabolism and efflux, especially 
within the context of macrophages. Miller et al (2010) have previously shown that 
obese mice treated with IL-33 exhibit reduced adiposity. Cultures of white adipose 
tissue from these mice display a protective gene expression profile in response to IL-33 
stimulation as the cytokine decreases the expression of genes involved in lipid 
metabolism and adipogenesis such as C/EBPα, SREBP-1c and LXRs (Miller et al. 
2010). Mclaren et al. (2010) also demonstrated that IL-33 reduces the expression of SRs 
within THP-1 macrophages and HMDMs and increases the expression of genes 
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involved in cholesterol efflux such as ABCA-1. These changes were accompanied by 
alterations in the expression of lipid storage and metabolic genes such as CPT-1, ADRP 
and ACAT-1. The results suggest that fatty acid availability is diminished for CE 
production and as a result the accumulation of CEs and TAGs are decreased (McLaren 
et al. 2010b). It would be interesting to determine whether the signalling pathways 
responsible for these actions are the same as those involved in the regulation of ICAM-1 
and MCP-1 by IL-33. 
DISCUSSION   Melanie Buckley       Melanie Buckley 
  
239 
 
CHAPTER 6.  
DISCUSSION 
 
6.1. Introduction 
Atherosclerosis and its complications are the leading cause of global mortality. The 
disease is characterised by chronic inflammation of the arterial wall and arises due to an 
imbalance in cholesterol and lipid homeostasis (Weber and Noels 2011). Macrophages 
are the prevalent cell type within the plaque and participate in many key stages from 
initial recruitment to the lesion site, uptake of modified lipoproteins and ensuing 
transformation into macrophage foam cells (Moore et al. 2013). Furthermore, 
macrophages can promote a maladaptive immune response through the secretion of pro-
inflammatory mediators like cytokines and lipid-derived messengers which augment 
atherosclerotic progression (Dickhout et al. 2008). Cytokines are highly expressed in 
the plaque and the interplay between pro- and anti-inflammatory cytokines dictates the 
inflammatory state (McLaren and Ramji 2009).  
Due to the prevalence of the disease and the resulting strain it exerts on healthcare 
services, there is a great level of interest in understanding the mechanisms that give rise 
to the disease state. IL-33 is a recently discovered cytokine which promotes the 
production of Th2-associated cytokines (Ait-Oufella et al. 2011) and has been reported 
to have a protective role within cardiovascular disease (Weinberg et al. 2003; Shimpo et 
al. 2004; Sanada et al. 2007; Miller et al. 2008). Studies from our group have 
demonstrated that the cytokine exerts beneficial effects by reducing foam cell formation 
and macropinocytosis, in addition to limiting the actions of ADAMTS enzymes in 
macrophages (McLaren et al. 2010b; Michael et al. 2013; Ashlin et al. 2014). As such 
the work detailed within this thesis has focused on exploring the role of this cytokine in 
two key aspects of the disease; inflammation and lipids. These studies provide an 
insight into the anti-atherogenic effects of IL-33 on inflammatory markers of the disease 
and also characterises the signalling pathways responsible for these actions. 
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Furthermore, the influence of IL-33 on the lipid and fatty acid profiles of macrophages 
was also explored. 
6.2. Summary of key findings 
The experiments presented within this thesis support the role of IL-33 as an anti-
atherogenic cytokine. The cytokine exerts a number of protective effects within the 
context of inflammation and lipid biochemistry. The key findings from these studies are 
outlined below: 
 IL-33 reduces the expression of a number of pro-atherosclerotic markers that are 
implicated in different aspects of the disease within murine RAW264.7 and 
human THP-1 macrophages and primary HMDMs. 
 The down-regulation of ICAM-1 and MCP-1 mRNA by IL-33 is mediated 
through ERK1, ERK2, p38α, JNK1, JNK2, PI3K-γ, p50 and p65 in THP-1 
macrophages.  
 IL-33 reduces the PL content of macrophages whilst increasing the content of 
TAGs within THP-1 and RAW264.7 macrophages. The proportions of SEs in 
RAW264.7 macrophages were unaltered by the cytokine. 
 Stimulation with IL-33 for 12 and 24 hours produced a range of effects on the 
fatty acid profile of human and murine macrophages. The cytokine increases the 
amounts of SFAs and n-3 PUFAs in THP-1 and RAW264.7 macrophages and 
reduces MUFA levels. The trend for n-6 PUFAs was less consistent but a 
general increase was present. 
 IL-33 raises the levels of precursors for eicosanoid production and affects the 
content of desaturase precursors and products.  
 The activities of Δ5- and Δ6-desaturases are increased by IL-33 stimulation. In 
contrast, SCD activity decreases following IL-33 treatment. 
 IL-33 significantly decreases the expression of SCD-1 mRNA in RAW264.7 
macrophages but has no effect in THP-1 macrophages. 
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 Overall, IL-33 promoted a protective phenotype against heart disease associated 
with increased production of PUFAs and beneficial changes in the expression of 
SCD-1. 
 Many of the trends within the data were conserved between the two time points 
tested and between species. 
6.3. The role of IL-33 in the regulation of expression of atherosclerotic 
markers 
In chapter three, RT-qPCR was used to determine the effects of IL-33 stimulation on the 
mRNA expression of several well-characterised atherosclerotic markers. THP-1 
macrophages were utilised for this purpose as the cell line has been used in a wide range 
of studies including those focusing on atherosclerosis (Banka et al. 1991; McLaren et al. 
2010a; Zhang et al. 2011a; Qin 2012). Key findings were then confirmed in the murine 
RAW264.7 macrophage cell line and primary HMDMs to assess whether these changes 
were conserved between species and to determine their physiological relevance. IL-33 
reduced the expression of a variety of genes implicated in atherosclerosis such as those 
involved in cholesterol uptake (Febbraio et al. 2000; McLaren et al. 2010a), metabolism 
(Van Eck et al. 2000; Mead et al. 2002; Mead and Ramji 2002; Lusis et al. 2004) and 
monocyte recruitment and attachment (Hwang et al. 1997; Blankenberg et al. 2003). 
The effect of IL-33 on the expression of CD36, SR-A and SR-B1 within THP-1 
macrophages were in agreement with a previous study from our group and validated the 
use of recombinant IL-33 for future experiments (McLaren et al. 2010b). The decrease 
in the expression of ICAM-1, IP-10, LPL, MCP-1 and MIP-1β within THP-1 
macrophages were novel and also supported the role of IL-33 as an anti-atherosclerotic 
mediator (Miller et al. 2008).  
ICAM-1 and MCP-1 were chosen to optimise the system for further studies. The 
greatest effects by IL-33 occurred at 12 hours of stimulation with a concentration of 
25ng/ml in THP-1 macrophages and murine RAW264.7 macrophages. The 
experimental conditions were also confirmed within primary HMDMs and therefore 
subsequent studies were performed using these parameters. IL-33 exhibited similar 
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responses within murine and human cells, demonstrating that the response was well 
conserved between the two species. 
6.4. The activation of signalling components by IL-33 
Using the conditions optimised in chapter three, RT-qPCR was performed to determine 
the effects of IL-33 stimulation on the mRNA expression of several signalling 
components implicated in atherosclerosis. Cytokine treatment did not signficantly 
induce the expression of any of the genes tested but caused a significant reduction in the 
mRNA expression of p38α, JNK2 and PI3K-γ. An additional study was performed in 
collaboration with Timothy Ashlin from the laboratory (Ashlin et al. 2014), whereby 
THP-1 macrophages were stimulated for 24 hours with IL-33 (10ng/ml) to determine 
the effect on the phosphorylation state of ERK1 and ERK2. IL-33 significantly 
increased the phosphorylation of these proteins and further studies by Ashlin et al. 
(2014) demonstrated that the cytokine additionally activates the JNK/c-Jun pathway 
(Ashlin et al. 2014). Schmitz et al. (2005) has also shown that IL-33 induces the 
phosphorylation of IκB, ERK1/2, p38 and JNK in HEK293 cells transfected with an 
expression vector for ST2 (Schmitz et al. 2005). Additional western blot experiments 
should be performed to assess whether IL-33 alters the protein expression of the other 
signalling components tested in chapter four using antibodies that recognise the active, 
phosphorylated forms (Werle et al. 2002; Costa et al. 2006; Zhou et al. 2010).  
6.5. The signalling pathways responsible for IL-33-mediated regulation 
of ICAM-1 and MCP-1 expression 
ICAM-1 and MCP-1 are involved in early events within the pathogenesis of 
atherosclerosis and have an integral role in the recruitment and attachment of leukocytes 
to the lesion site. Furthermore, levels of these proteins are raised in patients with 
atherosclerosis and correlate with incidences of CHD (Hwang et al. 1997; Hayashidani 
et al. 2003; Deo et al. 2004). Due to the importance of these proteins in initiating 
atherogenic processes, the studies next focused on characterising the signalling 
pathways that underlie the expression of ICAM-1 and MCP-1. Using the experimental 
conditions previously optimised, a combination of siRNAs and shRNAs were used to 
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determine whether the response from IL-33 was lost when the expression of key 
signalling genes implicated in the disease were attenuated. A significant or marked 
knock down in the mRNA expression of all targets following RNAi was achieved. For 
ERK1, ERK2, JNK2 and p38α, antibodies were also available and the knock down was 
confirmed at the protein level.  
Experiments utilising RNAi showed that IL-33 utilises ERK1, ERK2, p38α, JNK1, 
JNK2, PI3K-γ, p50 and p65 to reduce the expression of ICAM-1 in THP-1 macrophages 
(Table 17). The same signalling components were also utilised in the down-regulation 
of MCP-1 mRNA expression with the exception of p50 and p65 where the knock down 
did not affect the response to IL-33. The results were consistent with findings from 
other groups that have shown that IL-33 activates IκB, ERK1/2, p38, PI3K and JNK 
(Schmitz et al. 2005; Ashlin et al. 2014). As such, it would be useful to extend the 
studies by investigating whether these signalling components are involved in the 
regulation of ICAM-1 and MCP-1 protein expression by IL-33. Western blot analysis 
using ICAM-1 and MCP-1 antibodies could be performed following knock down of 
these signalling components to assess whether the response from IL-33 is attenuated.  
6.6. The influence of IL-33 on lipid levels in macrophages 
The studies from chapters three and four investigated the role of IL-33 in the regulation 
of atherosclerotic markers, many of which are involved in promoting the inflammatory 
state. However, atherosclerosis is a multifaceted disease and also has an integral lipid 
component (Schoenhagen 2006). As such it was decided to explore the impact of IL-33 
on lipids within macrophages. Analyses by TLC and GC were performed on human 
THP-1 and murine RAW264.7 macrophages following IL-33 stimulation (25ng/ml) for 
12 and 24 hours to assess the temporal and inter-species impact of the cytokine on the 
lipid profile of these cells.  
TLC analysis revealed that RAW264.7 macrophages contained PLs, TAGs and SEs; yet 
THP-1 macrophages were absent of detectable SEs. This was surprising as the THP-1 
cell line has been used in numerous lipid and cholesterol studies (Draude and Lorenz 
2000; Lada et al. 2002; Chanput et al. 2010) and contains many enzymes involved in 
cholesterol metabolism, transport and esterification such as ABCA-1, ABCG-1, ACAT-
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1, ADRP, ApoE, CD36, LDLR, NCEH, NPC-1, NPC-2 SR-A and SR-B1 (Kritharides 
et al. 1998; McLaren et al. 2010b; Yang et al. 2013). However, a study by Lada et al. 
(2002) indicated that levels of CEs were undetectable in unloaded THP-1 macrophages 
by gas-liquid chromatography. However, following loading with acLDL CEs were 
detected (Lada et al. 2002). In response to PMA treatment, the expression of LDLR is 
reduced within THP-1 cells, whilst SRs are up-regulated therefore facilitating the 
transformation of these cells into macrophage foam cells in the presence of modified 
LDL (Qin 2012).  
The time point chosen for these experiments was based upon the optimal uptake and 
efflux of lipids and peak expression of markers as previously discerned by our group 
and others. However, some groups have used three to seven day PMA-differentiated 
THP-1 macrophages and it is possible that the extended length of time is required for 
SEs to be synthesised and produced to a detectable amount (Banka et al. 1991; 
Kritharides et al. 1998). Experiments could also be extended to HMDMs to determine 
the presence of SEs in cells treated and untreated with modified LDL particles and the 
use of radioactive precursors could be employed to increase sensitivity.  
PLs were the major lipid fraction in THP-1 and RAW264.7 macrophages and treatment 
with IL-33 promoted the redistribution of fatty acids from PLs to TAGs within both sets 
of macrophages (Figures 56, 57, 62 and 63). TAGs and CEs are typically stored within 
lipid droplets to limit the amounts of potential lipotoxic FFAs within the cell. It would 
be interesting to assess whether the rise in TAGs was associated with increased 
formation of lipid droplets within the macrophages as previous studies using the 
Amplex Red cholesterol assay kit showed that IL-33 reduces the levels of CEs within 
THP-1 macrophages and HMDMs (McLaren et al. 2010b). Oil red O or Nile red could 
be used to stain intracellular lipid droplets before and after IL-33 treatment to determine 
potential changes (Greenberg et al. 2011; Walther and Farese 2012). The studies from 
chapter five also indicate that the cytokine may promote the redistribution of fatty acids 
without significantly altering the amounts of total lipid. Interestingly, disrupted plaques 
contain raised levels of total lipids associated with increased levels of phospholipids and 
TAGs as well as free cholesterol and CEs (Felton et al. 1997). Previous studies have 
shown that levels of free cholesterol and CEs are reduced in response to IL-33 
(McLaren et al. 2010b).  
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6.6.1. The influence of IL-33 on SFAs in macrophages 
There was a trend for increased levels of SFAs in response to IL-33 stimulation within 
THP-1 and RAW264.7 macrophages. The cytokine significantly increased levels of 
myristic acid and stearic acid within PLs and also raised stearic acid in total fatty acids 
in THP-1 macrophages. Within RAW264.7 macrophages, IL-33 significantly increased 
levels of palmitic acid in TAGs and stearic acid within SEs. However, this was 
accompanied by a reduction in the amounts of palmitic acid within PLs in both THP-1 
and RAW264.7 macrophages. Overall there was a trend for increased incorporation of 
fatty acids into TAGs, including SFAs. A study by Koliwad et al. (2010) demonstrated 
that the storage of SFAs into TAGs within murine macrophages was inversely related 
with the production of pro-inflammatory genes and the switch to the M1 phenotype. 
These beneficial effects were thought to arise by reducing the availability of free SFAs 
and therefore limiting the use of SFAs for pro-inflammatory pathways (Koliwad et al. 
2010).  
6.6.2. The influence of IL-33 on MUFAs in macrophages 
The effects of IL-33 on MUFAs within THP-1 and RAW264.7 macrophages were also 
assessed. Treatment with IL-33 significantly reduced the percentages of a number of 
MUFAs such as C16:1n7, C16:1n9 and oleic acid after 12 and 24 hours in THP-1 and 
RAW 264.7 macrophages. The role of cis-MUFAs in atherosclerosis is unclear and may 
not have a major impact, although a Mediterranean-style diet rich in MUFAs has been 
attributed with beneficial cardiac effects (Lee et al. 1989; Mensink and Katan 1990; 
Hayes and Khosla 1992).  
Many studies have demonstrated a positive association between trans-MUFAs, 
atherosclerosis and other cardiac disorders (Mensink and Katan 1990; Lichtenstein et al. 
1999; Djousse et al. 2012). Although it is most likely that any unsaturated fatty acids 
within the study are of the natural cis-double bond configuration, trans-double bonds 
could potentially be exogenously supplied and incorporated from the growing medium. 
MS could be used to determine the configuration of double bonds within the fatty acids 
(Nichols et al. 1985). The activity of desaturases such as SCD-1 and elongases are 
potentially a more relevant indicator of MUFA involvement in atherosclerosis. 
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Inhibition of SCD-1 promotes the production of SFAs and decreases the levels of 
MUFAs (Ariyama et al. 2010). As such the increase in the content of SFAs and 
reduction of MUFAs following IL-33 stimulation is likely to be a product of reduced 
activity of SCD-1. 
6.6.3. The influence of IL-33 on PUFAs in macrophages 
After 12 and 24 hours of IL-33 stimulation, levels of n-3 PUFAs were raised in 
macrophages; however the effects on n-6 PUFAs were more varied and species-specific. 
Treatment by the cytokine produced a significant increase in the n-3 PUFA DPA and n-
6 PUFA AA within THP-1 macrophages and there was a trend for raised levels of 
PUFAs in PLs from both families. Within RAW264.7 macrophages there was a 
significant increase in the n-3 PUFA EPA and n-6 PUFA LA and a significant reduction 
in the n-6 PUFAs DGLA and nervonic acid. The evidence for the beneficial role of n-3 
PUFAs in cardiovascular disease is controversial, whereas the involvement of n-6 
PUFAs in the disease state are more mixed (Table 19).  
An interesting result was the increase in the content of eicosanoid precursors such as 
LA, EPA and AA. The mutual increase occurred in opposition to known antagonistic 
mechanisms that exist between n-3 and n-6 PUFAs and could suggest that major 
changes occur in response to IL-33 treatment that override such methods of regulation. 
Both fatty acids function as precursors for eicosanoids so the mutual increase in content 
may reflect a general rise in eicosanoid production within the macrophages. As such 
further analysis should be performed to determine the effects of the cytokine on 
eicosanoid synthesis and, crucially, whether the resulting mediators are pro- or anti-
inflammatory.  
Due to the anti-inflammatory effects of IL-33 in atherosclerotic studies it may be 
predicted that the cytokine would enhance the formation of pro-resolving lipid-derived 
mediators. The resolution of the inflammatory state is an active process associated with 
alterations in PUFA metabolism that promote the switch from pro-inflammatory 
eicosanoid production to specialised pro-resolving mediators including lipoxins, 
resolvins, protectins and maresins (Levy et al. 2001; Bannenberg and Serhan 2010). 
However, there are several complications associated with measuring eicosanoid 
production as eicosanoids are not stored but are rapidly formed and released. Many 
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studies focus on immunolocalisation of eicosanoid-producing enzymes or detection of 
precursor fatty acids to determine sites of eicosanoid production (Marmor and Julius 
2001). However, Yang et al. (2011) outline a number of sensitive metabolomics and 
lipidomic approaches to assess eicosanoid synthesis. Briefly, cells or tissues are 
extracted prior to solid phase extraction with internal standards by enzyme-linked 
immunosorbent assay (ELISA), liquid chromatography-ultraviolet (LC-UV) or GC-MS. 
Lastly LC-UV-MS-MS is used to generate lipid mediator profiles that can be checked 
against lipidomic databases (Norris et al. 2011; Yang et al. 2011; Dalli and Serhan 
2012). Alternatively, High performance-LC (HPLC) /MS/MS or GC/MS can be used to 
detect the presence of multiple eicosanoids. HPLC distinguishes specific compounds 
based on physical properties and subsequent MS analysis utilises product ion spectra to 
identify the compounds. However such methods require preparation, as samples must be 
volatile and thermally stable (Lundstrom et al. 2009; Mesaros et al. 2009). 
6.6.4. IL-33-mediated regulation of desaturase activity and gene expression 
The activities of desaturases reflect metabolic changes in fatty acids and are directly 
associated with the disease state (Martinelli et al. 2008; Ebbesson et al. 2012). A 
reduction in the activity of Δ5-desaturase and increased Δ6-desaturase activity are 
exhibited during CAD and related disorders (Leng et al. 1999; Warensjo et al. 2005; 
Petersson et al. 2008; Warensjoe et al. 2008). However, the involvement of SCD within 
the disease state is complicated as high levels of SCD-1 are linked to adverse cardiac 
events (Warensjoe et al. 2008), yet complete ablation of the gene can also promote 
atherosclerosis (Brown et al. 2008; MacDonald et al. 2009). Therefore, the expression 
of SCD is carefully regulated (Heinemann and Ozols 1998) and there appears to be a 
fine balance between protective and detrimental effects by the enzyme (Warensjo et al. 
2005; Sampath and Ntambi 2014).  
Due to the involvement of the desaturases within CAD, the effects of IL-33 treatment 
on the activities of Δ5-desaturase, Δ6-desaturase and SCD were investigated using a 
ratio of products to precursors. Treatment with IL-33 resulted in a significant reduction 
in SCD activity within THP-1 and RAW264.7 macrophages and significantly increased 
the activity of Δ6-desaturase within THP-1 macrophages and Δ5-desaturase activity in 
THP-1 and RAW264.7 macrophages. Interestingly, a similar pattern of effects was 
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described by Leikin and Brenner (1998) during a study where rats were fed a diet 
deficient in cholesterol to determine the impact on desaturase activity and upon the 
cholesterol and fatty acid profile of liver microsomes. An absence in dietary cholesterol 
reduced the proportions of cholesterol and PC and was accompanied by a fall in 
MUFAs and an increase in SFAs, in addition to AA. Depletion of cholesterol decreased 
the activity of SCD over the time course, accompanied with increased Δ5- and Δ6-
desaturase activities. The authors suggest that the deficiency in cholesterol promoted 
Δ5- and Δ6-desaturase activity thereby increasing the unsaturation index of membrane 
fatty acids to enhance membrane fluidity (Leikin and Brenner 1988).  
The SCD-1 index is believed to be a stronger predictor of cardiac-related mortality than 
Δ5- and Δ6-indices and has therefore been the focus of many studies (Ntambi 1999; 
Attie et al. 2002; Warensjoe et al. 2008). RT-qPCR was used to explore the influence of 
IL-33 on the mRNA expression of the major SCD isoform in THP-1 and RAW264.7 
macrophages. Stimulation by IL-33 (25ng/ml) for 12 and 24 hours caused a significant 
reduction in the mRNA expression of SCD-1 in murine macrophages; however there 
was no change in human THP-1 macrophages.  
A fall in SCD-1 expression may produce an atheroprotective lipid profile as mice 
lacking SCD-1 exhibit a deficit of TAGs and CEs within VLDL and LDL particles 
accompanied with a fall in the expression of lipid synthesis genes (Ntambi et al. 2002). 
In contrast, overexpression of SCD-1 boosts the esterification of cholesterol to CEs 
(Miyazaki et al. 2000). The fall in expression and activity may have arisen from 
enhanced PUFA production as PUFAs from either family inhibit the expression of 
SCD-1 (Waters et al. 1997). Additionally, several studies have shown that the down-
regulation of SCD-1 expression is mediated through a reduction in SREPB-1c and LXR 
binding to promoter regions in the gene encoding the desaturase (Yoshikawa et al. 2002; 
Chu et al. 2006). DNase I footprinting and gel retardation assays have identified two 
key binding regions in the SCD-1 promoter where several transcription factors have 
also been shown to bind including PPAR-α, C/EBP-α and AP-1 (Christy et al. 1989; 
Mauvoisin and Mounier 2011). Interestingly several of these nuclear factors are also 
regulated by IL-33 (Miller et al. 2010) and would serve as suitable candidates for 
further investigations. RT-qPCR could be used to investigate any changes in SCD-1 
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mRNA expression in RAW264.7 macrophages following inhibition/knock down of 
these nuclear factors by pharmacological inhibitors or RNAi. 
Interestingly, the cytokine did not affect the gene expression of SCD-1 in THP-1 
macrophages yet significantly reduced SCD activity. The changes in SCD activity could 
potentially be due to alterations in the expression of the less prevalent isoform; SCD-2. 
However, SCD-2 is predominately expressed within the brain (Sampath and Ntambi 
2014) so is unlikely to have a major impact on activity but RT-qPCR using isoform-
specific primers for SCD-2 should be performed.  
Another possibility for the changes in activity could be due to post-transcriptional or 
post-translational modifications that could alter the activity of the enzyme without 
affecting the mRNA expression of SCD-1. The transcriptional inhibitor actinomycin D 
could be utilised for such a purpose whereby cells are either left untreated or stimulated 
with IL-33 and incubated with actinomycin D. Total RNA is then harvested at various 
time intervals to determine the effect of IL-33 on mRNA stability  (Fan et al. 2005). 
Alternatively, the cells could be incubated with radioactive nucleosides in pulse-chasing 
experiments. The radioactive probes are incorporated into RNA and the medium is 
replaced with fresh medium containing an excess of unlabelled nucleosides that ‘chase’ 
the radioactive substrates. The freshly produced mRNA can then be detected by filter 
hybridisation to determine the timescale for mRNA decay (Palade 1975). Additionally, 
analysis by western blotting may indicate whether the protein is post-transcriptionally 
regulated at the level of steady state protein. In regards to these findings, antibodies for 
total SCD or specific SCD isoforms could be used to determine whether any changes 
were isoform specific. Also enzymatic activity could be assessed through the use of 
radiolabelled substrates (Demcakova et al. 2001). For example using radiolabelled 
stearic acid, the distribution of radioactivity between substrate (stearic acid) and product 
(oleic acid) could be measured to determine the rate of desaturation mediated by SCD. 
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6.7. Future studies  
6.7.1. Exploring the role of IL-33 in the regulation of atherosclerotic 
markers 
The actions of IL-33 has been described as dichotomous whereby the cytokine can 
produce contradictory pro- and anti-inflammatory effects dependent on cellular 
conditions. In chapter four, the reduction in ICAM-1 and MCP-1 mRNA by IL-33 was 
mediated through ERK1, ERK2, p38α, JNK1, JNK2, PI3K-γ, p50 and p65. However, a 
number of these components are also utilised by IL-33 to induce the expression of 
ICAM-1 and MCP-1 within other cells. For example, IL-33 uses p65 to increase the 
expression of ICAM-1 in endothelial cells (Choi et al. 2012), whilst NF-κB, p38 and 
ERK facilitate the up-regulation of  ICAM-1 in eosinophils (Chow et al. 2010).  
Due to the mutual use of these signalling components it is essential to distinguish the 
underlying mechanisms that give rise to the opposing effects on ICAM-1 and MCP-1 
expression initiated by IL-33. Several approaches could be implemented to further 
investigate key differences in the cellular pathways responsible. RNAi could be used to 
knock down the expression of signalling elements that control ICAM-1 and MCP-1 
expression within alternative cell types. For example, other studies have implicated Akt 
(Radisavljevic et al. 2000), Rho kinase (Shimada and Rajagopalan 2010), Casein 
Kinase 2 and the JAK-STAT pathway (Harvey et al. 2007) in the regulation of ICAM-1 
and MCP-1 mRNA and protein expression. As such these signalling modules may 
potentially be involved in IL-33-regulation of ICAM-1 and MCP-1 expression within 
macrophages.  
IL-33 also utilises Akt, MyD88, IRAK, IRAK4 and TRAF6 during the regulation of 
other genes (Schmitz et al. 2005; Choi et al. 2009) and these components could be 
involved. The use of RNAi targeted towards these genes or bone marrow derived 
macrophages, or alternatively, peritoneal macrophages from knockout animals could be 
utilised in a similar approach as the one used in chapter four to determine whether these 
signalling modules are integral in the regulation of ICAM-1 and MCP-1 expression by 
IL-33. Analysis by RT-qPCR and western blotting would determine the effect at the 
mRNA and protein levels and give an indication if additional regulatory systems are 
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involved. Additionally, nuclear run-on transcription assays, whereby nuclei from chosen 
cells are isolated in the presence of labelled nucleoside triphosphates, could be used in 
combination with hybridisation techniques to measure rate of transcription initiation and 
transcriptional control (Farrell and Farrell 1993). The promoter could be dissected by 
targeted deletion and mutation analyses to determine the importance of cis-acting 
transcriptional elements for gene expression (Allen et al. 1992; Bruhn et al. 1993). 
As many common signalling elements are involved in both pro- and anti-inflammatory 
IL-33 signalling, it could become a lengthy procedure to systematically test individual 
components. Also, single-gene approaches may present a biased representation of the 
cellular environment as genes are often constituents of larger regulatory networks 
(Tuomisto et al. 2005). Therefore the use of commercially available microarrays could 
provide a rapid and cost-effective method of large-scale gene expression profiling. 
Microarray assays are comprised of thousands of cDNA sequences or oligonucleotides 
corresponding to sequences printed in a high-density array and a single experiment can 
provide a wealth of data about gene expression patterns (DeRisi et al. 1997). Statistical 
algorithms can then be used to cluster the data based on functionality or similarity in 
expression patterns (Eisen et al. 1998). This approach may identify well-characterised 
or novel genes involved in IL-33 signalling. Also, microarray analysis could be used to 
determine which particular signalling components dictate the pro- or anti-inflammatory 
effects of IL-33. The technique could be performed on material taken from 
atherosclerotic plaques and asthmatic samples subjected to IL-33 treatment to compare 
the differences in expression patterns. However, many diseases like atherosclerosis 
contain a heterogeneous population of cells that could complicate analyses and as such 
initial experiments should focus on particular cell types integral to both disease states 
such as macrophages. 
The dual functionality of IL-33 may also arise due to differential release of IL-33 and 
ST2. It has been proposed that full-length IL-33 is cleaved to limit the pro-inflammatory 
activities of the cytokine. On the other hand, functional full-length IL-33 is secreted by 
necrotic cells and is thought to function as an ‘alarmin’ to stimulate protective effects 
against damaged tissues or cells (Kunes et al. 2012). The activity of IL-33 is tightly 
controlled and IL-33 mRNA is quickly regulated within hours of synthesis (Polumuri et 
al. 2012). Full-length and mature versions of IL-33 should be tested to discern whether 
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maturation affects the actions of IL-33 on the expression of atherosclerotic markers or 
fatty acid profiles. Miller et al. (2011) suggest that alternative splicing of ST2 adds 
further control and can gives rise to functional membrane ST2 or the antagonistic decoy 
receptor sST2 (Miller and Liew 2011). ST2 can also dimerise with SIGIRR which 
hinders IL-33 activity (Bulek et al. 2009). The use of knockout animals deficient in ST2 
could be used to determine whether IL-33-signalling occurs independently of the 
receptor.  
The dual nature of IL-33 may also arise through its interactions with other inflammatory 
mediators including cytokines. IL-33 injections promotes inflammatory bowel disease 
in mice deficient in IL-10, however wild-type mice are protected against IL-33-induced 
mucosal inflammation (Sattler et al. 2014). Additionally, stimulation by IL-33 or IL-13 
alone does not affect levels of CCL17 and CCL24, whereas co-stimulation leads to 
enhanced concentrations of these chemokines and polarisation towards the alternatively 
activated macrophage phenotype (Kurowska-Stolarska et al. 2009). Synergistic 
interactions with other cytokines could function as a switch that determines the pro- or 
anti-inflammatory activities of IL-33. It would be interesting to see whether co-
stimulating cells with IL-10 and IL-13 affects the expression of ICAM-1 and MCP-1 by 
IL-33 and if the pathways responsible alter as a result. 
6.7.2. Future studies exploring the involvement of IL-33 in the regulation 
of macrophage lipids  
A number of studies exploring macrophage cholesterol homeostasis pre-incubate THP-1 
macrophages with modified LDL particles in order to promote the formation of foam 
cells (Banka et al. 1991; Rodriguez et al. 1994; McLaren et al. 2010b). The presence of 
macrophage foam cells is a hallmark of the disease and a similar approach could be 
adopted utilising TLC and GC following incubation of THP-1 and RAW264.7 
macrophages with modified LDL particles such as acLDL or oxLDL (Liu et al. 2014). 
Transformation of these cells could be validated by Oil Red O staining to assess the 
accumulation of lipids within these cells (Turunen et al. 2004; Kang et al. 2014; Liu et 
al. 2014).  
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Due to the role of IL-33 in modulating lipid composition and inflammatory gene 
expression, further experiments should be performed to integrate and consolidate these 
key areas as modifications to membrane composition can affect inflammatory processes 
such as macrophage chemotaxis and the binding of chemotactic mediators (Calder and 
Yaqoob 2003). A study by Komai-Koma et al. (2007) demonstrated that IL-33 serves as 
a chemoattractant for polarised Th2-cells in vitro and injections of IL-33 into ST2 
knockout mice induces the localised accumulation of adoptively transferred Th2 cells 
(Komai-Koma et al. 2007). The mechanisms underlying IL-33 chemotactic actions are 
unknown and it would be informative to determine whether the signalling cascades 
involved in other chemotactic events are also utilised by IL-33. Lipid-derived signalling 
components such as PI3K, PIP2 and PIP3 are integral to chemotaxis. Within neutrophils, 
formation of the leading edge is characterised by PI3K-γ-dependent accumulation of 
PIP3 and PIP2 at the plasma membrane (Fergus et al. 2007; Kolsch et al. 2008). Also, 
studies with mouse neutrophils have shown that chemoattractants influence the 
metabolism of inositol-derivatives; PIP2 hydrolysis is controlled by PLCβ2 and PLCβ3 
whereas the phosphorylation of PIP2 is induced by PI3K-γ (Wu et al. 2000). Knockout 
mice for key signalling mediators implicated in chemotaxis such as PLC and PI3K 
members, or an RNAi approach targeting these genes, could be used to determine 
whether IL-33-mediated chemotaxis is dependent on these signalling components. The 
effects on cellular motility could then be measured by chemotaxis assays based on 
analysing the redistribution of cells across a porous membrane or through agarose or 
ECM gels exposed to IL-33. The movement of cells can be detected microscopically or 
through the use of a colorimetric, fluorescent or radioactive marker (Zigmond et al. 
2001).  
Alterations in membrane PUFA content can also influence cellular activity. A study on 
peripheral blood neutrophils and monocytes taken from healthy subjects showed that 
there was a negative association between the proportions of palmitic and oleic acid and 
the phagocytic ability of these cells. On the other hand, levels of stearic acid, LA, ALA, 
AA, DHA and total PUFAs were positively linked with phagocytosis (Kew et al. 2003). 
Interestingly many of these fatty acids were affected in the experiments presented in 
chapter five so further studies could investigate whether IL-33 alters the phagocytic 
abilities of macrophages. For this purpose, the macrophages could be pre-incubated 
with phagocytotic agonists such as opsonised zymosan, immune complexes or urate 
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crystals to determine the rate and extent of phagocytosis before and after IL-33 
stimulation (Yang et al. 2011). These effects may arise due to changes in specific types 
of phospholipids. For example, IFN-γ increases the PUFA content of PC and PE 
phospholipids within murine and human macrophages. The authors suggest that the 
alterations in membrane structure and fluidity promote endotoxin and LPS binding to 
these cells (Jackson et al. 1992; Darmani et al. 1994; Darmani et al. 1995). Therefore, it 
would be interesting to determine whether the changes induced by IL-33 were specific 
to particular types of phospholipids. Lipid fractions from macrophages stimulated by 
IL-33 could be assessed by two-dimensional TLC to explore the effects on the fatty acid 
distribution of particular phospholipids.  
Lipid remodelling can also influence the distribution of signalling mediators and 
facilitate receptor-ligand interactions. For example, membrane-resident SFAs and 
PUFAs regulate the activation of TLR4 (MacDonald et al. 2009). Lauric acid promotes 
the dimerisation of TLR4 into lipid raft domains and therefore promotes the co-
ordination of TLR4 with downstream adaptors including MyD88. However, these 
effects are inhibited by the presence of DHA (MacDonald et al. 2009). Interestingly the 
IL-33/ST2 axis utilises TLR4 and MyD88 following exposure to LPS and within mice 
with experimental sepsis (Espinassous et al. 2009; Alves-Filho et al. 2010). It would be 
interesting to determine whether alterations in the fatty acid composition of 
phospholipids mediate the spatial localisation of IL-33 signalling components. Lateral 
interactions between phospholipids and sphingolipids give rise to lipid raft domains 
which are implicated in a number of cellular processes such as phagocytosis and the 
generation of pro-inflammatory cytokines (Schumann 2012). Several cytokines such as 
IL-1 (Veluthakal et al. 2005) and IL-2 (Marmor and Julius 2001) have been shown to 
modulate the formation of lipid raft domains. Investigations into the formation of such 
domains could utilise detergent or detergent-free methods to separate membrane rafts 
and non-raft regions. Triton X-100 is a non-ionic detergent frequently chosen to 
solubilise non-raft portions of membrane at 4ºC, the remaining detergent-resistant 
sections represent lipid domains and can be separated using density gradient 
centrifugation (Gaus et al. 2005; Wong et al. 2009). Alternatively, non-detergent based 
methods involving the disruption of the membrane by sonication and the isolation of 
buoyant lipid raft domains and heavier non-raft sections could be used (Gaus et al. 2005; 
Macdonald and Pike 2005).  
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Balsinde and Dennis (1996) reported that increased content of AA within murine 
macrophages was followed by the accumulation of AA within the medium mediated by 
phospholipases (Balsinde and Dennis 1996). Stimulation by IL-33 may trigger the 
release and secretion of lipid-derived factors that could potentially have a role in 
atherosclerosis. Fatty acids such as AA implicated in signalling events could be 
radiolabelled and supplemented into the growth medium for a requisite amount of time 
to allow incorporation of the exogenous fatty acid. Following a medium change to 
remove excess radiolabelled fatty acids, the effects of IL-33 treatment on the secretion 
of radiolabelled fatty acids into the medium could then be assessed by scintillation 
counting. Furthermore, the distribution and metabolism of radiolabelled fatty acids 
within the cells could also be explored. 
The studies presented within chapter five demonstrated that IL-33 significantly reduces 
the activity of SCD in human and murine macrophages and also decreases the 
expression of SCD-1 mRNA in RAW264.7 macrophages. Mice lacking SCD-1 are 
protected against diet-induced obesity (Ntambi et al. 2002) and men containing a 
polymorphism in the gene encoding SCD-1 have decreased adiposity and resistance to 
diet-linked weight gain (Warensjo et al. 2007). Interestingly, stimulation by IL-33 also 
produces a number of adipoprotective effects such as the down-regulation of C/EBP-α, 
LXR-α, LXR-β and PPAR-γ expression in white adipose tissue (Miller et al. 2010). The 
cytokine also reduces the expression of genes involved in cholesterol metabolism; 
ACAT-1 and NCEH and up-regulates those involved in cholesterol efflux such as 
ABCA-1 and ABCG-1 in THP-1 and HMDMs (McLaren et al. 2010b). Due to the 
mutual and complementary effects it would be useful to explore whether the 
adipoprotective effects by IL-33 are mediated through the modulation of SCD-1 
expression and activity. The expression of genes involved in lipid and cholesterol 
metabolism known to be affected by IL-33 could be compared in mice overexpressing 
SCD-1 (Rogowski et al. 2013) and mice lacking SCD-1 (Ntambi et al. 2002) following 
IL-33 treatment to determine whether SCD-1 is involved.  
6.8. The therapeutic implications of IL-33 research   
The clinical symptoms of CAD typically manifest during the later phases of the disease, 
therefore methods for earlier detection could be key to treating and combating CAD 
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(Ross 1993; Poredos 2011). Current methods in the prognosis of HF utilise 
echocardiography, electrocardiography and chest X-rays to assess changes in systolic 
and diastolic function, alterations in ECG and pulmonary congestion respectively 
(Dickstein et al. 2008). The use of soluble markers represents a promising field of 
diagnostics and could provide an early non-intrusive method of detection (Wattanakit et 
al. 2005). Currently the natriuretic peptides; B-type natriuretic peptide (BNP) and 
amino-terminal pro-BNP are the only biomarker assays recommended by the European 
Society of Cardiology committee for diagnostic assessment of patients with HF 
(McMurray et al. 2012). Studies have shown that atherosclerotic development can be 
monitored by measuring carotid intima media thickness by ultrasound and is also 
independently related to levels of CRP (Howard-Alpe et al. 2006; Benedetto et al. 
2008). However, due to a limited number of certified cardiac biomarkers within this 
field, further research is necessary to expand this promising field of early prognosis.  
sICAM-1 is the cleaved version of membrane-bound ICAM-1 (Gross et al. 2012) and 
several large cohort studies have linked raised levels of serum and plasma ICAM-1 to 
cardiovascular disease (Hwang et al. 1997; Ridker et al. 1998; Malik et al. 2001). MCP-
1 has also been highlighted as a potential biomarker of the disease as serum and plasma 
levels of the chemokine are positively associated with cardiovascular risk (Blanco-Colio 
et al. 2007; Tang et al. 2007; Gonzalez-Quesada and Frangogiannis 2009). During the 
disease state, levels of circulating adhesion molecues and chemokines are raised within 
the serum of patients with HF, likely due to insufficient clearance or increased 
production (Papayianni et al. 2002). Therefore, detection of elevated levels of these 
proteins could facilitate early therapeutic intervention. 
Recently, sST2 has received a lot of attention as a promising marker of CAD. In vitro 
experiments have shown that treatment with sST2 reverses the protective effects of IL-
33 and leads to increased atherosclerotic development in mice (Miller et al. 2008). 
Several epidemiological studies have also suggested that levels of serum sST2 can 
function as a biomarker for predicting mortality and HF in patients who have suffered a 
MI event (Weinberg et al. 2003; Shimpo et al. 2004) and increased concentrations of 
sST2 are associated with adverse prognosis of acute dyspnea (Januzzi et al. 2007; Shah 
et al. 2009). Additionally, circulating levels of sST2 are related to age, blood pressure, 
the use of anti-hypertensive medicine and diabetes (Ho et al. 2013). In a study by 
DISCUSSION   Melanie Buckley       Melanie Buckley 
  
257 
 
Pascual-Figal et al. (2011) three biomarkers were assessed in blood taken from patients 
with acutely decompensated HF: high-sensitivity troponin T, amino-terminal pro-BNP 
levels and sST2. Each biomarker independently predicted risk of death and the 
combination of the three markers improved prediction accuracy (Pascual-Figal et al. 
2011). 
Serum sST2 concentrations are typically detected by ELISA assays. Briefly, the method 
involves adding samples to microtitre plates coated with anti-human ST2 antibodies. 
The plates are washed before the addition of peroxidase-conjugated anti-human ST2 
antibodies and after another series of washes the peroxidase-associated substrate is 
added. The resulting change in colour can then be assessed at the appropriate 
wavelength to predict sST2 levels (Weinberg et al. 2002; Weinberg et al. 2003; Shimpo 
et al. 2004). However, issues over poor sensitivity have meant that the assay is unable 
to detect the low concentrations of sST2 present in healthy subjects (Januzzi 2013). 
However, a highly sensitive ELISA has been recently developed called Presage™ ST2 
assay. A large population cohort study demonstrated that the system could detect sST2 
levels in all subjects tested and that the amounts of sST2 were positively associated with 
incidences of HF. Furthermore, unlike BNP, levels of sST2 are not significantly 
influenced by renal function (Dieplinger et al. 2009). Promisingly, the assay has been 
recently approved by the United States food and drug administration as a prognostic test 
for HF (Januzzi 2013; Mueller and Dieplinger 2013).  
Additionally, due to the anti-atherogenic effects of IL-33, the cytokine serves as a 
promising therapeutic candidate. The use of IL-33
-/-
 mice (Oboki et al. 2010) crossed 
with ApoE
-/- 
or LDLR
-/-
 mice could be used to assess the loss of IL-33 on overall 
atherosclerotic development. Encouragingly, a recent study showed that administration 
of IL-33 after a MI event in mice reduced the size of the infarction and wall thinning 
and also improved left ventricular function (Yin et al. 2014). However, due to the 
dualistic nature of the cytokine, the role of IL-33 within atherosclerosis and the 
signalling pathways or cellular changes responsible for its actions should be better 
characterised before the cytokine can be considered for therapeutic applications. 
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6.9. Conclusions   
The studies presented within this thesis have demonstrated that IL-33 modulates a range 
of anti-atherogenic processes. The cytokine down-regulates the expression of several 
markers implicated in atherosclerotic events such as those involved in the recruitment 
and attachment of leukocytes and lipid and cholesterol metabolism. Furthermore, 
several signalling components involved in the IL-33-mediated down-regulation of 
ICAM-1 or MCP-1 have been identified; the MAPKs ERK1, ERK2, p38α, JNK1 and 
JNK2; the PI3K component PI3K-γ and NF-κB members p50 and p65. The cytokine 
also alters the fatty acid profile of macrophages by potentially promoting the 
redistribution of PLs to TAG fractions and also increases the content of SFAs and 
specific PUFAs known to function as eicosanoid precursors. Such changes may arise 
due to alterations in the expression of enzymes involved in fatty acid desaturation, as 
IL-33 increases the activities of Δ5- and Δ6-desaturases but reduces SCD activity. The 
fall in SCD activity was also accompanied by a reduction in SCD-1 mRNA expression 
in murine RAW 264.7 macrophages.  
There is growing interest in IL-33 due to the anti-atherogenic properties of the cytokine 
and as such a greater understanding of the mechanisms that give rise to these actions 
may translate to future therapeutic applications in the treatment of atherosclerosis and 
heart disease. Future studies will need to focus on delineating the anti-atherogenic 
properties of the cytokine and distinguishing why the activities of IL-33 are protective 
within cardiovascular disease and obesity but detrimental in other inflammatory 
diseases. 
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APPENDIX 
 
 
 
 
Figure 67. The effect of ERK1 knock down in regulation of ICAM-1 and MCP-
1 by IL-33 
RT-qPCR was performed using cDNA from primary macrophages expressing ERK1 shRNA 
and incubated in the presence or absence of IL-33 (25ng/ml) for 12 hours. Cells expressing 
shRNA targeting a scramble sequence were used as a control (Scr). The mRNA levels were 
calculated using the comparative Ct method and normalised to the house-keeping gene, 
GAPDH, with values from control samples given an arbitrary value of 1. Data represents mean 
± SD from a single experiment taken from Figure 49 performed in triplicate.   
 
Figure 68. The effects of p38α knock down in IL-33 regulation of ICAM-1 and 
MCP-1  
RT-qPCR was performed using cDNA from primary macrophages expressing p38α shRNA and 
incubated in the presence or absence of IL-33 (25ng/ml) for 12 hours. Cells expressing shRNA 
targeting a scramble sequence were used as a control (Scr). The mRNA levels were calculated 
using the comparative Ct method and normalised to the house-keeping gene, GAPDH, with 
values from control samples given an arbitrary value of 1. Data represents mean ± SD from a 
single experiment taken from Figure 52 performed in triplicate.   
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Figure 69. Human SCD-1 primer homology 
Primer-Blast search details identifying that the primer sequence is 100% specific for human SCD-1. 
Primer sequence taken from (Peter et al. 2009). 
 
 
Figure 70. Human SCD-1 primer optimisation 
The Products from RT-PCR were assessed on a 1.5% (w/v) agarose gel. cDNA was taken from the 
same experiment and subjected to a range of annealing temperatures. As a result an annealing 
temperature of 58ºC was chosen. The expected product size for human SCD-1= 347bp. Primer 
sequence taken from (Peter et al. 2009). 
 
 
-RT 
347bp 
Marker 58ºC 59ºC 60ºC 61ºC 62ºC 63ºC 64ºC 65ºC 66ºC 67ºC 68ºC 69ºC 
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Figure 71. Murine SCD-1 primer homology 
Primer-Blast search details identifying that the primer sequence is 100% specific for murine SCD-1. 
Primer sequence taken from (Thorn et al. 2010). 
 
 
Figure 72. Murine SCD-1 primer optimisation 
The Products from RT-PCR were assessed on a 1.5% (w/v) agarose gel. cDNA was taken 
from the same experiment and subjected to a range of annealing temperatures. As a result an 
annealing temperature of 65ºC was chosen. The expected product size for murine SCD-1= 
93bp. Primer sequence taken from (Thorn et al. 2010). 
 
64ºC -RT 60ºC 61ºC 62ºC 63ºC 65ºC 66ºC 67ºC 68ºC 
93bp 
APPENDIX       Melanie Buckley 
  
262 
 
 
 
** 
* 
* 
* 
* 
A B 
C D 
* 
 * 
 * 
 * 
* 
 * 
* 
 ** 
 ** 
APPENDIX       Melanie Buckley 
  
263 
 
  
 
 
Figure 73. Distribution of fatty acids in THP-1 macrophages 
PMA-differentiated THP-1 macrophages were incubated with IL-33 (25ng/ml) for 12 or 24 hours. An untreated control was included under the same 
conditions. Following TLC, fatty acids from fractions for PLs (Panels A and B) and TAGs (Panels C and D) were converted to FAMEs for analysis by GC. 
Total fatty acids (Panels E and F) represent the fatty acids from summation of PLs and TAGs. The results are presented as the concentration of cells 
normalised to µg/million cells for PLs (A and B), TAGs (C and D) or total fatty acids (E and F). Fatty acids are indicated with the number before the colon 
showing the number of carbon atoms, after which denotes the number of double bonds followed by the position of the first double bond. Data represents mean 
± SD from three independent experiments. The Student t test was used to determine the statistical significance of the results *p<0.05, **p<0.01, ***p<0.001.   
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Figure 74. Distribution of fatty acids in RAW264.7 macrophages 
RAW264.7 macrophages were incubated with IL-33 (25ng/ml) for 12 or 24 hours. An untreated control was included under the same conditions. Following 
TLC, fatty acids from fractions for PLs (Panels A and B), TAGs (Panels C and D) and SEs (E and F) were converted to FAMEs for analysis by GC. Total 
fatty acids (Panels G and H) represent the fatty acids from summation of PLs, TAGs and SEs. The results are presented as the concentration of cells 
normalised to µg/million cells for PLs (A and B), TAGs (C and D), SEs (E and F) or total fatty acids (G and H). Fatty acids are indicated with the number 
before the colon showing the number of carbon atoms, after which denotes the number of double bonds followed by the position of the first double bond. 
Data represents mean ± SD from three independent experiments. The Student t test was used to determine the statistical significance of the results *p<0.05, 
**p<0.01, ***p<0.001.   
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Figure 75. The effect of IL-33 on major lipid classes in THP-1 macrophages 
PMA-differentiated THP-1 macrophages were incubated with IL-33 (25ng/ml) for 12 or 24 
hours. An untreated control was included under the same conditions. TLC was used to separate 
lipids into different lipids groups; PLs and TAGs (A). Total lipids are shown as the summation 
of PLs and TAGs (B). The graph displays the concentration of lipids within each fraction (µg). 
Data represents three independent experiments.  
A 
B 
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Figure 76. The effect of IL-33 on major lipid classes in RAW264.7 
macrophages 
RAW264.7 macrophages were incubated with IL-33 (25ng/ml) for 12 or 24 hours. An 
untreated control was included under the same conditions. TLC was used to separate lipids into 
different lipids groups; PLs, TAGs and SEs (A). Total lipids are shown as the summation of 
PLs, TAGs and SEs (B). The graph displays the concentration of lipids within each fraction 
(µg). Data represents three independent experiments.  
A 
B 
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